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Although cannabis use following a first episode of psychosis (FEP) has been 
linked to poor outcome such as relapse, current understanding is limited regarding the 
nature of this association. To shed light on the nature of this relationship, this thesis 
employed multiple methodological approaches: First, I pooled together data from 
previous studies in order to estimate the cross-sectional effects of continued and 
discontinued cannabis use following the onset of psychosis and risk of relapse, using a 
meta-analytic design (Paper 1). Second, I prospectively collected follow up data from a 
cohort of patients presenting with a first episode psychosis to psychiatric services in 
south London. Paper 2 examined the magnitude of effect of continued cannabis use on 
risk of relapse and related outcomes by grouping patients into classes of different 
patterns of cannabis use following onset of psychosis. In Paper 3, longitudinal 
modelling was employed to further examine whether the link between continued 
cannabis use and risk of relapse persists when non-causal explanations for the 
association are taken into account (reverse causation, premorbid genetic confounding). 
My findings indicate that that former regular users who stopped using cannabis 
after the onset had the most favourable illness course with regard to relapse. The most 
unfavourable course was present in those who continued to use high-potency cannabis 
in a high frequency manner. The results also suggest that this association reflects a 
dose-dependent association that is unlikely to be a result of reverse causation (e.g. self-
medication) or genetic and environmental (e.g. other illicit drug use, medication non-
adherence) confounding. These findings point to reductions in cannabis use as a crucial 






1 FIRST EPISODE PSYCHOSIS 
1.1 INTRODUCTION 
Psychotic disorders are severe mental disorders that involve disturbances in 
thought, senses and perceptions, emotions and behavior. A psychotic episode is 
characterized by the presence of positive symptoms, including hallucinations (e.g. 
seeing, hearing, feeling things that are not there), delusions (e.g. fixed false beliefs) and 
thought disorder (e.g. disordered speech/writing, cognitive disorganization). 
Furthermore, the classification of psychotic disorders depends on the duration of the 
experience of the symptoms, as well as the presence or absence of affective symptoms, 
which can be classified according to the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) (WHO, 2004). Hence, the onset of the 
illness is usually defined as the first occurrence of delusions, hallucinations and/or 
formal thought disorders (Lenior, Dingemans, Schene, & Linszen, 2005). About 3% of 
the population is diagnosed with a psychotic disorder over the lifetime (Perälä et al., 
2007) and a recent study by the World Health Organisation (WHO) reported that the 
lifetime prevalence of any psychotic experience among adults was about 6% (J. J. 
McGrath et al., 2015). Despite the dimensional approach that is currently used to 
classify psychotic disorders, as evident in the ICD-10 (WHO, 2004) and the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-V) (APA, 2013), recent studies have 
reported that a substantial proportion (between 1%-31%) of individuals in the general 
population experience psychosis-like symptoms, implicating that the symptoms may lie 
on a continuum within normal experiences (Nuevo et al., 2010). However, not all 
individuals with subclinical psychotic symptoms develop a full-blown psychotic 
[14] 
 
disorder, e.g. in help-seeking high-risk individuals, only a proportion transition to 
psychosis in the first year (22%) and the second year (29%) following first presentation 
(Fusar-Poli et al., 2012). The symptoms of psychosis usually manifest in adulthood and 
a substantial proportion of patients (~ 19%) present with their first episode before the 
age of 18 (early onset psychosis) (Schimmelmann, Conus, Cotton, McGorry, & 
Lambert, 2007). Psychotic disorders constitute one of the highest disease burdens 
globally (Whiteford et al., 2013) and are one of the most costly disorders, representing 
about 9% of all economic costs of brain disorders in Europe (Olesen, Gustavsson, 
Svensson, Wittchen, & Jönsson, 2012).  
There is now increasing interest in the early stages of psychosis, i.e. the early 
period following the first episode of psychosis, which is also regarded as the “critical 
period” that determines long-term outcome in psychosis (Birchwood, Todd, & Jackson, 
1997). The critical period hypothesis proposes a natural rapid progression of 
symptomatic, psychosocial and cognitive decline in the early phases of the illness 
(including the period of untreated psychosis), specifically in the first two to three years 
of the disorder (Birchwood et al., 1997). This progression of decline stops or slows 
down following the critical period and the level of disability or functioning remains 
subsequently. For instance, some studies have reported that the course stabilises after 2-
5 years of the onset (Carpenter & Strauss, 1991; Crumlish et al., 2009). Other evidence 
showed that the greatest change (improvements in positive symptoms) occurred in the 6 
months following onset and no significant further improvement was present between the 
following assessment periods (6 months to 12 months, 12 months to 18 months, 18 
months to 24 months) (Szymanski, Cannon, Gallacher, Erwin, & Gur, 1996). This is in 
line with a study that reported that the greatest improvement in positive symptoms 
occurred within 1 year following the onset although improvement afterwards was still 
[15] 
 
significant (Jean Addington, Leriger, & Addington, 2003). Similarly, in a meta-analysis 
it was reported that the prevalence of patients with poor outcome did not increase with 
the duration of the follow up (Menezes, Arenovich, & Zipursky, 2006), which is a 
further indication of the stability of the course following the initial early stage of the 
illness. Together, evidence in support of a stable illness course following the early phase 
of illness does not greatly harmonise with the view of schizophrenia as a progressively 
deteriorating illness (Lieberman, 1999). The importance of early intervention to 
improve outcome in this period is also supported by the finding that early stage clinical 
markers (time spent experiencing psychotic symptoms in 2 years following the onset) 
were the strongest predictors for long-term outcome (25 years following the onset), 
including levels of symptoms, disability and course of illness (G. Harrison et al., 2001), 
implicating that the “critical period” is a crucial determinant of the long-term trajectory 
of psychosis. Hence, this very early phase of illness (e.g. the first 1-2 years) reflects a 
particularly sensitive period. For instance, premorbid factors appeared to have stronger 
effect in terms of predicting outcome in the early phases rather than later phases of the 
illness (R. J. Drake, Haley, Akhtar, & Lewis, 2000), for which reason this early stage of 
psychosis is considered as a crucial illness stage for research aiming to develop 
prediction models for outcome in FEP (Ram, Bromet, Eaton, Pato, & Schwartz, 1992). 
Follow up research in samples of FEP patients has the advantage that patients 
are homogeneous with respect to their illness and results may be considered as more 
generalizable than those from samples comprising more chronic patients - a group 
which is likely to be more heterogeneous with regard to illness stage (e.g. effect of 
institutionalizations, interaction with aging, disease processes, multiple antipsychotic 
drug treatments). Importantly, it has been stressed that longitudinal studies (as opposed 
to cross-sectional investigations) of patients with psychosis are crucial in order to better 
[16] 
 
understand the course of the illness and associated risk factors (Ram et al., 1992). In the 
following sections, I will therefore primarily focus on follow up studies in patients with 
a first episode psychosis, i.e. not reviewing much of the evidence that was conducted in 

























1.2 OUTCOME IN FIRST EPISODE PSYCHOSIS 
1.2.1 INTRODUCTION 
Earlier studies in FEP patients have typically defined outcome in terms of course 
patterns, in which outcome was defined as good outcome (e.g. about ~19% of patients 
exhibiting complete recovery without relapse) and poor outcome (~84% with one or 
more relapses or continuous illness course) (cf. Table 1. below). While those early 
studies on outcome in patients with psychosis suggest that for the majority of cases the 
course of the disorder is characterised by chronicity and deterioration (Hegarty, 
Baldessarini, Tohen, & Waternaux, 1993), recent studies are more in support of 
psychosis as an illness with a more favourable outcome than previously reported 
(Menezes et al., 2006). It has been pointed out that sample representativeness may have 
contributed to the high rates of reported poor outcome, e.g. earlier studies often included 
patients at different stages of their illness, which may have led to an over-representation 
of the more chronic, treatment-resistant patients (Menezes et al., 2006). Furthermore, 
outcome is heterogeneous and the reported rates for good/poor outcome vary depending 
on the definition of outcome. For instance, D. Addington et al. (2005) identified 44 
different potentially useful measures that were used in previous studies when assessing 
outcome in FEP, out of which the most commonly employed outcome measures 
evaluating treatment efficacy included global functioning, symptomatic remission, 
relapse, positive symptoms, negative symptoms and depression. A recent meta-analysis 
that pooled together results from follow up studies in FEP reported that 42% of the 
samples were characterised by a “good outcome”, which was defined by outcomes such 
as absence of relapse, achieved remission/recovery, improvement in scores from 
[18] 
 
symptom scales over time, being in employment, absence of committed/attempted 
suicide (Menezes et al., 2006).  
Table 1. Patterns of course  




























































1Thara, Henrietta, Joseph, Rajkumar, and Eaton (1994) (10-year follow up) 
2Shepherd, Watt, Falloon, and Smeeton (1989) (5-year follow up) 
3N Goater et al. (1999) (5-year follow up) 
*adapted from Thara et al. (1994) 
 
1.2.2 CLINICAL AND FUNCTIONAL OUTCOME IN FIRST EPISODE PSYCHOSIS 
Illness course has been heterogeneously defined (Nuechterlein et al., 2006), and 
has often been studied by looking at (1) relapse or significant exacerbation of symptoms 
(episodic course, i.e. the experience of a relapse following the onset), (2) remission of 
illness (e.g. defined as absence of positive/negative/disorganized symptoms for a 
defined period of time), (3) recovery of illness [e.g. defined as absence of major 
symptoms including positive and negative, absence of psychosocial impairments, 
absence of relapses (Harrow, Grossman, Jobe, & Herbener, 2005)] or (4) continuous 
illness course (e.g. persisting symptoms following the onset, non-response to treatment). 
[19] 
 
As shown in Figure 1. below, the highest rates for “poor outcome” are reported 
when outcome is defined as non-recovery of psychosis, with studies reporting an 
average estimate of about 79% [range 58% - 99%] in the short-term (2 years of follow 
up or less), 82% [range 76% -86%] within the first 3 to 5 years of their illness and 72% 
in the long-term (more than 5 years following the onset). Those estimates also implicate 
that the prevalence rates of recovery in the early stage may not improve substantially 
following the first few years of the illness. Similarly, a meta-analysis in patients with 
established schizophrenia reported that only about 14% of patients would meet the 
criteria for recovery at follow up (Jääskeläinen et al., 2012). This study (Jääskeläinen et 
al., 2012) also reported that the rates of recovery were not significantly different in FEP 
patients when compared to non-FEP patients (17% vs. 11%) and that there was no 
significant increase in rates of recovery over the time of the illness course, supporting 
the view that there might be an initial early phase in which the rates raise and then 
stabilize. These rather pessimistic estimates of outcome may reflect the strict definition 
of recovery, since recovery is only achieved by those who meet the criteria for both 
symptomatic remission as well as functional remission (Chang et al., 2012; Verma, 
Subramaniam, Abdin, Poon, & Chong, 2012; Wunderink, Sytema, Nienhuis, & 
Wiersma, 2009). Considering that the rates for symptomatic recovery are usually much 
higher compared to functional recovery (77% vs. 29% at 6-months follow up) (Tohen et 
al., 2000) and only moderate overlap between functional and symptomatic remission 
(Verma et al., 2012; Wunderink et al., 2009), the low rates of recovery as reported by 
numerous studies seem plausible. In this context, it is important to distinguish between 
the different symptom dimensions, i.e. positive and negative symptomatology. For 
instance, whereas positive symptoms generally improve in most cases in response to 
antipsychotic medication (Jean Addington et al., 2003; Baeza et al., 2009; Goldberg et 
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al., 2007; González-Ortega et al., 2013; Hinton et al., 2007; Jahshan, Heaton, Golshan, 
& Cadenhead, 2010; Kopala et al., 2006; Leeson, Harrison, Ron, Barnes, & Joyce, 
2012; Opjordsmoen et al., 2010; Prikryl et al., 2012; Renwick et al., 2015; Simonsen et 
al., 2007; Szymanski et al., 1996), the absence of changes in negative symptoms has 
often been reported (Baeza et al., 2009; Goldberg et al., 2007; González-Ortega et al., 
2013; Hinton et al., 2007; Renwick et al., 2015; Szymanski et al., 1996), which reflects 
a major challenge in the treatment of FEP. Despite this apparent reduction in positive 
symptoms from onset to follow up, it seems also crucial to distinguish between different 
stages of the illness. For instance, in accordance with the critical period hypothesis, 
improvements in psychotic symptoms were present within 3 months following the 
onset, with only limited further improvements up to 1 year follow up (Simonsen et al., 
2007). Similarly, the greatest improvement within 1 year following the onset in positive 
symptoms occurred within the first 6 months, although improvement afterwards was 
still significant (Jean Addington et al., 2003). Other evidence indicated that 
improvement in positive symptomatology occurred only in the first 6 months of the 
treatment in FEP patients and that no significant change occurred subsequently within 
the two years following the onset (Szymanski et al., 1996). Finally, it was reported that 
the degree of improvement in positive symptomatology was greater in the earlier 
(within 2 years following onset) than the later stages (5 years following onset) 
(González-Ortega et al., 2013) of illness. Finally, despite the symptomatic 
improvement, psychotic disorders are usually characterised by an episodic course, 
including high proportion of patients experiencing a relapse in the first two years 
following onset and/or non-remission of symptoms (cf. Figure 1.). 
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Note. Summary of prevalence rates reported by follow up studies in FEP patients (cf. 






Functional outcome has been assessed in different ways, including based on 
more objective criteria such as employment [e.g. functional recovery if in paid 
employment or enrolment in education (Fowler et al., 2009)] and/or in terms of change 
over time when assessed based on rating scales such as the GAF, SOFAS or PAS (cf. 
above, Table of abbreviations). A meta-analysis found that about 42% of FEP patients 
achieved functional recovery following the onset (Menezes et al., 2006). As shown in 
Figure 1., the majority (~60%-70%) of FEP patients did not achieve functional 
remission and remained impaired in their social functioning in both the early stages and 
the later stages of the illness. In accordance with the critical period hypothesis, 
functional improvement was found be greatest within the first 3 months following the 
onset and only little further improvements occurred up to the 1 year follow up 
(Simonsen et al., 2007). Similarly, it was reported that the degree of improvement was 
greater in the early stage of illness (2-year follow up) than in the later stages (5-year 
follow up) (González-Ortega et al., 2013). Assessing the trajectories of social disability, 
it was reported that the majority of FEP patients (66%) were characterised by high 
levels of disability at onset that did not improve over the 1-year follow up (Hodgekins et 
al., 2015). Level of function is also an important part of the concept of recovery in 
psychosis. For instance, while out of those who were classified as functionally remitted, 
73% of those also met the criteria for recovery, while in those classified as 
symptomatically remitted the proportion of individuals that achieved recovery was 
much lower (37%) (Wunderink et al., 2009). Other evidence showed that, at a 2-year 
follow up, symptomatic remission was achieved by 54% and functional remission by 
58%, while only a subset (29%) met the criteria for both symptomatic and functional 
remission (Verma et al., 2012). First, this may indicate that persistent functional 
disability can occur, even in the presence of symptom remission, but also that both 
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outcomes only partly overlap and, hence, somewhat different treatment approaches may 
need to be considered.  
The costs of loss of productivity due to impairments in functioning such as 
unemployment or premature mortality have been estimated to be around 3.4 billion 
pounds (Mangalore & Knapp, 2007). As shown in Figure 1., unemployment rates are on 
average around 50% or more in FEP patients throughout the different stages following 
the onset. A meta-analysis reported that about 39% of FEP patients were not in 
employment at follow up (Menezes et al., 2006). For instance, although a high 
proportion of  unemployed patients at onset were in employment after 1 year of follow 
up (37%), there was a substantial proportion of patients that was in employment at the 
onset of illness and became unemployed throughout the follow up (23%) (J Addington, 
Young, & Addington, 2003).  
The rates of completed suicides following onset are high and average prevalence 
rate range 2%-6% as found in follow up studies (cf. Figure 1.), which is similar to 
estimates reported by a meta-analysis (6%) (Palmer, Pankratz, & Bostwick, 2005). 
However, the rates of attempted suicides are higher (11%-22%) (cf. Figure 1.) and it 
has been reported that suicidal behaviour is particularly frequent in the early phase of 
the onset (Ayesa-Arriola et al., 2015; Mitter, Subramaniam, Abdin, Poon, & Verma, 
2013; H Verdoux et al., 2001) or just before the onset of the illness (Ayesa-Arriola et 
al., 2015). Previous research indicate that several predictors may increase the risk for 
suicide, such as presence of depressive symptoms, male sex level of education, higher 
positive symptomatology, presence of manic symptoms, unemployment at onset and 
level of insight (Dutta, Murray, Allardyce, Jones, & Boydell, 2011; Geoffroy & 
Turecki; Sönmez, Romm, Andreasssen, Melle, & Røssberg, 2013). The high rates of 
suicidal behaviour also reflect the presence of depressive symptoms in FEP patient, 
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which frequently co-occur during the acute and early phases following the onset of 
psychosis (D. Addington, Addington, & Patten, 1998; González-Ortega et al., 2013; 
Sönmez et al., 2013) but also when assessed at later stages (e.g. 5-year follow up 
(Shepherd et al., 1989). Encouragingly, depression symptomatology usually improves 
following the onset to improve (González-Ortega et al., 2013; Shepherd et al., 1989) 
and only few cases develop depression following the onset (Sönmez et al., 2013). 
Nevertheless, it has been proposed that the issue of risk factors of suicide/depression 
deserves greater attention in this population, particularly the early phase, in order to 
develop better prevention strategies (Geoffroy & Turecki, 2016). 
Other studies have investigated cognitive outcome in FEP patients. Cognitive 
deficits are considered as one of the core features of psychotic disorders (Kahn & 
Keefe, 2013). It has been suggested that neurocognitive function is an important 
dimension to be included in operational criteria for recovery (Wunderink et al., 2009) 
and it may also be considered as a correlate of functioning, given its association with 
the level of functioning in FEP patients (Allott, Liu, Proffitt, & Killackey, 2011; 
González-Ortega et al., 2013). Currently, there is fairly consistent evidence that 
cognitive deficits precede the onset of the illness. For instance, meta-analyses reported 
that cognitive impairments significantly predicted onset of psychosis, which was present 
in a dose-response fashion (Khandaker, Barnett, White, & Jones, 2011) and already 
present years prior to the onset (Dickson, Laurens, Cullen, & Hodgins, 2012).  A recent 
meta-analysis investigating cognitive functioning in FEP patients reported medium to 
large deficits that were present in most domains of cognitive functioning when 
compared to healthy controls, especially in domains such as memory and verbal 
learning, executive functioning, attention and motor skills (Mesholam-Gately, Giuliano, 
Goff, Faraone, & Seidman, 2009). Looking at change over time in patients with 
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established schizophrenia, a meta-analysis found that cognitive function generally 
improves (most robustly in the domain of verbal and visual memory) or stays stable 
over time (Szöke et al., 2008), while progressive impairment is unlikely to occur. 
However, it needs to be considered that identified improvements may reflect a practice 
effect due to the repeated measures design. For instance, one study reported that the 
performance in many of the memory tests administered (9 out of 16) improved over 
time, but that this effect disappeared when controlling for practise effects (by control 
group of healthy controls) (Goldberg et al., 2007). Similarly, studies that followed up 
patients with a first episode psychosis mainly reported that there are no major changes 
over time in neurocognitive function in a 10-year follow up (Hoff, Svetina, Shields, 
Stewart, & DeLisi, 2005). In accordance, a recent systematic review in FEP patients 
concluded that cognitive function can be expected to remain stable following the onset 
(Bozikas & Andreou, 2011). Other evidence reported that FEP patients significantly 
improved in their neurological soft signs (NSS) over time (Prikryl et al., 2012). 
However, despite greater improvements in NSS in FEP patients when compared to 
healthy controls, patients assessed at follow up still exhibited greater impairments in 
NSS when compared to healthy subjects (Mayoral et al., 2012), indicating that 
achievement to a normal level of cognition present in the general population is unlikely 
to occur despite treatment. Nevertheless, although some studies have found that FEP 
patients performed worse in some cognitive domains at follow up (Albus et al., 2002; 
Jahshan et al., 2010), overall there is little evidence to suggest that cognitive function 
deteriorates following the onset, which is somewhat opposed to the theory of psychosis 
as a neurodegenerative disorder. 
To summarize, several outcome measures have been employed when assessing 
“good” and “poor” outcome and the reported prevalence rates are likely to vary 
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depending on the specific outcome definition. Similarly, prediction models for the 
different outcomes are likely to yield more heterogeneous results due to the variety of 
outcome measures. Nevertheless, a recently published comprehensive review on 
predictors for outcome in FEP identified, several predictors have been identified that 
relatively consistently predicted outcome (clinical, functional, cognitive), including 
premorbid difficulties (premorbid adjustment, history of developmental disorder), 
longer duration of untreated psychosis (DUP), and greater baseline symptom severity 
(especially negative symptomatology) (Díaz-Caneja et al., 2015).  
In the following section I will focus on the main outcome measure employed in 
my thesis – namely relapse of psychosis –, which is one of most commonly employed 
outcome measures in follow up studies in FEP patients and I will provide an overview 
of factors that have been investigated in the context of risk factors for relapse following 

















1.3 RELAPSE IN FIRST EPISODE PSYCHOSIS 
1.3.1 DEFINITION 
Relapse is defined as the recurrence of psychotic symptoms, which are of 
clinical significance and follow a period of partial or full remission of symptoms (J. F. 
M. Gleeson, M. Alvarez-Jimenez, S. M. Cotton, A. G. Parker, & S. Hetrick, 2010). This 
outcome (relapse as exacerbation of psychotic symptoms) is the most commonly used in 
epidemiological research in psychosis (Olivares, Sermon, Hemels, & Schreiner, 2013). 
When assessing relapse of psychosis, a range of different approaches have been 
employed. To illustrate, relapse definitions usually fall into one of the broader 
categories, such as relapse of symptoms requiring hospital admission, relapse of 
symptoms based on standardized rating scales, relapse of symptoms based on 
screenings from medical records or clinical judgement. Although numerous studies have 
assessed relapse using standardized and validated scales such as Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987), Clinical Global Impression scale (CGI) 
(W Guy, 1976) or Brief Psychiatric Rating Scale (BPRS) (Nuechterlein et al., 2006), 
one problem that occurs is the apparent heterogeneity in the way relapse is 
operationalised, making comparisons across studies difficult (cf. below Table 2.). 
Similarly, in a recent review, it was outlined that studies have also lacked the use of 
standardized or validated observer measures for assessing relapse and that important 
aspects of it were not captured by how relapse was operationalized in many studies (J. 
F. Gleeson, M. Alvarez-Jimenez, S. M. Cotton, A. G. Parker, & S. Hetrick, 2010). In 
fact, the lack of a standardized measure for outcome such as relapse has been criticised 
in a recent review on outcome in FEP, since this variation in relapse definitions may 
have contributed to the inconsistencies in reporting across different studies (Díaz-
Caneja et al., 2015). 
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50% increase in the positive scale score (PANSS), sustained for at least 1 week 













PANSS positive subscale score >4 (Bergé et al., 2016) 
5 Rating of moderately/severe for at least 1 week PANSS positive  or at least two on 
PANSS negative following a period of improvements (PANSS no greater than 




Two-point increase and a score of six or seven on the TSR AND a score of six or 
seven on one of the key psychotic symptom items on the BPRS (Morken, Widen, 








Having at least one BPRS psychotic item scored > 5 or at least two BPRS 




Increase in the PANSS  > 10, CGI-Change score ≥ 6, and decrease in GAF score > 
20 between 2 visits (Gaebel et al., 2010) 
10 Relapse based on PPHS (emergence or exacerbation of positive, negative or 
disorganised symptoms following a period of remission of at least 30 days) 




Increase in PANSS positive score >10 and a CGI- Change score > 6 and a decrease 




(1) a rating of 6 or 7 on any items of the BPRS positive subscale for at least two 
weeks or (2) a rating of 5 plus a 2 point increase on one of the other two items 




A score of 4 (moderate) or higher on PANSS following a period of 30 days without 




A discrete period of symptomatology characterized by psychotic signs and 
symptoms of hallucinations, delusions, cognitive disorganization, marked 
psychomotor disturbance, and/or grossly inappropriate behaviour (based on LCS) 
(Alvarez-Jimenez et al., 2011) 
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Furthermore, there is only moderate overlap across different types of relapse 
definitions such as hospitalisation and those based on symptom rating scales, since only 
a subset of relapsing patients requires hospitalisation (Almond, Knapp, Francois, 
Toumi, & Brugha, 2004; Stefan Leucht et al., 2012). As shown in Figure 2., estimates 
of relapse are higher when assessed with symptom scores and/or clinical judgement 
than those estimates that rely on hospitalisation data as indicated by different follow up 
studies [e.g. 29% for hospitalisation vs. 35% rating scale based at 2-year follow up, 
43% vs. 72% at 5-year follow up, 68% vs. 74% at more than 5-year follow up, cf. 
Figure 1., above]. Similarly, out of all patients that were considered as relapsing based 
on rating scales (change in BPRS), only a subset was hospitalised as a result, with 
reported frequencies that range from 13% (Gitlin et al., 2001) to 35% (Üçok et al., 
2006). This may illustrate that symptom scales also capture less severe episodes that do 
not require hospital admission and can be treated by community mental health services. 
Although relapse defined as admission to the psychiatric hospital may be regarded as a 
rather conservative measure that may not capture all visible exacerbations of psychotic 
symptoms, relapse definitions based on rating scales may result in too inclusive criteria, 
leading to over-estimation and non-comparability of the relapse rates reported (Suzuki 
et al., 2014). Furthermore, relapse as admission to the hospital following the onset of 
illness remains the most commonly employed operationalization (J. F. M. Gleeson et 
al., 2010). This operationalization has been suggested as a valid measure for relapse (D. 
E. Addington, McKenzie, & Wang, 2012) that is universally applicable (Burns, 2007) 
and captures high rates of relapse that are based on clinical judgement (D. E. 
Addington, Patten, McKenzie, & Addington, 2013; Almond et al., 2004). Although the 
threshold for requiring hospital admission may vary depending on the setting, it 
represents a concrete measure that can be assessed in most if not all health care systems, 
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is fairly robust and an intuitively interpretable outcome measure. For this reason, 
relapse defined as hospitalisation has been proposed as a valuable outcome measure in 
RCT’s (Burns, 2007) that should be reported in all future RCT’s to facilitate 
comparability (Stefan Leucht et al., 2012). This reflects its advantage of high face 
validity (i.e. clinicians have a sense of when patients should be admitted and what this 
would mean for the individual) and accessibility for economic analysis. It may be worth 
noting that the definition of relapse does not necessarily take into account those 
individuals who suffer from a continuous illness course. For instance, even if a patient 
is considered as non-relapsing, the person may still experience a continuous course of 
illness. However, majority of patients are characterised by a relapsing rather than 
continuous course of illness (cf. Table 1. above). To illustrate, when classified into 
different groups, a 5-year follow up reported that out of the whole sample 78% relapsed, 
8% had a continuous course and only 14% did not belong to any of those groups 
(Andreasen et al., 2013). On the other hand, this also indicates that only a small 
proportion of patients experience a single psychotic episode (SPE = non-relapsing and 
non-continuous illness course). In another follow up study (7.5 years), the prevalence of 











Figure 2. Proportion of FEP patients surviving without relapse/readmission during 
follow up  
 
Note. Graph taken from R. J. Drake et al. (2007): Rates of readmission and relapse 
(exacerbation of positive symptoms lasting at least two weeks, leading to a change in 
management, including increase in medication and/or hospitalisation)  in 18 months 
following the onset. 
 
 
1.3.2 RELAPSE CHARACTERISTICS WITHIN THE COURSE OF PSYCHOSIS 
Discouragingly, the occurrence of a relapse is common following the onset of 
psychosis, e.g. upto 50% of first episode psychosis patients experience a relapse that 
results in hospital admission within the first 2 years of illness, with the risk increasing to 
over 80% by the 8th year as reported by a recent meta-analysis (M Alvarez-Jimenez et 
al., 2012). Relapse rates are high in the early critical periods of the course of illness, 
with average rates of 29% (when defined as hospital admission) and 35% (when defined 
based on rating scales) within the first two years following onset (cf. Figure 1.above). 
In accordance with the critical period hypothesis (Birchwood et al., 1997), studies that 
assessed relapse rates in yearly intervals following onset reported that most relapses 
occurred within the first and second year in a 3-year follow up (D. Addington et al., 
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2010) and 5-year follow ups (Patel R et al., 2016; Wiersma, Nienhuis, Slooff, & Giel, 
1998). In this context, it has also been reported that the early phases of psychotic illness 
are characterised by multiple episodes of short duration, and whilst frequency of 
episodes decrease their duration lengthens as the illness progresses (Andreasen et al., 
2013) (cf. below Figure 3.).   
 
Figure 3. Plot of Duration of Relapse 
 
Note. From Andreasen et al. (2013): Scatterplot depicts the pattern of symptomatic 
relapse in schizophrenia patients during the longitudinal follow-up period. Duration of 
relapse is plotted against each interscan interval (years). Early phases of the illness are 
characterized by multiple relapses of shorter durations. 
 
Average time until a first rehospitalisation occurs is relatively short, which is 
estimated to occur on average about 5 months following the hospitalisation for the first 
episode (Üçok et al., 2006). Average length of time spent in a psychotic episode (based 
on PANSS) has been estimated to be about 8 months within the first 2 years following 
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onset of psychosis (Holthausen et al., 2007). Time spent in hospital following onset in a 
5-year follow up was on average 6 months (Shepherd et al., 1989). Similarly, it has been 
reported that over the course of a 9-year follow up in FEP patients, they spend a 
substantial amount of this period in a relapse episode (14% of the time), even though 
the majority of this time was spent in remission (84% of the time) (Girgis et al., 2011). 
As shown in Table 3. (cf. below), not only do a high proportion of patients experience at 
least one relapse, but a substantial proportion of them is at risk to experience multiple 
relapses, including 2 (10% % - 36%), 3 (6% - 10%), 4 (4%-5%) and even more than 5 
relapse (2%-22%) following onset.  
 
Table 3. Prevalence rates for number of relapses following the onset 
Study FU N 0 R 1 R 2 R  3 R 4 R > 5 R 
Chi et al. (2016) 10 Y 808 30% 20% 13% 10% 5% 22% 
Thara et al. (1994) 10 Y 76 17% 39% 36% 2% 
Eaton et al. (1992) 16 Y 1150 50% 19% 10% 6% 4% 11% 
E. Y.-H. Chen et al. (2005) 3 Y 93 60% 27% 13% 
Shepherd et al. (1989) 5 Y 49 45% 29% 17% 9% 
Note. FU = Number of years (Y) of follow up; N = Number of subjects; R = Number of 
relapses during the follow up 
 
There is also consistent evidence that those who experienced a relapse are at 
higher risk for a subsequent relapse (Ascher-Svanum et al., 2010; Carpenter & Strauss, 
1991; Chabungbam et al., 2007; Doering et al., 1998; Heider, Kilian, Matschinger, 
Toumi, & Angermeyer, 2004; Kam, Singh, & Upthegrove, 2015; San, Bernardo, 
Gómez, & Peña, 2013a). To illustrate, D. Robinson et al. (1999) reported that about 
82% of FEP patients experience a relapsed following the onset. In this first-relapse 
group, 78% had a second relapse and in the second-relapse group about 86% showed a 
third relapse. Another report found that the emergence of one relapse during the period 
of mental health care following the onset was predictive of further relapses following 
discharge from the services (Kam et al., 2015). As illustrated in Figure 4., it has been 
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reported that each additional relapse increase the duration of time until remission of the 
episode occurs. To illustrate, (Lieberman et al., 1995) reported that in FEP patients, the 
mean duration until remission following antipsychotic treatment was about 40 days, 
while this duration increased to a mean of about 60 days following the second episode 
and increased further (more than 120 days until remission) following the third episode. 
In accordance, it has also been reported that relapsing patients with established 
schizophrenia had a shorter time since the most recent relapse when compared to non-
relapsing patients (Almond et al., 2004). Hence, patients with recurrent episodes are 
more likely to develop residual symptoms that only partially respond to the available 
treatment (Lieberman et al., 1998), again supporting the view that multiple relapses can 
be seen as a poor prognostic factor linked to disease progression to the worse.  Number 
of relapse has also been linked to poorer cognitive functioning (Eberhard, Riley, & 
Levander, 2003), which is consistent with the observation that a relapsing course of 
illness (number of hospitalisations) is associated with loss of grey matter density in the 
frontal lobe (van Haren et al., 2007). Although a recent study failed to replicate the 
association between brain volume change and number of relapse, they found an 
association between duration of relapse and frontal lobe tissue loss that was independent 











Figure 4. Psychotic episodes and time to remission!
!
Note. Duration of treatment until the achievement of remission of symptoms during the 
different episodes of psychosis [from Lieberman et al. (1995), modified by Müller 
(2004)] 
 
1.3.3 COSTS OF RELAPSE  
The experience of a hospital admission due to a psychotic relapse is an event 
that has a significant impact on the lives of both patients and families. In terms of 
economic costs, hospitalisation is suggested to be one of the most costly treatments. For 
instance, it has significant implication for the utilisation of healthcare resources, with 
about 4 times the average estimated service costs in patients with psychosis that relapse, 
compared to those that do not (over a 6-month period) (Knapp, Locklear, & Järbrink, 
2009a). Similarly, in other studies conducted in the UK that looked at relapse defined as 
re-emergence of psychotic symptoms in patients with established schizophrenia, it was 
suggested that service costs were about 2 to 4-times higher in in those who relapsed 
when compared to non-relapsing patients within a 6-months follow up period (Almond 
et al., 2004) or a 3-year follow up (Hong et al., 2009). In those studies, most of the cost 
difference was related to in-patient days (Almond et al., 2004) or to the event of 
hospitalisation (Hong et al., 2009). In the US, patients with established schizophrenia 
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who relapsed in a 6-months follow up were about 3-times more costly than those who 
did not (Atwood & Mackie, 2010). It has also been reported that the presence of 
psychosis (in comparison to absence of psychosis) in mentally ill patients admitted to 
the psychiatric hospital significantly increased the costs spent per patient (Curto, 
Masters, Girardi, Baldessarini, & Centorrino, 2016). Finally, relapsing FEP patients are 
more likely to be unemployed in the year following the onset than non-relapsing 
patients (Schennach et al., 2012; Üçok et al., 2006), for which reason this event results 
in indirect costs for society due to loss of productivity. 
Despite the high economic costs associated with hospitalisation, there are some 
concerns that this outcome may not necessarily represent a patient-centered outcome 
(Burns, 2007). However, different lines of evidence implicate relapse as an event that 
crucially impacts on the patient’s life and illness course. It has been consistently 
implicated as a maker for increased illness severity (D. E. Addington et al., 2012; 
Almond et al., 2004; Chabungbam et al., 2007), a chronic illness course (Köhler, 
Petersen, Benros, Mors, & Gasse, 2016) , lower quality of life (D. E. Addington et al., 
2012; Almond et al., 2004; Pencer, Addington, & Addington, 2005) and lower level of 
functioning (Chabungbam et al., 2007; Kam et al., 2015; Üçok et al., 2006) in patients 
with psychosis. Furthermore, other evidence indicated that those who relapsed were 
more likely to be depressed (Atwood & Mackie, 2010), characterised by higher rates of 
suicide of suicidal ideation (Almond et al., 2004; Kazadi, Moosa, & Jeenah, 2008a) and 
higher number of suicide attempts (Togay, Noyan, Tasdelen, & Ucok, 2015). In terms 
of patient’s experiences linked to the event of hospitalisation as a results of a relapse, it 
was reported that young people with a first episode perceive described this as a 
distressing, confusing and overwhelming experience (Fenton et al., 2014).  !
!
1.3.4 PREDICTORS FOR RELAPSE IN FIRST EPISODE PSYCHOSIS 
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A number of predictors have been identified to impact on risk of relapse 
following the onset, some of which are fixed (e.g. gender, mode of onset, age of onset 
etc.) and some of which are potentially modifiable following the presentation for the 
first episode of psychosis, i.e. amendable for intervention. The following section will 
therefore focus on both types of predictors (time-invariant vs. time-variant) in 
separation. 
1.3.2.1 TIME-INVARIANT  
Several predictors have been identified as predictors for relapse that reflect 
stable, i.e. unchangeable factors that are not amendable by treatment. Knowledge on this 
issue is important since it helps to identify individuals that may be at a particular risk 
for relapse, e.g. based on their onset and premorbid characteristics (e.g. premorbid 
adjustment, DUP when presenting with the first episode, age of onset of illness) or their 
biological profile (genetic code, gender, family history of mental illness, ethnicity).  
Overall, evidence with regard to onset demographics and risk of relapse is relatively 
inconsistent and studies implicate that onset characteristics are generally not very 
predictive with regard to relapse (Wiersma et al., 1998).  
First, a recent meta-analysis further indicated that out of those time-invariant 
factors that are commonly assessed in studies, premorbid adjustment stood out as the 
most consistent predictor for relapse (M Alvarez-Jimenez et al., 2012). For instance, 
poor premorbid adjustment was significantly related to risk of relapse or earlier relapses 
in a 1-year follow up (Levy, Pawliuk, Joober, Abadi, & Malla, 2012; Üçok et al., 2006), 
a 5-year follow up (D. Robinson et al., 1999) and an 8-year follow up (Alvarez-Jimenez 
et al., 2011). To the contrary, in other studies this factor was not predictive of relapse in 
a 2-year follow up (A Malla et al., 2008) or a 3 year follow up (Caseiro et al., 2012) as 
well as length of relapses throughout a 5-year follow up period (Lenior et al., 2005). 
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Other evidence indicated that the effect of premorbid adjustment on symptomatic 
improvement following the onset of illness was stronger in the early than later stages of 
psychosis (R. Drake et al., 2016), which would be in accordance with the critical period 
hypothesis. It has also been reported that the effect depends on how relapse is defined, 
since there was an effect of premorbid adjustment on relapse if defined based on 
symptom rating scales but not if defined as change in medication due to worsening of 
symptoms (Levy et al., 2012).  
Second, the impact of DUP has been investigated in studies evaluating 
prediction models for outcome in FEP patients. Some studies reported that a longer 
DUP predicted time until a rehospitalisation occurred (Üçok et al., 2006) as well as risk 
of relapse following the onset (Alvarez-Jimenez et al., 2011; Wiersma et al., 1998). 
Nevertheless, the results are also conflicting with regard to risk of hospitalisation (D. 
Addington et al., 2010; T. J. Craig et al., 2000; Tarricone et al., 2014) and relapse 
(defined based on rating scales) (Caseiro et al., 2012; Levy et al., 2012; Üçok et al., 
2006). Similarly, other studies reported that DUP was not predictive of length of 
relapses throughout the follow up period (Lenior et al., 2005). Overall, DUP may to 
contribute to poorer outcome, at least in the early stages. For instance, when evidence 
was pooled together in a meta-analysis, the results suggested that DUP significantly 
predicted outcome 6-months and 1-year follow up, including symptomatology (general, 
negative, positive), remission-status, quality of life, functioning and depression/anxiety 
(Marshall et al., 2005). At 2-year follow up, DUP predicted positive symptomatology 
but was not linked to negative symptoms or functioning (Marshall et al., 2005). In 
accordance, recovery in the two years following the onset was predicted by DUP 
(Wunderink et al., 2009). 
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Other studies have looked at the effects of childhood trauma and risk of relapse, 
although there is no available evidence from follow up studies in FEP to date (Petros et 
al., in press). A recent review suggests that the accumulated evidence data is not 
consistent with regard to the effect of childhood trauma and its risk on relapse (Petros et 
al., in press), which may be related to methodological weaknesses comprised by those 
studies. Since there is good evidence attributing a contributing role to childhood trauma 
for the development of psychosis and persistence of symptomatology (Stowkowy et al., 
2016; Trotta, Murray, & Fisher, 2015), further studies are therefore needed to clear the 
picture with regard to relapse.  
Third, several other onset severity measures have been evaluated. For instance, 
some studies found that severity of baseline symptomatology (D. Addington et al., 
2010; Alvarez-Jimenez et al., 2011; Möller et al., 2002; Üçok et al., 2006), lower level 
of functioning (D. Addington et al., 2010; Gearing et al., 2009; Üçok et al., 2006), 
poorer cognition at onset (Stirling et al., 2003) and longer duration of hospitalisation at 
onset (Hui et al., 2013) significantly predicted relapse. Although these results are not 
consistent considering that replications failed to link risk of relapse to onset marker of 
illness severity, including severity of positive symptoms at onset (Alvarez-Jimenez et 
al., 2011), longer duration of hospitalisation at onset as a predictor (Alvarez-Jimenez et 
al., 2011; Hui et al., 2013) and age of onset of psychosis (D. Addington et al., 2010; 
Alvarez-Jimenez et al., 2011; Caseiro et al., 2012; Chi et al., 2016; Levy et al., 2012; A 
Malla et al., 2008; Üçok et al., 2006), IQ (Levy et al., 2012) or cognitive performance at 
onset (Brinkmeyer et al., 2008; Holthausen et al., 2007). 
When comparing the risk of relapse in those with a diagnosis of affective 
psychosis (e.g. psychotic depression, bipolar disorder) to those with non-affective 
psychosis (e.g. schizophrenia, schizoaffective disorder), studies mainly reported no 
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significant differences in risk for relapse following the onset (Bergé et al., 2016; 
Gearing et al., 2009; Levy et al., 2012; Tarricone et al., 2014). Other studies suggest 
that the risk of relapse may depend on the diagnosis. For instance, there is evidence that 
those with a diagnosis of schizophrenia are at higher risk for relapse (Hui et al., 2013) 
and longer durations of relapse (Lenior et al., 2005) when compared to other diagnosis 
of psychosis (Hui et al., 2013). Overall, a recent meta-analysis did not find an effect of 
diagnosis on risk of relapse (M Alvarez-Jimenez et al., 2012).  
Some studies have looked at ethnicity but did not report a link to risk of relapse 
(D. Addington et al., 2010; N. Goater et al., 1999). However, in a sample of patients 
with established schizophrenia, it was reported that black ethnic minority was 
significantly linked to relapse (Almond et al., 2004). In this context, it might be 
important to consider immigration as a separate factor, since the classification based on 
ethnicity does not necessarily completely overlap with this. Problematically, the results 
are largely inconsistent in FEP patients, e.g. there is some evidence that reported a 
greater risk of relapse in those who migrated in an 8-year follow up (Alvarez-Jimenez et 
al., 2011) and evidence that migration status was not linked to the number of 
hospitalisations in a 2-year follow up (Abdel-Baki, Ouellet-Plamondon, Medrano, 
Nicole, & Rousseau, 2015).  
So far there is no consistent evidence with regard to the effect of gender. For 
instance, while some studies reported an increased risk for women to relapse (Gearing et 
al., 2009; Parker & Hadzi-Pavlovic, 1995), the majority of studies did not report an 
effect of gender for risk of relapse (D. Addington et al., 2010; Chi et al., 2016; Levy et 
al., 2012; A Malla et al., 2008; Tarricone et al., 2014; Wiersma et al., 1998) or time 
until a relapse occurred (Lenior et al., 2005). Only one study published to date 
implicated male gender as a risk factor for relapse (Üçok et al., 2006).  
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Finally, the current evidence is not in support of an association between family 
history of (any) mental illness and risk of relapse in FEP patients (Alvarez-Jimenez et 
al., 2011; Caseiro et al., 2012; Gearing et al., 2009). 
To summarise, the relationship between premorbid and onset clinical and social 
factors and risk of relapse is complicated and inconsistencies across studies are 
common. Nevertheless, the most frequently identified risk factors for relapse seem to 
more premorbid illness characteristics such as longer DUP or premorbid adjustment. 
This is in line with a recent review on outcome, in which it was reported that several 
predictors relatively consistently predicted outcome (clinical, functional, cognitive), 
including premorbid difficulties (premorbid adjustment, history of developmental 
disorder) longer DUP, and greater baseline symptom severity (especially negative 
symptomatology (Díaz-Caneja et al., 2015). Evidence with regard to other factors such 
as gender, diagnosis, family history of mental illness or ethnicity is less clear. 
Therefore, further research in larger samples of FEP patients that include multiple risk 






The identification of treatment and environmental factors that have an effect on 
risk of relapse and are potentially amenable to change would inform public health 
policies and would aid to the development of novel therapies targeting these factors. 
First, it is now well established that antipsychotic drug treatments is effective in 
reducing relapse rates in patients with psychosis (Stefan Leucht et al., 2003; Stefan 
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Leucht et al., 2012). Although latter meta-analysis revealed that new generation 
antipsychotics were more effective in preventing relapse when compared to the 
conventional antipsychotics, this finding may relate to differences in adherence between 
patients treated with the two types of antipsychotics (Stefan Leucht et al., 2003). 
Subsequent evidence in FEP samples is rather mixed, i.e. studies reported either a 
higher risk related to typical antipsychotic medication (Üçok et al., 2006) or did not 
report risk differences between patients taking atypical and patients taking typical 
antipsychotic medication (Gearing et al., 2009). Clozapine was identified as the most 
effective medication in preventing relapse in FEP patients (Tiihonen et al., 2011) and 
those with established psychosis (Haro et al., 2006). Interestingly, the effect of 
antipsychotic medication appears to be more effective in preventing relapse in the early 
stage of the illness (1 year following the onset) than at the later stage of the illness 
(Hogarty, 1993), which is in support of the critical period hypothesis. Furthermore, 
medication discontinuation has been linked to relapse (Hirsch et al., 1996; D. Robinson 
et al., 1999), which was also reported by a recent study that showed 1-year relapse rate 
of 79% in those who discontinued treatment one year following the onset versus 41% in 
those who continued treatment (E. Y. Chen et al., 2010). Other studies reported that a 
poor response to antipsychotic treatment (indexed by a high number of medications 
prescribed following the onset) significantly predicted relapse in FEP (Gearing et al., 
2009; Patel R et al., 2016). Despite the established effect of the maintenance/non-
maintenance, prescription/non-prescription and response/non-response to antipsychotic 
medication in predicting relapse, many studies have linked medication non-adherence to 
relapse (Barbeito et al., 2013; Caseiro et al., 2012; Coldham, Addington, & Addington, 
2002; Gearing et al., 2009; Michele Hill et al., 2010; Hui et al., 2013; Martin Lambert et 
al., 2010; Levy et al., 2012; Morken et al., 2008; Üçok et al., 2006; H Verdoux et al., 
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2000) and involuntary readmission (H Verdoux et al., 2000) and there are only few 
studies that are not in support of this (Favre, Huguelet, Vogel, & Gonzalez, 1997; A 
Malla et al., 2008; Parker & Hadzi-Pavlovic, 1995). In fact, medication non-adherence 
has been reported to be the strongest predictor for relapse in multifactorial prediction 
models (Caseiro et al., 2012). Other relapse-related outcomes that were also found to be 
linked to medication non-adherence included days spent in hospital, number of 
hospitalisations and  days under section (Morken et al., 2008). As a matter of fact, 
medication non-adherence therefore reflects a major problem in clinical practise, since 
the proportion of patient that become non-adherent following the onset is substantial (cf. 
Figure 1., e.g. 37% non-adherence in patients followed up within the first 2 year of the 
illness, 29% in those followed up between 2 to 5 years and about 49% in those followed 
up for more than 5 years). Estimates from systematic reviews indicate that an average of 
26% of patients with psychosis are not adherent (Nose, Barbui, & Tansella, 2003), 
although a recent review concluded that rates vary greatly (reported rates between 47% 
and 95%) across studies (Sendt, Tracy, & Bhattacharyya, 2015). To illustrate, more than 
60% of FEP patients had at least one or more gaps in their antipsychotic medication use 
in one year following the discharge for their first episode (Mojtabai et al., 2002). 
Despite the strong effects of medication non-adherence, relapse rates in fully adherence 
FEP patients are still relatively high within the first year (about 22%) (Levy et al., 2012) 
or in the three year following the onset (about 36%) (E. Y.-H. Chen et al., 2005), 
indicating that non-adherence alone cannot fully explain the risk of relapse in medicated 
patients. In this context, another factor usually linked to medication adherence is insight 
into the illness (Lacro, Dunn, Dolder, Leckband, & Jeste, 2002). This has been found to 
increase the risk of relapse (Bergé et al., 2016; R. J. Drake et al., 2007), although not in 
all studies are in support of the link between relapse and insight (Caseiro et al., 2012) or 
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attitude towards medication and relapse (R. J. Drake et al., 2007). Overall, it can be 
summed up that medical treatment is a crucial determinant for outcome defined as 
relapse of psychosis, and several factors may modulate its effects, such as the prescribed 
type, timing of discontinuation, treatment response, a patient’s adherence and the stage 
of illness when the treatments is started. 
Second, psychosocial factors have been suggested to impact on the risk of 
relapse in FEP patients.  With regard to the family environment, those exposed to high 
Expressed Emotions (EE) were more likely to relapse (Barrelet, Ferrero, Szigethy, 
Giddey, & Pellizzer, 1990), which is consistent with what has been found in samples of 
patients with established schizophrenia (Butzlaff & Hooley, 1998b). This is also in line 
with evidence that showed that psychoeducational family interventions were able to 
reduce rehospitalisation rates in schizophrenia (non-FEP) by reducing family burden, 
changing EE behavior from high to low, improving compliance, quality of life and 
social adjustment (Pitschel-Walz, Leucht, Bäuml, Kissling, & Engel, 2004). However, it 
has also been reported that parental expressed EE did not predict lengths of relapse in a 
5-year follow up (Lenior et al., 2005). Another study reported that number of 
rehospitalisation was significantly predicted by the level of social support, independent 
from potential confounders such as DUP, premorbid adjustment and ago of onset 
(Norman et al., 2005). Similarly, those FEP patients that experienced a decrease in their 
level of social support following the onset were at higher risk for relapse compared to 
those who didn’t (Gearing et al., 2009). However, in this context it appears difficult to 
disentangle as to whether the increased risk actually reflects a lack of social support per 
se or whether those who are characterized by a more severe illness course (i.e. relapsing 
course) are less socially skilled and therefore appear to have lower levels of social 
support. Considering the relationship between exposure to adult life events and the 
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subsequent development of FEP (Beards et al., 2013), other lines of evidence have 
looked at life events as a potential risk factor relapse, indicating that recent life-stress 
was a significant predictor for relapse in patients with established schizophrenia (Hirsch 
et al., 1996; Hultman, Wieselgren, & Öhman, 1997; AK Malla, Cortese, Shaw, & 
Ginsberg, 1990). In accordance with the critical period hypothesis, it was found that 
number of life events prior to rehospitalisation were more a contributing factor in the 
early stages of the illness (less than 3 episodes) than at a later stage (more than 3 
episodes) (Castine, Meador-Woodruff, & Dalack, 1998). 
Third, an important factor that has relatively consistently been linked to relapse 
is substance use following the onset of the illness. The most commonly abused 
substances in patients with psychosis include legal substance as alcohol and cigarettes 
or illicit drugs such as cannabis, stimulants and opioids (Cooper et al., 2012; Kivimies 
et al., 2016; Van Mastrigt, Addington, & Addington, 2004). Studies looking at the 
effects of substance use in FEP have applied different parameters, i.e. they may 
classified user into those with any substance use (including legal and illegal), they 
distinguished between legal and illegal drugs of abuse, or they investigated the effect of 
specific drugs separately. The main problem inherent to this approach is that there is 
usually a high overlap across the substances that are used (Arndt, Tyrrell, Flaum, & 
Andreasen, 1992), e.g. there is a substantial proportion of SUD patients diagnosed 
polysubstance abuse (A Malla et al., 2008), for which reason it is often difficult to 
identify groups of patients that can be classified as users of “cannabis only” , “cigarettes 
only” or “alcohol only”. For instance, investigating the effect of lifetime SUD as a 
predictor for relapse may not lead to valid conclusions regarding the questions as to (1) 
whether it is a specific substance in separation or the combination of multiple 
substances that may have harmful effects and (2) whether one substance is more 
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harmful than the other (Kivimies et al., 2016). The other challenge when investigating 
this issue is the change in pattern of use over time that needs to be taken into 
consideration. For instance, substance use is not a stable lifestyle characteristic, since it 
has been shown that substance use is often reduced following the onset of psychosis (M 
Lambert et al., 2005; Turkington et al., 2009). With regard to the effect on outcome, 
follow up studies reported that cessation of substance use significantly reduced the risk 
of relapse (Turkington et al., 2009) and increased the chance of achieving remission (M 
Lambert et al., 2005). Other studies are in further support of the association between 
post-onset substance use and increased risk of relapse (A Malla et al., 2008), which was 
also present in form of a dose-response relationship (D Wade et al., 2006). Although 
some studies are not in support of substance abuse predicting relapse (here defined as 
change in medication due to worsening of symptoms) (Levy et al., 2012), latter study 
found an effect of SUD on outcome when relapse was defined based on changes in 
symptom scales (Levy et al., 2012), while controlling for medication-adherence. 
Similarly, a recent meta-analysis reported that substance use discontinuation was linked 
to reduced positive symptom severity, lower levels of depression and better functioning, 
although there was no significant association with number of hospitalisations (Mullin et 
al., 2012a). However, this may reflect the methodological issue of including patients 
that are at different stages of their illness rather than a clean FEP sample. In an FEP 
sample, D Wade et al. (2006) reported an increased risk for inpatient admission for 
substance abusers, which was present for a subgroup of cannabis users and stimulant 
users but not those with AUD. Only limited evidence exists with regarding cigarette use 
and risk of relapse, a substance that came into focus only recently since studies noticed 
and increased risk for the development of psychosis and earlier onset of psychosis in 
heavy smokers (Gurillo, Jauhar, Murray, & MacCabe, 2015). Although one studies 
[48] 
 
reported that ongoing cigarette use but not former cigarette use was linked to an 
increased risk of relapse (Hui et al., 2013), this effect was not controlled for other 
substance use or cannabis use, which is problematic since cigarette use is closely related 
to substance abuse (Myers & Kelly, 2006). Nevertheless, this sample (Hui et al., 2013) 
was recruited from a catchment area in which substance abuse is less common than in 
the Western culture (e.g. only 3% of patients reported to use other substances), i.e. the 
effect is unlikely to be confounded by the use of other substances. Overall, while 
substance abuse is likely to affect outcome negatively and increases the risk for relapse, 
further studies should be conducted to investigate the substances abused in separation. 
Interestingly, there is some evidence that suggests that those patients with comorbid 
substance use are characterised by a better premorbid adjustment (Arndt et al., 1992) 
and may present with less severe negative symptomatology at onset (Jean Addington & 
Addington, 1998; Green et al., 2004). To put this in context, it has been proposed that 
substance abusing patients may represent a neurodevelopmentally less impaired 
subgroup of patients (Schoeler, Kambeitz, Behlke, Murray, & Bhattacharyya, 2015) 
(see Chapter 2.5 for a more detailed discussion).  
To summarise, while those identified factors are non-fixed (i.e. time-invariant), 
it should be pointed out that certain factors may be more easily amendable for 
intervention, including substance use or medication adherence. While robust evidence 
exists regarding the beneficial effects of medication adherence in preventing relapse, 
less is known regarding the longitudinal effects of the use and abuse of different 
substances following the onset and causality in this context has yet to be established. 
Other potential risk factors are not easily directly treatable (e.g. stressful life events). In 
those cases, intervention may try to elucidate mechanisms of actions that mediate those 
relationships such as the strengthening of coping mechanism to deal with stress or the 
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prescription of anxiolytic drugs. Identifying modifiable factors that impact on the course 
of the illness is therefore crucial in order to further provide evidence based specialized 

























2 COMPLEXITIES IN THE CANNABIS STORY  
2.1 INTRODUCTION 
The term cannabis refers to the different types of preparations derived from the 
plant Cannabis Sativa. Although the substance is known for its medical and textile use 
since ancient times (Russo et al., 2008), the recreational use of cannabis or use for 
medical purposes was rather uncommon until the 16th century but became more popular 
through medical prescribing or self-medication in the 19th and 20th century. There are 
now marked shifts in public attitudes to cannabis use and its legal standing in society in 
many countries (Benac & Caldwell, 2013; Reuter, 2010), making it to one of the most 
controversial topics debated by the public, policy makers and within the academic 
environment. In response to this, there has been a drastic increase in studies 
investigating the effects of cannabis (cf. Figure 5.), with about 13% investigating its 
neurobiological effects and approximately 27% aiming to elucidate its effects on 














Figure 5. Cannabis research: Number of publications over time 
Note. Taken from Szutorisz and Hurd (2016): Increase in research studies over recent 
decades that coincides with changes in the legalization status (~1996) and debates of 
recreational and medical marijuana use.  
* The drop in publications in the 1970s marks changes in state laws and local 
regulations banning possession or sale of cannabis and cannabis becoming a schedule I 
drug in the US 
 
The substance has now been recognized for both its toxic and therapeutic 
properties (Robin M Murray, Morrison, Henquet, & Di Forti, 2007). On the one hand 
there is evidence for its therapeutic effects for a range of pathological conditions such as 
cancer, neuropathic pain, movement disorders such as Parkinson’s and Huntington’s 
disease, multiples sclerosis, appetite stimulation and mood and anxiety disorders 
(Kumar, Chambers, & Pertwee, 2001; Whiting et al., 2015). On the other hand, there is 
now robust empirical ground to suggest that cannabis use may increase the risk for the 
development of psychiatric disorders, such as onset of psychosis (Di Forti, Vassos, 
Lynskey, Craig, & Murray, 2015; David M Fergusson, Horwood, & Ridder, 2005) and 
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its relapse (Patel R et al., 2016; Schoeler, Monk, et al., 2016; Schoeler, Petros, Di Forti, 
Klamerus, et al., 2016). Research on potential harmful and beneficial effects is crucial 
and has major public-health implications considering that cannabis remains the most 
commonly reported drug of dependence in the world after tobacco and alcohol 
(UNODC, 2014). The United Nations Office of Drugs and Crime (UNODC) reported a 
12-month prevalence rate of cannabis use of 4% in the global populations aged between 
15 to 64, corresponding to a total number of about 180 million of cannabis users 
worldwide (UNODC, 2014). In the EU, about 6%  of the population (age 15-64) used 
cannabis within one year and the rates are particularly high (12%) in young adults (age 
15-64) (EMCDDA, 2015) – e.g. the peak of the prevalence of cannabis use has been 
reported to be between the ages 20 and 24. The prevalence of cannabis use has 
increased in the last 10 years (Hasin et al., 2015), especially among young users (under 
18) there was an 18-fold increase in prevalence (Hickman, Vickerman, Macleod, 
Kirkbride, & Jones, 2007). Cannabis use disorders (CUD) are defined as a set of 
consequences related to the drug use that can include impaired control, 
social/interpersonal problems, risky and hazardous use, legal problems and 
pharmacological effects such as tolerance, withdrawal or craving (APA, 2013). The 12-
months prevalence rate of CUD is estimated to range between 2% and 5% globally 
(Hasin et al., 2015; UNODC, 2014). Given the increases in rates of cannabis use in the 
general population, the gathering of knowledge regarding its potential health risks is 
therefore of major interest for policy makers, especially in light of the current political 







2.2 CANNABIS AND THE ENDOCANNABINOID SYSTEM 
For the research community, a major milestone was the isolation of delta-9-
tetrahydrocannabinol (THC) in the 1960th by chemist Raphael Mechoulam (Mechoulam 
& Hanuš, 2000), which contributed to the growing interest into the plants pharmacology 
and epidemiology.  This was followed by the discovery of two new receptors in the 
brain, namely the CB1 and the CB2 receptor. Latter receptors - the CB2 receptors - are 
mainly located on immune cells in the periphery and do not produce psychoactive effect 
but instead suppress immune function (Atwood & Mackie, 2010). The CB1 receptors, G 
protein-coupled cannabinoid receptors, are mainly found in the brain, with the highest 
densities found particularly in brain areas involved in mental states and cognition such 
as basal ganglia, cerebellum, hippocampus and cortex (Herkenham et al., 1991).  
Nevertheless, it has been suggested that the response to cannabinoids varies depending 
on the specific brain area (Romero, Garcia, Fernandez-Ruiz, Cebeira, & Ramos, 1995), 
e.g. one feature of cannabinoid signalling in the brain is the lack of correlation between 
the CB1 density and the efficiency of receptor coupling, which may explain why 
responses can be triggered even in brain regions sparse of CB1 receptors (Pacher, 
Bátkai, & Kunos, 2006). To date, five endocannabinoids (eCBs) have been identified, 
the two most intensively studied being anandamide (N-arachidonylethanolamide 
[AEA]) – discovered in 1992 (Devane et al., 1992) – and 2-arachidonoylglycerol (2-
AG) – discovered in 1995 (Mechoulam et al., 1995). eCBs are synthesised by neurons 
in the cerebellum, pyramidal neurons hippocampus and cortex, medium spiny neurons 
in the striatum and dopaminergic neurons in the midbrain (Freund, Katona, & Piomelli, 
2003). They act as retrograde messenger and are released “on demand” 
postsynaptically, binding to presynaptic receptors and thereby regulating both the 
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excitatory and inhibitory neurotransmission. Unlike conventional neurotransmitters that 
are stored in vesicles, cannabinoids are released “on demand” from lipid precursors 
(Piomelli, 2003).  
Among the more than 100 different cannabinoids identified today (M. ElSohly 
& Gul, 2014), only THC has been shown to have psychoactive properties. Most of the 
psychoactive effects of THC are mediated through activation of CB1 receptors, located 
mainly at the terminals of peripheral and central neurons, on either pre-synaptic 
glutamatergic or GABAergic neurons, resulting in a decrease in either glutamate or 
gamma-aminobutyric acid (GABA) release (cf. Figure 6. below). Numerous studies 
have shown that the activation of CB1 receptors also play a role in modulating 
neurotransmitters such as dopamine – affecting its release indirectly via CB1-dependent 
inhibition of glutamate release into GABAergic neurons in the nucleus accumbens and 
the ventral tegmental areal (VTA) (Fakhoury, 2016; Kuepper et al., 2013; R. Pertwee, 
2008). This might explain the only modest effect of THC on dopaminergic signalling 
reported by acute challenge studies in humans and animals [cf. Sami, Rabiner, and 
Bhattacharyya (2015) for a systematic summary of studies]. This pathway has attracted 
a substantial attention in research on psychiatric disorders, considering that the 
administration of THC has been linked to psychotic symptomatology and that dopamine 
is thought to play a major role in psychosis pathophysiology (Howes & Kapur, 2009). 
The exogenous cannabinoids, as well as related synthetic compounds (e.g. naboline), 
bind to the cannabinoid receptors on the presynaptic neuron and mimic the endogenous 
synaptic modulatory effect. It has been suggested that exogenous overstimulation of 
CB1 receptor on GABAergic and glutamatergic terminals from the brain stem to the 
striatum represents a pathway by which THC induces psychotic-like symptoms (P. D. 
Morrison & Murray, 2009). Cannabidiol (CBD), the other main cannabinoind present in 
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the cannabis plant,  exhibits much lower affinity for CB1/CB2 and its actions have been 
attributed to inhibition of anandamide degradation or its interaction with as yet 
unidentified cannabinoid receptors (Pacher et al., 2006). CBD appears to be able to 
antagonize cannabinoid CB1/CB2 receptor agonists in animals and humans, for which 
reason CBD has also been described as an “inverse agonist” (R. G. Pertwee, 2005). For 
instance, CBD has been shown to ameliorate some of the psychotomimetic effects 
induced by THC (Sagnik Bhattacharyya et al., 2010a).  
 
Figure 6. Endocannabiniod synaptic signalling 
Taken from Kuepper et al. (2013): The convergence of dopamine and the 
endocannabinoids in the VTA:  
A.! Firing patterns in midbrain dopaminergic (DA) neurons are influenced by a host 
of excitatory (glutamatergic, GLU, as indicated in grey) and inhibitory 
(GABAergic, GABA, as indicated in grey) inputs. DA neurons regulate 
neighboring pre-synaptic terminals via retrograde endocannabinoid (2-AG, as 
indicated in blue) signaling.  
B.! When exogenous cannabinoids (THC, as indicated by cannabis leaves) bind to 
CB1 receptors located on glutamatergic (GLU) and GABAergic (GABA) 
terminals, retrograde endocannabinoid signaling (2-AG, as indicated in blue) is 
disrupted and stimulation of CB1 receptors by THC inhibits glutamate and 









2.3 TYPES OF CANNABIS 
Cannabis is not a homogenous drug - by now, more than 500 different natural 
chemical constituent have been identified within the plant and more than 100 of them 
are considered to be cannabinoids (M. ElSohly & Gul, 2014). The main cannabinoids 
that have been investigated in research are mainly THC and CBD, although there is now 
growing interest in delta-9-tetrahydrocannabivain (THCV). THC, the psychoactive 
ingredient of cannabis, has been suggested to cause psychotic-like effects and cognitive 
disturbances during acute intoxication [(Sagnik Bhattacharyya et al., 2009) & see 
Chapter 2.4 for a summary on acute effects]. THC is a partial agonist at CB1 receptors, 
while CBD has little affinity for these. There is now a particular interest in cannabinoid 
receptor antagonists or reverse agonists given their ability to inhibit THC-induced 
hyperactivity of the eCB. Among them, CBD has been shown to reverse some of the 
adverse effects of the acute administration of THC, including psychotic symptoms 
(Sagnik Bhattacharyya et al., 2010a), impairments in perception of emotional 
expression (Hindocha et al., 2015) and cognitive impairments (Englund et al., 2015). 
CBD may also have antipsychotic properties (Leweke et al., 2012). CBD is thought to 
have neuroprotective effects and perhaps minimise the harmful effects on hippocampal 
volume present in long-term cannabis users (M Yücel et al., 2016). Other neuroimaging 
studies have documented opposing effects of THC and CBD on brain activation during 
cognitive testing, such as in the striatum during recall and the amygdala during an 
emotional response task (Sagnik Bhattacharyya et al., 2010a). CBD has therefore been 
described as a functional antagonism of CB1 signalling (R. Pertwee, 2008). 
The varieties of cannabis forms typically available in the street are traditional 
imported herbal cannabis (marihuana or grass) (cf. Table 4. below), home grown 
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sensimilla (without seeds) or herbal smelling “skunk”, resin (hash or hashish) and, since 




Table 4. Visual depiction of different types of cannabis 





a Herbal (“traditional”) cannabis (Marijuana in US) [picture from Hardwick and King 
(2008)] 
b Herbal home grown cannabis (“Sinsemilla”) [picture from Sirius (2016)]   
c Resin (hash, hashish in US) [picture from Lochfoot (2016)] 
d Synthetic cannabis (“legal highs”) [picture taken from  Von Teese (2016)] 
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The different types of cannabis, their characteristics, as well as their average 
potency are summarized below in Table 5. and Table 6. The potency of cannabis 
[defined as the concentration (%) of THC or THC:CBD ratio] has increased over time 
(Burgdorf, Kilmer, & Pacula, 2011; M. A. ElSohly et al., 2016; Mehmedic et al., 2010; 
Niesink, Rigter, Koeter, & Brunt, 2015) . For instance, while samples of traditional 
herbal/skunk-type cannabis collected in the 1990th had an average THC content of 3%-
5% / 5%-6% and a detectable content of CBD (~0.2%) (Burgdorf et al., 2011; 
Mehmedic et al., 2010), samples collected in the 2000th have up to 12%/20% and almost 
no visible CBD content (Burgdorf et al., 2011; Niesink et al., 2015). The rise of potency 
has been suggested to be the result of various factors, including selective breeding of 
specific cannabis strains high concentration of THC, a preference for the female plants 
and the consumption of more potent parts of the plant (e.g. buds instead of leafs), the 
usage of indoor cannabis cultivation and the purchase of seeds and equipment from the 
internet (Swift, Wong, Li, Arnold, & McGregor, 2013). Although the cannabis plants 
have generally a low CBD content, its concentration has declined even further in the 
recent years, leading to an increase in the THC:CBD ratio (M. A. ElSohly et al., 2016). 
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Mehmedic et al. (2010): 
- loose material (loose cannabis plant material with leaves, stems, and seeds 
- cannabis plant material consisting primarily of leaves 
- kilo bricks (compressed cannabis with leaves, stems, and seeds) 
- buds (flowering tops of female plants with seeds) 
Niesink et al. (2015): 
- consists of fresh or dried leaves and flowering tops but excludes the stalk, 
roots and seeds 
Zamengo, Frison, Bettin, and Sciarrone (2015) and Tsumura et al. (2012) 
- leaves (loose material without buds) 
- buds with seeds 
- whole cannabis plants 
Bruci et al. (2012) 
- different parts of the female plants (flowers, leaves, seeds, stems and roots, 
flowering tops) that is grown outdoor 
M. A. ElSohly et al. (2016): 
- male or female cannabis 
- pressed cannabis made of leaves, heads, stems, and seeds 
Potter, Clark, and Brown (2008) 






















Mehmedic et al. (2010): 
- flowering tops of unfertilized female plants with no seeds 
Zamengo et al. (2015) and Tsumura et al. (2012) 
- buds without seeds (sinsemilla) 
Niesink et al. (2015): 
- Nederwiet (dutch for “skunk), including the viarieties White Widow, K-2, 
Power Plant, Amnesia Haze, Jack Herrer) 
M. A. ElSohly et al. (2016): 
- female cannabis plants that have not been pollinated  
- may grow from cutting or from seed 
- may contain some seed (if unpollinated, the seed will be sterile) 
Hardwick and King (2008) 
- grown indoors from selected seed varieties and propagation of female plant 
















Mehmedic et al. (2010): 
- composed of the resinous parts of the flowering tops of cannabis 
- mixed with some plant particles and shaped into a variety of forms, 
e.g., balls, sticks, or slabs. - generally hard with a dark green or brownish colour 
Niesink et al. (2015): 
- the material produced by separating the resinous parts of the flowering tops 
from the other vegetable matter 
M. A. ElSohly et al. (2016): 
- concentrated resin cake or ball produced from pressed kief 
- the detached trichomes and fine material that falls off the cannabis flowers and 
leaves 
- varies in color from black to golden brown depending on the purity and 





Table 6. THC/CBD content in different types of cannabis samples over time 
Study Country Year 
collected 
% THC % CBD 
Herbal (“traditional”) cannabis  
Mehmedic et al. (2010) US 1993 3% 0.2% 
Burgdorf et al. (2011) US 1996 5% 0.2% 
Potter et al. (2008) UK 2005 2% <0.10% 
Niesink et al. (2015) NL 2005 7% 1% 
Mehmedic et al. (2010) US 2008 6% <0.10% 
Hardwick and King (2008) UK 2008 8%  <0.10% 
Burgdorf et al. (2011) US 2008 12% <0.10% 
Bruci et al. (2012) Albania 2010 8% 1% 
Tsumura et al. (2012) Japan 2010 3% 0.1% 
Tsumura et al. (2012) Japan 2010 7% 0.3% 
Niesink et al. (2015) NL 2015 7% 1% 
Zamengo et al. (2015) Italy 2013 8% - 
Herbal cannabis (“Sinsimilla/Skunk”)  
Mehmedic et al. (2010) US 1993 6% 0.2% 
Burgdorf et al. (2011) US 1996 5% 0.2% 
Potter et al. (2008) UK 2005 14% <0.10% 
Niesink et al. (2015) NL 2005 20% <0.10% 
Mehmedic et al. (2010) US 2008 12% <0.10% 
Hardwick and King (2008) UK 2008 16%   <0.10% 
Burgdorf et al. (2011) US 2008 12% <0.10% 
Swift et al. (2013) Australia 2010 15% <0.10% 
Tsumura et al. (2012) Japan 2010 11% 0.1% 
Zamengo et al. (2015) Italy 2013 11% - 
Niesink et al. (2015) NL 2015 17% <0.10% 
Resin (hashish)  
Niesink et al. (2015) NL 2005 17% 2% 
Niesink et al. (2015) NL 2015 18% 2% 
Mehmedic et al. (2010) US 1993 7% 4% 
Mehmedic et al. (2010) US 2008 24% 2% 
Zamengo et al. (2015) Italy 2010 6% - 
Zamengo et al. (2015) Italy 2013 10% - 
Hardwick and King (2008) UK 2008 6%  4%  
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Interestingly, my meta-analysis (Schoeler et al., 2015) indicated that the change 
of cannabis over time might be linked to adverse consequences for cannabis users. For 
instance, the memory impairments present in cannabis users were less prominent in 
earlier studies (published before the year 2000) than in more recent studies (published 
between 2000 and 2015) (cf. Figure 7. below). Although rather speculative, this 
difference in the memory-impairing effect linked to cannabis across time could perhaps 
be related to the rise in potency in the last decade. 
 
Figure 7. Cannabis and memory: Changes in impairments over time 
 
Note. Taken from  Schoeler et al. (2015) (cf. Paper 5, Appendix I): Before 2000 = if 
study was published before the year 2000; After 2000 = if study was published after the 
year 2000; p=estimated significance level the categorical moderator year of publication 
(before 2000 vs. after 2000); SMD = Standardized Mean Difference in memory 
outcome between non-users and cannabis users, with larger SMD reflecting worse 
performance in cannabis users.  
 
Historically, the main ways of preparation of cannabis in the UK fall broadly 
into two categories, cannabis resin or herbal cannabis, while cannabis oil (the 
concentrated extract from the cannabis plant) is less prevalent (Hardwick & King, 
2008). In recent years, there was an increase in the use of herbal cannabis as opposed to 
the previously more commonly used resin (or Hash/Hashish in the US) (Hardwick & 
King, 2008). Nowadays, this type of cannabis has usually higher levels of CBD and 
lower levels of THC when compared to herbal cannabis (Hardwick & King, 2008). 
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Herbal cannabis may be further divided into two groups, including traditional herbal 
cannabis (derived from the pollinated female plant) and higher potency cannabis such as 
skunk (also called sinsemilla) (Potter et al., 2008). Sinsemilla is derived from the 
unpollenated (unseeded; sinsemilla=without seeds) females cannabis plant. As shown in 
Table 6., samples identified as sinsemilla generally have the highest levels of THC and 
low concentrations of CBD. Recently, the user’s preferences have changed from the use 
of traditional (seeded) herbal cannabis to sinsemilla, which appears to now dominate the 
UK market (Hardwick & King, 2008).  
The most recent trend is the use of synthetic cannabis (SC), whose recreational 
use has increased in recent years (Wells & Ott, 2011). Synthetic cannabis products are 
legal (therefore called “legal highs”) due to their structural dissimilarity to THC. 
However, they produce effects that resemble those of traditional cannabis since they 
exert their effects through the eCB. While THC is a weak partial agonist at the CB1 
receptors, the synthetic cannabinoids (e.g. HU-210, CP-55,950, WIN-55,212-2, JWH-
018[naphthoylindoles], THJ-018[napthoylindazoles], AKB-045[indazole 
carboxamides]) are more potent full agonists at the same receptor. Although the 
substance is sold as cannabis-like compounds, SC is cause more negative and 
unpredictable effects (Winstock & Barratt, 2013) than the natural cannabis due to the 
uncontrollable variety of chemicals. For instance, while intoxicated, those users that 
consumed SC as opposed to traditional cannabis exhibited higher levels of 
disorientation, incoherent speech and confusion in comparison (Chase et al., 2016). On 
the illicit drug market, this group of psychoactive drugs is now the fastest growing 
group (UNODC, 2015). Commonly used products are known as “Spice”, “K2” or 
“Kronic”. This product usually contains dried and shredded plant material with no 
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intrinsic psychoactive ingredient, but which is sprayed with one or several synthetic 






























2.4 CANNABIS AND MENTAL HEALTH: ACUTE EFFECTS  
In recent years, greater research has focused on investigating the acute effects of 
cannabis on mental states, using experimental designs such as the “gold-standard” 
double-blind, placebo-controlled and within-subject pharmacological challenge study. 
Acute effects are transient and present during the period in which the subject is 
intoxicated (i.e. feeling “high”) with the drug, which lasts for about 5 to 200 minutes 
(D'Souza et al., 2004). Among the chemical constituents of cannabis, THC has been the 
most frequently investigated. Studies of acute effects may differ in some aspects of their 
methods, such as study design (within-subject vs. between-subject comparison), route of 
administration (oral, smoked, intravenous), the dose administered, the time-point of 
administration or the cannabis use history of a participants – all factors that need to be 
taken into account when interpreting and comparing the results across studies. In those 
randomized controlled trials (RCT), either a single dose or multiple doses of THC are 
administered and compared to the placebo condition in order to elucidate its (dose-
response) effects on human behaviour and mental states and its underlying neural 
mechanism. Several areas of mental health related outcome have been investigated in 
this field of research, including mood states (e.g. depression, happiness, anxiety), 
perceptions (e.g. positive symptoms, dissociations), behavior (e.g. impulsivity, control 
inhibition) and cognition (e.g. learning and memory, emotion recognition) (cf. Table 7. 
below). This evidence is therefore crucial when evaluating potential mechanisms [i.e. 
biological plausibility (A. B. Hill, 1965)] by which cannabis exerts its effects on human 
mental health conditions such as psychosis, mood or deviant behavior (cf. Chapter 2.5 
below).  
A consistent finding reported by most acute challenge studies is that THC 
induces positive symptoms, including in those with minimal previous cannabis exposure 
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(Sagnik Bhattacharyya, Atakan, et al., 2015b; D'Souza et al., 2008; Englund et al., 2015; 
P. Morrison et al., 2009; Radhakrishnan, Skosnik, et al., 2015; Tunbridge et al., 2015) 
and those who use cannabis at a regular basis (Barkus et al., 2011; Van Wel et al., 
2015), implicating that the level of tolerance may not prevent from the psychotomimetic 
effects of smoked cannabis. Furthermore, adverse acute effects were reported by studies 
using lower doses of THC (e.g. ~1mg intravenous THC) (Radhakrishnan, Skosnik, et 
al., 2015) and higher doses of THC (~12mg smoked THC) (Van Wel et al., 2015) and 
those who tested for dose-response effects (D'Souza et al., 2004). However, although it 
was reported that THC significantly induced psychotic and dissociative symptoms in 
non-users as well as frequent users, the effect in frequent users was blunted, which may 
implicate some tolerance-effects to symptom-inducing effects of cannabis in regular 
users (D'Souza et al., 2008). Furthermore, the effects of THC were stronger in those 
with a with a pre-existing psychotic disorder when compared to healthy controlled 
(D’Souza et al., 2005) and were modulated by variation in genes for the dopamine 
transporter (DAT1/AKT1) (S Bhattacharyya et al., 2012), suggesting some genetic 
sensitivity to its psychoactive effects. However, it was reported that there were no 
significant differences between patients with psychosis, their unaffected relative and 
healthy controls in their subjective perceptual experiences of cannabis following THC 
administration (Kuepper et al., 2013). Studies also reported that the administration of 
THC significantly elevated levels on scales measuring negative symptoms (Barkus et 
al., 2011; D'Souza et al., 2004; Englund et al., 2015; Fusar-Poli et al., 2009), although 
the effect was not present in those who were current regular users of cannabis (Marieke 
Liem-Moolenaar et al., 2010). 
Acute administration of THC has also consistently been linked to the production 
of cognitive impairments in a dose-dependent manner, including impairments in recall 
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(V. H. Curran, Brignell, Fletcher, Middleton, & Henry, 2002; D'Souza et al., 2004; 
Marieke Liem-Moolenaar et al., 2010) and working memory (Marieke Liem-Moolenaar 
et al., 2010; McDonald, Schleifer, Richards, & de Wit, 2003; P. Morrison et al., 2009). 
Those impairments are not just present in those with minimal previous exposure 
(Englund et al., 2015; P. Morrison et al., 2009; Tunbridge et al., 2015), but also in those 
who are current regular users of cannabis (Marieke Liem-Moolenaar et al., 2010; 
Weinstein et al., 2008), implicating that tolerance to the cognitive-impairing effects is 
unlikely to occur. In this context, it has been proposed that THC affects the encoding of 
new memories during intoxication which then perhaps leads to the deficits in recalling 
those memories, while old memories that were consolidated outside the state of acute 
intoxication remain unaffected (H. V. Curran et al., 2016). The presence of a dose-
response relationship is also supported by a study that found greater memory 
impairments in those users who consumed forms of cannabis with a low content of 
CBD when compared to forms with a higher content of CBD (C. J. Morgan, Schafer, 
Freeman, & Curran, 2010), suggesting that the type of the cannabis smoked plays a role 
with regard to the cognitive performance in users. Other evidence comes from a 
naturalistic observational study using Ecological Momentary Assessment (EMA, 
involving a seven-day monitoring period) in cannabis users, in which it was found that 
working memory performance was significantly worse in periods of acute use than in 
periods of non-use (Schuster, Mermelstein, & Hedeker, 2016). Similarly, in a 
naturalistic study, the effects during acute intoxication in cannabis users on working 
memory were moderated by genetic variations within the AKT1 gene (CJA Morgan, 
Freeman, Powell, & Curran, 2016), implicating that a genetic vulnerability to psychosis 
may modulate also modulate its effects on cognition. This is in line with experimental 
evidence that found greater cognitive impairments following THC administration in 
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patients with pre-existing psychotic disorder when compared to healthy controls 
(D’Souza et al., 2005). Accumulating evidence has also implicated the eCB in the 
perception of emotional expressions (Lafenêtre, Chaouloff, & Marsicano, 2007), an 
ability that is an essential aspect of appropriate social interactions and interpersonal 
relationships. This ability has been reported to be impaired in people with mental health 
problems such as depression, anxiety or schizophrenia (Phillips, Drevets, Rauch, & 
Lane, 2003). It has been found that the induction of cannabis significantly impaired 
emotion recognition in a dose-dependent manner in healthy subjects with previous 
cannabis experiences (Ballard, Bedi, & de Wit, 2012). Other evidence found that THC 
significantly reduced accuracy for stimuli with negative emotional content but not for 
stimuli with positive emotional content (Bossong et al., 2013). Interestingly, CBD 
protected against the impairments in emotional processing induced by THC (Hindocha 
et al., 2015).  
There is also evidence that the acute intoxication of THC leads to increased 
levels of anxiety in those with some previous cannabis exposure (Sagnik Bhattacharyya, 
Atakan, et al., 2015b; Englund et al., 2015), as well as in those who are currently using 
(Ballard et al., 2012; Hindocha et al., 2015; Van Wel et al., 2015). Despite the anxiety-
inducing that are present in both non-users of cannabis and regular users of cannabis, 
the effect has been shown to be stronger in those without previous regular cannabis 
exposure, indicating that the level of tolerance plays a role in this context (D'Souza et 
al., 2008). Less consistent are the results with regard to depressive symptoms. In fact, 
there is little ground to believe that THC acutely elicits depressive symptoms (Englund 
et al., 2015; Wachtel, ElSohly, Ross, Ambre, & De Wit, 2002) or results in changes in 
mood (Marieke Liem-Moolenaar et al., 2010), although results are somewhat mixed 
(Van Wel et al., 2015).  
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Cannabis may also indirectly exert potential negative effects on conduct by 
altering the system that is responsive for regulating impulses and inhibitions. Impulsive 
behavior can be described as a variety of maladaptive behavior, e.g. the predisposition 
towards rapid, unplanned reactions without regard to the negative consequences and the 
inability to inhibit inappropriate actions (Moeller, Barratt, Dougherty, Schmitz, & 
Swann, 2001). Some evidence from acute challenge studies is indicative of THC 
increasing impulsive or risk behavior in non-users (Sagnik Bhattacharyya, Atakan, et 
al., 2015b), regular users (Ramaekers et al., 2006) and heavy users (Weinstein et al., 
2008), especially if exposed to high doses of THC (Weinstein et al., 2008). The effects 
seem to be present in tasks measuring psychomotor control (Weinstein et al., 2008), 
response inhibition (Sagnik Bhattacharyya, Atakan, et al., 2015b), as well as decision 
making (Weinstein et al., 2008), although the latter dimension was not impaired in all 
studies (Ramaekers et al., 2006). 
To summarise, evidence from acute challenge studies is relative consistent with 
regard to its acute adverse effects on outcome such as psychosis-like symptoms, 
cognitive function and behavioural control, as well its anxiogenic effects, while the 
results regarding the acute effects on mood such as depressive symptoms are less clear. 
However, the acute administration only mimics the intoxication effects and leads only 
to sub-clinical symptoms, i.e. conclusions are limited with regard to the long-term 
effects within a person’s natural environment. For instance, its effects are likely to 
depend on additional factors that are ethically often not feasible to explore in acute 
challenge studies in humans such as the modulating effects of pharmacological 
parameters (e.g. the effect of duration/chronicity of use, age of onset of use, frequency 
of use, abstinence from cannabis). In other words, despite the evidence suggestive of 
adverse effects during acute intoxication, uncertainty remains as to whether those 
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effects persist over the long-term. For instance, one THC challenge study reported none 
of the observed adverse effects on cognition and psychotic symptomatology remained 
following a period of abstinence when THC was no longer detectable in plasma (V. H. 




Table 7. Acute challenge studies investigating the effect of THC on outcome 
Study N Dose THC (in mg) Outcome  
Psychotic effect 













1mg* Total PANSS 
 
 




1.5mg Psychotic symptoms 
(CAPE) 
 






2.5mg Positive symptoms 
(PANSS) 
 
























10mg Positive symptoms 
(CAPE) 
 











12mg*** Positive symptoms 
(B-VAS) 
 

























1mg* Anxious (VAS) 
 
 
Englund et al. (2015) 10 
(RC) 
 Single dose 
(IV) 
1mg Anxiety symptoms 
(BAI) 
 































10mg Anxious (STAI) 
 
 




6 mg Anxious (VAS) 
 
 




12mg*** Anxiety symptoms 
(POMS) 
               
Negative symptoms 




1mg Negative symptoms 
(CAPE) 
      













10mg Negative symptoms 
(PANSS) 
 
Barkus et al. (2011) 10 Single dose 2.5mg Negative symptoms  
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(LC) (IV) (PANSS) 
Marieke Liem-










Cognitive effects (memory) 




1mg Memory (HVLT) 
 
 




1mg Digit Span Backwards  
Tunbridge et al. (2015) (LC) Single dose 
(O) 
1.5mg Digit Span Backwards  






2.5mg Memory (RAVLT)  









Fogel, Kelly, Westgate, 


















Memory (BSRT)  






Attention (WCST)  






Attention (DSST)  





























Impulsive/risk behaviour – inhibitory control 
Sagnik Bhattacharyya, 





10mg Go/No-Go  






Critical tracking task  






Stop signal task  






The Iowa gambling 
task 
 






Gambling task  















Impulsivity (ST)  
Depression/mood 




10mg Depressive symptoms 
(CAPE) 
 




12mg*** Depressive symptoms 
(POMS) 
 

















Mood (VAS)  
Emotion recognition 













8 mg Emotional processing 
task 
 




6 mg Emotional  processing 
task  
 
Note. CC1 (Current cannabis user); CC2(>monthly use/current); CC3(>daily 
use/current); LC (lifetime cannabis use >1); RC (regular lifetime cannabis use <25); O 
(Oral); IV (Intravenous), IH (Inhaled)  
         = Poor outcome (reduced cognition, higher positive/negative symptom severity, 
higher depression/anxiety, increased dissociation) 
         = No effect of acute administration when compared to placebo 
* administration of 0.15 mg/kg (10.5mg in a 70 kg individual) 
** administration of 0.25 and 0.5 mg/kg (17.5mg/35mg in a 70 kg individual) 
*** administration of 0.30 mg/kg (12mg in a 70 kg individual) 
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2.5 CANNABIS AND MENTAL HEALTH: LONG-TERM EFFECTS  
2.5.1 INTRODUCTION 
While most adolescent cannabis use remains experimental, an incidence of 
increased cannabis use typically occurs within the period of early adolescence to late 
adolescence (Coffey, Lynskey, Wolfe, & Patton, 2000). It has been estimated that about 
1 out of 10 individuals goes on to develop a cannabis use disorder (CUD) following the 
first use (Hall & Pacula, 2003). In particular, early onset and frequent use of cannabis 
during adolescence have been identified as risk factors for later ongoing problematic 
cannabis use, other drug and substance use problems, mental health conditions, as well 
as delinquency, risky behaviour and criminal offending (Feingold, Weiser, Rehm, & 
Lev-Ran, 2015; David M Fergusson, Horwood, & SwainCampbell, 2002; Schoeler, 
Monk, et al., 2016; Swift, Coffey, Carlin, Degenhardt, & Patton, 2008). However, 
causality in this context has often been questioned, since there is the concern that those 
individuals initiating cannabis use at an early age may already be psychopathological 
different from their non-using peers before initiating cannabis use, e.g. are more likely 
to exhibit antisocial and non-conformist behavior, affiliating with drug-using peers, 
perform poorly at school and comprise genetic vulnerability to initiate cannabis use 
(Coffey et al., 2000; Copeland & Swift, 2009; Hall & Degenhardt, 2007; R. A. Power et 
al., 2014). 
With regard to mental health correlates, those individuals seeking treatment for a 
cannabis use disorder (CUD) are at high risk to have at least one other comorbid 
psychiatric diagnosis (~60%-94%, cf. Table 8. below) and a substantial proportion 
(~14%) was found to be diagnosed with more than 3 comorbid conditions (Norberg, 
Battisti, Copeland, Hermens, & Hickie, 2012). Within samples of individuals diagnosed 
with CUD, the highest rates of comorbidity seem to be present for anxiety and mood 
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disorders (Dorard, Berthoz, Phan, Corcos, & Bungener, 2008; Guillem, Arbabzadeh-
Bouchez, Vorspan, & Bellivier, 2015; Norberg et al., 2012; Oliveira & Malbergier, 
2014), followed by psychotic disorders (Guillem et al., 2015; Norberg et al., 2012; 
Oliveira & Malbergier, 2014). Although those prevalence rates may indicate that 
cannabis is a drug linked to mental health problems in general and has a rather non-
specific effect with regard to outcome, those cross-sectional studies are only of limited 
interpretability when evaluating causal effects of cannabis on mental health outcome. 
For instance, one problem that arises is that there is no assertion as to whether the 
diagnosis of an Axis I disorder preceded the diagnosis of CUD or whether the receipt of 
the diagnosis was a subsequent event. For instance, in a recent study Farmer et al. 
(2016) reported that the estimates for precursory comorbidity (disorders that had their 
onset prior to CUD) were higher than the estimates for ensuing comorbidity (disorders 
that had their onset following the onset of CUD) for mood disorders (26% vs. 16%) and 
anxiety disorders (7% vs. 3%), which indicates that a proportion of comorbid 
psychiatric diagnoses linked of CUD could be result of reverse causation. Furthermore, 
a study that compared CUD prevalence rates across different psychiatric disorders 
reported that the lifetime presence of CUD was highest in subjects with schizophrenia 
(21%), which was higher when compared to bipolar disorder (6%) and depression (2%) 
(Heilbronner et al., 2015).  
Hence, in the following paragraphs I will review the literature investigating the 
effects of cannabis on the most commonly investigated outcomes, including cognition, 
anxiety and affective disorders, deviant behavior and substance use disorders, before 






Table 8. Comorbid psychiatric diagnoses in patients with cannabis use disorder 
Study N group Comorbid diagnosis % 


















Notzon et al. (2016) 99 CUD Childhood disorder (ADHD) 34% 




















N = Number of subjects 
 
First, one area of great interest in research on cannabis use is the question that is 
concerned with cognitive outcome linked to the use. There is now accumulating 
evidence that has linked long-term and heavy cannabis use to poor neuropsychological 
performance (Schoeler & Bhattacharyya, 2013). Recent meta-analyses reported that 
there are small but aversive effects of cannabis on global neurocognitive performance 
(d=0.14) following a period of abstinence (Schreiner & Dunn, 2012), with more 
pronounced impairments being present if started at an earlier age (Ganzer, Bröning, 
Kraft, Sack, & Thomasius, 2016). Similarly, the results from my meta-analysis 
(Schoeler, Kambeitz, et al., 2016), in which I investigated the effects of cannabis use on 
memory function, suggest that cannabis use had a robust but modest adverse effect on 
global memory function as well as its multiple component dimensions in cannabis users, 
with the precise magnitude of the effect depending on the specific dimension of 
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memory tested.  There is also evidence in support of a dose-response relationship in this 
context. For instance, cognitive impairments increased with increasing frequency of use, 
longer duration of use and earlier age of onset of use (V. H. Curran et al., 2002; Fried, 
Watkinson, & Gray, 2005; Lisdahl, Gilbart, Wright, & Shollenbarger, 2015; Tapert, 
Schweinsburg, & Brown, 2008). Only a few longitudinal studies investigated the course 
of cannabis use and with regard to changes in cognitive function. For instance, one 
study has linked ongoing cannabis use to a decline in IQ which was not present in non-
users (N. J. Jackson et al., 2016). Meier et al. (2012) reported that the level of 
persistence of heavy cannabis use throughout the time of follow up was significantly 
linked to a decline in IQ , processing speed and verbal memory, while taking into 
consideration the level of pre-cannabis IQ, acute effects of cannabis, other illicit drug us 
and alcohol. Although this study seem to provide relatively robust evidence in support 
of cannabis as a causal risk factor for neurocognitive impairments, it has been argued 
out that this association was possibly due to uncontrolled confounding and may reflect 
an over-estimation of effects (Rogeberg, 2013). For instance, a recently published study 
investigating the longitudinal effects of cannabis, in which a sibling-design was 
employed, found that the adverse effects of cannabis on IQ over time disappeared when 
controlled for genetic confounding, which may indicate that there is a genetic and/or 
family-environmental predisposition to both decline in IQ and initiation of cannabis use, 
which would mean that the association between cannabis and cognitive decline is the 
result of a “shared-vulerability” (N. J. Jackson et al., 2016).  
Another area of interest in the context of cannabis and mental health outcome is 
its relation with anxiety and affective disorders. The results from my meta-analysis 
(Schoeler, Kambeitz, et al., 2016), in which I compared the depression scores between 
cannabis users and non-users, indicated that cannabis user were characterised by 
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significantly higher depression scores. However, this cross-sectional summary does not 
allow drawing conclusions regarding the causal effects of cannabis. Unlike the acute 
effects of cannabis that are present for outcome such as psychotic symptoms or 
cognitive impairments (cf. Chapter 2.4 above), cannabis may not exerts its effects 
immediately (acutely) with regard to depression and its adverse effects on mood may 
only become present following long-term continued/chronic use. For instance, 
experimental studies did not find that the administration of THC increased depressive 
symptoms in healthy subjects (Englund et al., 2015; Wachtel et al., 2002). Similarly, 
within 6 months of follow up, changes in cannabis use were not significantly related to 
changes in depressive symptomatology (Park et al., 2015). Another study looking at the 
effects of cannabis potency and depressive symptoms reported that the THC:CBD ratio 
in the cannabis consumed was not linked to depression scores in cannabis users 
(Schubart et al., 2011). Studies that have explored dose-response relationships reported 
both the absence of effect of frequency of cannabis use on depression (Feingold et al., 
2015; Repetto, Zimmerman, & Caldwell, 2008) and the presence of a dose-response 
relationship between cannabis use and depression (D. W. Brook, Brook, Zhang, Cohen, 
& Whiteman, 2002; Suzanne H Gage et al., 2015). In a longer follow up, integrating 
data from 4 different cohorts, Horwood et al. (2012) reported that two of the cohorts 
suggested that cannabis use leads to the development of depression (Anstey et al., 2011; 
David M. Fergusson & Horwood, 2001), a third cohort suggested that depression leads 
to cannabis use (Patton et al., 2007) while the fourth one did not find that either of those 
relationships were significant when employing longitudinal modelling (Prior, Sanson, 
Smart, & Oberklaid, 2000). The lack of clear evidence with regard to depression 
outcome may be linked to the main limitations of evidence to date, which is the absence 
of a life-span prospective design, the non-consideration of important confounders and 
[78] 
 
the non-exploration of the direction of association. Hence, in order to address those 
limitations, I recently analysed data from the Cambridge Study of Delinquent 
Development (CSDD) study, in which boys were followed up from age 8 to 48 years, 
which allowed me to prospectively investigate the association between cannabis use and 
risk of Major Depressive Disorder (MDD) (cf. Paper 8 (Schoeler et al., under review), 
Appendix I). Here, I found that early onset cannabis use (before age 18) but not late 
onset cannabis use (after age 27) was associated with a higher risk of a subsequent 
diagnosis of MDD diagnosis, while controlling for observed (e.g. other illicit drug use 
and presence of other mental health diagnoses) and non-unobserved time-invariant 
factors (e.g. shared genetic or stable environmental factors). This is consistent with 
evidence from animal research, in which long-term exposure of cannabinoids resulted in 
depression-like symptoms only in adolescent but not adult rats (Bambico, Nguyen, 
Katz, & Gobbi, 2010), which is in further support of a neurodevelopmental sensitivity 
to the adverse effects cannabis use in this context. 
Adverse effects following cannabis use have also been implicated with regard to 
risk of suicide; a recent meta-analysis concluded that heavy cannabis use also increased 
the risk for suicide (Borges, Bagge, & Orozco, 2016), even when adjusted for 
confounders such as other illicit drug and alcohol use and history of depression. When 
assessing both directions over a period of 30 years, it was found that frequency of 
cannabis use was linked to subsequent suicidal ideation, while the reverse direction 
(suicidal ideation as a predictor for initiation of cannabis use) was not significant (Jan 
C. van Ours, Williams, Fergusson, & Horwood, 2013). The link to suicidality also 
remained when controlled for time-invariant unobserved sources of confounding. For 
instance, using a discordant twin design, cannabis use prior age 17 was linked to 
suicidal attempts (Lynskey et al., 2004). Similarly, in another study that used a fixed-
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effects design (i.e. the adoption of the discordant twin design), it was reported that in 
periods of heavier use there was a higher risk of suicidal ideation and suicide attempts 
when compared to periods in which cannabis was not used or was used less frequently 
(David M Fergusson et al., 2002). This would indicate that the relationship between 
cannabis use and risk of suicide cannot be explained solely by shared genetic or stable 
environmental influences.  
With regard to anxiety disorders, a recent meta-analysis found that cannabis 
significantly predicted anxiety disorders (Kedzior & Laeber, 2014), although wider 
conclusions are limited by the mainly cross-sectional nature of the studies included. It 
has also been reported that cannabis use predicted the subsequent emergence of anxiety 
disorders in longitudinal studies (Whiteford et al., 2013), but this finding has not been 
replicated in a recent longitudinal study (Blanco, Hasin, Wall, & et al., 2016). Several 
lines of investigations have raised doubts as to whether there is a causal relationship. 
For instance, it was reported that the risk for subsequent anxiety in cannabis use did not 
persist beyond the effect of co-occurring cigarette use, implicating that this factor may 
play a role within this association (Zvolensky et al., 2008). Furthermore, longitudinal 
evidence in an age-mixed population (aged 20-64) reported that cannabis use was not 
predictive of subsequent anxiety but that anxiety predicted subsequent onset of cannabis 
use (Danielsson, Lundin, Agardh, Allebeck, & Forsell, 2016), suggesting that reverse 
causation has to be considered as one potential explanation for the high rates of anxiety 
disorders found in individuals with CUD (Dorard et al., 2008; Farmer et al., 2016; 
Guillem et al., 2015; Norberg et al., 2012; Oliveira & Malbergier, 2014). Studies that 
looked at multiple outcomes together reported either no significant effects of cannabis 
on subsequent risk of anxiety and depression (Blanco et al., 2016; Danielsson et al., 
2016) or provide rather mixed results. For instance, in controlled models, the effects of 
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cannabis on incidence of psychiatric disorders remained significant for MDD and 
bipolar disorder but not anxiety disorders (Van Laar, Van Dorsselaer, Monshouwer, & 
De Graaf, 2007). To the contrary, it was found that frequency of adolescent cannabis 
use predicted subsequent adulthood anxiety but not depression (Whiteford et al., 2013). 
Inconsistent with studies reporting uni-directional effects of cannabis on affective 
disorders, a 10-year prospective study reported that the presence of anxiety disorders, 
depression and substance use disorders significantly predicted the incidence of cannabis 
use (any use) and development of CUD (Wittchen et al., 2007). Furthermore, other drug 
use may play an important role with regard to mood and anxiety disorders. For instance, 
it was reported that frequency of cannabis use was not linked to depressive symptoms or 
symptoms of anxiety in a sample of polystimulant dependent users – instead, those 
outcomes were linked to frequency of cocaine use and alcohol use (Willi et al., 2016). 
Although evidence from epidemiological research remains inconclusive as to whether 
(non-acute) cannabis use is in fact a risk factor for the development of anxiety disorders, 
experimental evidence implicate that cannabis use may acutely induces anxiety, e.g. the 
acute administration of THC increased levels of anxiety in those will little previous 
cannabis exposure (Sagnik Bhattacharyya, Atakan, et al., 2015b; Englund et al., 2015), 
as well as in those who are currently using (Ballard et al., 2012; Hindocha et al., 2015; 
Van Wel et al., 2015) and evidence from animal research is suggestive of increased 
anxiety-like symptoms as a result of long-term exposure of cannabinoids in adolescent 
rats (Bambico et al., 2010).    
Cannabis use also been investigated with regard to the development of “problem 
behavior” such as psychosocial difficulties, deviant behavior or other substance use 
disorders. For instance, there is experimental evidence suggestive of a dose-response 
relationship between the dose of the THC administered and impairments in decision 
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making (Weinstein et al., 2008), which could implicate cannabis as a potential risk 
factor for impulsive behavior and deviant behavior. Cross-sectional observational 
evidence also suggested that poorer decision making skills were linked to the level of 
severity of CUD symptomatology (Gonzalez et al., 2012).  Longitudinal studies 
reported that adolescent cannabis use was linked to subsequent work and school 
difficulties (J. S. Brook, Brook, Rosen, & Rabbitt, 2003) and fewer years of completed 
education (Jan C Van Ours & Williams, 2007). Similarly, a recent study that looked at 
frequency of cannabis use reported significant dose-response relationships between 
adolescent cannabis use and outcome young adulthood, including reduced likelihood to 
complete highschool, increased risk of subsequent illicit drug and cannabis abuse and 
higher risk of suicide (Silins et al., 2014). In this context, pprevious research has also 
shown that violent behavior (Johnson, Wish, Schmeidler, & Huizinga, 1991; 
Monshouwer et al., 2006; Nabors, 2010; E. N. Peters, Schwartz, Wang, O’Grady, & 
Blanco, 2014) or delinquency and aggression in adolescence may result from cannabis 
use. In a recently published paper [Paper 7(Schoeler, Theobald, et al., 2016), Appendix 
I], I examined whether ‘continued use’ is the critical determinant that underpins the 
association between cannabis use and violence. I found that compared with never-users, 
continued exposure to cannabis (use at age 18, 32 and 48 years) was associated with an 
increased risk of subsequent violent behavior, while taking into consideration time-
varying and time-invariant factors of confounding and the effect of reverse causation. 
Therefore, long-term cannabis exposure may cause impairments in response inhibition 
resulting in behavioral control in vulnerable individuals that may underlie impulsive, 
violent behaviour, by altering the normal functioning of its underlying neural substrate, 
the ventrolateral prefrontal cortex in man (S. Bhattacharyya et al., 2014). 
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Finally, relative consistent evidence exists with regard to the relationship 
between cannabis use and the risk of being diagnosed with subsequent other substance 
use disorders. For instance, in a follow up study, it has been reported that CUD at T1 
predicted the incidence of alcohol used disorder (AUD) at T2 (in those with no prior 
AUD) and predicted persistence of AUD (in those with prior AUD) (Weinberger, Platt, 
& Goodwin, 2016). This was replicated in a recent study that reported a link between 
adult frequency of cannabis use and risk of subsequent development of AUD, other 
SUD and cigarette dependence (Blanco et al., 2016). Hence, the evidence summarised 
here indicates that cannabis use in adolescence may be a risk factor for later-life 
“problem behavior”, which might be driven by a use pattern that reflects a continuous, 
early onset and high-frequency use throughout the life span. 
 
2.5.2 CANNABIS AND THE DEVELOPMENT OF PSYCHOSIS 
 
Although the link between cannabis and psychosis has already been reported 
almost 70 years ago (Ames, 1958), it did not became the focus of further attention since 
the first longitudinal study published in the 80th (Andréasson, Engström, Allebeck, & 
Rydberg, 1987), which reported that there were increased cases of cannabis users seen 
in patients referred for their first episode psychosis. Today, there is consistent evidence 
that the rates of cannabis users seen in FEP are substantially higher than those estimated 
in the general population (Degenhardt & Hall, 2001; Di Forti, Marconi, et al., 2015). 
Several meta-analyses have concluded that cannabis use significantly increased the risk 
for developing psychosis roughly by the odds of two (T. H. Moore et al., 2007), and a 
meta-analysis investigating dose-response relationships reported an increase in risk by 
the odds of 4 for the most severe cannabis users (Marconi, Di Forti, Lewis, Murray, & 
Vassos, 2016). Hence, in accordance with the concept of causality (A. B. Hill, 1965), 
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several lines of evidence suggest that the effect of cannabis on risk of psychosis is 
present in a dose-dependent manner. To illustrate, population studies reported that those 
users who had a higher THC:CBD ratio reported significantly more psychotic 
symptoms than those with a low ratio (Schubart et al., 2011). Similarly, a recent study 
reported that 24% of cases with a first episode could be attributed to the use of high-
potency (skunk-type) cannabis around the time of onset, independent from cigarette, 
alcohol and other drug use (Di Forti, Marconi, et al., 2015). Another study found that 
heavy users of cannabis (daily) prior to the onset were more likely to experience an 
acute mode of onset (as opposed to non-acute) when compared to those who used it less 
frequently (Compton, Broussard, Ramsay, & Stewart, 2011). It was also reported that 
duration of cannabis use predicted psychotic symptoms (J. McGrath et al., 2010) – in 
fact, has been suggested that the duration of exposure from early adolescence may 
underlie the emergence and persistence of psychotic symptoms (Kuepper et al., 2011b). 
Furthermore, other studies found that cannabis use predicted an earlier age of onset of 
psychosis (Large, Sharma, Compton, Slade, & Nielssen, 2011; N. C. Stefanis et al., 
2013) and that this effect was more prominent in those who used it heavily (Di Forti et 
al., 2014; N. C. Stefanis et al., 2013), in those who used high-potency (skunk-type) 
forms of cannabis (Di Forti et al., 2014) and if cannabis was started at an earlier age 
(Leeson et al., 2012). Age of onset of cannabis use was reported to directly predict age 
of onset of psychosis and age of first hospitalisation, while the mean between first 
cannabis use and onset of psychosis was found to be 7 years (Galvez-Buccollini et al., 
2012). Studies in individuals at high-risk reported that the (unadjusted) risk of transition 
to psychosis following the help-seeking presentation was 3.4 times higher in those who 
continued compared to those who discontinued (19% vs. 6%) (Valmaggia et al., 2014). 
In other patient samples in which psychotic features are common, cannabis was also 
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found to be linked to psychotic symptomatology. For instance, it was reported in a 
sample of patients with bipolar disorder that the presence of a lifetime cannabis use 
disorder significantly predicted the presence of a lifetime psychotic episode (Braga, 
Burdick, DeRosse, & Malhotra, 2012) and that comorbid CUD in bipolar disorder was 
associated with the presence of psychotic features when admitted to the hospital 
(Weinstock, Gaudiano, Wenze, Epstein-Lubow, & Miller, 2016). Hence, unlike the 
results from cannabis research with regard to other mental health outcomes (cf. above 
Chapter 2.4), there is a rarely seen consistency in findings across epidemiological 
studies investigating (dose-response) effects of cannabis on risk of subsequent 
psychosis, which has been used as a strong argument to raise concerns regarding the 
risks associated with heavy cannabis use in the general population, especially in light of 
the increase in potency over time (M. A. ElSohly et al., 2016), the increase in 
prevalence of cannabis use in recent years (Hasin et al., 2015) and the high prevalence 
rates especially in young people (UNODC, 2014). Nevertheless, the relationship 
between cannabis use and the development of psychotic disorders is complex and 
causality is still questioned (Ksir & Hart, 2016a). Although there is now experimental 
evidence that THC induces psychotic-like symptoms in those without a mental illness 
(Sagnik Bhattacharyya et al., 2009; V. H. Curran et al., 2002; Englund et al., 2015) and 
exacerbate symptoms in those with a pre-existing psychotic disorder (D’Souza et al., 
2005; Henquet et al., 2010), this does not necessary implicate that those effects lead to 
the development of a psychosis disorder. Sceptics that question the causal nature of the 
association between cannabis use and the development of psychosis have proposed 
several alternative explanations for this association, including:  
(1)!The link is non-specific, such as any (psychoactive) substance would lead to an 
increased risk of psychosis. For instance, cigarette use has now been linked to 
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the development of psychotic disorders (Gurillo et al., 2015) and separating 
these two substances (tobacco -  cannabis) in prediction models can be 
challenging since most cannabis users are also cigarette smokers and/or 
consume cannabis mixed with tobacco (Feeney, 2015). So far evidence with 
regard to the causal effects of cigarette use is considered as too weak to draw 
more definite conclusions (Alderson & Lawrie, 2015), partly because there is no 
research to date on whether the effect persist beyond a “shared-vulnerability” to 
both cigarette use and psychosis (Alderson & Lawrie, 2015; Suzanne H. Gage & 
Munafò, 2015). Little evidence is in support of alcohol use as a predictor for 
onset of psychosis when controlled for cannabis use (Galvez-Buccollini et al., 
2012). Other lines of research have looked at the link between psychotic 
symptoms and different illicit substances in separation. To illustrate, studies 
have reported increased risk of developing psychotic symptomatology in relation 
to methamphetamine use (McKetin, Lubman, Baker, Dawe, & Ali, 2013) and 
cocaine use (B. D. Power et al., 2014; Vorspan et al., 2012). Nevertheless, when 
looked at the effects of multiple substances in separation in a sample of 
polystimulant dependent users, it was reported that frequency of cannabis use in 
the last month had the strongest association with positive symptoms severity, 
followed by frequency of methamphetamine use (Willi et al., 2016). Similarly, 
in stimulant users, a history of CUD was linked to risk of transient psychotic 
symptoms in cocaine abusers (cocaine-induced psychosis, CID) (Roncero et al., 
2013). It was also reported that age of onset of cannabis use predicted CID in 
cocaine abusers (Kalayasiri et al., 2010; Trape, Charles-Nicolas, Jehel, & 
Lacoste, 2014) and increases in cannabis use over time significantly increased 
the risk for the emergence of psychotic symptoms in chronic methamphetamine 
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user (McKetin et al., 2013). Finally, it was reported that frequency of cannabis 
use in the last month but not frequency of cocaine, opioid and alcohol use in the 
last month was significantly linked to positive symptomatology in polystimulant 
users (Willi et al., 2016). Together those results may indicate some specificity 
related to cannabis, i.e. cannabis as a substance that induces psychotic symptoms 
(even in polysubstance users). Furthermore, when controlled for tobacco, 
alcohol and other drug use, heavy use of high-potency cannabis remained a 
significant and strong predictor for onset of psychosis (Di Forti, Marconi, et al., 
2015), indicating that those substances did not (fully) mediate the effects of 
cannabis use. Other independent studies that controlled for comorbid illicit drug 
use and cigarette use are in further support of an association between cannabis 
use and risk of psychosis (David M Fergusson et al., 2005; Henquet et al., 2004; 
Zammit, Allebeck, Andreasson, Lundberg, & Lewis, 2002)  
(2)!The association between cannabis and psychosis is the results of “self-
medication”, i.e. those who are mentally less well are more likely to use the 
substance in order to relieve their symptoms (Khantzian, 1985). For instance, it 
has been suggested that the emergence of psychotic symptoms in the context of 
cannabis use may be associated with a pre-existing (genetic) vulnerability for 
psychosis (McGuire et al., 1995). Some longitudinal studies have addressed this 
issue by temporal sequencing of the variables of interest (Henquet et al., 2004; 
Kuepper et al., 2011b), i.e. assessing subsequent development of psychosis 
following the onset of cannabis use. Furthermore, when adjusting for pre-
existing psychotic symptoms, cannabis use was still a significant predictor for 
subsequent psychotic symptomatology (David M Fergusson et al., 2005; 
Henquet et al., 2004; J. McGrath et al., 2010). However, those studies do not 
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fully address the question as to whether the association may be a result of 
reverse causation (i.e., psychosis risk leading to cannabis use). Studies 
examining the issue of reverse causation support either a bi-directional 
relationship (Ferdinand et al., 2005) or a unidirectional risk-effect (David M 
Fergusson et al., 2005; Henquet et al., 2004; Henquet et al., 2010; Kuepper et 
al., 2011b; Hélène Verdoux, Gindre, Sorbara, Tournier, & Swendsen, 2003) 
from cannabis use to risk of development of psychosis. Hence, there is no clear 
evidence in support of an increase in cannabis use as a result of self-medication 
that could explain the association found in cross-sectional studies. Using a more 
short-term temporal analysis by employing the experience sampling method 
(ESM), it was reported that cannabis use in healthy subjects was linked to 
subsequent increase in psychotic symptoms (Henquet et al., 2010), but that this 
effect was only present during the intoxication status and did not remain beyond 
a 3h interval (Hélène Verdoux et al., 2003). Furthermore, the emergence of 
psychotic symptoms were not linked to a subsequent increase in cannabis use 
(Henquet et al., 2010; Hélène Verdoux et al., 2003), which adds to the body of 
evidence that opposes the notion of self-medication, at least during the acute 
phase of symptoms.  
(3)!The link between cannabis use and psychosis is due to uncontrolled sources of 
confounding. For instance, the first longitudinal study on this topic (Andréasson 
et al., 1987) was criticized since the important confounding factors were not 
considered in their analysis. However, re-analysing this data revealed that the 
effect of cannabis use on risk of developing schizophrenia – which was present 
in a dose-dependent manner – could not be explained by the inclusion of the 
confounders defined as other drug use, cigarette and alcohol use, as well as 
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personality traits (Zammit et al., 2002). Besides, the most recent debate is 
concerned with the “shared-vulnerability” hypothesis, which proposed that the 
association reflects the result of a (genetic) liability for both cannabis use and 
the risk of developing psychosis. To illustrate, it has been proposed that some 
individuals have and increased susceptibility for generally “problem behavior”, 
including cannabis use, psychosis and other mental health conditions (Ksir & 
Hart, 2016a). For instance, a meta-analysis reported that the proportion of 
variance accounted for by genes for (i) initiation of cannabis use and (ii) 
problematic cannabis use was (i) 48%/40% (males/females) and (ii) 51%/59% 
(males/females) and there was evidence of a genetic overlap between cannabis 
initiation and problematic use of cannabis (Verweij et al., 2010), indicating that 
the genetic vulnerability to continue using cannabis partly overlaps with the 
genetic vulnerability to initiate cannabis. The question of interest from a 
“shared-vulnerability” point of view is now whether such genetic vulnerability 
also overlaps with the vulnerability for psychosis, which has been explored in 
only a few studies to date. For instance, one study showed that a small 
proportion of frequency of cannabis use in the general population was explained 
by the polygenic risk score for schizophrenia (R. A. Power et al., 2014). 
Similarly, it was reported that a higher morbid risk of schizophrenia was present 
in relatives of patients who use cannabis when compared to patients who did not 
use cannabis (McGuire et al., 1995). If cannabis had a unique contribution, one 
would also expect a higher risk of having a family history of schizophrenia in 
those not using cannabis prior to the onset when compared to those who were 
using the substance, which was not the case in the report by J. Boydell et al. 
(2007). Finally, a higher familial risk for psychosis was present in cannabis 
[89] 
 
using subjects who developed subsequent psychosis when compared to cannabis 
using subjects who did not develop psychosis, indicating that cannabis alone 
may not increase the risk for psychosis without the genetic component (Proal, 
Fleming, Galvez-Buccollini, & DeLisi, 2014). In sum, although this evidence 
may indicate that there is some shared genetic vulnerability between cannabis 
use and schizophrenia, those studies do not allow to draw conclusions as to 
whether the effect of cannabis on psychosis can be fully explained by such a 
contribution and some evidence is rather opposed to the hypothesis of a fully 
genetically confounded association. For instance, one study compared GWAS 
data concerning cannabis use with GWAS data on 5 different psychiatric 
disorders; they found a very small overlap with depression but none with 
schizophrenia (Sherva et al., 2016a). Similarly, Di Forti, Vassos, et al. (2015) 
reported that cannabis using FEP patients did not significantly differ in they 
polygenic risk score for psychosis when compared to non-users. Finally, a 
longitudinal study found an increased risk for the development of schizophrenia 
that was significantly linked to frequency of premorbid cannabis use when 
family history of schizophrenia was taken into account (Andréasson, Allebeck, 
& Rydberg, 1989). Taking this line of evidence into consideration, it seems 
more plausible that – if any shared genetic vulnerability exists – it would explain 
only a small proportion of the cannabis-psychosis association. Nevertheless, in 
order to properly address issues of confounding (including genetic and 
environmental), it has been suggested that an “unequivocal proof of cannabis 
exposure causing psychosis would require the experimental manipulation of 
cannabis use, with other confounding factors controlled for by random 
assignment of participants to different groups” [cf. Ksir and Hart (2016a), Page 
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3, Paragraph 4], i.e. a placebo-controlled, randomised clinical trial (RCT) 
involving experimental cannabis administration, which is not feasible in FEP 
patients for of ethical reasons. Nevertheless, a quasi-experimental approach 
involving the assessment of within-individual changes in cannabis use over time 
has been proposed as a compelling alternative, an approach that is considered 
only second best to RCT when examining causality (J. Murray, Farrington, & 
Eisner, 2009). The application of such a design, also called fixed-effects analysis 
of longitudinal panel data (McKetin et al., 2013; Schoeler, Monk, et al., 2016), 
would allow the adjustment of unobserved time-invariant confounding factors 
such as shared genetic and environmental factors that do not change over time  
as well as those observed potential confounding factors that change over time. 
This model is comparable to the method of the sibling-pair design, in which 
identical twins discordant for cannabis use are matched in unmeasured time-
invariant factors including genetic and environmental factors. When employing 
such analysis, David M Fergusson et al. (2005) reported that the effect on risk of 
psychotic symptoms remained significant, which does not support the 
hypothesis that the association arose due to a shared a genetic vulnerability, 
consistent with independent evidence in chronic methamphetamine users 
without a comorbid diagnosis of psychosis, in whom change in frequency of 
cannabis use was linked to the risk of presence of psychotic symptoms (McKetin 
et al., 2013). This is also in accordance with a study that employed a sibling-pair 
design to control for some of the shared genetic (<50%) and environmental 
influence by J. McGrath et al. (2010), which found that duration of cannabis use 
was a significant predictor of psychotic outcome in young adults. Those studies 
(David M Fergusson et al., 2005; J. McGrath et al., 2010; McKetin et al., 2013) 
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are also suggestive of a dose-response relationship between frequency of 
cannabis use and psychotic symptoms when controlling for pre-exposure 
confounding factors, an important criteria when establishing causality (A. B. 
Hill, 1965). In accordance, there is evidence that reported an increased risk for 
subsequent psychosis linked to cannabis frequency when controlled for other 
factors that indicate risk taking behavior/addictive traits (other drug use, alcohol 
use, cigarette use) (Zammit et al., 2002). Therefore the accumulated evidence is 
in favour of cannabis as a contribution factor for psychosis, even if genetic 
influences such as “shared-vulnerability” are taken into consideration.  
To summarise, although there are still scepticisms questioning a causal relationship 
between cannabis use and risk of psychosis (Ksir & Hart, 2016a) and patients with 
psychosis often do not believe that cannabis is a causal factor linked to their illness 
(Buadze, Stohler, Schulze, Schaub, & Liebrenz, 2010), there is nevertheless good-
quality evidence to believe that cannabis use is a causal risk factor for the development 
of psychotic disorders (Robin M. Murray & Di Forti, 2016). Nevertheless, it has been 
concluded that cannabis is not a sufficient cause for psychosis but rather constitute a 
component cause (Henquet et al., 2004), interacting with other factors such as family 
history of psychosis, genetic factors, childhood trauma/abuse and age of onset of use 
(Radhakrishnan, Wilkinson, & D’Souza, 2015). 
 
2.5.3 SUMMARY 
Chapter 2 has shown that cannabis is a complex plant and extracts of the plant 
contain a range of chemicals that affect human behaviour in different ways.  Although 
longitudinal evidence regarding the effects of cannabis use and the risk of development 
of psychiatric disorders has accumulated over the last decade, this topic is still a matter 
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of debate. There is now evidence supporting a link between cannabis use and the risk of 
poor mental health outcomes, such as the development of psychosis (Di Forti, Marconi, 
et al., 2015; David M Fergusson et al., 2005; Marconi et al., 2016; T. H. Moore et al., 
2007), depression (Schoeler et al., under review), anxiety (Whiteford et al., 2013), 
bipolar disorder (Lagerberg et al., 2011; Van Laar et al., 2007), cognitive impairments 
(Meier et al., 2012; Schoeler et al., 2015) and substance use disorders (SUD) (Blanco et 
al., 2016). While the results are largely consistent with regard to conditions such as 
psychosis and SUD, there is evidence that does not support a link between cannabis and 
other outcomes, such as depression (Blanco et al., 2016; Danielsson et al., 2016; 
Whiteford et al., 2013),  anxiety (Blanco et al., 2016; Danielsson et al., 2016), changes 
in cognition (N. J. Jackson et al., 2016) and bipolar disorder (Blanco et al., 2016). 
Discrepancies across studies perhaps relate to the different methodologies employed and 
the limitations inherent to them, such as the use of cross-sectional designs, insufficient 
power to detect significant effects, the non-consideration of important confounders, the 
lack of exploration of dose-response patterns, a focus on varying age ranges or 
differences in geographic locations, which makes it difficult to derive at a more 
confident conclusion regarding the effects of cannabis use mental health conditions. 
Furthermore, different outcomes of interest (in this case mental health conditions) 
require the implementation of different methodological considerations. For instance, 
period of abstinence from cannabis is a crucial factor when assessing the non-acute 
effect of cannabis on cognitive outcome, while close monitoring of early patterns of 
cannabis use is particularly important for conditions that usually manifest early in life 
such as psychotic disorders. The application of a life-span approach would be 
particularly important when looking at behavioral changes that are more likely to occur 
later in life such as depressive disorders. Finally, once a (causal) risk factor is identified, 
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it needs to be evaluated whether its impact is of relevance for policy makers, i.e. 
whether efforts for prevention would actually lead to noticeable changes in terms of 
personal costs (e.g. preventing mental health problems, improving cognition) and 
economic costs (e.g. decreased hospital costs, reduced loss in productivity due to 























2.6 CONTINUED CANNABIS USE IN PATIENTS WITH PRE-EXISTING 
PSYCHOSIS 
2.6.1 INTRODUCTION 
Cannabis use and the presence of cannabis use disorders (CUD) are common in 
patients with a first episode psychosis. Varying rates of comorbidity have been reported, 
depending on the specific definition of cannabis use. For instance, as shown in Figure 
8., the presence of lifetime (light) cannabis use was reported by an average of 58% 
(range 20%-89%) of patients at onset of the illness, while a history of heavy lifetime use 
prior to the onset was reported by about 32% (19%-50% range). The prevalence rates of 
patients who reported current use at onset come to estimates of about 39% (10%-56%) 
for current (light) cannabis use and 30% (10%-55% range) for current heavy cannabis 
use (cf. Figure 9.). Those rates are much higher when compared to estimates from the 
general population for annual use in young adults (~12%) in Europe (EMCDDA, 2015). 
A meta-analysis found that 44% of FEP patients present with a lifetime cannabis use 
disorder (CUD) and 29% with a current CUD (Johanna Koskinen, Löhönen, Koponen, 
Isohanni, & Miettunen, 2010), whereas the general population rates are usually around 
10% for lifetime CUD (Haberstick et al., 2014) and about 3% in those aged 14-17 
(Wittchen et al., 2007). In a separate meta-analysis, the pooled prevalence rate of 
cannabis use present at onset (presence of CUD or at least monthly use) was identified 
as 35% (35 samples, 95% Confidence Interval = [31%-39%]) (Myles, Myles, & Large, 
2015). This is in line with case-control studies that reported much higher rates of current 
cannabis use in patients with an FEP when compared to healthy controls [30% vs. 11% 
for current use (at least daily)] (Di Forti, Marconi, et al., 2015) and when compared to 
controls with non-psychotic mental illness [38% vs. 17% for current use (any use in the 
3 months prior onset)] (Paruk, Jhazbhay, Singh, Sartorius, & Burns, 2016), although 
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those groups did not differ with regard to lifetime history of cannabis use (Di Forti, 
Marconi, et al., 2015; Paruk et al., 2016). In contrast, rates for other substances 
including tobacco and alcohol are not always higher in FEP patients and when 
compared to non-psychotic controls with mental illness (Paruk et al., 2016) and FEP 
patients did not differ from healthy controls with regard to alcohol consumption and use 
of other illicit drugs (Di Forti et al., 2012). Those mainly self-report based prevalence 
rates for cannabis use at onset  are likely to be representative estimates, considering that 
results from urine drug screens usually have high concordance with data from self-
reports (Baeza et al., 2009; Batalla et al., 2013b; Di Forti et al., 2012). Other evidence 
suggests that the rates of cannabis use in FEP patients may have risen over time. For 
instance, in London the prevalence of cannabis use (any use in the year prior to the 
presentation) in first episode psychosis individuals (first presentation schizophrenia) 
was found to be about 5% in the 1960th and has risen to 50% in the 1990th (J Boydell et 
al., 2006). This increase in prevalence was not found in patients with other non-
psychotic psychiatric disorders from the same area (J Boydell et al., 2006). When 
compared to other SUDs, CUD has been reported to be the most commonly SUD 
diagnosed at onset (17%), followed by AUD (alcohol use disorder) (11%) and stimulant 
use disorder (2%) in FEP patients (Cantwell et al., 1999), which is similar to the rates 
that were reported at onset of illness in another FEP cohort (e.g. 14% CUD only, 10% 
AUD only, 3% other SUD) (Van Mastrigt et al., 2004). Similarly, in ultra-high-risk 
individuals, cannabis is the most commonly used and abused drug, with higher 
prevalence when compared to other illicit drugs (Valmaggia et al., 2014) and rates of 
abuse that are higher when compared to alcohol (Auther et al., 2015). FEP patients may 
also differ from the general population with regard to their preferred type, since it was 
found that patients were more likely to use high-potency forms of cannabis (skunk-type) 
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than healthy controls (53% vs. 19%) and less likely to use milder forms (hash-type) 
(14% vs. 44%) (Di Forti, Marconi, et al., 2015). From these estimates it is clear that 
cannabis is a commonly used drug of abuse in those presenting with their first episode 
of psychosis. However, with regard to the effects of cannabis use on outcome in FEP, 
the crucial question is whether cannabis use remains a prevalent problem following 
onset of psychosis, i.e. whether those who are users at onset continue to use the 
substance or whether non-users at onset start using the substance following the onset. 
Frist, cannabis remained the most prevalent drug of use when assessed at follow up 
(Lange et al., 2014). In fact, all FEP subjects that with a diagnosis of SUD at follow up 
reported to be cannabis abusers (Levy et al., 2012). Similarly, D Wade et al. (2006) 
reported that CUD was most common (42%) at follow up, followed by AUD (30%) and 
stimulant use disorder (17%) (D Wade et al., 2006). This is consistent with reports from 
patients with established schizophrenia, in which the most prevalent use disorder was 
found to be CUD (11%), followed by stimulant use disorder (9%) and opioids use 
disorder (4%) (Kivimies et al., 2016). Encouragingly, there is a relatively high 
proportion of patients who stop using the substance following the onset. For instance, 
studies reported that there is a significant decrease in the prevalence of cannabis use 
between onset and the first year of follow up (Baeza et al., 2009; Hinton et al., 2007; 
Seddon et al., 2015). In line with this, a recent meta-analysis reported that patients with 
FEP significantly reduced cannabis intake (number of days used) between onset and 
follow up (Rebgetz, Kavanagh, & Hides). As illustrated in Figure 9. below., between 
24% and 66% (mean of 46%) of those with baseline cannabis use decrease or stop using 
the substance. Moreover, the rate of those who start following the onset is relatively 
low, ranging between 0% and 33% (mean of 11%). On the other hand, there is a large 
proportion of patients who continue using the substance, with an overall estimate of 
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46% found here (range 26% - 63%, cf. Figure 9.). The results implicate that data on 
premorbid (lifetime cannabis use) or cannabis use at onset may not be valid measures 
for risk on outcome, since the course of cannabis use varies greatly following the onset. 
However, one limitation inherent to these follow up studies potentially lies in their way 
of classifying cannabis users into continuers, discontinuers, starters and non-users, 




























                                                             
1 Note. Summary of prevalence rates reported by studies in FEP patients (cf. aTable 




Table 9. Cannabis use profiles in follow up studies in FEP patients 
Study Non-user Discontinuer Continuer Starter 
B. 
Schimmelmann 
et al. (2012) 
Absence CUD at 
BL and FU 
Presence CUD at 
BL, decrease in 
quantity >50% at 
FU 
Presence CUD at 
BL and no change 
in quantity of 
increase (>50%) at 
FU 
Absence of CUD 
at BL and 
presence of CUD 
at FU 
Seddon et al. 
(2015) 
No use reported at 
BL and FU 
Use (>1) 3 months 
prior BL but not 3 
months prior FU 
Use (>1) 3 months 
prior BL but and 
use 3 months prior 
FU 
No use (<1) 3 
months prior BL 
but and use (>1) 3 
months prior FU 
J. Stone et al. 
(2014) 
No use (<1) 
reported at BL and 
FU 
Reduced use at FU 
than BL 
Use (>1) reported 
at BL and FU 
- 
L. Clausen et al. 
(2014) 
No use (<1) one 
year prior BL and 
one year prior FU 
Use (>1) one year 
prior BL, no use 
(<1) one year prior 
FU 
Use (>1) one year 
prior BL, use (>1) 
one year prior FU 
No use (<1) one 
year prior BL, use 
(>1)  one year 
prior FU 
Faber et al. 
(2012) 
No use (>1) at 
onset and FU 
Use (>1) at onset, 
discontinued 
subsequently 







Absence CUD at 
BL and FU 
Presence CUD at 
BL, absence CUD 
FU 
Presence CUD at 
BL, absence CUD 
FU 
Absence CUD at 
BL, presence CUD 
FU 
González-Pinto 
et al. (2011) 
No use (< 4) in 
year before onset, 
no use (< 4) in 
year before FU 
Use (> 4) in year 
before onset, no 
use (< 4) in year 
before FU 
Use (> 4) in year 
before onset, use 
(> 4)  in year 
before FU 
No use (< 4) in 
year before onset, 
use (> 4)  in year 
before FU 
Miller et al. 
(2009) 
Absence CUD at 
BL no use (<1) 
throughout FU 
Presence CUD at 
BL, no use (<1) 
throughout FU 
Presence CUD at 
BL, use (>1) 
throughout FU 
Absence CUD at 
BL, use (>1) 
throughout FU 
Anton Grech, 
Jim Van Os, 
Peter B. Jones, 
Shon W. Lewis, 
and Robin M. 
Murray (2005a) 
No history of 
(regular/frequent) 
use at BL, no use 




use at BL, no use 




use at BL, use (>1) 
in 3 months prior 
FU 
No history of 
(regular/frequent)  
use at BL, use (>1) 
in 3 months prior 
FU 
Barbeito et al. 
(2013) 
No use (<1) at BL 
and FU 
Use (>1) at BL 
and no use (<1) 
FU 
Use (>1) at BL 
and use (>1) FU 
No use (<1) at BL 
and use (>1) FU 
Hinton et al. 
(2007) 
No use (<1) in 1 
month prior BL, 
no use at FU 
Use (>1) in 1 
month prior BL, 
no use at FU 
Use (>1) in 1 
month prior BL, 
use at FU 
No use (<1) in 1 
month prior BL, 
use at FU 
Baeza et al. 
(2009) 
No use (<1) in 1 
month prior onset, 
no use (<1) in 1 
month prior FU 
Use (>1) in 1 
month prior onset, 
no use (<1) in 1 
month prior FU 
Use (>1) in 1 
month prior onset, 
use (>1) in 1 
month prior FU 
No use (<1) in 1 
month prior onset, 
use (>1) in 1 
month prior FU 




When presenting with a first episode psychosis, cannabis-using patients have 
been shown to be different from non-using patients in a range of variables. For instance, 
cannabis-using FEP patients were characterised by a younger age of onset (Barnes, 
Mutsatsa, Hutton, Watt, & Joyce, 2006; Clausen et al., 2013; Di Forti, Marconi, et al., 
2015; Foti, Kotov, Guey, & Bromet, 2010; González-Pinto et al., 2011; Patel R et al., 
2016; Seddon et al., 2015; Stirling, Lewis, Hopkins, & White, 2005; Van Mastrigt et al., 
2004), higher uses of other illicit drugs (Gonzalez-Blanch et al., 2015), more severe 
psychotic symptoms (Baeza et al., 2009; Seddon et al., 2015; Stirling et al., 2005), as 
well as reduced insight into the illness (B. G. Schimmelmann et al., 2012). These 
correlates are similar to those that were linked to continued cannabis use following the 
onset. For instance, continued cannabis use was linked to higher uses of alcohol 
(González-Pinto et al., 2011) and other illicit drug use (González-Pinto et al., 2011), 
younger age of onset (L. Clausen et al., 2014; González-Pinto et al., 2011), higher 
premorbid IQ (L. Clausen et al., 2014), medication non-adherence (L. Clausen et al., 
2014; Foglia et al., 2017). Therefore, those factors are important to consider in 
prediction models looking at the effect of continued cannabis use in patients with 
psychosis, since they may confound the association between cannabis use and outcome. 
 
2.6.2 CONTINUED CANNABIS USE IN FIRST EPISODE PSYCHOSIS: CLINICAL AND 
FUNCTIONAL OUTCOME 
Numerous studies have looked at levels of symptoms severity by comparing 
cannabis using patients to non-using controls. When assessed at onset, the evidence is 
rather mixed, reporting either increased positive symptoms in cannabis using patients 
when compared to non-users (Baeza et al., 2009; Seddon et al., 2015; Stirling et al., 
2005), although there are several studies that did not find differences between the two 
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groups in terms of positive symptoms (Compton, Furman, & Kaslow, 2004; Gonzalez-
Blanch et al., 2015; González-Pinto et al., 2011; Hinton et al., 2007; Van Mastrigt et al., 
2004). Findings are more consistent if studies investigated the effect of different 
patterns of cannabis use following the onset, such as continuation and discontinuation of 
cannabis use. For instance, in my meta-analysis (Schoeler, Monk, et al., 2016), I found 
that continued use was linked to higher positive symptoms, while no such effect was 
present in those who discontinued using cannabis following the onset. Other FEP 
studies have reported that continued cannabis use was linked to an increase in 
symptoms from onset to follow up (Foti et al., 2010; Rais et al., 2008; Seddon et al., 
2015). Continued cannabis use was also linked to higher risk of non-remission at follow 
up when compared to non-users (B. Schimmelmann et al., 2012). Those who 
discontinue or reduced their cannabis intake following the onset appeared to have the 
best outcome in terms remission status (B. Schimmelmann et al., 2012).  
Unlike the more robust findings on positive symptomatology in the context of 
ongoing cannabis use, the association between level of functioning over the course of 
the illness, as well as the severity of negative symptomatology in the context of 
cannabis use has not yet been well established. When assessed at onset, cannabis using 
patients are generally not significantly different from non-using patients in their level of 
functioning (L. Clausen et al., 2014; Gonzalez-Blanch et al., 2015; González-Pinto et 
al., 2011; Hinton et al., 2007). This is also in accordance with reports of no significant 
differences in premorbid adjustment between cannabis users and non-users in FEP 
patients (Baeza et al., 2009; Elkins, 2004; Stirling et al., 2003; Van Mastrigt et al., 
2004). Similarly, with regard to negative symptoms, studies that assessed FEP patients 
at onset have reported that cannabis users were characterised by fewer negative 
symptoms (Baeza et al., 2009; Compton et al., 2004), although other studies did not find 
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differences in negative symptomatology between users and non-users in FEP patients at 
onset (Gonzalez-Blanch et al., 2015; González-Pinto et al., 2011; Hinton et al., 2007; 
Seddon et al., 2015; Stirling et al., 2005). Overall, there is no consistent evidence that 
cannabis use is linked to higher levels of functioning, including premorbid adjustment 
and negative symptoms when assessed at onset. This association is perhaps somewhat 
different over the course of the illness, e.g. frequency of cannabis use assessed at onset 
of illness has been found to predict level of functioning 10 years later (Bergh et al., 
2016). Furthermore, continued cannabis use was linked to lower GAF scores at follow 
up when compared to non-users (B. Schimmelmann et al., 2012). Interestingly, those 
FEP patients who discontinued or reduced their cannabis intake following the onset 
appeared to have the best outcome in terms of functioning (B. Schimmelmann et al., 
2012). This was also confirmed in my recently published meta-analysis (Schoeler, 
Monk, et al., 2016), which showed that patients with psychosis (at all stages of their 
illness) who continued to use cannabis were not different in their level of functioning, 
while those discontinued to use cannabis following the onset where characterised by 
higher levels of functioning when compared to non-users. No effect of discontinuation 
was present with regard to negative symptom severity at follow up (Schoeler, Monk, et 
al., 2016). Nevertheless, studies that looked at changes over time reported that 
discontinued cannabis users had larger improvements in functioning when compared to 
those continued (González-Pinto et al., 2011; J. Stone et al., 2014), although not all 
studies are in support of this (Hinton et al., 2007).  No differences in changes in 
symptoms between continuer and discontinuer were present for negative symptoms 
(González-Pinto et al., 2011; Hinton et al., 2007). Using a longitudinal analysis to 
estimate the effects of change in cannabis use over time, it was reported that FEP 
patients were not characterised by higher negative symptoms in periods when they were 
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using cannabis when compared to periods when they were not using cannabis following 
the onset (Foti et al., 2010).  
With regard to cognitive outcome in psychosis, its relation to continued cannabis 
use is still poorly understood. In fact, there is an almost consistent paradoxical finding 
that has been reported by studies investigating this issue; First, when tested at onset, 
heavy cannabis users (daily use) were characterized by fewer neurological soft signs 
when compared not non-users (Ruiz-Veguilla et al., 2009) and onset users (any use) 
performed better in measures for short-term memory (Stirling et al., 2005) , visual 
memory (Stirling et al., 2005), tests assessing attention and psychomotor speed 
(Donoghue & Doody, 2012), and performance in reasoning, problem-solving and visual 
memory (Potvin, Joyal, Pelletier, & Stip, 2008). Similarly, it was reported that 
premorbid cannabis use significantly predicted better cognitive function at onset 
(Leeson et al., 2012), and that this effect was explained by higher levels of premorbid 
function present in cannabis users when compared to non-users (Leeson et al., 2012). 
With regard to cognitive outcome following the onset, the findings seem equally 
paradoxical: For instance, cannabis users were not significantly different in tests 
assessing short-term memory (Power et al., 2015; Sevy et al., 2007) or long-term 
memory (Sevy et al., 2007) or decision making (Sevy et al., 2007). Furthermore, a 
recent study found that FEP patients with a history of early onset cannabis use 
performed better on cognitive measures than those without (Hanna et al., 2016).  When 
pooling together the available evidence in my meta-analysis (Schoeler, Kambeitz, et al., 
2016), I found that cannabis using patients performed better in tests assessing memory 
function when compared to non-users (d = −0.11), particularly for the domains of visual 
immediate recall (d = −0.73), verbal recognition (d = −0.34) and visual recognition (d = 
−0.41). A recent meta-analysis also reported that psychotic patients with unspecified co-
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morbid substance use disorder performed significantly better in tests measuring verbal 
learning and memory (d = −0.26) than those without (Donoghue & Doody, 2012). In 
this context, it has been proposed that while patients with schizophrenia are thought to 
have a neurodevelopmental disorder (R. M. Murray & Lewis, 1987), drug abuse may 
provide an alternative pathway to developing psychosis (Robin M Murray, Paparelli, 
Morrison, Marconi, & Di Forti, 2013). Such a view would suggest that cannabis using 
patients with psychosis may represent a subgroup with less neurodevelopmental 
pathology and less neurocognitive impairment than non-using patients in the first place 
(Schoeler et al., 2015). Problematically, those studies cited here are cross-sectional in 
their nature and do not allow to draw conclusions regarding the effects of ongoing 
cannabis use and cognitive outcome, which should be assessed in terms of cognitive 
change between onset of illness and follow up. For instance, using a longitudinal 
assessment, a neuroimaging study reported a loss of cortical thickness linked to 
cannabis use in the 5 years following the onset, which was reported to be present in 
areas rich of CB1 receptors such as ACC and the DLPFC (Rais et al., 2010). This may 
indicate adverse effects of ongoing cannabis use on cognition, although further studies 
are necessary that specifically test this hypothesis. 
Other follow up studies looked at outcome defined in terms of affective 
symptoms and anxiety, although evidence on the effect of continued cannabis use in 
FEP patients is still sparse. For instance, substance abuser (60% cannabis user) where 
more likely to report suicidal behaviour in 2 years following the onset (H Verdoux et 
al., 2001). Similarly, FEP subjects with onset cannabis use were more likely to commit 
a suicide attempt following the onset than non-users (Ayesa-Arriola et al., 2015). A 
recent review concluded that there is a relatively robust link between suicidal behavior 
and cannabis use in patients with psychosis (that are  at different stages of their illness), 
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although a summary of the current evidence appears challenging due to the 
heterogeneous methodological designs employed by the studies (Serafini et al., 2012). 
Other studies reported that patient who continued to use cannabis (use at baseline and 
follow up) were more severely depressed than non-users at follow up (Seddon et al., 
2015; J. Stone et al., 2014). However, other reports do not support the link between 
continued cannabis use and depression when assessed at follow up (Baeza et al., 2009; 
Hinton et al., 2007). More conclusive evidence comes from studies that assessed 
changes in depression severity over time. For instance, in a longitudinal study using 
fixed effects analysis that allowed to control for time-invariant sources of 
(environmental and genetic) confounding, change in cannabis use in FEP patients was 
not linked to changes in depression severity (Foti et al., 2010). Similarly, Degenhardt et 
al. (2007) reported that changes in cannabis use were not significantly linked to changes 
in depressive symptoms, which were only predicted by level of prior depressive and 
psychotic symptoms and prior use of amphetamines in a sample with established 
schizophrenia. Similarly, when testing the reverse direction, changes in cannabis use 
were not preceded by change in depressive symptoms (Degenhardt et al., 2007). In fact, 
when comparing patients with psychosis (at all stages of psychosis) in my meta-
analysis, I found that cannabis using patients were less depressed than those who were 
considered as non-users (Schoeler, Kambeitz, et al., 2016). Overall, while there is some 
(although conflicting) evidence suggestive of cannabis use as a potential risk factor for 
later life affective symptoms and anxiety in the general population (cf. Chapter 2.5 
above), so far the evidence regarding the effects of cannabis use on depressive 
symptoms in young patients with a first episode psychosis is not indicative of changes 
in depressive symptoms following cannabis use. Nevertheless, future follow up studies 
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using longer follow up durations when investigating changes in depression severity are 
needed in this context to draw more confident conclusions. 
Finally, an important factor to outline in this section is the issue of medication 
non-adherence in patients with psychosis, which is considered as a major problem in the 
treatment of patients with psychosis. For instance, estimates from systematic reviews 
indicate that an average of 26% of patients with established psychosis are not adherent 
(Nose et al., 2003), although a recent review concluded that rates vary greatly (reported 
rates between 47% and 95%) across studies (Sendt et al., 2015). Reports from follow up 
studies in FEP patients indicate a rate of approximately 37% non-adherence in patients 
followed up within the first two year of the illness, 29% in those followed up between 
two to five years and about 49% in those followed up for more than five years (cf. 
Figure 1. above). This factor has been consistently linked as a predictor for poor 
outcome, including risk of relapse and suicide (Higashi et al., 2013; Schoeler, Petros, Di 
Forti, Klamerus, et al., 2016). Studies investigating adherence to treatment in the 
context of cannabis use mainly reported that patients who continued using cannabis 
following the onset were less adherent to their medical treatment plan than their non-
using comparisons, as reported by a recent meta-analysis (Foglia et al., 2017). It is 
therefore plausible that medication non-adherence could act as a mediator between 
cannabis use and outcome. For instance, it has been reported that non-compliance 
mediated the relationship between continued cannabis use in the first year following the 
onset and risk of non-remission in patients with psychosis (Colizzi et al., 2015). In this 
context, it has been suggested that patients may use cannabis as a form of self-
medication to relive their symptoms (Khantzian, 1985) and prefer using the cannabis 
instead of antipsychotic medication due to the lack of side effects. Nevertheless, it was 
reported that cannabis use remained a predictor for poor outcome even if patients are 
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adherent to antipsychotic medication (Faridi et al., 2012; Hides, Dawe, Kavanagh, & 
Young, 2006; Sorbara, Liraud, Assens, Abalan, & Verdoux, 2003). As one mechanism 
of action, it has been proposed that cannabis may increase the risk of non-response to 
antipsychotic medication (Patel R et al., 2016). For instance, onset cannabis use 
predicted treatment failure (defined as the number of unique antipsychotics prescribed) 
within the 2 years following the onset (Patel R et al., 2016). In contrast, another 
observational study reported that onset presence of CUD was not significantly linked to 
response to antipsychotic medication within the acute phase of the illness (6 weeks from 
start of treatment) (Crespo-Facorro et al., 2007) and in a 5-year follow up, continued 
cannabis use was not linked to the cumulative amount of antipsychotic medication 
prescribed (Rais et al., 2010). However, this is not in line with experimental evidence 
that showed that haloperidol did not reduce the psychotogenic effects following THC 
administration (D’Souza et al., 2008). To conclude, there is no clear evidence to date as 
to whether cannabis is likely to lead to non-response to antipsychotic medication, for 
which reason further research is warranted to shed light into this question. 
 
2.6.3 SUMMARY  
While to date there is good evidence to believe that cannabis plays a causal role 
in the development of psychotic disorders (Robin M. Murray & Di Forti, 2016), 
evidence with regard to outcome in first episode psychosis is less clear. Overall, it 
seems important to distinguish between the different outcomes that have been assessed 
(functional, symptomatic, cognitive). The evidence appears to be more consistent with 
regard to symptomatic outcome than functional outcome. For instance, while FEP 
patients were characterised by more severe positive symptoms in periods in which they 
used cannabis, no such effects were present for negative symptoms or levels of 
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depression (Foti et al., 2010). Furthermore, it became obvious that cannabis measures 
that incorporate the varying course of the cannabis use patterns following the onset are 
of crucial relevance since those changes may be drivers in the cannabis-outcome 
association. Taking into account the limitations from the available evidence therefore 
highlights the importance of using longitudinal assessments of change in outcome (e.g. 
change in symptoms, relapse following the onset) instead if comparing the groups in 
outcome measures at follow up in a cross-sectional manner. For instance, while 
continued cannabis users did not differ from FEP non-users in their negative or positive 
symptoms at follow up, continued users did in fact show significant less improvements 
in their symptoms when compared to non-users (Rais et al., 2010). Evaluating the 
outcome in cannabis using patients is further complicated by the fact that users are 
likely to differ in many factors – i.e. factors that may confound the relationship- from 
the non-users, including the more easily assessable demographic characteristics such as 
age (age of onset), gender, ethnicity, or observable factors that can be measured over 
time such as medication adherence, other drug use, as well as unmeasured time-
invariant factors that may impact on the association such as genetic contributions. 
Considering that cannabis use is a modifiable factor that is accessible for direct 
treatment, there is the urgent need to further investigate the role of continued cannabis 
use following the onset of psychosis since this has the potential to reduce the emotional 






3 PAPER 1: CONTINUED VERSUS DISCONTINUED CANNABIS USE 
IN PATIENTS WITH PSYCHOSIS: A SYSTEMATIC REVIEW AND 
META-ANALYSIS 
3.1 ABSTRACT 
Background. Although the link between cannabis use and development of psychosis is 
well established, less is known about the impact of continued versus discontinued 
cannabis use after the onset of the illness. No meta-analysis has as yet summarized the 
evidence focusing on the relationship between continued and discontinued cannabis use 
following onset of psychosis and its relapse. 
Methods. Studies were identified through a systematic literature search. Relapse 
outcomes were compared between those who continued (CC) or discontinued (DC) 
cannabis use or were non-users (NC). Cohen’s d was estimated and entered into 
Random Effects Models (REM) to compare (1) CC-NC, (2) CC-DC and (3) DC-NC. 
Meta-regression and sensitivity analysis were employed to address the issue of 
heterogeneity.  
Findings. Twenty-four studies (N=16565) were included. Independent of the stage of 
illness, continued cannabis users had significantly (p<0.05) worse relapse outcome than 
both non-users (dCC-NC=0.36) and discontinued users (dCC-DC=0.28), as well as longer 
hospitalisations (dCC-NC=0.32). In contrast, cannabis discontinuation was not associated 
with relapse (dDC-NC=0.02, p=0.82). Meta-regression indicated greater effects of 
continued compared to discontinued cannabis use (p<0.05) on relapse, positive 
symptoms and level of functioning but not negative symptoms. 
Interpretation. Continued cannabis use after onset of psychosis predicts adverse 
outcome, including higher relapse rates, longer hospitalisations and more severe 
positive symptoms - adverse effects that are absent in those who discontinue use of 
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cannabis. These findings point to reductions in cannabis use as a crucial interventional 



























Cannabis is the most commonly used illicit drug in patients with an existing 
psychotic disorder (Barrowclough, Emsley, Eisner, Beardmore, & Wykes, 2013). In 
some studies about one out of every four patients with psychosis meet the criteria for 
cannabis dependence (J. Addington & Addington, 2007; J. Koskinen, Lohonen, 
Koponen, Isohanni, & Miettunen, 2010) with rates of use especially high in young 
people presenting with their first psychotic episode (J. Koskinen et al., 2010). These 
rates are much higher than those of the general population (Regier et al., 1990) or those 
with other psychiatric diagnoses (Agosti, Nunes, & Levin, 2002b). While the 
association between cannabis use and onset of psychotic disorders is well-established 
(Arseneault, Cannon, Witton, & Murray, 2004; Stepniak et al., 2014), suggesting that 
cannabis use is a component cause of the disorder (Di Forti, Marconi, et al., 2015), its 
effect on the course of psychosis following onset is less clear. This lack of clarity seems 
mainly related to limitations of study design such as cross-sectional approach, 
underpowered samples and lack of consideration of potential confounders [reviewed 
here (Zammit et al., 2008b)]. However, more recent studies implicate cannabis use as a 
potential risk factor for relapse of psychosis as indexed by readmission to hospital (San, 
Bernardo, Gómez, & Peña, 2013b; Sorbara et al., 2003; D. van Dijk, M. W. J. Koeter, 
R. Hijman, R. S. Kahn, & W. van Den Brink, 2012c), with some evidence supporting a 
dose-response relationship (Hides et al., 2006). Other studies reported worsening of 
positive psychotic symptoms (Foti et al., 2010; Anton Grech, Jim Van Os, Peter B 
Jones, Shon W Lewis, & Robin M Murray, 2005b) or shorter time to symptom re-
emergence (Linszen, Dingemans, & Lenior, 1994) in cannabis-using patients with 
psychosis. These findings are in line with experimental pharmacological challenge 
studies reporting that delta-9-tetrahydrocannabinol (THC), the main psychoactive 
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constituent in cannabis, can induce transient psychotic experiences in healthy 
individuals and worsen existing symptoms in patients with pre-existing psychosis (S. 
Bhattacharyya, Z. Atakan, et al., 2012; S. Bhattacharyya et al., 2009; Cortes-Briones et 
al., 2015; D’Souza et al., 2005).  
If cannabis use were really associated with worse outcome in those with 
established psychosis, then one would expect that those who continue using cannabis 
would have far worse outcome compared to those who stop. However, while some 
evidence suggests that discontinuation of cannabis use may lead to a reduction in 
readmission rates (González-Pinto et al., 2009; van der Meer & Velthorst, 2015) and 
improvement in symptomatic and functional outcome of psychosis (Baeza et al., 2009; 
Clausen et al., 2013; Grech et al., 2005b; B. G. Schimmelmann et al., 2012; J. M. Stone 
et al., 2014; van der Meer & Velthorst, 2015), others suggest that this may not 
necessarily be the case (Barrowclough et al., 2013; Faber et al., 2012; van Dijk et al., 
2012c). Although about 30-50% of cannabis users stop using it after the onset of their 
psychotic illness (González-Pinto et al., 2009; Grech et al., 2005b; I. Harrison et al., 
2008b; J. M. Stone et al., 2014; van der Meer & Velthorst, 2015), suggesting that this 
may be a clinically relevant issue worth exploring, there is lack of clarity in terms of 
existing evidence as outlined earlier. Furthermore, conclusions from the individual 
studies need to be treated with caution in light of the relatively modest sample sizes. 
Meta-analytic techniques offer a method of overcoming the sample size issue by 
statistically integrating the results from a number of separate studies thereby improving 
the power to detect significant effects (Kambeitz et al., 2012). Considering the 
conflicting evidence from individual studies investigating the relationship between 
continued cannabis use and relapse and from studies looking at discontinued use and 
outcome, I have attempted to quantitatively summarize the current evidence. In this 
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study, I aimed to (a) establish whether ongoing cannabis use is associated with poor 
outcome in established psychosis and (b) establish the magnitude of this effect by 
pooling together the results of all available studies using a meta-analytic approach. In 
particular, I focused on outcome defined as ‘relapse of psychosis’, operationalized as 
either readmission to hospital or based on investigator-determined psychotic relapse. 
Since cannabis use is potentially amenable to treatment and given that a substantial 
proportion of patients with psychosis continue using the drug following onset of their 
illness, there is a particular need to estimate the effect of ongoing cannabis use on a 
robust measure of outcome which is indicative of relapse, such as hospitalisation. This 
is a reliably estimated measure, with significant implications for the cost of healthcare 
(Knapp et al., 2014). Although previous meta-analyses have investigated the association 
between continued and discontinued cannabis use and outcome in psychosis, these have 
mainly focused on symptomatic outcome measures such as positive and negative 
symptoms or depression scores, while outcome indexed by hospitalisation was only 
considered in the context of the effects of substance use in general (Gupta, Mullin, 
Nielssen, Harris, & Large, 2013; Large, Mullin, Gupta, Harris, & Nielssen, 2014; 
Mullin et al., 2012b). I therefore set out to investigate whether (i) continued use of 
cannabis following the onset of psychosis is associated with worse relapse outcome 
relative to non-users, (ii) discontinued use of cannabis subsequent to the onset of 
psychosis is associated with a worse relapse outcome comparable to non-users and (iii) 
discontinued use of cannabis is associated with a better relapse outcome compared to 
continued use. Furthermore, I investigated whether the effect of cannabis use on 
outcome was consistent across different outcome measures by also examining effect on 





3.3.1 STUDY SELECTION 
A systematic search strategy was used to identify all relevant studies, following 
the methods recommended by the Cochrane Handbook (J. P. Higgins, Green, & 
Collaboration, 2008) and in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Beller et al., 2013). 
Firstly, the MEDLINE database was searched for English language studies using a 
combination of search terms describing the cannabis terms (marijuana/marihuana, 
cannabis, illicit, substance), the outcome of interest (outcome, hospital*, relapse, 
readmission) and the study population (psycho*, bipolar, schizophrenia), with the final 
search conducted on the 21st of April 2015. Following this, bibliographies of the 
identified publications and previous published meta-analyses were hand-searched in 
order to identify additional studies that met the inclusion criteria but might have been 
missed by the database search. Studies were selected if they included a sample of 
patients with a pre-existing psychotic disorder (schizophrenia, schizoaffective, bipolar if 
outcome was reported as number of psychotic episodes [e.g. Ringen et al. (2010)]), with 
a follow-up duration of at least 6 months. The primary predictor variables were defined 
as (1) continued cannabis use (yes/no) after onset of illness and (2) discontinued 
cannabis use after onset (yes/no). Only a subset of the total pool of studies that 
examined the effect of continued cannabis use on outcome also examined the effect of 
discontinuation of the drug. I excluded studies if ‘continued cannabis use’ (CC)/ 
‘discontinued cannabis use’ (DC) could not be established, e.g. studies that assessed 
cannabis use only around the onset of illness (Basu, Malhotra, Bhagat, & Varma, 1999; 
Batalla et al., 2013a; Manrique-Garcia et al., 2014a; Grant E Sara, Philip M Burgess, 
Gin S Malhi, Harvey A Whiteford, & Wayne C Hall, 2014b) and studies that only 
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reported lifetime cannabis use (Alterman, Erdlen, LaPorte, & Erdlen, 1982; Dervaux et 
al., 2002; Kazadi, Moosa, & Jeenah, 2008b; Mueser et al., 1990). The primary outcome 
was defined as ‘relapse of psychosis’, which was indexed as either (1) readmission to 
hospital, (2) investigator-determined relapse [operationalized in manuscript as 
‘psychotic episode’ or exacerbation of psychotic symptoms (Koenders et al., 2014; 
Linszen et al., 1994; van der Meer & Velthorst, 2015)] or (3) investigator-determined 
relapse but without any reported criteria for operationalization (Faridi et al., 2012) (cf. 
Table 10. below). If the identified studies reported symptom scores (positive, negative), 
length of hospitalisation (time spent in hospital) or level of functioning [as measured 
with the Global Assessment of Functioning Scale (American Psychiatric, 1987)] 
alongside the relapse information, this data was also extracted and used in separate 
outcome analyses. An initial data extraction protocol was drafted in 2013 and data 
extraction was piloted from studies identified through a systematic search by at least 
two independent researchers to finalize the selection criteria and variables of interest. 
Data was extracted by two independent researchers. Disagreements were resolved 










Table 10. Study summary: Effects of cannabis continuation after onset and discontinuation after onset on relapse outcome 
Continued Cannabis use 




Relapse outcome Length of Illness 
(LI) in years at 
FU; Illness stage 











Baeza et al. (2009) / 
Spain 
Use in 1 month prior FU 
assessment (n=15) 
No cannabis history 
(n=69) 
Number of re-





0.5 (CAN +)  
0.5 (CAN -) 
[YES] 




Barrowclough et al. 
(2013) / UK 
Use (any) in previous 90 
days (n=160) 
No use in previous 90 days 
(n=167) 




1 (CAN +)  









Kotzalidis, and Pancheri 
(2002) / Italy 
Current user (NS) (n=54) No cannabis history 
(n=71) 




8  (CAN +)  
13 (CAN -) 
[NO] 




Caspari (1999) / 
Germany 






5 (CAN +)  






Faridi et al. (2012) / 
Spain 
Presence of CUD at FU 
(n=28) 
Absence of CUD at FU 
(n=20) 




1 (CAN +)  
1 (CAN -) 
[YES] 






González-Pinto et al. 
(2009) / Spain 
Continued use 
throughout 7 years FU 
(n=25) 
No cannabis history 
(n=40) 
Number of 




8 (CAN +)  






Maria Isaac, Isaac, and 
Holloway (2005b) / UK 
+ve UDS (n=69) at 
admission 
-ve UDS (n=46) at 
admission 








Jockers-Scherubl et al. 
(2007) / Germany 
Presence of CUD (n=19) No Use < 5 times/ lifetime 
(n=20) 




6 (CAN +) 
9 (CAN -) 
[NO] 




Koenders et al. (2014) / 
Netherlands 
Presence of CUD (n=80) 
 
Use <  5 times/ lifetime 
(n=33) 
 





1 (CAN +)  
1 (CAN -)  
[YES] 




Linszen et al. (1994) / Presence of CUD (n=24) Absence of CUD (n=69) in Relapse (y/n) LI: 3 1 (CAN +)  93 0.45 2.27 
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US in 1 year FU 1 year FU (exacerbation of 
psychotic symptomsb) 
in 1 year FU 






Maremmani et al. (2004) 
/ Italy 
Lifetime CUD and +ve 
UDS (n=43) 
No cannabis history 
(n=45) 




7 (CAN +)  
12 (CAN -) 
[NO] 






Prieto (1994) / Spain 
Use during 1 year FU 
(NS) (n=14) 
No cannabis history 
(n=24) 
Hospitalisation (y/n) in 
1 year FU 
LI: 2 
Early stage 
1 (CAN +)  
1 (CAN -)  







Douglas, and Smith 
(1986) / Canada 
Use in 6 months prior to 
FU assessment and/or 
+ve UDS (n=25) 
No cannabis history 
(n=61) 




6 (CAN +)  






Peralta and Cuesta 
(1992) / Spain 
Use > 1 time/week in 
year prior to assessment 
(n=23) 
Use < 1 time/week in year 
prior assessment (n=72) 




5 (CAN +)  
6 (CAN -) 
[YES] 




Rehman and Farooq 
(2007) / Pakistan 
Use in 1 year prior 
assessment (n=50) 
No use in year prior 
assessment (n=50) 




4 (CAN +)  
5 (CAN -) 
[YES] 







(2011) / Germany 
Current user (> 5 
days/week for > 1 year) 
(n=27) 
Use < 5 times/ lifetime 
(n=26) 




5 (CAN +) 
7 (CAN -) 
[NO] 




Ringen et al. (2010) / 
Norway 
Use in 6 months prior FU 
assessment (NS) (n=41) 
No use in 6 months prior 
FU assessment (n=232) 




7 (CAN +)  
9 (CAN -) 
[NO] 




Salyers and Mueser 
(2001) / US 
> 1 time during 6 months 
prior FU assessment (n= 
363) 
Never used in 6 months 
prior FU (n=41) 
Number of 
hospitalisations in 2 




2 (CAN +)  







San et al. (2013b) / Spain Use in 4 years prior FU 
assessment (n=553) 
No use in 4 years prior FU 
assessment (n=1093) 
Hospitalisation (y/n) in 
1 year FU 
LI: >10 years for 
57% of the sample 
Chronic 
1 (CAN +)  








G. E. Sara, P. M. 
Burgess, G. S. Malhi, H. 
A. Whiteford, and W. C. 
Hall (2014) / Australia 
Presence of CUD in 5 
years FU (n=3946) 
Absence of CUD in 5 
years FU (n=7672) 
Number of 
rehospitalisations in 5 
years FU 
LI: > 7  
Chronic 
5 (CAN +)  








Sorbara et al. (2003) / 
France 
Presence of CUD in 2 
years following onset 
(n=9) 
Absence of CUD in 2 
years following onset 
(n=49) 
Hospitalisation (y/n) in 
2 years following onset 
LI: 2 
Early stage 
2 (CAN +)  








D. van Dijk, M. W. 
Koeter, R. Hijman, R. S. 
Kahn, and W. van Den 
Brink (2012b) / 
Netherlands 
> 4 times during 1 year 
FU or use 1 month prior 
FU assessment (n=68) 
< 4 times during 1 year FU 
or no use 1 month prior FU 
assessment (n=77) 
Number of 




1 (CAN +)  






van der Meer and 
Velthorst (2015) / 
Netherlands 
Use < 5 times/ in 3 year 
FU (n=146) 
No cannabis history 
(n=257) 




in 3 year FU 
LI: 4 
Early stage 
3 (CAN +)  












Presence of CUD during 
FU (n=40) 







1.3 (CAN +)  








Discontinued Cannabis use   





Relapse definition Length of Illness 
(LI) in years at FU; 






N d (p)  
Baeza et al. (2009) / 
Spain 
Use at baseline but no 
use 1 month prior FU 
assessment (n=16) 




6 months FU 
LI: 1 
Early stage 
0.5 (CAN +)  
0.5 (CAN -) 
[YES] 




González-Pinto et al. 
(2009) / Spain 
Stopped use between 
onset and 7 years FU 
(n=27) 
No cannabis history 
(n=40) 
Number of 




8 (CAN +)  




0.75]   
N/A 
Maremmani et al. (2004) 
/ Italy 
Lifetime CUD but  -ve 
UDS / (n=23) 
 
No cannabis history 
(n=45) 




9 (CAN +)  
12 (CAN -) 
[NO] 




Martinez-Arevalo et al. 
(1994) / Spain 
No use during 1 year FU 
but previous use (n=25) 
No cannabis history 
(n=24) 
Hospitalisation (y/n) 
in 1 year FU 
LI: 2 
Early stage 
1 (CAN +)  
1 (CAN -)  






 [YES] 0.60] 2.95] 
Negrete et al. (1986) / 
Canada 
History of use but no use 
in 6 months prior FU 
assessment (n=51) 
No cannabis history 
(n=61) 




9 (CAN +)  
13 (CAN -) 
[NO] 




van der Meer and 
Velthorst (2015) / 
Netherlands 
Past use < 5 times/ 
lifetime but no use in 3 
year FU (n=266) 
No cannabis history 
(n=257) 
Number of relapses 
(hospitalisation 
and/or drop score on 




3 (CAN +)  
3 (CAN -) 
[YES] 




CI = Confidence interval; CUD = Cannabis use disorder (DSM or ICD based diagnosis of cannabis abuse or dependence); d = Effect size Cohen’s d with 
p-value for Random Effects Model; FU = Follow up; LI = Length of illness in years at time of follow up assessment; Matched = YES if difference in 
follow up between CAN(+) and CAN(-) not more than 1 year, NO = if difference more than 1 year; NS = Not specified; N/A = Not applicable; OR = 
Odds Ratio; UDS = Urine drug screen; Stage of illness = Early stage (illness less < 5 years), Chronic (illness > 6 years).   
a Based on rating scale: Comprehensive Assessment of Symptoms and History (Andreasen, Flaum, & Arndt, 1992) 
b Based on rating scale: Brief Psychiatric Rating Scale (Overall & Gorham, 1962)  
c Diagnosed if consumed regularly for several months and if this interfered with social functioning or was prominent during therapy. Patients with 
occasional use were not included 
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3.3.2 QUALITY ASSESSMENT 
I used a modified seven-point ‘strength of reporting scale’ which has been 
employed in previous meta-analyses conducted in a related area of research (Large et 
al., 2014; Mullin et al., 2012b). This scale is based on items describing methodological 
aspects in the ‘Strengthening the Reporting of Observational Studies in Epidemiology’ 
(STROBE) (Von Elm et al., 2008) checklist. Studies with a score of >5 were classified 
as higher quality studies (cf. aTable 5., Appendix III). 
 
3.3.3 STATISTICAL ANALYSIS 
Analyses were conducted with R and its package metaphor (Viechtbauer, 2010), using 
random effects models (REM) (Lane, Cherek, Lieving, & Tcheremissine) that assume 
that effect sizes vary from study to study (Borenstein, Hedges, Higgins, & Rothstein, 
2011). Effect sizes were estimated using Cohen’s d, where d-values of 0.2 represent 
small effects, d-values between 0.4 and 0.6 represent moderate effect and d-values of 
0.8 or higher indicate large effects (Cohen, 1988). d per study was calculated for the 
comparisons (1) continued cannabis use vs. non-user (CC-NC), (2) continued use vs. 
discontinued use (CC-DC)  and (3) discontinued use vs. non-user (DC-NC). The R-
package Compute.es (Del Re, 2012) was used, which allows data from included studies 
to be entered in the form of means and standard deviations (Ringen et al.), p-values for 
mean comparisons or chi square statistics to reach an approximated d. In addition, the 
package allowed the estimation of d for those studies that reported odds ratios (San et 
al., 2013b; Sorbara et al., 2003). In those cases where the SD was not reported (M. Isaac 
& Holloway, 2005; Negrete et al., 1986), the SD was extrapolated from other studies 
with similar outcome and sample characteristics. I carried out meta-regression analysis 
for categorical variables to compare the estimated d’s between the groups CC-NC and 
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DC-NC for outcome (relapse, length of hospitalisation, positive symptoms, negative 
symptoms, functioning). In addition, meta-regression was used to test whether the effect 
of cannabis was confounded by the stage of illness of participants in the studies 
included [i.e. early psychosis vs. chronic psychosis, with chronic psychosis referring to 
those subjects with an illness length of more than 5 years as classified in previous 
studies (Fulham et al., 2014)]. Finally, meta-regression for continuous moderators was 
used to test the effect of gender (percentage of sample being male) and age at the time 
of study assessment. The possibility of publication bias was examined using funnel 
plots, followed by the Egger’s linear regression test (Egger, Smith, Schneider, & 
Minder, 1997) to test funnel plot asymmetry for significance.  Homogeneity of the 
distribution of weighted effect sizes was tested with the Q test, and degree of 
heterogeneity was quantified using the I2 test, which describes the percentage of 
observed heterogeneity that would not be expected by chance (J. P. T. Higgins, 
Thompson, Deeks, & Altman, 2003). I2 values between 0 and 25% suggest small 
heterogeneity, while I2 values in the range 25% and 50% suggest moderate 
heterogeneity, and those >50% indicate large heterogeneity.  
 
3.3.4 SENSITIVITY ANALYSIS 
Given the heterogeneity in the definition of relapse employed by the studies, I carried 
out sensitivity analyses restricting the studies to only those investigating hospital 
admissions, which has been reported to be a valid measure of relapse in psychosis (D. 
E. Addington, Patten, et al., 2013).  Similarly, in the light of variation in follow-up 
duration between cannabis users and non-users in the studies (cf. Table 10. above), I 
carried out subset analyses by including only those studies in which cannabis users were 
matched to the non-users with respect to their follow up duration (indicated as 
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“Matched = YES” if the difference was not more than 1 year between the groups, cf. 
Table 10. above). 
3.4 RESULTS 
3.4.1 STUDY SELECTION 
Out of 1903 identified studies, 24 met inclusion criteria, comprising 5849 
individuals with continued cannabis use following psychosis onset and 10308 who were 
classified as non-users (cf. Flow Chart,  Figure 10.). A subset (n=6) of the included 
studies included an additional group of patients that were classified as discontinued 



















Figure 10. Flow chart: Study selection 
 
Note. Taken from Schoeler, Monk, et al. (2016) 
3.4.2 RANDOM EFFECTS MODEL: EFFECT OF ONGOING CANNABIS USE ON RELAPSE  
As shown in Figure 11. (below), continued cannabis use post-onset of illness 
was significantly associated with relapse of psychosis (dCC-NC=0.36, p<0.0001 [95% CI 
0.22; 0.50]). An effect of a similar magnitude was found on length of hospitalisation 
after onset (dCC-NC=0.36, p=0.02[95% CI 0.13; 0.58]).  




Note. Taken from Schoeler, Monk, et al. (2016) 
For a subset of studies (k=4, n=688) I was able to calculate the number of days 
spent in hospital per year of illness following onset, estimated as the weighted mean 
difference (WMD). The analysis was carried out using the software provided by 
Cochrane Collaboration, Review Manager (Rev Man 5.3) (Cochrane, 2014). One study 
(M. Isaac & Holloway, 2005) included in the Random Effects Model for length of 
hospital stay could not be included in this estimation since no precise time interval for 
“Number of days spent in hospital” was provided (e.g. by referring to the duration of 
illness for cannabis users and non-users). The results indicated that cannabis users spent 
[125] 
 
an additional 8.47 days in hospital per year of illness, although this difference was 




Among the studies that examined the risk of relapse (k=7, n=2298, cf. Table 10. 
above), the pooled odds were 1.97[95% CI 1.46; 2.65] times greater among those who 
continued to use cannabis compared with those who did not (p<0.0001). Limiting 
analysis to only those studies that reported on relapse rates in individuals with the three 
patterns of cannabis use of interest in this context, i.e. continued cannabis user, 
discontinued user and non-user (CC-DC-NC, k=6; N=1172) revealed that this adverse 
effect of cannabis in continued users remained when compared to those who 
discontinued (dCC-DC=0.28, p=0.0005, [95% CI 0.12; 0.44]). In contrast, those who 
discontinued cannabis use did not significantly differ from the non-users in their relapse 
outcome (dDC-NC=0.02, p=0.82[95% CI -0.11; 0.15]) (cf. Figure 12. for a summary).  
Table 11. Mean number of days spent in hospital per illness-year 
 Cannabis user Non-user  





van Dijk et al. 
(2012b) 











et al. (2007) 










Overall WMD N=688 
Heterogeneity: Tau² = 65.47; Chi² = 4.50, df = 
3 (p = 0.21); I² = 33% 





Note. WMD = Weighted Mean Difference 
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Figure 12. Random effects model of relapse (continued vs. discontinued vs. non-use of 
cannabis) 
 
Note. Taken from Schoeler, Monk, et al. (2016) 
 
Including all identified studies in meta-regression to compare the difference in 
effect size d between continued cannabis users and those who discontinued relative to 
corresponding non-user groups (dCC-NC=0.36 vs. dDC-NC=0.02) also confirmed that the 
effect-sizes were significantly different between the two sets of comparisons (p=0.04; 
cf. aTable 6., Appendix III).  Egger’s test and funnels plot (cf. Figure 13. below and 
aTable 6., Appendix III) indicated evidence of funnel plot asymmetry for relapse 
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(p=0.0002), but the trim-and-fill method (R0 estimator) did not indicate missing studies, 
suggesting that the asymmetry may be due to other causes such as study heterogeneity 
(J. L. Peters, Sutton, Jones, Abrams, & Rushton, 2007; Terrin, Schmid, Lau, & Olkin, 
2003). 
 
Figure 13. Funnel plot for continued cannabis use and relapse 
 
Note. Taken from Schoeler, Monk, et al. (2016) 
 
 
3.4.3 RANDOM EFFECTS MODEL: EFFECTS OF ONGOING CANNABIS USE ON OTHER 
OUTCOME MEASURES 
As summarized in Figure 14., continued cannabis use significantly predicted 
positive symptom severity (dCC-NC=0.15, p=0.04[95% CI 0.01; 0.29]). These effects on 
positive symptoms were not present in those who discontinued using the substance (dDC-
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NC=-0.30, p=0.39[95% CI -0.99; 0.38]) and meta-regression indicated that the effect-
sizes (dCC-NC vs. dDC-NC) were significantly different (p=0.05). Interestingly, while 
continued cannabis users showed comparable levels of functioning when compared to 
the non-users (dCC-NC=0.04, p=0.68[95% CI -0.14; 0.21]), those who discontinued using 
cannabis had significantly higher levels of functioning when compared to non-users 
(dDC-NC=-0.49, p=0.002[95% CI -0.81; -0.17]). This difference in effect-size (dCC-NC vs. 
dDC-NC) was significant as indicated by meta-regression (p=0.0075). Continued cannabis 
use was not a significant predictor for negative symptomatology (dCC-NC=-0.09, 
p=0.37[95% CI -0.30; 0.11]) and there was a trend for reduced negative symptoms in 
those who discontinued compared to non-users (dDC-NC=-0.31, p=0.10[95% CI -0.67; 
0.05]). However, the difference in effect size (dCC-NC vs. dDC-NC) was not significant 
(meta-regression, p=0.41). This is also in accordance with the direct comparison 
between continued and discontinued users (CC-DC, cf. aTable 6., Appendix III), which 
suggested that those who continued smoking cannabis had higher levels of negative 
symptoms than those who discontinued. However, this was only significant at a trend 
level (p=0.07) and generalizability may be limited due to the few studies included in 
this analysis (k=2, n=83).
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Note. Taken from Schoeler, Monk, et al. (2016) 
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3.4.4 SENSITIVITY ANALYSIS  
There was substantial heterogeneity in the effect of continued cannabis use on 
relapse (83.62%, p<0.0001[95% CI 68.04%; 92.89%]). Hence, sensitivity analysis was 
carried out with more homogeneous groups of studies (for a summary see Table 12.): 
Studies were selected if they matched the follow up duration between continued 
cannabis users and non-users (cf. Table 10., “Matched=YES”) (k=17, n=15371, d CC-
NC=0.42, p<0.0001[95% CI 0.26; 0.57]), were rated as “high quality” (k=10, n=1366, d 
CC-NC=0.50, p<0.0001[95% CI 0.32; 0.68], included either only early stage psychosis 
(k=10, n=1120, d CC-NC=0.30, p=0.0004[95% CI 0.13; 0.47])  or chronic psychosis 
(k=13, n= 14922, d CC-NC=0.37, p=0.0006[95% CI 0.16; 0.58]) and defined relapse as 
hospital admission (k=19, n=15412, d CC-NC=0.36, p<0.0001[95% CI 0.19; 0.52]). 
Effect-sizes estimated for studies including only patients with non-affective psychosis 
(k=9, n=1280, d CC-NC=0.34, p=0.0036[95% CI 0.11; 0.58]) and those including only 
affective psychosis (k=15, n=14877, d CC-NC=0.37, p<0.0001[95% CI 0.19; 0.55] were 
not significantly different (p=0.89). Gender and age at follow up assessment did not 
significantly (p=0.87 and p=0.38) reduce the heterogeneity in relapse outcome, as 

















Table 12. Sensitivity analysis: Continued cannabis use and relapse 
 k n d p CI-L CI-U I 2 p (Q test) 
Total sample 
 
24 16157 0.36 <0.0001  0.22 0.50 83.62% <0.0001 
Moderator: Illness Stage (p-mod = 0.68) 
Early stage 
 
10 1120 0.30 0.0004 0.13 0.47 34.76% 0.1218 
Chronic 
 
13 14922 0.37 0.0006 0.16 0.58 91.00% <0.0001 
Moderator: Diagnosis (p-mod = 0.89) 
Non-affective 
 
9 1280 0.34 0.0036 0.11 0.58 71.30% 0.0045 
Affective 
 
15 14877 0.37 <0.0001 0.19 0.55 85.89% <0.0001 
Moderator: Study quality (p-mod = 0.08) 
High (> score of 5) 
 
10 1366 0.50 <0.0001 0.32 0.68 55.73% <0.0001 
Other (< score of 5) 
 
14 14791 0.25 0.0104 0.06 0.44 87.70% <0.0001 
Moderator: Matched follow up years (p-mod = 0.07) 
Yes 
 
17 15378 0.42 <0.0001 0.26 0.57 84.20% <0.0001 
No 6 664 0.13 0.4019 -
0.17 
0.42 63.03% 0.0259 
Moderator: Relapse definition (p-mod = 0.97) 
Hospital admission 
 
19 15412 0.36 <0.0001 0.19 0.52 86.27% <0.0001 
Other/unspecified 
 
5 745 0.35 0.0047 0.11 0.59 50.43% <0.0001 
Male gender  
(% per study)  
k=20;  p-mod=0.87;  coefficient estimate= -0.0008 
Age at date of follow  
up assessment  
k=22;  p-mod=0.38;  coefficient estimate= 0.0116 
Note. d= Cohen’s d; k=number of studies, n=number of subjects; p ( Murat Yücel et al.) 





To my knowledge, this is the first meta-analysis to demonstrate that, regardless 
of the stage of their psychotic disorder, patients who continue using cannabis are more 
likely to suffer from a relapsing course when compared both to non-using patients (d CC-
NC=0.36) and to patients who discontinue using the substance after onset (d CC-DC=0.28). 
Furthermore, considering that those who discontinue do not differ from the non-users in 
their relapse outcome (d DC-NC=0.02), these results suggest that the increased relapse rate 
associated with cannabis use may resolve following discontinuation of its use. Gradient 
in the effect of cannabis use (continued use > discontinued use >  non-use) on outcome 
in psychosis observed in the present analysis is consistent with that noted in other 
studies not included here (Grech et al., 2005b; B. G. Schimmelmann et al., 2012), with 
the effect on outcome being most adverse in those who continue to use the drug. This is 
also compatible with other epidemiological evidence of the adverse effects of cannabis 
being dose-dependent (Hides et al., 2006; Linszen et al., 1994) and with evidence that 
the magnitude of cognitive impairments associated with cannabis exposure tend to 
diminish following abstinence (Rabin, Zakzanis, Daskalakis, & George, 2013). 
Additionally, my results suggest that continued cannabis users suffered significantly 
longer hospitalisations following their onset than non-users (d CC-NC=0.36), which may 
suggest perhaps more severe relapses requiring longer inpatient care to stabilize. It is 
worth noting that longer hospital stay may also be related to other factors unrelated to 
the severity of the illness, such as lack of suitable accommodation for the patient to be 
discharged to.  
In terms of symptomatic outcome, continued cannabis users experienced more 
severe positive psychotic symptoms at follow-up assessment.  This effect was not 
present in those who discontinued using the substance (d CC-NC=0.15 vs. d CC-DC=-0.30). 
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This is consistent with other follow-up studies that compared positive symptom levels 
between continued users, discontinued users and non-users of cannabis (Clausen et al., 
2013; B. G. Schimmelmann et al., 2012; J. M. Stone et al., 2014; van der Meer & 
Velthorst, 2015) and a report from a longitudinal population-based sample suggesting 
that continuation of cannabis use predicted subsequent persistence of psychotic 
symptoms (Kuepper et al., 2011a). Other studies have reported a temporal association 
between changes in cannabis use and subsequent changes in psychotic symptom 
severity, both in the short (Degenhardt et al., 2007) and long-term (Foti et al., 2010). 
Evidence that cannabis use has a particularly harmful effect on different outcome 
measures of psychosis (relapse, psychotic symptoms) when use is continued compared 
to when one stops using is intuitive and consistent with effects of cannabis use on 
cognition (Rabin et al., 2013). However, the effect of cannabis and continuity of its use 
was not observed across certain other domains of outcome in the present meta-analysis: 
continued cannabis users did not differ from the non-user groups in their negative 
symptomatology (dCC-NC=-0.09, p=0.37). A similar result was reported in a separate 
meta-analysis focusing on symptoms (Large et al., 2014). Discontinued users also did 
not differ significantly from non-users (dDC-NC=-0.31, p=0.10), though they had less 
negative symptoms when compared directly with continued users (dCC-DC=0.41, 
p=0.07). This may appear to contradict the results of the meta-regression suggesting no 
difference between the effects of continued and discontinued use on negative symptoms. 
However, it is worth noting that meta-regression compared the estimates from two 
different random effects models (i.e., dCC-NC and dDC-NC) examining effect on negative 
symptoms, rather than a direct comparison between discontinued and continued 
cannabis users. Furthermore, while the direct comparison involved data from only two 
studies, the meta-regression compared data from a larger sample of studies. 
[134] 
 
Nevertheless, it is worth noting that the general direction of effect in different groups is 
consistent across all comparisons. Continued cannabis users showed similar levels of 
functioning when compared to the non-users (dCC-NC=0.04, p=0.68), while discontinued 
users had better functioning scores compared to non-users (dDC-NC=-0.49, p=0.002). In 
line with this, other studies have reported that those who discontinue cannabis have 
better functioning (Baeza et al., 2009; Clausen et al., 2013; B. G. Schimmelmann et al., 
2012; van der Meer & Velthorst, 2015) compared to non-users and a recent meta-
analysis suggested that cessation of substance use in general was associated with 
improvement of negative symptoms and global functioning (Mullin et al., 2012b). 
These findings suggest that cannabis-using patients may have better functioning to 
begin with (though this is not something that could be tested in the present analysis). 
This is also compatible with the view that cannabis-using patients represent a subgroup 
with a less neurodevelopmental pathology (Ferraro et al., 2013; Murat Yücel et al., 
2012); perhaps for this reason the adverse effects of cannabis use on functioning and 
negative symptoms only become apparent when continued users are compared to those 
who discontinued use rather than non-users. Patients who are able to stop using 
cannabis may also represent an etiologically and clinically distinct subgroup suffering 
from a less severe illness with less of a need to use cannabis for self-medication. The 
observed association between cannabis exposure and relapse of psychosis and related 
outcome variables may be mediated through the effect of its key psychoactive 
ingredient, THC, on the neural substrates implicated in psychosis (Sagnik 
Bhattacharyya, Atakan, et al., 2015a; S. Bhattacharyya, Z. Atakan, et al., 2012; S. 
Bhattacharyya, Crippa, Allen, & et al., 2012; Sagnik Bhattacharyya et al., 2014; S. 
Bhattacharyya et al., 2009; Cortes-Briones et al., 2015). The observed strength of 
association between continued cannabis use and relapse is comparable to other 
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identified environmental risk factors for relapse of psychosis such as high expressed 
emotions (d=0.31) (Butzlaff & Hooley, 1998a), as well as the effects of interventions 
that prevent relapse, such as psychoeducation (d=0.21) (Lincoln, Wilhelm, & Nestoriuc, 
2007) or reduce psychotic symptoms, such as antipsychotic treatment (d=0.48) (S 
Leucht, Arbter, Engel, Kissling, & Davis, 2009). Hence, these results emphasize the 
importance of cannabis use as a clinically relevant target for treatment development.  
 
3.5.1 LIMITATIONS 
Some limitations are noteworthy, which are mainly related to the 
methodological heterogeneity among the studies included (cf. Table 10. above). 
Different criteria were applied by the studies included in this meta-analysis to classify 
those who continued to use cannabis (e.g. presence of cannabis use disorder/use more 
than once in a defined time-period), or discontinued the drug (e.g. history of use but 
negative UDS/no use in given time period), as well as non-users (e.g. less than daily 
use/non-abuser/no use in given time period/never use). Follow-up durations also 
differed between cannabis users and non-users in some studies [e.g. 7 year relapse 
window for cannabis users vs. 12 year relapse window for non-users in Maremmani et 
al. (2004)]. In fact, excluding those studies with differing follow-up windows between 
the participant groups as part of sensitivity analysis revealed a slightly larger effect of 
cannabis use on relapse than found in the main analysis (d=0.42 vs. d=0.36). The study 
by Baeza et al. (2009) may need to be highlighted in this context, considering that their 
report of absence of adverse effects of cannabis use on relapse may reflect their six 
months follow up, an interval perhaps too short to detect differences in relapse rates 
between the groups. 
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It may be argued that the patients differed in their stage of illness across the 
included studies (e.g. early stage vs. chronic psychosis), but sensitivity analysis revealed 
that this did not significantly influence the results. It was not possible to control for the 
effect of other potential confounding factors that may be associated with cannabis use 
such as medication adherence (Barrowclough et al., 2013; Clausen et al., 2013; 
Martinez-Arevalo et al., 1994; Rehman & Farooq, 2007; B. G. Schimmelmann et al., 
2012), engagement with the services (B. G. Schimmelmann et al., 2012) or other abuse 
of other drugs (Barrowclough et al., 2013). However, the present results are also 
consistent with studies that have systematically controlled for age, gender, alcohol and 
drug use, illness characteristics (e.g. duration, diagnosis, severity) and medication 
adherence when measuring the effect of cannabis use on relapse (San et al., 2013b; 
Sorbara et al., 2003; van Dijk et al., 2012c). Another limitation inherent to the meta-
analytical design relates to our inability to analyse raw data, which limited my ability to 
carry out moderation analysis to directly test for more defined dose-response patterns 
such as frequency, duration or age of onset of use or type of cannabis consumed - 
factors that are also likely to moderate the effect of cannabis on relapse (Hides et al., 
2006; Linszen et al., 1994). A further potential source of heterogeneity may be related 
to the use of different types of cannabis containing differing proportion of the main 
ingredients such as delta-9-tetrahydrocannabinol or Cannabidiol that are known to have 
opposing effects (Sagnik Bhattacharyya et al., 2010b). However, I was unable to assess 
the effect of type of cannabis used, as this information was not available for the 
included studies. Finally, although our systematic search may have been somewhat 
restricted by using MEDLINE only, I aimed to address this potential limitation by 
screening bibliographies from previous conducted meta-analyses, systematic reviews 
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and original studies for additional studies that may have been missed out in the database 
search. 
Nevertheless, despite lack of more fine-grained measures, this meta-analysis 
detected a fairly robust pooled effect of continued cannabis exposure on relapse 
outcome and other measures suggestive of adverse outcome, which were absent in those 
who discontinued use of the drug. The fact that the effects of continued use of cannabis 
or its discontinuation are consistent across different measures of outcome only serves to 
underline the importance of addressing continued cannabis use in patients with 
psychosis in the clinical setting, by highlighting that outcomes are likely to be better in 


















3.6 PAPER 4: CORRELATION STILL DOES NOT IMPLY CAUSATION 
Following the publication of the meta-analysis, Lancet Psychiatry has received a 
correspondence letter, in which the issue of causality was raised. The correspondence 
letter (Ksir & Hart, 2016b) as well as my response to the letter (Schoeler, Murray, et al., 
2016) are printed below: 
3.6.1 CORRESPONDENCE LETTER  
From Ksir and Hart (2016b): “We read with intense interest the meta-analysis 
by Schoeler and colleagues (Schoeler, Monk, et al., 2016) on continued cannabis use in 
patients with psychosis. Clearly, this issue is timely and important, and the authors 
should be commended for attempting to provide empirical evidence to inform public 
policy. However, our enthusiasm was dampened because the interpretation extends 
beyond the available data. 
It is of utmost importance for us to remember that the meta-analysis was based 
on correlational studies. Each study points out that causation has not been shown; 
however, a strong tendency exists to accept cannabis use as a so-called component 
cause of psychosis, which then leads to the conclusion that it is imperative to reduce 
cannabis use in patients with or at risk for psychosis. Although we understand this 
impulse is motivated by a concern for public health, we should not allow the consistency 
of these correlational findings to substitute for actual evidence of causality. 
In 2016, we did a critical review (Ksir & Hart, 2016a) of the scientific literature 
on cannabis and psychosis and concluded that the literature supports the hypothesis 
that both psychosis and cannabis use are more likely in individuals with a shared 
vulnerability to misuse of various substances and increased risk for various mental 
disorders. In other words, the correlation between cannabis use and psychosis is not 
specific, either with regard to the chemicals found in cannabis or to psychosis as 
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opposed to other disorders. 
Schoeler and colleagues (Schoeler, Monk, et al., 2016) stated that rates of 
cannabis use in patients with psychosis are “higher than…those of people with other 
psychiatric diagnoses”. To support this statement the authors cited an article by Agosti 
and colleagues (Agosti, Nunes, & Levin, 2002a), even though Agosti and colleagues 
clearly concluded, “Alcohol dependence, antisocial personality disorder, and conduct 
disorder had the strongest associations with cannabis dependence, followed by anxiety 
and mood disorders”. They did not report any association between cannabis and 
psychosis, presumably because of the low frequency of psychosis in the participants 
studied. 
In our own review (Ksir & Hart, 2016a), we included seven studies published in the 
past 3 years that provided information on the issue of specificity. After reviewing the 
scientific literature we found evidence that bipolar disorder, anxiety disorder, and mood 
disorder have all been correlated with cannabis use, and reported that psychosis has 
been correlated with heavy tobacco smoking, heavy alcohol use, stimulant misuse, and 
sedative misuse. We found no clear evidence for a causal relation between cannabis 
and psychosis (Ksir & Hart, 2016a).  
According to our shared vulnerability hypothesis, in a given group of cannabis 
users who have had psychotic episodes, the individuals with the greatest degree of the 
shared vulnerability would be the most likely to continue cannabis use rather than to 
discontinue, and they would be the most likely to have recurring episodes of psychosis 
and require more hospital treatment. As such, these two outcomes should be correlated, 
even if neither is a cause of the other. 
As to whether a public health benefit can be obtained from efforts to reduce 
cannabis use in patients with psychosis, two randomised controlled trials (Hjorthøj et 
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al., 2013; Madigan et al., 2013) published in 2013, comparing treatment as usual with 
treatment as usual plus motivational interviewing and cognitive behaviour therapy that 
focused on cannabis use, found no beneficial effect of either intervention on either 
psychotic symptoms or amount of cannabis use. 
Our greatest concern is not that someone might be advised to stop using 
cannabis. We are concerned that a misunderstanding of the relation between cannabis 
use and psychotic behaviour leads to an oversimplification of the complex 
developmental nature of substance use and mental disorders. Furthermore, we propose 
that future studies that limit their data collection to focus only on cannabis and only on 
psychosis will do little to enhance our understanding of the complexity of this 
comorbidity.” 
3.6.2 AUTHORS’ REPLY 
From Schoeler, Murray, et al. (2016): “We thank Charles Ksir and Carl Hart for 
their interest in our Article (Schoeler, Monk, et al., 2016). We agree that we cannot 
draw definite conclusions regarding causality from our meta-analysis of cannabis use 
continuation versus discontinuation in people already psychotic. This was not our 
purpose because there are already both prospective and experimental studies 
implicating cannabis use as “a component cause” for psychotic symptomatology (Robin 
M. Murray & Di Forti, 2016). In this regard we should point out that contrary to the 
authors' assertion, Agosti and colleagues (Agosti et al., 2002a) did in fact find an 
increased risk (odds ratio 3.49, 95% CI 1.35–9.02) of psychosis in patients dependent 
on cannabis. 
Ksir and Hart suggest that the association between continued cannabis use and 
psychotic relapse is the result of a “shared-vulnerability”, presumably genetic. 
However, two recent GWAS studies suggest that the overlap in genetic vulnerability for 
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psychosis and cannabis use is likely to be only modest (cf. aSupplementary 1, Appendix 
III). Furthermore, the association of cannabis use with psychotic symptomatology 
remained significant when the main effect of genetic predisposition was fully (David M 
Fergusson et al., 2005; Foti et al., 2010) or partly factored out (cf. aSupplementary 1, 
Appendix III). Dose–response relationships in those studies further oppose a shared-
vulnerability hypothesis. Contrary to Ksir and Hart's assertion, shared vulnerability 
also does not explain why discontinuation of cannabis use might be associated with a 
reduced severity of symptoms in the same individuals who had more severe symptoms 
while they were using cannabis (Foti et al., 2010). Finally, the notion of cannabis use as 
a risk factor does not contradict the results from the two randomised controlled trials 
cited by the authors. Considering that the interventions were not effective in reducing 
cannabis use in those studies (cf. aSupplementary 1, Appendix III), no differences in 
outcome between the two intervention groups would be expected, which was the case. 
Although we appreciate Ksir and Hart's advice for caution, on the basis of the available 
evidence, we would argue that it seems unlikely that shared genetic vulnerability fully 










4 PAPER 2: EFFECTS OF CONTINUATION, FREQUENCY AND TYPE 
OF CANNABIS USE ON RELAPSE IN THE FIRST TWO YEARS 
FOLLOWING ONSET OF PSYCHOSIS - AN OBSERVATIONAL STUDY 
4.1 ABSTRACT 
Background. Although cannabis use following a first episode of psychosis (FEP) has 
been associated with relapse, current understanding is limited regarding the 
determinants of this most preventable risk factor for relapse of psychosis. 
Methods. 256 FEP patients presenting to psychiatric services in South London were 
prospectively recruited and followed up. Relapse of psychosis within two years 
following onset of psychosis was defined as risk of subsequent admission to hospital. 
Patients were classified into different patterns of cannabis use based on (a) continuity of 
use following onset of psychosis, (b) potency of cannabis consumed and (c) frequency 
of use following onset of their illness. Multiple regression analyses (logistic/binominal) 
were employed to compare the different cannabis use groups. Propensity score analysis 
was used to validate the results. 
Findings. Simple analyses showed that former regular users who stopped after onset 
had the most favourable illness course with regard to relapse. In multiple analysis, 
continued high-frequency users (daily use in all 24 months) of high-potency cannabis 
(“skunk-like”) had the worst outcome, indexed as an increased risk for a subsequent 
relapse (OR=3.28; 95%CI[1.22-9.18]), more numerous relapses (p=0.07), fewer months 
until a relapse occurred (p=0.02) and more intense psychiatric care (p=0.01) following 
onset of psychosis.  
Interpretation. Adverse effects of continued use of cannabis following the onset of 
FEP depend on the specific patterns of use. Interventions may focus on persuading 
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There is good grounds to believe that cannabis use is a contributory cause of 
psychotic disorders, especially if used frequently and initiated at an early age (T. H. M. 
Moore et al., 2007; Stepniak et al., 2014). Cannabis remains the most commonly used 
illicit drug in patients with established psychosis (Moore, Mancuso, Slade, Galletly, & 
Castle, 2012) and rates are particularly high in young people presenting with their first 
episode of psychosis (Patel R et al., 2016). Relatively few patients with established 
psychosis start using cannabis after onset of psychosis (González-Pinto et al., 2011), but 
a major concern is the substantial proportion that continues using the drug (Faridi et al., 
2012; Hinton et al., 2007). A recent meta-analysis suggests that continued cannabis use 
following onset predicts poor outcome in psychosis as indicated by higher number of 
relapses, hospitalisation and more severe positive symptomatology (Schoeler, Monk, et 
al., 2016), consistent with evidence that experimental administration of the key 
psychoactive ingredient in cannabis is associated with transient psychotic symptoms 
and cognitive impairments in healthy individuals and exacerbation of symptoms in 
patients with a pre-existing psychotic disorder (Sagnik Bhattacharyya et al., 2009; 
D’Souza et al., 2005). However, whether the association between cannabis use and 
worse outcome in pre-existing psychosis is causal in nature has remained inconclusive 
(Schoeler, Monk, et al., 2016) because prospective evidence to date has not always 
successfully established that cannabis use actually preceded and was in reasonable 
temporal proximity to the outcome interest, i.e. relapse of psychosis. More importantly, 
how parameters of cannabis use, such as type and potency of cannabis used and 
frequency of use affect outcome has remained unclear. This is especially important in 
light of evidence that dose, type and pattern (Di Forti, Marconi, et al., 2015) of cannabis 
use are important determinants of its effect on onset of psychosis. In particular, for such 
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evidence to be translated into real world meaningful solutions in the clinical setting, it is 
important to develop a more nuanced understanding of the association between one of 
the most potentially preventable risk factors of psychosis, i.e., cannabis use and its 
determinants and the risk of relapse in psychosis.   
Understanding the role of cannabis in relapse of psychosis is important not just 
because prevention of relapse is critical for better long-term outcome in psychosis 
(Wiersma et al., 1998), but also because of the substantial financial implications 
associated with need for hospital care in those who relapse (Knapp, Locklear, & 
Järbrink, 2009b), as upto 50% of first-episode psychosis (FEP) patients experience a 
relapse that results in hospital admission within the first 2 years of illness, with the risk 
increasing to over 80% by the 8th year (M Alvarez-Jimenez et al., 2012).  
In the current study I aim to address the limitations in existing evidence [cf. 
Table 13. and Schoeler, Monk, et al. (2016)], such as lack of detailed assessment of 
cannabis use pattern following onset of psychosis, modest sample size and lack of 
consideration of potentially important confounders,  by investigating the effects of 
continued cannabis use on risk of relapse as indexed by hospital admission over the first 
two years following onset of psychosis. I employ a precise definition of continued use 
(use at least once within each month throughout the two years following the onset of 
illness), examine dose-response relationships that incorporate potency of cannabis 
consumed and address the effects of potential confounders such as medication non-
adherence (Caseiro et al., 2012; Leeson et al., 2012), illness severity at onset (Baeza et 
al., 2009; Hinton et al., 2007), ethnicity (N. Goater et al., 1999), gender (Moore et al., 
2012) and other drug use such as alcohol use, cigarette use or other illicit drug use 









Cannabis profiles  
NU: Non-user   
SU: Started user  















Sorbara et al. 
(2003)/ France 
T1: Onset (age 
31) 
T2: 24 Months 
FU 
NU: Absence of CUD 
between T1 and T2 
SU/CU: Presence of 






 3.1  
[1.01-9.4] 




58 1: (+) 
2: (–)  












T1: Onset (age 
20) 
T2: 15 Months 
FU 
NU: Absence of CUD 
between T1 and T2 
SU/CU: Presence of 









 4.87  
[2.09-
11.32] 
0.0003 - 88 1: (–) 
2: (–)  
3: (–) 
 
Baeza et al. 
(2009) / Spain 
T1: Onset (age 
16) 
T2: 6 Months 
FU 
NU: no use 1 month 
prior T1 
FU: use 1 months prior 
T1, no use 1 month prior 
T1 
SU/CU: use in 1 month 
prior FU assessment 
(NU) vs. 
(SU/CU)  






 1 - 84 1: (–) 




et al. (2011)/ 
Spain 
T1: Onset (age 
30) 
T2: 8 Y FU 
NU: never user 
SU: stopped use 












 0.03 - 65 1: (–) 
2: (–)  
3: (–) 
 
Leeson et al. 
(2012)/ UK 
T1: Onset (age 
26) 
T2: 24 Months 
FU 
FU: use 1 year prior to 
T1, no use 3 months 
prior T2 
CU: use at T1, use 3 
months prior T2 
(NU) vs. 
(CU)         
Number of days 





 <0.0001 - 50 1: (–) 
2: (–)  
3: (–) 
 
Caseiro et al. 
(2012)/ Spain 
T1: Onset (age 
27) 
T2: 36 Months 
FU 
NU: no use at T1 and T2 
CU: use at T1 and T2 (> 


















140 1: (+) 








Faber et al. 
(2012)/ 
Netherlands 
T1: Onset (age 
28) 
T2: 6 Months 
FU 
T3: 15 Months 
FU 
T4: 24 Months 
FU 
NU: no use T1 and T4 
(<1 time) 
SU/CU: use between T1 










0.78 - 124 1: (–) 
2: (–)  
3: (–) 






Faridi et al. 
(2012)/ Canada 
T1: Onset (age 
22) 
T2: 12 Months 
FU 
NU: Absence of CUD 
between T1 and T2 
CU: Presence of CUD at 










0.89 - 48 1: (–) 










L. Clausen et al. 
(2014)/ 
Denmark 
T1: Onset (age 
27) 
T2: 5 Y FU 
NU: no use at T1 and T2 
FU: stopped between T1 
and T2 
SU: started between T1 
and T2 
CU: continued between 
T1 and T2 
(NU) vs. 
(CU)  
Number of days 





 0.76 - 228 1: (–) 
2: (–)  
3: (+) 
 
Note. BPRS = Brief Psychiatric Rating Scale (Overall & Gorham, 1962); DUP =  Duration of untreated psychosis; CGI = Clinical Global 
Impression scale (W Guy, 1976); CUD = Cannabis Use Disorder; FU= Follow up; d= effect size Cohen’s d; NOS = Not otherwise specified; 
OR= Odds Ratio; PAS = Premorbid Adjustment Scale (Cannon-Spoor, Potkin, & Wyatt, 1982a),  SANS = Scale for the Assessment of Negative 
(Andreasen, 1989b); SAPS = Scale for the Assessment of Positive Symptoms (Andreasen, 1984a) 
aOR and Cohen’s d reported as applicable to results reported in original study 
bQuality assessment based on whether a study did (+) or did not (–):  1: Control for confounders; 2: Based cannabis profile on multiple cannabis-
parameter (e.g. frequency/duration/type); 3: Included adequate sample size (>200)  
cRelapse based on either (1) BPRS score or (2) CGI rating or (3) hospitalisation or (4) completed suicide 





Patients with first-episode non-organic [non-affective (ICD10 codes F20-F29) or 
affective (F30-F33)] psychosis (WHO, 2004), aged 18-65 who were referred to local 
psychiatric services in South London were recruited into the study. They were assessed 
twice, first close to the onset of their illness using face-to-face interviews and 
subsequently for follow-up, using either a face-to-face or a telephone interview (if the 
individual was unable to appear in person). Face-to-face or phone interview data was 
complemented by a screening of their clinical records to extract healthcare usage data 
(e.g. dates of admission/discharge, information on involuntary admission, medication 
usage). All patients were followed up for at least two years following the onset of their 
illness. I focused on this early stage following onset of psychosis as this is considered as 
the “critical period” that determines long-term outcome in psychosis (Birchwood et al., 
1997). Follow-up assessments were carried out until September 2015. Data from 
clinical records regarding hospital admissions were also collected for those who refused 
to take part in the follow-up interview (n=133) over the same 2-year window following 
onset of psychosis. Risk of relapse was not significantly different (36.3% vs. 38.3% 
relapsed, χ2= 0.15, p=0.70) in those patients who agreed to take part (n=256) in the 
follow-up (Completers) compared to those who refused (Refusers). Furthermore, the 
two groups (Completers and Refusers) did not significantly differ in baseline 
characteristics such as premorbid cannabis use (ever used prior onset), gender, ethnicity 
and age of onset of psychosis (cf. Table 14. below). When considering separately those 
who relapsed and those who did not over the 2-year follow-up period, Completers and 
Refusers did not significantly differ in these baseline characteristics (cf. Table 14.). This 
study was granted ethical approval by South London & Maudsley NHS foundation trust 
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and Institute of Psychiatry Local Research Ethics Committee. All subjects included in 





Cannabis use was assessed using a modified version of the Cannabis Experience 
Questionnaire (CEQmv, cf. Chapter 8.2.2, Appendix II) (Di Forti, Marconi, et al., 
2015), collecting data on premorbid cannabis use, as well as use over the first two years 
following onset of psychosis. To assess the reliability of the retrospective assessment of 
cannabis use, I compared data for n=206 subjects on premorbid cannabis use (ever used 
before onset) collected at onset of psychosis with data on premorbid cannabis use 
reported at follow up. In 92.7% of those compared, reporting of premorbid cannabis use 
was consistent across both assessments (i.e., at onset and at follow-up); 3.4 % those 





(n=133) χ2 p 
Relapse (yes) 93 (36.3%) 51 (38.3%) 0.15 0.7 
Premorbid cannabis use (yes) 193 (75.4%) 98 (73.7%) 0.14 0.71 
Gender (male) 156 (60.9%) 88 (66.2%) 1.02 0.31 
Ethnicity (non-white)* 170 (66.4%) 69 (65.1%) 0.06 0.81 
Age of onset (<21) 48 (18.8%) 22 (16.5%) 0.29 0.59 
Subsample (Not relapsed) Included (n=163) 
Refused 
(n=82) χ2 p 
Premorbid cannabis use (yes) 117 (71.8%) 60 (73.2%) 0.05 0.82 
Gender (male) 101 (62%) 58 (70.7%) 1.84 0.17 
Ethnicity (non-white) 99 (60.7%) 44 (63.8%) 0.19 0.66 
Age of onset (<21) 26 (16%) 12 (14.6%) 0.07 0.79 
Subsample (Relapsed) Included (n=93) 
Refused 
(n=51) χ2 p 
Premorbid cannabis use (yes) 76 (81.7%) 38 (74.5%) 1.04 0.31 
Gender (male) 55 (59.1%) 30 (58.8%) 0.001 0.97 
Ethnicity (non-white) 71 (76.3%) 25 (67.6%) 1.06 0.31 
Age of onset (<21) 22 (23.7%) 10 (19.6%) 0.31 0.58 
* missing data (refusers) for n=27 
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who denied premorbid use when assessed at the onset of psychosis admitted it when re-
examined at the follow up assessment, while 3.9% denied pre-morbid cannabis use at 
follow-up assessment although they had admitted use when assessed at onset. Cannabis 
users were classified based on their pattern of use into different cannabis use profiles, 
depending on continuity and frequency of cannabis use following onset. Type of 
cannabis (hash-like vs. skunk-like) used was assessed by asking subjects to describe 
their preferred type of cannabis. Based on this information, grouping was done in the 
same fashion as reported previously (Di Forti, Marconi, et al., 2015), and consistent 
with previous reports on the characteristics of the cannabis samples seized by the police 
in London (Potter et al., 2008).  
Information regarding service use, number, duration and legal status 
(voluntary/involuntary) of in-patient admissions, referral to crisis intervention team or 
standard treatment by a community mental health team was obtained from electronic 
patient records. Data was extracted using the WHO Life Chart Schedule (Susser et al., 
2000b), which allows prospective recording of the course of illness in terms of 
treatment history. As the main outcome measure, relapse was defined as admission to a 
psychiatric inpatient unit owing to exacerbation of psychotic symptoms within two 
years following first presentation to psychiatric services and receiving a diagnosis of 
psychosis. If the patient was hospitalized at their first presentation to psychiatric 
services with a diagnosis of psychosis, this was not considered as a relapse event. All 
patients received care from a specialized Early Intervention community team for 
Psychosis. 
Alcohol use, other illicit drug use and cigarette use, illness severity at onset 
(indexed as onset care intensity) and medication adherence were assessed and included 
in the analysis as potential confounders based on previous literature. Measurements of 
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cannabis use, relapse and confounders estimated are described in Table 15. (below). 
Demographic and clinical information recorded at onset were used to compare the 
different cannabis use groups in terms of family history of mental illness [diagnosis of 
axis I psychiatric illness in at least one first degree relative], ICD10 diagnosis [affective 
vs. non-affective psychosis (based on ICD-10 diagnosis assessed with OPCRIT 
(McGuffin, Farmer, & Harvey, 1991))] and employment status [employed=in full-time 
or part-time employment, self-employed; unemployed = not employed, economically 
inactive, student]. Several covariates were assessed and included in the analysis (cf. 




Table 15. Study variables 
Cannabis profile (categorical variable) 
0: Former (regular) 
user 
Subject who had a history of regular cannabis use (defined as 
use at least once/month for 6 consecutive months) prior to their 
onset but who used cannabis only infrequently (< 6 times) in the 
two years following the onset of psychosis. 
1: Never (regular) 
user 
Subjects who were never regular users of cannabis either prior to 
(less than once/month for 6 consecutive months) or following (< 
6 times over the follow-up period) the onset of psychosis. 
2: Post-onset 
intermittent user 
Subjects who used cannabis more than infrequently (> 6 times) 
following the onset of psychosis but not consistently every 
month over the first two years following the onset of illness. 
3: Post-onset 
continued user – 
hash-like  
Subjects who used low-potency cannabis (“hash-like” like hash, 
resin) [cf. Di Forti, Marconi, et al. (2015) for classification] 
continuously (defined as use at least once in each month of the 
years following the onset). 
4: Post-onset 
continued user – 
skunk-like (low-
frequency) 
Subjects who used l high-potency cannabis (“skunk-like”) 
[grouping was done in the same fashion as reported 
previously(Di Forti, Marconi, et al., 2015), and consistent with 
previous reports on the characteristics of the cannabis samples 
seized by the police in London(Potter et al., 2008).] continuously 
(defined as use at least once in each month of the years 
following the onset) but in a low-frequency manner (less than 
daily). 
5: Post-onset 
continued user – 
skunk-like (high-
frequency) 
Subjects who used high-potency cannabis (“skunk-like”) [cf. 
row above for classification] continuously in a high-frequency 
manner (daily use). 
Relapse definition 
Risk of relapse Relapse (yes/no) of psychosis was coded as ‘yes’ if a patient was 
admitted to a psychiatric inpatient unit at least once following 
the onset of illness over the two ensuing years. Any hospital 
admission that was part of the first episode was not included as a 
relapse. 
Number of relapses Number of relapses was calculated as a continuous variable by 
estimating the cumulative number of hospital admissions 
following the onset of illness over the 2 year period.  
Length of relapse Length of relapse was calculated by estimating the cumulative 
number of months spent in hospital over the two years following 
the onset of illness. The time spent in hospital as part of the first 
episode was not included in this measure. 
Time to first relapse Time to first relapse was measured as the consecutive number of 
survival months without experiencing a relapse. Those subjects 
who did not relapse following the onset were allocated a survival 
time of 24 months. 
Care intensity at 
follow-up 
This outcome was computed as an ordinal variable by rating 
each subject’s intensity of service use within two years 
following the onset [0=Required only community treatment 
without crisis intervention; 1=Required crisis intervention 










without compulsory admission; 3=Required compulsory hospital 
admission (admitted under section 2, section 3, section 136, 
through crown and magistrates (Section 35, 36, 37, 41 & 48), 
section 4 or section 5 if converted to sec 2 or 3 subsequently)].  
Confounders 
Alcohol use Alcohol use (yes/no) since onset derived from CEQmv .  Similar 
to previous ratings (Faber et al., 2012), subjects were considered 
as users if they had a history of daily use for at least one month 
within the two years following the onset of illness. 
Other illicit drug use Other illicit drug use (yes/no) derived from the CEQmv. Subjects 
were considered as users if they had consumed illicit drugs 
recreationally (> 6 times) within the two years following the 
onset of illness.  The cut-off used was comparable to previous 
studies (e.g.González-Pinto et al. (2011), which used < 4 times 
used in the previous year as the cut-off for non-regular user). 
Cigarette use Cigarette use data was collected using the CEQmv. Subjects were 
considered as smokers if they consumed cigarettes regularly (> 
365 days of use) within the two years following the onset of 
illness. 
Care intensity at 
onset 
Care intensity at onset was computed as an ordinal variable by 
rating each subject’s intensity of service use at onset (cf. coded 
as above for care intensity at follow up).  In order to arrive at a 
measure reflective of onset illness severity, I included this 




Similar to previous reports (Faridi et al., 2012), medication 
adherence was dichotomized (adherence vs. non-adherence), 
rating a patient’s adherence as compliant if the prescribed 
medication was taken regularly for more than 34% of the time 
within the two years following the onset of illness. 
Other Other covariates included gender (male/female), ethnicity 
(white/non-white), age of onset of psychosis (age at first 
presentation to the psychiatric services for psychosis) 
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4.3.3 DATA ANALYSIS 
Data analysis was performed using R (Bossong et al., 2013). Follow-up data for 
a fixed two-year period following onset of psychosis was modeled for every subject. 
The cannabis profile variable was coded as an ordered categorical variable (cf. Table 
15.), with the former (regular) user group acting as the reference group. I chose the 
former user group as reference because it allowed us to account to a substantial extent 
for the effect of any putative shared stable vulnerability factors (such as genetic 
vulnerability) (Schoeler, Murray, et al., 2016) that have been argued to underlie the 
association between cannabis use and psychosis relapse (Ksir & Hart, 2016b) as both 
the continued cannabis user groups and the former user group would have been affected 
by common shared stable vulnerability factors. The argument that cannabis-using 
patients with psychosis may represent a neurodevelopmentally distinct subgroup 
compared to never using psychosis patients (Schoeler, Kambeitz, et al., 2016; Murat 
Yücel et al., 2012), also makes the former cannabis user group a better choice. 
Clinically as well, they are the most meaningful comparison group because they are the 
discontinued users as opposed to continuing users.  
First, exploratory simple analyses, including chi-square (χ²) test for categorical 
variables and Kruskal-Wallis test and Mann-Whitney U (two-sided) test for continuous 
outcomes were used to compare the different cannabis use groups for continuous 
outcomes (number of relapses, length of relapse, time to relapse, care intensity at follow 
up). This non-parametric test was chosen as the Shapiro-Wilk Normality Test statistic 
was highly significant for those outcomes (p<0.001).  Following common practice 
(Stepniak et al., 2014), I generated Kaplan-Meier curves and compared the different 
cannabis use groups using log-rank tests. Pairwise comparisons were adjusted using 
Bonferroni correction to account for multiple testing.  
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Second, to test the hypothesis whether the different cannabis use groups were 
significantly different to the former (regular) user group in their relapse outcome, I 
employed multiple regression models to test whether the categorical cannabis use 
variable predicted outcome after controlling for confounders. Antipsychotic medication 
adherence was included in a separate regression model on its own as this data was only 
available for a subset of cases, considering that antipsychotic medications were not 
prescribed for all subjects following the onset of illness. Multiple logistic regression 
analyses were employed to compute the odds ratio (OR) and 95% CIs, using binary 
logistic regression for binary outcomes (risk of relapse) and ordinal logistic regression 
analysis for ordered categorical outcome (care intensity at follow-up).  Multiple 
negative binominal regression models were employed for continuous outcomes (number 
of relapses, length of relapse, time to relapse). This regression analysis was preferred 
over Poisson regression since there was evidence of over-dispersion for the outcome 
variables (i.e. the conditional variance was higher than the conditional mean). As there 
was an excess of zero observations for count data (number of relapses), I tested whether 
a zero-inflated negative binominal regression model (ZINB) was a better fit for the data 
compared to a negative binominal regression model, which it was not, and hence not 
considered (Vuong p>0.05). Sensitivity analysis was performed by calculating 
propensity scores (PS) in order to validate the results and to address the limitations by 
confounding adjustment in regression analysis (Rubin, 2001). PS was defined as the 
patients’ probability of being classified as one of the treatment groups [never (regular) 
user; post-onset intermittent user; post-onset intermittent user; post-onset continued user 
– hash-like; post-onset continued user – skunk-like (low frequency); post-onset 
continued user – skunk-like (high frequency)] versus the control group (former regular 
users), based on their individual observed covariates. Probability was estimated using a 
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multiple logistic regression model with the dichotomized (treatment vs. control) 
variable as the dependent variable, which included all covariates as specified in Table 
15. The treatment group was matched to controls by PS using an optimal nearest 
neighbourhood-matching algorithm. The balance of all covariates among the treatment 
group and their PS-matched controls was checked using the p-value estimates from 
logistic regression analysis (cf. aTable 7., Appendix III) before carrying out the 






















4.4.1 SAMPLE CHARACTERISTICS 
Two hundred fifty-six FEP patients took part in this study. Majority of patients 
(78.1%) were admitted to hospital around the onset of illness; over half of those 
(59.5%) experienced involuntary admission. Within the first 2 years following onset of 
illness, 36.3% of patients experienced a relapse leading to hospital admission. Three 
relapses within the two years following the onset was the maximum number of relapses 
that occurred in this sample, while the longest time spent in hospital was 14.8 months. 
Out of N=153 subjects with pre and/or post-onset regular cannabis use, only n=2 (1.3%) 
subjects started using cannabis following onset (with no previous history of regular 
use), while n=97 (63.4 %) had used cannabis regularly prior to onset and used it 
subsequently either intermittently or continuously and n=54 (35.3%) had a history of 
regular use prior to onset but did not use it regularly following onset. 24.6% (n=63) of 
the patients had never tried cannabis in their lifetime. Use of other illicit drugs was 
reported by n=27 (10.5%) in the two years following onset of psychosis. In this group, 
n=19 (70.4%) used cocaine, n=8 (29.6%) used opioids, n=8 (29.6%) used 
amphetamines, n=3 (11.1%) used hallucinogens, n=2 (7.4%) used poppers and n=1 
(3.7%) used ketamine following the onset. On comparing the different groups based on 
their cannabis use patterns it appeared that they significantly (Kruskal-Wallis, p=0.02) 
differed in the age of onset of their psychosis, with continued cannabis users comprising 
the group with the youngest age of onset. The cannabis user groups as shown in Table 
16. did not differ with regard to the proportion of patients taking antipsychotic 
medication (χ²=0.93, p=0.82), the type of antipsychotic medication prescribed at onset 
(first-generation vs. second-generation antipsychotics) (χ²=2.61, p=0.46) or their ICD-
10 psychosis diagnosis at onset (affective vs. non-affective) (χ²=1.68, p=0.64). They 
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also did not differ significantly in their employment status at onset (χ²=5.24, p=0.15.) or 
family history of mental illness (χ²=1.84, p=0.61). Non-white ethnicity was significantly 
associated with risk of relapse (χ²=6.46, p=0.01), while type of antipsychotic medication 
(first-generation vs. second-generation antipsychotics) (χ²=0.31, p=0.46), non-
prescription of antipsychotic treatment (χ²=0.19, p=0.66), type of psychosis (affective 
versus non-affective psychosis) (χ²=0.64, p=0.42), employment status (χ²=0.37, 
p=0.54), family history of mental illness (χ²=0.70, p=0.58), gender (χ²=0.20, p=0.66) 


























Table 16. Sample characteristics 









Number of subjects 256 (100%) 54 (21.1%) 103 (40%) 35 (13.7%) 64 (25%)  
Age of onset (M/SD) 28.06 (8.03) 28.05 (7.65) 29.74 (8.96) 27.95 (8.21) 25.43 (5.83) 0.02 
Gender (n male) 156 (60.9%) 37 (68.5%) 44 (42.7%) 24 (68.6%) 51 (79.7%) <0.0001 
Ethnicity (non-white) 170 (66.4%) 23 (42.6%) 78 (75.7%) 22 (62.9%) 47 (73.4%) 0.0002 
Care intensity at onset (n) 
   Referral to community team only 
   Required contact with crisis team 
   Required hospital admission (non-compulsory) 



























Months stayed in hospital at onset (M/SD) 1.72 (3.37) 2.10 (6.28) 1.57 (2.09) 1.31 (1.20) 1.88 (2.16) 0.57 
Employment status at onset (n in employment)b 83 (32.8%) 21 (40.4%) 38 (36.9)% 9 (25.7%) 15 (23.8%) 0.15 
Family history of mental illness (n yes)c 96 (49%) 20 (44.4%) 40 (54.8%) 11 (42.3%) 25 (48.1%) 0.61 
Onset diagnosis (non-affective) 211 (82.4%) 47 (87%) 82 (79.6%) 30 (85.7%) 52 (81.2%) 0.64 
Medication prescribed at onset (n yes) 240 (93.8%) 52 (96.3%) 96 (93.2%) 33 (94.3%) 59 (92.2%) 0.82 
Type of medication at onset (n) 
   Second-generation antipsychotic  

















Note. M=Mean; n=number of subjects; SD=Standard Deviation. 
a p-value estimates from Kruskal-Wallis test for means and Chi-square tests for independence for percentages to compare all cannabis groups 
bMissing data for n=3 
cData available for n=196 
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4.4.2 CANNABIS USE PROFILES AND RELAPSE OUTCOME: UNADJUSTED ANALYSIS  
Risk of relapse was significantly different across all groups (χ²=15.33, p=0.009). 
The greatest risk was present in continued high-frequency users of high-potency 
cannabis (“skunk-like”), while it was lowest in former cannabis users (58.1% vs. 
24.1%) currently abstaining. Former cannabis users had the highest rate of community 
treatment only, requiring no referral for crisis intervention or inpatient care (cf. Table 
17.). In contrast, low/high-frequency users of high-potency (“skunk-like”) were more 
likely to experience compulsory admissions than former cannabis users (29%/37.5% vs. 
7.4%). As shown in Table 17., there was a significant effect of pattern of cannabis use 
on total number of relapses (Kruskal Wallis, p=0.01), length of relapses (Kruskal 
Wallis, p=0.009), time to relapse (Kruskal Wallis, p=0.02) and care intensity (Kruskal 
Wallis, p=0.005). Kaplan-Meier curves further indicated that the different groups 
significantly differed with regard to their time to relapse (Kaplan-Meier p=0.007). More 
specifically, the user group high-frequency /“skunk-like” user was more likely to 
experience an earlier relapse than the former (regular) user group (Kaplan-Meier with 






















Care intensity at follow-up (n/%)a 
0 1 2 3 
Former (regular) user 13 (24.1) 0.35 (0.73) 0.59 (1.74) 20.86 (6.55) 40 (74.1) 1 (1.9) 9 (16.7) 4 (7.4) 
Never (regular) user 31 (30.1) 0.43 (0.74) 0.66 (1.46) 20.24 (6.57) 59 (57.3) 13 (12.6) 16 (15.5) 15 (14.6) 
Intermittent user 14 (40.0) 0.51 (0.70) 1.66 (3.53) 18.75 (6.88) 16 (45.7) 5 (14.3) 4 (11.4) 10 (28.6) 
Continued user (Hash-like) 4   (44.4) 0.67 (1.00) 1.11 (2.07) 21.23 (5.22) 5 (55.6) 0 (0.0) 1 (11.1) 3 (33.3) 
Continued user (Skunk-like/low frequency) 13 (54.2) 0.62 (0.65) 1.69 (3.34) 20.27 (4.67) 11 (45.8) 0 (0.0) 4 (16.7) 9 (37.5) 
Continued user (Skunk-like/high frequency) 18 (58.1) 0.87 (0.92) 1.71 (2.85) 16.03 (8.21) 12 (38.7) 1 (3.2) 9 (29.0) 9 (29.0) 
Note. Care intensity at follow-up (0=Required only community treatment without crisis intervention; 1=Required crisis intervention without hospital 
admission; 2= Required hospital admission without compulsory admission; 3=Required compulsory hospital admission); M=Mean; SD=Standard 
Deviation. 
a Chi-square test for independence to compare all groups for risk of relapse (p=0.009, χ2=15.33) and care intensity at follow up (p=0.004, χ2=33.49) 
b Kruskal-Wallis test to compare all groups in number of relapses (p=0.01), length (months) of relapses (p=0.009), time (months) to relapse (p=0.02) 
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Figure 15. Time until relapse per cannabis group 
 
Note. Kaplan-Meier curves. p-values are estimated from the log-rank tests to compare 
the different groups [reference group = former (regular) user] 
*Bonferroni-corrected significance level 
 
 
4.4.3 CANNABIS USE PROFILES AND RELAPSE OUTCOME: MULTIPLE REGRESSION 
ANALYSES 
In multiple logistic regression analysis, continued high-frequency use of high-
potency (“skunk-like”) (indexed as at least daily use throughout the follow-up period) 
remained a significant predictor for relapse [OR=3.28; 95%CI 1.22-9.18], when 
compared to former users (cf. Table 18. below). The effect also remained significant 
when medication non-adherence was included in the model [OR=2.73; 95% CI 1.02-
7.56]. None of the other cannabis groups were significantly different in their risk of 
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relapse when compared to former users. In those risk models, only three other predictors 
remained significant, including non-white ethnicity [OR=2.36; 95% CI 1.23-4.69], care 
intensity at onset [OR=1.37; 95% CI 1.05-1.84] and antipsychotic medication non-
adherence [OR=3.25; 95% CI 1.79-6.09] (cf. Table 18.). The results from the other 
multiple regression analyses confirmed that the adverse effects of continued high-
frequency “skunk-like” use were also evident on the number of relapses [IRR=1.77; 
95% CI 0.96-3.25], time to relapse [b= -0.22; 95% CI -0.40-(-0.04)] and a higher care-
intensity at follow up [OR=3.16; 95% CI 1.29-8.09], while controlling for the above 
confounders. Including medication adherence into the model did not substantially 
change the results, although high-frequency “skunk-like” use remained a significant 
predictor only for length of relapse in this model [b= 0.98; 95% CI 0.09-0.1.90)] (cf. 
Table 18.). In propensity score-matched analyses considering all covariates (cf. Table 
19.), the effect of high-frequency “skunk-like” use was reduced in its magnitude but 
remained a significant predictor for risk of relapse [56.7% vs. 30%, OR=3.05; 95% CI 




Table 18. Cannabis use pattern and relapse outcome: Multiple regression analyses 
 Risk of relapse Number of relapses Length of relapse Time to relapse Care intensity at 
follow-up 
Model 1 (N=256) ORa 
95% 
CI p IRRb 
95% 
CI p bc 
95% 
CI p bc 
95% 
CI p ORd 
95% 
CI p 
Never (regular) user 
 1.24 
0.53-
3.03 0.63 1.27 
0.70-
2.29 0.43 -0.01 
-0.81-
0.79 0.99 -0.01 
-0.15-






4.64 0.25 1.22 
0.64-
2.34 0.54 0.78 
-0.09-
1.66 0.07 -0.06 
-0.23-
0.10 0.46 2.78 
1.14-
6.91 0.03 
Continued user (Hash-like) 
 1.82 
0.36-
8.76 0.45 1.13 
0.43-
2.97 0.80 -0.33 
-1.84-
1.25 0.65 0.07 
-0.20-




like/low frequency) 2.42 
0.80-
7.52 0.12 1.11 
0.54-
2.31 0.77 0.41 
-0.64-
1.49 0.41 0.05 
-0.14-




like/high frequency) 3.28 
1.22-
9.18 0.02 1.77 
0.96-
3.25 0.07 0.61 
-0.31-
1.55 0.17 -0.22 
-0.40- 






4.69 0.01 1.82 
1.16-
2.85 0.01 0.97 
0.35-
1.59 0.002 -0.12 
-0.23- 






2.60 0.26 1.20 
0.82-
1.74 0.35 -0.27 
-0.83-
0.30 0.33 -0.04 
-0.14-
0.06 0.44 1.51 
0.88-
2.61 0.13 
Other illicit drug use 
 1.79 
0.68-
4.76 0.24 1.79 
1.05-
3.04 0.03 0.70 
-0.17-
1.60 0.10 -0.11 
-0.28- 






2.83 0.23 1.73 
1.12-
2.67 0.01 0.37 
-0.17-
0.92 0.20 -0.07 
-0.18-
0.04 0.24 1.66 
0.92-
3.02 0.09 
Age of onset 
 1.01 
0.97-
1.04 0.78 1.00 
0.97-
1.02 0.82 -0.02 
-0.05-
0.01 0.30 0.00 
-0.01-






3.94 0.20 1.14 
0.69-
1.88 0.60 -0.09 
-0.85-
0.69 0.81 -0.01 
-0.15-
0.14 0.90 1.96 
0.95-
4.08 0.07 
Care intensity at onset 
 1.37 
1.05-
1.84 0.03 1.32 
1.08-
1.60 0.01 0.59 
0.32-
0.87 <0.001 -0.03 
-0.07-





Table 18. Cannabis use pattern and relapse outcome: Multiple regression analyses (cont’d) 
 Risk of relapse Number of relapses Length of relapse Time to relapse Care intensity at 
follow-up 
Model 2 (N=236) ORa 
95% 
CI p IRRb 
95% 
CI p bc 
95% 
CI p bc 
95% 
CI p ORd 
95% 
CI p 
Never (regular) user 
 1.28 
0.58-
2.88 0.55 1.13 
0.65-
1.98 0.65 0.20 
-0.55-
0.94 0.59 -0.01 
-0.15-






4.29 0.37 1.22 
0.62-
2.42 0.56 0.78 
-0.14-
1.74 0.09 -0.06 
-0.23-
0.12 0.53 2.47 
1.00-
6.20 0.05 
Continued user (Hash-like) 
 2.54 
0.50-
12.98 0.25 1.74 
0.67-
4.52 0.25 0.57 
-0.80-
2.23 0.45 0.04 
-0.25-




like/low frequency) 2.63 
0.91-
7.91 0.08 1.34 
0.66-
2.7 0.42 0.89 
-0.06-
1.91 0.08 0.03 
-0.16-




like/high frequency) 2.73 
1.02-
7.56 0.05 1.74 
0.94-
3.24 0.08 0.98 
0.09-
1.90 0.04 -0.20 
-0.38- 






6.09 <0.001 2.29 
1.46-
3.57 <0.001 0.57 
-0.01-
1.15 0.05 -0.15 
-0.25- 
(-0.05) 0.01 3.36 
1.93-
6.00 <0.001 
Note. Reference group = Former (regular) users 
a OR = Odds Ratio estimates from multiple logistic regression analysis 
b IRR = Incidence Rate Ratio estimated from negative binomial regression 
c b = Coefficient estimate from negative binomial regression 





Table 19. Sensitivity Analysis (Propensity Score Matching) 





FC NC ORa p FC IC ORa p FC CC-
H 
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ORb (NC vs. FC) p ORb (NC vs. IC) p ORb (NC vs.  CC-H ) p ORb (NC vs.  CC-SL) p ORb (NC vs.  CC-SH) p 
1.83 (0.66-5.31) 0.25 2.37 (0.90-6.52) 0.09 3.26 (0.44-31.93) 0.26 2.88 (0.93-9.39) 0.07 3.18 (1.19-8.97) 0.02 
Note. Cannabis profiles [FC = Former (regular) cannabis user; Never (regular) cannabis user; IC = Intermittent cannabis user; CC-H: Continued cannabis 
user (Hash-like); CC-SL = Continued cannabis user (Skunk-like/low frequency);  CC-SH = Continued cannabis user (Skunk-like/high frequency)]. 
a OR = Odds Ratio (95% Confidence Interval) estimates from multiple logistic regression analysis 
b IRR = Incidence Rate Ratio (95% Confidence Interval) estimated from negative binomial regression 
c b = Coefficient estimate from negative binomial regression 
d OR = Odds Ratio estimates from multiple ordinal regression analysis 
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As shown in Table 18., several other predictors were significantly linked to 
relapse in the multiple regression analyses. Ethnicity and medication non-adherence 
remained a significant predictor in all models, including risk of relapse, number and 
length of relapses, time to relapse and care intensity at follow up. Number of relapses 
was predicted by cigarette use [IRR=1.73; 95% CI 1.12-2.67] and other illicit drug use 
[IRR=1. 79; 95% CI 1.05-3.04]. Finally, higher care intensity at onset was associated 
with risk of relapse [OR=1.37, 95% CI 1.05-1.84], an increase in number of relapses 
[IRR=1.32; 95% CI 1.08-1.60] and increase of length of relapse [b=0.59; 95% CI 0.32-
0.87], as well as a higher care intensity throughout the two years following the onset of 
illness [OR=1.33; 95% CI 1.03-1.73]. Further analyses with the continued user group 
(skunk-like/high-frequency) as the reference group additionally indicated that this group 
relapsed earlier when compared to continued user (hash-like) [b=0.29; 95% CI 0.01-
0.58] and continued user (Skunk-like/low frequency) [b=0.27 95% CI 0.06-0.48] as well 












For the first time, this study on outcome in FEP was able to investigate the effect 
of different patterns of cannabis use on risk of relapse in psychosis by incorporating 
information on continuation, frequency and type of cannabis used. My results indicate 
that effects of cannabis use on outcome vary depending on specific cannabis use profile. 
While former regular cannabis users who stopped using the substance regularly 
following onset of psychosis had the lowest risk of relapse, those who continued to use 
at least on a monthly basis were most likely to experience a relapse. More specifically, 
continued users of high-potency cannabis (“skunk-like”) who were using on a daily 
basis had the highest risk of relapse of psychosis (OR 3.28), when compared to former 
cannabis users. This effect was independent of other putative risk factors for poor 
outcome, including ethnicity, gender, age of onset, alcohol, cigarette and illicit drug and 
care intensity at onset. Furthermore, high-frequency “skunk-like” users also had higher 
number of relapses, longer duration of hospital stay, shorter time to relapse and more 
severe (as indexed by care intensity at follow up) relapses, when compared to former 
users. More rigorous adjustment for confounders using propensity score matching 
showed similar results, with high-frequency “skunk-like” users having a 1.9 times 
higher risk (57% vs 30%) of relapse of psychosis. This is comparable, albeit in the 
opposite direction, to the effect of antipsychotic medication treatment on risk of relapse 
in psychosis [e.g. 2.4 (64% vs 27%) times higher risk for placebo versus drug-treated 
patients (Stefan Leucht et al., 2012)]. High-frequency “skunk-like” users also relapsed 
earlier when compared to “hash-like” and low-frequency “skunk-like” continued 
cannabis users as well as never (regular) users. Together, these results extend previous 
observational (Bergé et al., 2016; Hides et al., 2006; Stepniak et al., 2014) and 
experimental evidence (D’Souza et al., 2005) of dose-response effects of cannabis in 
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patients with psychosis to demonstrate that the effects of cannabis use on outcome in 
psychosis depend on the type of cannabis consumed as well as frequency of use. This is 
consistent with similar evidence on the onset of psychosis (Di Forti, Marconi, et al., 
2015). High-potency (“skunk-like”) cannabis has become dominant in the UK 
(Hardwick & King, 2008) and is characterized by high levels of delta-9-
tetrahydrocannabiniol (THC), the main psychoactive ingredient in cannabis, which  may 
exerts its effects through its impact on the neural substrates implicated in psychosis 
(Sagnik Bhattacharyya et al., 2012; Sagnik Bhattacharyya et al., 2009). Furthermore, it 
has minimal concentrations of cannabidiol (CBD) (Hardwick & King, 2008), which has 
been shown to ameliorate some of the effects of THC (Sagnik Bhattacharyya et al., 
2010a) and may have antipsychotic properties (Leweke et al., 2012) and is more present 
in hash-forms of cannabis (Hardwick & King, 2008). Higher relapse rates and shorter 
time to relapse in high-frequency skunk users may be the result of a failure to respond 
to antipsychotic treatment (Patel R et al., 2016) either on its own or in combination with 
an increase in the severity of psychotic symptoms in those frequently exposed to a 
higher dose of THC (D’Souza et al., 2005), which were not investigated in the present 
study. This may explain why some previous studies that did not differentiate between 
the type of cannabis, may have failed to observe an association between cannabis use 
and relapse (Baeza et al., 2009; Faber et al., 2012). This may also explain why the risk 
estimate observed in our study for the high-dose group (high-frequency/skunk-like) was 
substantially higher when compared to the pooled odds from previous studies that 
investigated the risk of cannabis on relapse [ORsimple 4.37 vs. ORsimple 1.97] (Schoeler, 
Monk, et al., 2016). Interestingly, the cannabis users who remained abstinent following 
the onset of psychosis (35%) did not differ from the non-user group with regard to 
outcome. This would imply that the effects of previous cannabis use on outcome in 
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psychosis are not irreversible (Schoeler, Monk, et al., 2016) and suggest a need to move 
beyond investigations of the effects of lifetime cannabis use or cannabis use assessed at 
onset only (Manrique-Garcia et al., 2014c; Wunderink et al., 2009). Considering the 
variable course of cannabis use following the onset of psychosis, future investigations 
should therefore focus on changes in pattern of use and type of cannabis used following 
psychosis onset, since the specific pattern of use as well as type of cannabis used may 
be the key factors driving adverse outcomes associated with cannabis use in psychosis. 
Consistent with previous reports (Caseiro et al., 2012; Leeson et al., 2012), 
cannabis users were less likely to be adherent to antipsychotic medication and non-
adherence remained the strongest predictor for relapse in our sample. The reduced 
magnitude of the effect of cannabis on risk of relapse when medication non-adherence 
was included in the multiple model [from ORsimple 4.37 (95% CI 1.72-11.85) to 
ORmultiple 2.73 (95% CI 1.02-7.56)] suggest that some of the effects of cannabis on 
outcome may perhaps relate to its association with non-adherence to antipsychotic 
medication. Nevertheless, similar to experimental evidence (D’Souza et al., 2005) and 
studies that reported reduced but significant adverse effects of cannabis in adherent 
patients on relapse and symptomatic outcome (Faridi et al., 2012; Hides et al., 2006; 
Sorbara et al., 2003), my data suggest that high-frequency use of potent forms of 
cannabis will adversely affect outcome even in adherent patients. This is consistent with 
evidence that cannabis use may reduce the effectiveness of antipsychotic treatment 
(Patel R et al., 2016). In line with independent evidence (Schaub, Fanghaenel, & 
Stohler, 2008), my results are also not in favour of the notion that the adverse outcomes 
seen in cannabis users were a result of self-medication due to a more severe 
psychopathology, since higher intensity of care at onset did not confound the effect and 
one would then expect a similar association between cannabis use and outcome in 
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ongoing users of hash-like cannabis, which was not present. Other illicit drug or 
cigarette use were only associated with the number of relapses but none of the other 
outcomes suggesting that this effect may reflect their common association with cannabis 
use. However, I did not investigate dose-response relationships for cigarette use and 
other drug use as I did with cannabis use patterns. Finally, my finding that black 
ethnicity remained a significant and consistent predictor for all outcomes is in line with 
previous reports of its association with poor outcome in psychosis in the UK (N. Goater 
et al., 1999).  
In summary, my results are opposed to a non-causal explanation for the 
association between cannabis use and outcome, such as reverse causation or 
confounding and indicate that change in cannabis use following onset in an important 
determinant for outcome in psychosis. I was able to show an increased risk of relapse in 
patients who continued with their cannabis use in a pattern that involved frequent 
(daily) use of high-potency (“skunk-like”) forms, when compared to former cannabis 
users. Previous RCTs have failed to effectively diminish cannabis use in patients with 
psychosis [e.g.C. Barrowclough et al. (2014)]. Furthermore, there is a lack of effective 
pharmacological treatments that can help treat comorbid cannabis use (Wilson & 
Bhattacharyya, 2016) in patients with psychosis, highlighting a need for effective 
interventions. Our results suggest that reducing frequency of use or shifting to less 
potent forms may be potentially useful intervention strategies in psychotic patients who 
are otherwise unable to stop using cannabis.  
This study has certain limitations that need to be outlined. First, cannabis and 
other substance use following onset were assessed retrospectively using self-report 
based measures and are therefore subject to under-reporting. However, interview data 
were validated by screening clinical notes and comparison of data on premorbid 
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cannabis use collected at onset of illness and again at follow-up revealed high 
concordance, suggesting minimal risk of under-reporting. Lack of objective 
measurement of cannabis use by screening hair or urine samples may have resulted in 
under-reporting of cannabis use. While this may have resulted in underestimation of the 
effect of cannabis use on outcome, it is unlikely to have affected the general direction of 
results reported herein. Furthermore, underreporting of cannabis use has been found to 
be less of an issue in research studies, when self-report data on cannabis use has been 
compared to objective measures such as urine drug screen (Di Forti et al., 2012). Few 
subjects (n=8) in the continued hash(resin)-user group may have undermined our ability 
to detect harm related to ongoing hash use. Also, I did not separately investigate those 
who started using cannabis following the onset of psychosis but had no history of 
premorbid regular use, as only two subjects fell into this category. It may be argued that 
I did not control for the effect of migrant status, which may have confounded the results 
of our study, as migrant status may be associated with a worse outcome. However, I did 
in fact control for the effect of ethnicity, and the main results presented here survive 
after controlling for ethnicity. While it is true that our measure of ethnicity does not 
reflect an accurate measure of migration status, the non-white ethnic group is still likely 
to capture a majority of the first-generation migrants (Coid et al., 2008) and thus 
account for a substantial proportion of any confounding effect of migrant status on 
relapse. Furthermore, in a subset-analysis (n=86) in the white ethnic group, I compared 
non-British (i.e. those who are likely to have migrated) white ethnic subjects to British 
subjects. The results indicate that there was no difference between the two groups with 
regard to risk of relapse (23% vs. 32%, χ2= 0.72, p=0.38). This is also consistent with 
independent evidence that in FEP patients, migration status was not linked to the 
number of hospitalisations in a 2-year follow up (Abdel-Baki et al., 2015). Hence, it is 
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unlikely that this would have affected the conclusions of the present study. Another 
potential caveat worth considering is the effect of type and dose of antipsychotic 
medication on relapse. While type of antipsychotic medication prescribed did not differ 
between the different cannabis user groups examined, nor was it related to relapse of 
psychosis, I could not test the effect of dose of antipsychotics prescribed as this data 
was not available. However, I do not think that this would have substantially affected 
the results of the present study as antipsychotic dose titration was carried out by 
consultant psychiatrists who were independent of the research team and blind to the 
specific hypotheses examined in the present study, making it highly unlikely that 
antipsychotic dosing would have been systematically associated with the cannabis use 
status of patients rather than their symptom status, response to antipsychotics and 
tolerability of dose prescribed. Perhaps the more important potential confounder that is 
relevant is adherence to antipsychotic medications, which I have taken into 
consideration.  
As in any longitudinal study, I cannot rule out that this sample may comprise a 
selective subset of inner city FEP patients who were more likely to engage with 
community mental health services and suffer from less severe psychopathology. 
However, this is unlikely to have affected the conclusions of the present study as 
engagement and recruitment of patients with more severe psychopathology was unlikely 
to have been systematically better in those with a comorbid cannabis use history. 
Finally, those who refused to take part in the follow-up were excluded from the analysis 
as relevant data was missing for them. It is possible that refusal to take part in the 
follow-up study may in part be directly related to their cannabis use over the follow-up 
period and also to their course of illness, which may have biased the results of the study. 
High rates of attrition such as that observed here is a particular problem that is inherent 
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with observational studies that follow up large cohorts of patients with psychiatric 
conditions such as the one reported here. While it is not possible to satisfactorily 
address this limitation in the absence of information about the main predictor of interest, 
i.e., cannabis use over the follow-up period, I have compared those who participated in 
the follow-up with those who refused on several baseline measures, including 
premorbid cannabis use, age of onset of psychosis, ethnicity and gender and the main 
outcome measure (relapse within 2 years following the onset). These comparisons 
suggest that those who participated did not differ from those who refused to take part in 
the follow-up on these measures as well as on the risk of relapse over the 2-year follow-
up period. However, I cannot completely rule out the possibility that missing data from 
those who refused to take part in follow-up may have still biased the results of the 
present study.  
Nevertheless, this is the first study that suggests that those who continue to use 
high-potency cannabis even after the onset of their psychosis are at the greatest risk of 
relapse of their illness and of experiencing more frequent and earlier relapses that 













5 PAPER 3: EXAMINING THE ASSOCIATION BETWEEN 
CONTINUED CANNABIS USE AND RISK OF RELAPSE IN FIRST 
EPISODE PSYCHOSIS: A QUASI-EXPERIMENTAL INVESTIGATION 
WITHIN AN OBSERVATIONAL STUDY 
5.1 ABSTRACT 
Background. Cannabis use following a first episode of psychosis (FEP) has been 
associated with poor outcome, but it is unclear whether this effect is causal in its nature. 
Methods. Patients (N=220) presenting to psychiatric services in South London with 
first episode non-organic [non-affective (ICD10 codes F20-F29) or affective (F30-F33)] 
psychosis were followed up for at least 2 years following onset of psychosis. 
Longitudinal modelling was employed (fixed-effects analysis, cross-lagged path 
analysis) to examine whether the association between changes in cannabis use and risk 
of relapse over time is the result of shared vulnerability between psychosis and cannabis 
use, psychosis increasing the risk of cannabis use (reverse causation) or indeed a causal 
effect of cannabis use on psychosis relapse. I assessed exposure to cannabis within the 
first and the second year (t1/t2) following onset of psychosis. Relapse of psychosis 
defined as subsequent hospitalisation for psychosis. Effect of continued cannabis use 
(Ct1/ Ct2) and its pattern (CPt1/ CPt2) were modelled for risk of relapse within the first 
(Rt1) and the second year (Rt2) following psychosis onset. 
Findings. Fixed-effects models adjusting for time-variant (other illicit drug use, 
antipsychotic medication adherence) and time-invariant unobserved confounders (e.g. 
genetic/premorbid environment) revealed that there was an increase in odds of 
experiencing a relapse of psychosis in periods of cannabis use relative to periods of no 
use (1.13[95% CI 1.03-1.24]). Change in pattern of continuation (CP) significantly 
increasing the risk (1.07[95% CI 1.02-1.13]), suggesting a dose-dependent relationship. 
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Cross-lagged analysis confirmed that this association reflected an effect of cannabis use 
(Ct1) on subsequent risk of relapse (Rt2) (β =0.44, p=0.04) rather than an effect of 
relapse (Rt1) on subsequent cannabis use (Ct2) (β =-0.29, p=0.59). 
Interpretation. These results demonstrate a dose-dependent association between 
change in cannabis use and relapse of psychosis that is unlikely to be a result of self-


























Understanding the nature of the association between cannabis use and psychotic 
disorders is crucial for the formulation of evidence-based health policies concerning 
cannabis, especially in light of changing public attitudes and legalisation of use in 
several states in the US as well as in other countries (Lavender, 2016; Reuter, 2010; 
Scheuer, 2015; Waugh, 2016). This is particularly important because psychotic 
disorders such as schizophrenia cause the most severe health loss of all human disorders 
(Whiteford et al., 2013) and are associated with considerable financial burden (Almond 
et al., 2004; Knapp et al., 2009b) and a very high rate of comorbid abuse of cannabis 
(Faridi et al., 2012; Johanna Koskinen et al., 2010) , the most commonly used illicit 
drug worldwide (UNODC, 2015). Cannabis use typically continues following the onset 
of psychosis and meta-analytic evidence from studies on over 16,500 patients suggest 
that continued cannabis use following the onset of psychosis is associated with 
increased relapse rates, length of hospitalisations and psychotic symptom severity 
(Schoeler, Monk, et al., 2016). However, methodological questions remain (Ksir & 
Hart, 2016b; Schoeler, Murray, et al., 2016), such as the concern that association 
between cannabis use and psychotic relapse may reflect the confounding of a shared 
genetic and environmental risk, or the possibility of reverse causation (Ksir & Hart, 
2016b), i.e., psychosis leading to cannabis use rather than cannabis use leading to 
relapse of psychosis. Studies that have examined the issue of reverse causation in those 
with pre-existing psychosis report either a bi-directional relationship between cannabis 
use and symptom severity (Foti et al., 2010), or that frequency of cannabis use predict 
an increase in subsequent psychotic symptoms, but not vice versa (Degenhardt et al., 
2007; Henquet et al., 2010). However, such evidence does not rule out the possibility 
that systematic differences between cannabis-using and non-using psychotic patients, 
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such as a genetic predisposition that underlies both psychosis and cannabis use (R. A. 
Power et al., 2014) may underlie the association between cannabis use and relapse or 
exacerbation of psychosis. The gold standard of evidence for establishing that cannabis 
use is causally linked to a risk of relapse in those with pre-existing psychotic disorder 
would be a placebo-controlled, randomised clinical trial (RCT) involving experimental 
cannabis administration, which is unlikely to be realized because of ethical reasons. 
Short of that, a quasi-experimental approach involving the assessment of within-
individual changes in cannabis use over time provides a compelling alternative that is 
considered only second best to RCT when examining causality (J. Murray et al., 2009). 
The application of such a design, also called fixed-effects analysis of longitudinal panel 
data (McKetin et al., 2013; Schoeler, Monk, et al., 2016), would allow the control of 
unobserved time-invariant confounding factors such as shared genetic and 
environmental factors that do not change over time (Ksir & Hart, 2016b; Schoeler, 
Murray, et al., 2016) as well as those observed potential confounding factors that 
change over time. This design has also been employed to factor out all unobserved time-
invariant sources of confounding and establish an association between cannabis use and 
increased risk of psychotic symptoms in the general population (David M Fergusson et 
al., 2005) and independently in chronic methamphetamine users without a comorbid 
diagnosis of psychosis (McKetin et al., 2013). Studies (David M Fergusson et al., 2005; 
J. McGrath et al., 2010; McKetin et al., 2013) also suggest a dose-response relationship 
between frequency of cannabis use and psychotic symptoms when controlling for pre-
exposure confounding factors, an important criteria when establishing causality (A. B. 
Hill, 1965). While these methodological approaches strengthen the argument for 
causality and have been employed in investigations conducted in the general population 
(David M Fergusson et al., 2005), they have not been fully incorporated in studies 
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investigating the effect of cannabis use on outcome in first episode psychosis (FEP) 
patients (cf. below Table 20.) to systematically address the issues of confounding from 
shared predisposition, reverse causation and dose-response relationship and establish 
whether cannabis use can affect outcome of psychosis leading to hospitalisation. 
Hospitalisation can be reliably measured and objectively compared across studies and 
has hence been proposed as an ideal outcome measure for RCTs (Burns, 2007) and 
studies on illness course in FEP (Stefan Leucht et al., 2012). It is also linked to high 
personal, economic and societal costs (Ascher-Svanum et al., 2010) and therefore 
remains a major public health concern. 
To address the limitations in existing evidence (Matthew Hill, 2015; Ksir & Hart, 
2016b) (cf. also Table 20. for an overview of studies), I investigated the nature of 
relationship between continued cannabis use and relapse of psychosis in a large sample 
of first-episode patients, by: 
(1)!controlling for unobserved, time-invariant sources of confounding (e.g. genetic 
profile) and observed time-variant sources of confounding (other illicit drug use, 
medication adherence) using a fixed-effects analysis approach  
(2)!employing cross-lagged path analysis to investigate the directionality of the 
relationship between continued cannabis use and risk of relapse following the 
onset of psychosis 
(3)!using two measures of cannabis use, including (i) change in cannabis use status 
over time (non-user status vs. user status) and (ii) a more detailed measure of 
cannabis use over the follow-up period that takes into account the pattern of 




Table 20. Observational studies investigating the temporal relationship between cannabis use and (a) onset of psychosis or (b) outcome in psychosis 
Study / Cohort Study time 
points (T) 






(a) Population studies investigating cannabis use as a risk factor for onset of psychosis 
David M 
Fergusson et al. 
(2005) / New 
Zealand /  General 
population   
t1: Age 18 
t2: Age 21 
t3: Age 25 
C1: Changes in 
frequency of cannabis 
use (t1-t3) 
C2: Frequency of 
cannabis use in 12 
months prior assessment 
(t1-t3) 
P1: Changes in psychotic 
symptom severity (SCL) 
(t1-t3) 







(1)  C2 ! P2* 
(2)  C1 ! P1*  
(3)  C2 ! P2* 









stressful life events, 
deviant peer 
affiliations 





Kuepper et al. 
(2011b)/ Germany 
/  General 
population   
t1: Age 14-24 (R) 
t2: Age 17-27 (R) 
t3: Age 26-36 (R) 
C1: Initiation of use 
between t1 and t2 (use > 
5 times) 
C2: Initiation of use 
between t2 and t3 (use > 
5 times) 
C3: Persistence of use 
(use at t2 and t3) 
P1: P2t: Incidence of 
psychosis between t2 and 
t3 (CIDI) 
P2: Persistence of 
psychosis (presence at t2 
and t3) 
P3: Incidence of psychosis 




C1 ! P1* 
C3 ! P2* 
P3  ! C1 (NS) 
Age, sex, SES, other 
drug use, childhood 
trauma, urbanicity  
 
1923 A: (+) 




Ferdinand et al. 
(2005) / Denmark 
/  General 
population   
t1: Age 4-16 (R) 
t2: Age 18-30 (R) 
C1: Initiation of 
cannabis use prior 
symptom assessment 
C2: Initiation of 
cannabis use following 
symptom assessment 
P1: Psychotic symptoms 
(CIDI) following cannabis 
use 
P2: Psychotic symptoms 
prior to cannabis use 
Cox regression C1 ! P1* 
P2 ! C2* 
Age, gender 1580 A: (+) 





et al. (2003) / 
France /  General 
population   
t: ESM: 1 week, 
with 5 
assessments/day  
C1: Cannabis use prior 
symptom assessment 
C2: Cannabis use 
following symptom 
assessment 
P1: Risk of psychotic 
experience following 
cannabis use (MINI) 
P2: Risk of psychotic 





C1 ! P1* 
P2 ! C2 (NS) 
Age, gender, other 
illicit drug use 
79 A: (+) 






Henquet et al. 
(2004) / Germany 
/  General 
population   
t1: Age 14-24 (R) 
t2: Age 17-27 (R) 
 
C1: Cannabis use 
(yes/no) between t1 and 
t2 (> 4 times used) 
C2: Cannabis frequency  
between t1 and t2 
P1: Risk of psychosis 
(CIDI) at t2 
P2: Psychotic symptoms 




C1 ! P1* 
C2 ! P1* 
P2 ! C1 (NS) 
 





alcohol and other 
drug use, baseline 
cannabis use 
2437 A: (+) 




Henquet et al. 
(2010) /  
Netherlands /  
General 
population    





C1: Cannabis use prior 
symptom assessment 
C2: Cannabis use 
following symptom 
assessment 
P1: Level of psychotic 
experience following 
cannabis use  
P2: Level of psychotic 





C1 ! P1 (NS) 
P2 ! C1 (NS) 
Age, gender, alcohol 
use and other drug 
use, level of 
38 A: (+) 




J. McGrath et al. 
(2010) / Australia 
/  General 
population   
t1: Age 5 
t2: Age 14 
t3: Age 21 
C1: Duration since first 
cannabis use 
C2: Duration since first 
cannabis use (following 
age 15) 
P1: Risk of psychosis 
(CIDI) 






C1 ! P1* 
P2 !C2* 
sex, age, parental 
mental illness, 
psychotic symptoms 
at t2  
3801 A: (+) 




McKetin et al. 
(2013) / Australia/ 
Methamphetamine 
abusers 
t1: Age 32 
t2: Age 33 
t3: Age 35 
C1: Changes in 
frequency of cannabis 
use (t1-t3) 
P1: Presence of psychotic 
symptoms (BPRS) in 1 
months prior assessment 
FEM C1 ! P1* 
 
Other drug use 268 A: (+) 








Emsley (2015) / 




t2: 9 months FU 
t3: 18 months FU 
C1: Cannabis dose* 
prior to outcome 
assessment 
C2: Change in cannabis 
dose* ( t1-t3) 
* measured based on 
frequency, type and 
P1: Severity psychotic 
symptoms (PANSS) 
following cannabis use 
P2: Relapsea (yes/no) 
following cannabis use 





C1 ! P1 (NS) 
C1 ! P2 (NS) 
C1 ! P3 (NS)  
C2 ! P4 (NS) 
Age, gender, living 
status, employment, 
education, SES, DAI, 
other substance use 
110 A: (+) 






grams used cannabis use 
P4: Changes in positive 
symptoms (PANSS) (t1-
t3) 
Degenhardt et al. 
(2007) / Australia 
/  Established 
psychosis 
t1: Baseline 
t2: 1 month FU 
t3: 2 months FU 
t4: 3 months FU 
t5: 4 months FU 
t6: 5 months FU 
t7: 6 months FU 
t8: 7 months FU 
t9: 8 months FU 
t10: 9 months FU 
t11: 10 months FU 
C1: Frequency of use 
(number of days per 
month) prior symptom 
assessment (t1-t10) 
C2: Frequency of use 





P1: Level of positive 
symptoms following 
cannabis use (BPRS) (t2-
t11) 
P2:  Level of positive 
symptoms prior to 




(1) C1 ! P1* 





101 A: (+) 
B: (–)  
C: (+) 
D: (+)   
E: (+)          
Henquet et al. 
(2010) / 










C1: Cannabis use prior 
symptom assessment 
C2: Cannabis use 
following symptom 
assessment 
P1: Level of psychotic 
experience following 
cannabis use (ESM 
psychosis score) 
P2: Level of psychotic 





C1 ! P1* 
P2 !C2 (NS) 
Age, gender, alcohol 
use and other drug 
use, level of cannabis 
use during the week 
42 A: (+) 




Foti et al. (2010)/ 
US /  First episode 
psychosis 
t1: Baseline  
t2: 0.5 years FU 
t3: 2 years FU 
t4: 4 years FU 
t5: 10 years FU 
C1: Change in cannabis 
use status (non-user – 
user; use > 1) (t1-t5) 
C2: Cannabis use status 
prior symptom 
assessment 
C3: Cannabis use status 
following symptom 
assessment 
P1: Changes in psychotic 
symptoms (SAPS) (t1-t5) 
P2: Level of psychotic 
symptoms following 
cannabis use 
P3: Level of psychotic 




(1) C1 ! P1* 
(2) C2 ! P2* 









sex, and SES) 
229 A: (+) 






Note. BPRS = Brief Psychiatric Rating Scale;  CUD = Cannabis Use Disorder;  DAI = Drug attitude Inventory; DUP =  Duration of untreated 
psychosis; ESM = Experience Sampling Method; FEM = fixed effects models; FU= Follow up;  Mini = Mini-International Neuropsychiatric Interview 
(Sheehan et al., 1998)  ; NOS = Not otherwise specified; PAS = Premorbid Adjustment Scale,   R= Range; SANS = Scale for the Assessment of 
Negative Symptoms; SAPS = Scale for the Assessment of Positive Symptoms ;  SCL = Symptom Checklist 90 (Derogatis, 1996);  SEM = Structural 
Equation Modeling; SES = socioeconomic status 
a Relapse was defined as an exacerbation of psychotic symptoms that lasted for longer than 2 weeks and resulted in a change in patient management 
(increased observation by the clinical team; increase in antipsychotic medication or both).  
b Quality assessment based on whether a study did (+) or did not (–):  A: Control for observed confounders B: Applied Fixed Effects Analysis (Fixed 
effects or sibling pair analysis)  C: Used temporal ordering of risk factor (lagged outcome); D: Tested for directionality; E: Explored dose-response 
relationships 
*      p< 0.05 






Patients with first episode non-organic [non-affective (ICD10 codes F20-F29) or 
affective (F30-F33)] psychosis (WHO, 2004), aged 18-65 were recruited from local 
psychiatric services in South London and assessed twice as part of research, first 
assessment being close to the onset of their illness. Follow-up assessment involved 
either a face-to-face or a telephone interview (if the individual was unable to appear in 
person) at least two years following the onset of their psychotic illness. Interview data 
was complemented by a screening of clinical records to extract healthcare use data (e.g. 
dates of admission/discharge, medication use). Outcome data (admission to hospital 
following psychosis onset) was also collected from clinical records for those who 
refused to take part in follow up (n=133). Comparison of outcome (risk of relapse) 
between those patients who agreed to take part and those who refused revealed that they 
were not significantly different in their risk of relapse over the two-year follow-up 
period following onset (χ2 =0.30, p=0.58). This study was granted ethical approval by 
South London & Maudsley NHS foundation trust and Institute of Psychiatry Local 
Research Ethics Committee. All subjects included in the study gave written informed 
consent. 
5.3.2 MEASURES 
Diagnosis (affective vs. non-affective psychosis) was based on ICD-10 
diagnosis assessed with OPCRIT (McGuffin et al., 1991). Cannabis use over the first 
two years following onset of psychosis was assessed using a modified version of the 
Cannabis Experience Questionnaire (CEQmv, cf. Chapter 8.2.2, Appendix II) (Di Forti, 
Marconi, et al., 2015). To assess the reliability of the retrospective assessment of 
cannabis use, I compared data on premorbid cannabis use (ever used before onset) 
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collected at onset of psychosis with data on premorbid cannabis use reported at follow-
up. In 93% of those compared, reporting of premorbid cannabis use was consistent 
across both assessments (i.e., at onset and at follow-up); 4% denied premorbid use when 
assessed at the onset of psychosis but admitted it when re-examined at the follow up 
assessment, while 3% denied pre-morbid cannabis use at follow-up assessment although 
they had admitted use when assessed at onset. Subjects were classified based on their 
pattern of reported cannabis use following onset, assessing cannabis use within the first 
year following onset [Ct1] and cannabis use within the second year following onset 
[Ct2]. Two cannabis use variables were defined, including the dichotomized variable 
‘cannabis use status’ (Ct1/Ct2) and the ordinal variable ‘pattern of cannabis continuation’ 
(CPt1/CPt2).  The dichotomized variable ‘cannabis use status’ (Ct1/Ct2) classified patients 
during the respective time periods (t1 & t2) into ‘not cannabis user’ (NCU; no use or use 
only once or twice within the period under consideration) and ‘cannabis user’ (CU; used 
cannabis more than twice) categories. The ordinal variable ‘pattern of cannabis 
continuation’ (CPt1/CPt2, scored from 0 to 2) classified patients based on their pattern of 
cannabis use following onset of psychosis into (0) not cannabis user (NCU; as above), 
(1) intermittent cannabis user (ICU; used cannabis more than twice but not every month 
within the period under consideration) or (2) continued cannabis user (CCU; used 
cannabis every month throughout all of the follow-up months within the period under 
consideration). Relapse was defined as admission (yes/no) to a psychiatric inpatient unit 
owing to exacerbation of psychotic symptoms within the first year [Rt1] and the second 
year following the first presentation of psychosis [Rt2]. If the patient was hospitalized at 
their first presentation to psychiatric services with a diagnosis of psychosis, this was not 
considered as a relapse event. This definition of relapse is most commonly used in 
epidemiological research in psychosis (D. E. Addington, McKenzie, Norman, Wang, & 
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Bond, 2013; Olivares et al., 2013).  Covariates included in the analyses were selected 
based on previous literature [including the strongest predictors for relapse in psychosis 
(M Alvarez-Jimenez et al., 2012)] and exploratory analysis to identify those factors that 
were linked to both cannabis use and relapse within the two years following onset (cf. 
below Table 21.). Taking these into consideration, I included two covariates in our 
analysis: (i) adherence to antipsychotic treatment plan and (ii) other drug illicit use 
within the first two years following onset of psychosis.  Adherence to treatment plan 
was indexed in accordance with previous reports (L Clausen et al., 2014), whereby 
patients were allocated a score ranging from 1 to 3 based on information on prescription 
and ratings of adherence: 3=medication not prescribed or good adherence with the 
prescribed medication (0% - 33% of the time non-adherent) within the two years 
following the onset of illness; 2=medication prescribed and irregular compliance (34%-
66% of the time non-compliant); 1=medication prescribed and non-compliance (67%-
100% of the time non-compliant). Other drug use was defined as use of illicit drugs 
other than cannabis within the two years following onset. This variable was coded as an 
ordinal variable, ranging from 0 to 2: 0=no use; 1=experimental use (less than 6 times); 







Table 21. Exploratory analysis (Chi-square tests) to select covariates for multiple analysesa 
Covariatesb  Relapseb Cannabis (Ct)b Cannabis (CDt)b 
 χ2 p χ2 p χ2 p 
Gender 0.36 0.55 13.06 0.0003 13.07 0.001 
Ethnicity 4.24 0.04 1.45 0.23 1.80 0.41 
Age of onset  1.11 0.29 0.92 0.34 0.92 0.63 
Medication adherence 15.88 0.0004 10.48 0.005 11.99 0.02 
Premorbid cannabis use 2.13 0.14 71.36 <0.0001 71.57 <0.0001 
Other illicit drug use (following onset) 8.91 0.01 21.92 <0.0001 26.33 <0.0001 
Alcohol use (following onset) 4.26 0.12 11.10 0.004 13.30 0.01 
a Covariates were included in multiple analysis if significantly (p<0.05) linked to relapse and cannabis use 
bDefined as: Relapse within the two years following the onset (coded as 1: admission to a psychiatric inpatient unit owing to 
exacerbation of psychotic symptoms following the first presentation of psychosis, 0: no admission to a psychiatric inpatient unit 
following the first presentation of psychosis); Cannabis use status (Ct) within the two years following the onset of illness (coded as 
0: no use or use only once or twice; 1: used cannabis more than twice); Cannabis use (CDt) within the two years following the onset 
of illness (coded as 0: no use or use only once or twice, 1: used cannabis more than twice but not every month, 2: used cannabis 
throughout all of the follow-up months); Gender (coded as 0: Female, 1: Male); Ethnicity (coded as 0: white ethnicity, 1: non-white 
ethnicity), age of onset (coded as 0: referral for psychosis before age 18, 1: referral for psychosis after age 18), medication 
adherence within the two years following the onset of illness [coded as 1:medication prescribed and non-compliance (67%-100% of 
the time non-compliant), 2: medication prescribed and irregular compliance (34%-66% of the time non-compliant), 3: medication 
not prescribed or good adherence with the prescribed medication (0% - 33% of the time non-adherent)], premorbid cannabis use 
(coded as 1:Subject who had a history of regular cannabis use (defined as use at least once/month for 6 consecutive months) prior to 
their onset), 0: Subjects without a history of regular cannabis use prior to their onset, other illicit drug use within the two years 
following the onset of illness [coded as 0=no use; 1=experimental use (less than 6 times); 2=regular use (6 times or more)], Alcohol 




5.3.3 DATA ANALYSIS 
In the first step, fixed-effects logistic regression models were fitted using the R 
package lme4 (Bates et al., 2015) for binary outcome in order to adjust for factors that 
vary across individuals and may affect outcome, but were not measured and do not vary 
over time, such as familial and genetic factors, duration of untreated psychosis or 
premorbid adjustment. This approach allows estimation of the effect of within-person 
changes over time in their pattern of cannabis use in the first year [Ct1/ CPt1] and the 
second year [Ct2/ CPt2] following onset of psychosis. This analysis estimates the 
likelihood of an event (e.g. here defined as relapse) during periods when an individual is 
exposed to the risk factor of interest (e.g. cannabis use) compared to when the same 
individual is not exposed to the risk factor (cf. exemplified in Figure 16.). Hence, each 
subject becomes their own control in fixed-effects models, wherein only subjects with a 
change in exposure (Ct1-Ct2/CPt1-CPt2) over the specified time-period are selected. As a 
result, if one subject is more likely to relapse during a period in which the subject was 
exposed to cannabis than during a period in which the subject was unexposed, this 
would indicate an effect of cannabis that is independent of the unmeasured potential 
confounding factors that did not change over this time period, such as the genetic make-
up of the person, personality, age, gender and life events prior to the onset. Factors that 
vary over time following onset (e.g. other drug use, medication adherence) are adjusted 
for, as done in conventional multiple regression analysis. Other illicit drug use and 







Figure 16. Adaptation of sibling-design for fixed-effects analysis to assess change in 
cannabis use (Ct) over time 
 
 
In the second step, cross-lagged autoregressive path models were estimated 
using the lavaan package (Rosseel, Oberski, & Byrnes, 2011) to investigate the 
directionality of association. Relapse variables (Rt1-Rt2) were treated as dependent 
variables with cannabis use (Ct1- Ct2/CPt1- CPt2) variables as the independent variables 
to examine whether cannabis use predicted subsequent risk of relapse and vice versa for 
the reverse lagged association to examine whether relapse (Rt1-Rt2) predicted cannabis 
use (Ct1- Ct2/CPt1- CPt2). Model paths were estimated while controlling for other illicit 
drug use and medication adherence. The models were fitted using the robust weighted 
least squares (WSL) approach. In the first step, I fitted a saturated path model in which 
all possible paths to the endogenous variables (Ct2 and Rt2) were specified. In the second 
step, a more parsimonious model was tested that included only the statistically 
significant (p< 0.05) pathways tested. Model goodness of fit was assessed on the basis 
of a number of fit indices, including the model chi-squared goodness of fit statistic 
(non-significant or small chi-square value indicating that the model fitted the data well), 
[190] 
 
the root mean-squared error of approximation (RMSEA, with values of 0.05 indicating 
good fit and values up to 0.08 representing reasonable errors of approximation) 
(MacCallum, Browne, & Sugawara, 1996) and the comparative fit index (with values of 

























5.4.1 SAMPLE CHARACTERISTICS 
Two hundred and twenty patients with a first episode of psychosis were included 
in the analysis, comprising 213 (96.8%) subjects that were interviewed face-to-face and 
7 (3.2%) that were interviewed in a phone conversation. Within the first two years 
following onset of illness, 35.5% of patients experienced a relapse in the form of 
admission to psychiatric hospital. Out of 121 subjects with pre and/or post onset regular 
cannabis use, only 3 (3.7%) subjects started using cannabis (use > 2 times) following 
onset of psychosis (with no previous history of regular use). Sixty-nine (57 %) had used 
cannabis regularly prior to the onset and used it subsequently either intermittently or 
continuously, and 52 (43%) had a history of regular use prior to the onset of psychosis 
but did not use it regularly following onset. Fifty-nine (26.8%) patients had never tried 
cannabis in their lifetime. On comparing the different groups based on their cannabis 
use patterns (Table 22.), it appeared that they significantly differed in the age of onset of 
their psychosis (Kruskal-Wallis, p=0.02) and with regard to gender (χ²=13.07, p=0.001). 
No differences between the groups were found for diagnosis (affective vs. non-affective 
psychosis) (χ²=4.18, p=0.12). With regard to outcome, the different cannabis use groups 
(NCU vs. ICU vs. CCU in the two years following the onset) were significantly 
different with regard to risk of relapse (χ²=13.96, p=0.0009). To illustrate, the highest 
risk of relapse was present in those who used it continuously following the onset while 
those who did not continue cannabis use were at lowest risk (59.1% vs. 28.5%). 
Furthermore, the cannabis use groups significantly differed with regard to the level of 
medication adherence (χ²=11.99, p=0.02), e.g. those who continued to use cannabis 
were less likely to have remained adherent to their antipsychotic treatment. Similarly, 
the degree of other illicit drug use (other than cannabis) was different between the 
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cannabis use groups (χ²=26.33, p<0.0001), which indicated that those who continued to 
use cannabis also used other illicit drugs more frequently throughout the two years 



















Table 22. Demographic information  
Onset characteristics All subjects Non-use (NCU) Intermittent user (ICU) Continued user (CCU) p 
Number of subjects 220 (100%) 151 (68.6%) 25 (11.4%) 44 (20%)  
Age of onset (M/SD) 28.62 (8.58) 29.52 (8.92) 28.79 (8.94) 25.44 (6.32) 0.02 
Gender (n male) 130 (59.1%) 77 (51%) 19 (76%) 34 (77.3%) 0.001 
Ethnicity (n non-white) 147 (66.8%) 97 (64.2%) 17 (68%) 33 (75%) 0.41 
Onset diagnosis (n non-affective) 184 (83.6%) 126 (83.4%) 18 (72%) 40 (90.9%) 0.12 
Pre-onset (regular) cannabis use (n 
yes) 
118 (53.6%) 52 (34.4%) 23 (92%) 43 (97.7%) <0.0001 
Course characteristics All subjects Non-use (NCU) Intermittent user (ICU) Continued user (CCU) p 
Other illicit drug use 
    No use n 
    Experimental use n 



















    Non-adherence n 
    Irregular-adherence n 


















Relapse (yes) in 2 years following 
onset 
78 (35.5%) 43 (28.5%) 9 (36%) 26 (59.1%) 0.0009 
Note. M=Mean; n=number of subjects; SD=Standard Deviation. 




5.4.2 FIXED-EFFECTS ANALYSIS: CHANGES IN CANNABIS USE AND RELAPSE 
As shown in Table 23., the unadjusted fixed-effects analysis showed that risk of 
relapse was higher during the year in which cannabis was used (more than twice) 
1.18[95% CI 1.08-1.29] when compared to the year in which cannabis was not used, 
and this effect remained significant when controlling for time-varying factors such as 
medication adherence and other illicit drug use 1.13[95% CI 1.03-1.24]. Furthermore, 
there was a dose-response relationship between pattern of cannabis continuation and 
risk of relapse, such that one unit change in cannabis use pattern signifying greater 
regularity in cannabis use over time [e.g. from intermittent cannabis use (CPt1) to 
continued cannabis use (CPt2)] was associated with an increase in odds for risk of 
relapse of 1.10[95% CI 1.05-1.15]. This effect was reduced but remained significant 
when controlled for medication adherence and other illicit drug use (1.07[95% CI 1.02-
1.13]). In this model, medication non-adherence (0.92[95%CI 0.87-0.97]) but not other 
illicit drug use (1.04[95% CI 0.98-1.12]) remained a significant predictor for risk of 






5.4.3 CROSS-LAGGED MODELLING: CONTINUATION OF CANNABIS USE AND 
SUBSEQUENT RELAPSE 
Examining the different pathways in the saturated cross-lagged path model (cf. 
Model A1 and Model B1, Figure 17.) revealed that the effect of cannabis use (during 
the first year of follow-up; t1) on subsequent (during the second year of follow-up; t2) 
risk of relapse was significant for ‘cannabis use status’ (Ct1!Rt2:β =0.44, p=0.04), as 
well as ‘pattern of cannabis continuation’ (CPt1!Rt2:β =0.23, p=0.05), while 
controlling for medication adherence and other illicit drug use. The alternative paths, i.e. 
relapse within the first year (t1) following onset of psychosis predicting subsequent (t2) 
‘cannabis use status’ (Rt1!Ct2:β =-0.29, p=0.59) and ‘pattern of cannabis continuation’ 
(Rt1!CPt2: β =-0.10, p=0.76) were not significant, indicating a uni-directional effect of 
cannabis use on risk of relapse of psychosis. Of the autoregressive pathways tested in 
Table 23. Fixed-effects logistic regression analysis: Risk of relapse  
 OR 95% CI 
Change in ‘cannabis use status’ (Ct) 
Simple Analysis   
Cannabis use status (Ct1 – Ct2) 1.18 1.08 – 1.29 
Multiple Analysis   
Cannabis use status (Ct1 – Ct2) 1.13 1.03 – 1.24 
Medication adherence* 0.92 0.87 – 0.97 
Other illicit drug use* 1.05 0.98 – 1.12 
Change in ‘pattern of cannabis continuation’ (CPt) 
Simple Analysis 
Pattern of cannabis continuity (CPt1 – CPt2) 1.10 1.05 – 1.15 
Multiple Analysis 
Pattern of cannabis continuity (CPt1 – CPt2) 1.07 1.02 – 1.13 
Medication adherence* 0.92 0.87 – 0.97 
Other illicit drug use* 1.04 0.98 – 1.12 
Note.  Change (increase) in ‘cannabis use status’ (Ct) = change from ‘not 
cannabis user’ to ‘cannabis user’; Change (increase) in ‘pattern of cannabis 
continuation’ (CPt) = change in one unit [(0) not cannabis user; (1) intermittent 
cannabis user; (2) continued cannabis user] 
*Included as random effects 
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those models, presence of cannabis use at t1 predicted presence of cannabis use at t2 
(Ct1!Ct2:β =3.82, p<0.001) and pattern of cannabis continuation at t1 was a significant 
predictor for pattern of cannabis continuation at t2 (CPt1!CPt2:β =1.8, p<0.001), while 
relapse at t1 was not significantly associated with relapse at t2 (Model A1: Rt1!Rt2:β 
=0.32, p=0.18; Model B1: Rt1!Rt2:β =0.33, p=0.17). Consistent with the results from 
the fixed-effects model, only medication adherence (MA) (Model A1: MAt!Rt2:β =-
0.28, p=0.04; Model B1: MAt!Rt2:β =-0.27, p=0.05) but not other illicit drug use (ID) 
(Model A1: IDt!Rt2:β =0.26, p=0.10; Model B1:IDt!Rt2:β =0.25, p=0.11) was 
significantly linked to risk of relapse. Cannabis use at t2 was not predicted by other 
illicit drug use (Model A1: IDt!Ct2:β =0.52, p=0.70; Model B1: IDt!CPt2:β =0.11, 
p=0.66) or medication adherence (Model A1: MAt!Ct2:β = -0.19, p=0.58; Model B1: 
MAt!CPt2:β =0.12, p=0.53). Model 2, in which all non-significant paths from Model 
1were dropped yielded a good fit to the data (Model A2: CFI=1.00, RMSEA<0.001, 
Model B2: CFI=1.00, RMSEA<0.001). The strengths of associations are presented for 
cannabis use predicting subsequent relapse (Model A2: Ct1! Rt2: β = 0.58, p=0.004; 
Model B2: CPt1! Rt2: β = 0.31, p=0.004), cannabis use predicting subsequent cannabis 
use (Model A2: Ct1! Rt2: β = 3.8, p<0.001; Model B2: CPt1! CPt2: β = 1.9, p<0.001) 
and medication non-adherence predicting relapse (Model A2: MAt1! Rt2: β = -0.30, 
p=0.02; Model B2: MAt!Rt2: β = -0.29, p=0.03).  
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Note. Ct = ‘Cannabis use status’ (non-user – user) in the first year (Ct1) and in the second year (Ct2) following the onset; CPt = ‘Pattern of 
cannabis continuation’ (non-user – intermittent user – continued user) in the first year (CPt1) and in the second year (CPt2) following the 
onset; IDt: Illicit drug use (score 0-2) within the two years following the onset; MAt: Medication adherence (score 0-2) within two years 
following the onset; Rt = Relapse (yes – no) in the first year (R1) and in the second year (R2) following the onset. 
a Goodness of fit indices: χ2 (1) = 0.33, p=0.565; RMSEA = 0.00, p=0.659; CFI = 1.00. 
b Goodness of fit indices: χ2 (1) = 0.24, p=0.625; RMSEA = 0.00, p=0.708; CFI = 1.00. 




In this study, I estimated the longitudinal effects of cannabis use status and 
pattern of continued cannabis use following the onset of psychosis on risk of relapse. 
The results implicate both change in cannabis use status (e.g. from user to non-user) as 
well as change in pattern of continued cannabis use within the first two years following 
onset as a risk factors for relapse. By virtue of the study design employed here, I was 
able to compare periods of use with periods of non-use within the same individual, 
signifying that this association cannot be explained by stable premorbid confounding 
factors such as shared familial and genetic vulnerability, predisposing personality traits, 
duration of untreated psychosis, childhood trauma, expressed emotion or cannabis use 
history prior to the onset of psychosis. Furthermore, changes in cannabis use status and 
pattern of cannabis continuation over time were linked to relapse independent of the 
effects of other potential confounders that vary over time such as medication adherence 
and other illicit drug use. These results indicate that the association found here is 
unlikely to result from a common underlying vulnerability shared by cannabis use and 
psychotic relapse, such as a genetic predisposition for psychosis that is also linked to 
cannabis use (R. A. Power et al., 2014). This is consistent with a study that failed to 
replicate the association between polygenic risk for psychosis and cannabis use (Di 
Forti, Vassos, et al., 2015), indicating that even if a shared genetic vulnerability exists, 
this contribution would not fully account for the adverse effects of cannabis use on 
outcome in those patients with psychosis who continue using the substance. In line with 
this, another study (Sherva et al., 2016a) that compared genome wide association 
(GWAS) data concerning cannabis use with GWAS data on 5 different psychiatric 
disorders found a very small overlap with depression but none with schizophrenia. 
Overall, this line of evidence and my results are in accordance with previous research 
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employing fixed-effects analysis which reported that change in cannabis use status 
(from non-user to user) was linked to change in psychotic symptom severity (Foti et al., 
2010). My findings also support a dose-response relationship, i.e. the longer the period 
of continued (monthly) cannabis use following onset of psychosis, the more likely a 
patient is to experience a relapse, consistent with previous evidence (J. McGrath et al., 
2010) that duration of exposure since first use of cannabis was significantly linked to 
psychotic outcome in previously healthy individuals. My results from cross-lagged path 
analysis also indicate that cannabis use status/ pattern of continued cannabis use 
following onset of psychosis is predictive of subsequent relapse but not vice versa, 
suggesting that continuation of cannabis use following onset of psychosis is a direct 
risk-modifier for relapse in psychosis. These results are consistent with previous studies 
in patients with pre-existing psychosis that reported cannabis use as a predictor for an 
increase in severity of psychotic symptoms in both the short-term (1 week) (Henquet et 
al., 2010) and longer-term (10 months) (Degenhardt et al., 2007) and suggest that the 
association between cannabis use and relapse of psychosis is unlikely to be the 
consequence of self-medication (Dixon, Haas, Weiden, Sweeney, & Frances, 1991).  
Some limitations need to be considered when interpreting my results. While 
clinical data was assessed prospectively using patients’ clinical records, cannabis use 
pattern following the onset of illness relied on retrospective self-reported assessments 
without objective drug screens. However, cannabis use information obtained at research 
interview was further validated by screening patient records as well as reports of 
premorbid cannabis use (ever used) that was collected at the baseline research 
assessment at onset, revealing a very high concordance (93%) between self-report data 
of cannabis use at the two research assessment points (onset and follow-up). 
Underreporting of cannabis use has also been found to be less of an issue in research 
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studies, when self-report data on cannabis use has been compared to objective measures 
such as urine drug screen (Di Forti et al., 2014). It is also important to note that the main 
predictor variable (pattern of cannabis continuation following onset) did not capture 
cumulative exposure to cannabis per year of follow up, since this was not feasible to 
assess with the retrospective cannabis assessment I employed in this study. 
Furthermore, although the statistical methods applied in this study were designed to 
minimize the possibility of a non-causal explanation for the association between 
continued cannabis use and relapse, it is possible that other unmeasured factors 
changing over time may have influenced the relationship. Nevertheless, I controlled for 
the most significant previously identified time-variant risk factors that have been linked 
to psychosis relapse (M Alvarez-Jimenez et al., 2012). Hence, it seems unlikely that this 
was the case. Notwithstanding these limitations, results presented here have important 
implications. Together, these results suggest that it is more likely than not that 
continued cannabis use following onset of psychosis is causally associated with 
increased risk of relapse of psychosis resulting in psychiatric hospitalisation. As 
cannabis use is a potentially modifiable risk factor that has an adverse influence on the 
risk of relapse of psychosis and hospitalisation in a given individual, with limited 
efficacy of existing interventions (Wilson & Bhattacharyya, 2016), these results 
underscore the importance of developing novel intervention strategies and demand 
urgent attention from both clinicians and health policy makers. Results from both of the 
analytical methods employed (fixed-effects and cross-lagged path analysis) were 
consistent and point towards a dose-response relationship between continued cannabis 
use and relapse of psychosis resulting in hospitalisation. They implicate cannabis use as 
a risk-modifying factor, suggesting that discontinuation of cannabis use following the 



































6 GENERAL DISCUSSION 
The prevalence rates of young people using cannabis as risen in recent years, as well 
as the potency of cannabis (M. A. ElSohly et al., 2016; Hasin et al., 2015). This has 
added fuel to debate around cannabis legislation and its medical or recreational use, 
especially in light of the high rates of cannabis use that are reported in those presenting 
with their first episode. Of particular concern is that this group of users has been found 
to be more vulnerable to the psychotomimetic effects of THC (D’Souza et al., 2005; 
Henquet et al., 2010) and that those individuals often comprise high rates of users that 
continue using the substance following the onset of the illness. Given the ongoing 
debate regarding its link with psychosis (Robin M. Murray & Di Forti, 2016), and the 
reliance on cross-sectional uncontrolled investigations looking at outcome such as 
relapse and symptom exacerbation (Schoeler, Monk, et al., 2016; Zammit et al., 2008a), 
it is critical from a translational research point of view to better understand whether 
cannabis use may play a causal role within the course of illness following a first episode 
psychosis – in particular since “cannabis represents the most potentially modifiable risk 
factor for psychosis” [(Suzanne H. Gage, Hickman, & Zammit, 2016), Page 549, 
Paragraph 2]. However, studies evaluating multifactorial  risk models for relapse in 
patients with psychosis often left out cannabis use in their considerations  (D. 
Addington et al., 2010; M. Alvarez-Jimenez et al., 2012; Austin et al., 2015; Gearing et 
al., 2009; Hui et al., 2013; D. Robinson et al., 1999; Sipos, Harrison, Gunnell, Amin, & 
Singh, 2001; Üçok et al., 2006). In my thesis, I therefore used a combination of methods 
in order to minimize the effect of potential confounding factors when establishing 
causality, resulting in the following main findings: 
(1)!Paper 1 (Schoeler, Monk, et al., 2016): Investigation of the unadjusted effects 
of continued and discontinued cannabis use following the onset and risk of 
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relapse in patients with FEP and established psychosis (meta-analysis): Data was 
pooled together from 24 studies (16 565 participants) to compare the groups (1) 
continued cannabis user, (2) discontinued cannabis user and (3) non-user in their 
relapse outcome. Independent from the stage of illness, continued cannabis users 
had more numerous relapses, longer hospitalisations and more severe positive 
symptoms when compared to non-users. These adverse effects were not present 
in patients who discontinued following the onset. The findings implicate that 
reductions in cannabis use may improve outcome in patients with psychosis, 
although causality cannot be established due to the correlational nature of the 
association. 
(2)!Paper 2 (Schoeler, Petros, Di Forti, Klamerus, et al., 2016): Investigation of the 
adjusted effects of continuation, frequency and type of cannabis use on relapse 
in the first two years following onset of psychosis (follow-up study): 256 FEP 
patients presenting to psychiatric services in South London were prospectively 
recruited and followed up in order to estimate the effect of different patterns of 
cannabis use based on (a) continuity of use following onset of psychosis, (b) 
potency of cannabis consumed and (c) frequency of use following onset of their 
illness, while taking into consideration important confounding factors. The 
results showed that former regular users who stopped after onset had the most 
favourable illness course with regard to relapse. Those who continued high-
frequency users (daily use in all 24 months) of high-potency cannabis (“skunk-
like”) had the worst outcome, indexed as an increased risk for a subsequent 
relapse, more numerous relapses, fewer months until a relapse occurred and 
more intense psychiatric care following onset of psychosis. The results indicate 
that the adverse effects of continued use of cannabis following the onset of FEP 
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depend on the specific patterns of use, even when controlled for confounders 
such as medication non-adherence, other substance use and other onset 
demographic and clinical measures. Interventions may focus on persuading 
cannabis-using patients with psychosis to reduce use or shift to less potent forms 
of cannabis. 
(3)!Paper 3 (Schoeler, Petros, Di Forti, Pingault, et al., 2016): Investigation of the 
temporal relationships between continued cannabis use and risk of relapse in the 
first two years following onset of psychosis using a quasi-experimental design: 
Longitudinal modelling was employed (fixed-effects analysis, cross-lagged path 
analysis) to examine whether the association between changes in cannabis use 
and risk of relapse over time is the result of non-causal explanations, including 
shared-vulnerability between psychosis and cannabis use, confounding effects of 
other illicit drug or medication non-adherence, reverse causation (psychosis 
increasing the risk of cannabis use) or indeed a causal effect of cannabis use on 
psychosis relapse. Within-subject comparisons (thereby controlling for time-
invariant unobserved confounders such as genetic/premorbid environment) 
revealed that there was an increased risk of experiencing a relapse of psychosis 
in periods of cannabis use relative to periods of no use. The effect was also 
present for change in pattern of continuation of cannabis use, suggesting a dose-
dependent relationship. The exploration of directionality confirmed that this 
association reflected an effect of cannabis use on subsequent risk of relapse, 
rather than an effect of relapse on subsequent cannabis use. The results 
demonstrate a dose-dependent association between change in cannabis use and 
relapse of psychosis, that is unlikely to be a result of self-medication or genetic 




Overall, my results implicate that cannabis is likely to represent a causal risk factor 
for relapse in first episode psychosis – an effect that (a) is likely to be of a magnitude 
that is clinically relevant, (b) likely to exerts its effects in the form of a dose-response 
relationship, (c) unlikely to be explained by other sources of confounding, (d) unlikely 
to be the result of self-medication (reverse causation) and (e) reflects one risk factor 
among numerous others (i.e. cannabis constitute a component cause of psychotic relapse 
rather than a sufficient cause). Several findings in my thesis provide evidence for this 
conclusion, i.e. speak for causality. Those are illuminated in the following paragraphs, 
using the structure suggested by the Hill-criteria (A. B. Hill, 1965): 
 
1.! Strength: Is the magnitude of association between continued cannabis use and risk 
of relapse strong enough to raise clinical concerns? 
The results from my meta-analysis [Paper 1, (Schoeler, Monk, et al., 2016)] 
indicate that cannabis users are significantly at higher risk for relapse when compared to 
non-users or those who discontinued following the onset. When looking at a more 
detailed definition of cannabis use in Paper 2 (Schoeler, Petros, Di Forti, Klamerus, et 
al., 2016), I found that heavy use of high-potency cannabis was one of the strongest 
predictors for relapse (OR = 3.28). Among the other predictors included in this model, 
significant increases in risk for relapse were only present for medication non-adherence 
(OR = 3.25), non-white ethnicity (OR = 2.36) and increased onset severity (indexed as 
care intensity at onset, OR = 1.37). While early studies proposed that medication 
adherence was the most crucial factor with regard to relapse-prevention (D. Robinson et 
al., 1999), my findings suggest that the strength of effect of cannabis is most likely to be 
of at least equal significance. To illustrate, the adjusted risk estimates found in my 
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analysis indicated a 1.9 higher risk for relapse in continued skunk users (taken from 
propensity score matched analysis, with RR = 1.9, 57% vs. 30%). When putting the 
magnitude of effect into context, this estimate is similar the adjusted effects of 
antipsychotic treatment (placebo group vs. medicated group), in which a 2.4 times 
higher risk (64% vs. 27%) for relapse was found for those not being treated with 
medication (Stefan Leucht et al., 2012). The estimate is also comparable to that found 
for the effect of psychotherapy (TAU vs. CBT), in which a 1.9 times higher risk (34% 
vs. 18%) was present in those not receiving psychotherapy (Gumley et al., 2003). 
These results therefore suggest that reductions in cannabis use may lead to clinically 
meaningful improvement in outcome that is comparable in its efficacy to those 
interventions recommended by the NICE (National Institute for Health and Care 
Excellence) guidelines for early intervention in psychosis, including antipsychotic drug 
treatment in conjunction with psychological interventions (NICE). Furthermore, 
although antipsychotic treatment is an effective intervention reducing the risk of relapse 
(Stefan Leucht et al., 2012), its preventative effects often remain unrealized in those not 
adhering to the treatment plan, which is often related to side-effects such as weight gain 
and metabolic syndrome (Patel et al., 2009). Hence, especially in those unwilling to take 
their medication, a reduction in cannabis use would be crucial in order to reduce risk of 
relapse.  
 
2.! Consistency: Is the effect consistent across different measures of relapse? 
In the meta-analysis (Paper 1), I found that continued cannabis use was related to 
an increased risk of relapse, longer times spent in hospital and more severe positive 
symptoms, which speaks for its consistency across measures that capture positive 
psychotic symptomatology. Although this analysis did not control for important 
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confounders, the results are in accordance with those from the adjusted prediction 
models (Paper 2), in which the effect of continued high-frequency use (daily use in all 
24 months) of high-potency cannabis (“skunk-like”) was linked to risk of a subsequent 
relapse, more numerous relapses, fewer months until a relapse occurred and a higher 
care intensity index (i.e. a higher risk that the relapse event involved admission under 
section) in the two years following onset of illness. Hence, these findings are in 
accordance with Hill’s (A. B. Hill, 1965) criteria of  consistency, as well as with other 
longitudinal studies that reported a link between continued use of cannabis and risk of 
relapse (Bergé et al., 2016; B. Schimmelmann et al., 2012), duration of stay in hospital 
(Leeson et al., 2012), time until a relapse occurred (Linszen et al., 1994), and positive 
symptoms severity (Baeza et al., 2009; L. Clausen et al., 2014; Foti et al., 2010; Harrow 
et al., 2005; Hinton et al., 2007; Seddon et al., 2015). 
 
3.! Specificity: Does continued cannabis use has a specific relationship with psychotic 
relapse?  
When elaborating the issue of specificity of the effects of continued cannabis use, it 
should be evaluated (a) whether the effect of cannabis is linked solely (i.e. specifically) 
to measures of psychotic symptom exacerbation or, alternatively, whether it is also 
linked to a range of other clinical (non-psychotic) and functional outcomes (i.e. non-
specific with regard to outcome). Second, it should be elaborated (b) whether the effect 
found for cannabis is also present for other (psychoactive) substances such as cigarettes  
and other illicit drugs. With regard to question (a), the results from the meta-analysis 
(Paper 1) indicated that cannabis was linked to all measures assessing psychotic 
symptoms (relapse, time spent in hospital, positive symptom severity), while there was 
no clear effect on negative symptoms or level of functioning, indicating some level of 
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specificity with regard to outcome. Similarly, in my other meta-analysis (Schoeler, 
Kambeitz, et al., 2016), no aversive effects of cannabis use in patients with psychosis 
were present for memory function, level of functioning or severity of depression. 
Unfortunately, the results from my follow up study (Paper 2 and Paper 3) do not allow 
to draw conclusions regarding the specificity of effects with regard to outcome, since I 
focused exclusively on exacerbation of positive symptoms (i.e. risk of psychotic 
relapse, time until a relapse occurred, length of hospital stay, care intensity at follow 
up). When looking at the available literature, the evidence from follow up studies is 
rather mixed. For instance, continued cannabis use significantly predicted poor outcome 
for a range of outcomes assessed at follow up, including risk of relapse (Bergé et al., 
2016; B. Schimmelmann et al., 2012), length of time spent in hospital (Leeson et al., 
2012), positive symptoms severity (Baeza et al., 2009; L. Clausen et al., 2014; Foti et 
al., 2010; Harrow et al., 2005; Hinton et al., 2007; Seddon et al., 2015), risk of non-
remission (B. Schimmelmann et al., 2012), risk of continuous illness course (Grech et 
al., 2005a), illness severity (B. Schimmelmann et al., 2012), functioning (L. Clausen et 
al., 2014; Gonzalez-Blanch et al., 2015; B. Schimmelmann et al., 2012; Seddon et al., 
2015), negative symptoms severity (Seddon et al., 2015), depressive symptoms (Seddon 
et al., 2015; J. Stone et al., 2014) and quality of life (Pencer et al., 2005). To the 
contrary, other follow up studies did not find a link between continued cannabis use and 
risk of relapse (Caseiro et al., 2012; Faber et al., 2012; Faridi et al., 2012), positive 
symptoms severity (Faber et al., 2012; Faridi et al., 2012; González-Pinto et al., 2011; 
Rais et al., 2010; Stirling et al., 2005), time spent in hospital/time spent in relapse (L. 
Clausen et al., 2014; Faber et al., 2012; Rais et al., 2008), symptomatic remission 
(Colizzi et al., 2015; Faber et al., 2012; Faridi et al., 2012), risk of continuous illness 
course (Sorbara et al., 2003), functional remission (Faber et al., 2012), level of 
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functioning (Baeza et al., 2009; Bergé et al., 2016; Faber et al., 2012; González-Pinto et 
al., 2011; Hinton et al., 2007; Stirling et al., 2005), clinical recovery (Faber et al., 2012), 
employment status (Pencer et al., 2005; Sorbara et al., 2003), negative symptom 
severity (Baeza et al., 2009; L. Clausen et al., 2014; Faridi et al., 2012; González-Pinto 
et al., 2011; Grech et al., 2005a; Hinton et al., 2007; Rais et al., 2010; J. Stone et al., 
2014), disorganized symptoms (L. Clausen et al., 2014) and depressive symptoms 
(Baeza et al., 2009; Foti et al., 2010; Hinton et al., 2007). Nevertheless, overall it seems 
that a greater body of evidence is in support of the link between cannabis use and 
psychotic symptoms, while findings regarding functioning and affective symptoms are 
less consistent. Furthermore, evidence is more clear when a more valid methodological 
approach was employed, i.e. by assessing changes is symptoms over time. For instance, 
continued cannabis use predicted worsening of psychotic symptoms (Degenhardt et al., 
2007; Foti et al., 2010; Henquet et al., 2010), and discontinued cannabis use was 
associated with fewer improvements in functioning (González-Pinto et al., 2011; J. 
Stone et al., 2014). Adverse effects with regard to other clinical measures are less 
obvious, e.g. no effect of changes in cannabis patterns on changes in depressive 
symptoms was found in FEP patients (Foti et al., 2010; Hinton et al., 2007) and patients 
with established psychosis (Degenhardt et al., 2007), and there were no differences in 
changes in symptoms between continuer and discontinuer were for negative symptoms 
(González-Pinto et al., 2011; Hinton et al., 2007). This is in line with experimental 
evidence of the acute effects, which clearly supports a link with psychotic symptoms 
(Barkus et al., 2011; Sagnik Bhattacharyya, Atakan, et al., 2015b; D'Souza et al., 2008; 
Englund et al., 2015; P. Morrison et al., 2009; Radhakrishnan, Skosnik, et al., 2015; 
Tunbridge et al., 2015; Van Wel et al., 2015), while the acute administration of THC 
did not result in  changes in depressive symptoms (Englund et al., 2015; Wachtel et al., 
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2002) or mood (Marieke Liem-Moolenaar et al., 2010). Nevertheless, in order to arrive 
at a more robust conclusion, future follow up studies looking at changes in cannabis use 
and outcome other than psychotic symptoms are warranted. 
Regarding question (b), I controlled for the effects of cigarette and alcohol use, as 
well as for other illicit drug use in my prediction models (Paper 2). When predicting 
risk of relapse, none of those predictors independently predicted relapse beyond the 
effects of cannabis, although there was an effect of cigarette use and illicit drug use 
following onset of psychosis on the number of relapses (IRR=1.73, p=0.01 and 
IRR=1.79, p=0.03).  Results from observational evidence are rather inconclusive in this 
context; For instance, a 3-year follow up of FEP patients reported that cigarette use 
following the onset was significantly linked to relapse (HR = 1.4) when controlled for 
medication non-compliance (Hui et al., 2013), which is also supported by one study in 
FEP patients that found a link between cigarette use and number of readmissions 
following the onset (Kobayashi et al., 2010). However, both studies did not consider 
cannabis use and other illicit drug use in their prediction models (Hui et al., 2013; 
Kobayashi et al., 2010) and other studies failed to find a link between cigarette use and 
relapse/level of positive symptomatology when controlled for alcohol and other illicit 
drug use in patients with established psychosis (Cooper et al., 2012).  Regarding other 
illicit drug use, several studies that have investigated the effects of substance use in 
general are in accordance with my findings and have reported that ongoing substance 
use significantly predicted risk of relapse (Levy et al., 2012; A Malla et al., 2008; 
Turkington et al., 2009; D Wade et al., 2006). Problematically, no distinction between 
the different substances that were used was made and, in fact, cannabis use remained the 
most commonly used drug of abuse in those studies (Levy et al., 2012; D Wade et al., 
2006) or the most commonly used drug following alcohol use (A Malla et al., 2008; 
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Turkington et al., 2009), for which reason conclusions regarding the independent effects 
of illicit drug use other than cannabis are limited. Nevertheless, when distinguishing 
between the different drugs of abuse, D Wade et al. (2006) reported an increased risk 
for inpatient admission following the onset for those with CUD, those with SUD (other 
than cannabis or alcohol), but not those with alcohol use disorder (AUD). In line with 
this, it was reported that amphetamine use after a period of abstinence in patients with 
chronic psychosis increased the risk of the emergence of a subsequent relapse (Sato, 
Chen, Akiyama, & Otsuki, 1983). Similarly, it has been reported that amphetamine can 
induce psychotic symptoms in healthy subjects (C. Curran, Byrappa, & Mcbride, 2004) 
and exacerbate symptoms in those with a pre-existing psychotic disorder (Abi-
Dargham, 2004), implicating that ongoing stimulant use may increase the risk for re-
emergence of psychotic symptoms in FEP patients. Nevertheless, my results suggest 
that the adverse effects of cannabis use were independent from the effects cigarette use 
and other illicit drug use each other, pointing to the possibility that cannabis perhaps 
exerts its effects via different neural pathways.  For instance, while psychostimulants 
such as cocaine, amphetamines and nicotine increase cortical and subcortical dopamine 
levels (Berke & Hyman, 2000; Centonze et al., 2004; Drevets et al., 2001; Yoder et al., 
2007), THC does not act on dopamine release directly but via the CB1-driven 
modulation of glutamate and GABA neurons in the nucleus accumbens and ventral 
tegmental area [(Kuepper et al., 2010), cf. Figure 6., Chapter 2.2]. To illustrate, 
whereas haloperidol (DA D2) receptor antagonist reversed the amphetamine-induced 
psychotic symptoms in healthy human subjects (Angrist, Lee, & Gershon, 1974) and 
patients with a pre-existing psychotic disorder (Sato et al., 1983), no such preventative 
effects of haloperidol were present for THC-induced psychotic symptoms in healthy 
subjects (D’Souza et al., 2008). Consistent with this, while THC administration led to a 
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small decrease in the binding of a dopamine tracer (3%) in the striatum (Bossong et al., 
2009), larger effects were reported for other stimulant drugs such as nicotine (8%-37%)  
(Brody et al., 2009; Brody et al., 2004), alcohol (15%) (Boileau et al., 2003), 
amphetamine (12%-16%) in the striatum (Drevets et al., 2001; Martinez et al., 2007; 
Oswald et al., 2005), or cocaine (12%) (Schlaepfer, Pearlson, Wong, Marenco, & 
Dannals, 1997) in the striatum – this may further implicate that the psychotomimetic 
effects of THC are only partially mediated by striatal dopamine release. My results also 
indicate that ongoing alcohol use following onset is not a predictor for relapse. This is 
consistent with other studies in FEP patients that reported no effect of alcohol use on 
risk of relapse (D Wade et al., 2006), as well as population based studies that did not 
find a link between alcohol use and onset of psychosis (Di Forti, Marconi, et al., 2015; 
David M Fergusson et al., 2005; Henquet et al., 2004; Zammit et al., 2002). In 
accordance, another study in cocaine-dependent users found that cannabis use but not 
alcohol use predicted cocaine-induced psychosis (CIP) (Trape et al., 2014). 
Overall, the results are in favour of rather specific effects of cannabis on relapse and 
psychotic symptomatology, i.e. are not supportive of the hypothesis stated by the 
shared-vulnerability model, which proposed that individuals who develop (any/non-
specific) mental illness are also more likely to use (any/non-specific) substance as a 
results of a common genetic contribution (Ksir & Hart, 2016a). Instead, my results 
indicate that cannabis exerts its adverse effects on psychotic symptoms exacerbation 
independent from the use of other substances. However, this does not rule out the 
possibility of interactive effects between cannabis use and other drug use in predicting 





4.! Temporality: Does cannabis use precede the relapse event or is it a subsequent 
event following the relapse of psychosis? 
Whereas the data summarized in my meta-analysis (Paper 1) indicated that there is an 
association between continued use of cannabis and risk of relapse in psychosis, this 
evidence is of a cross-sectional nature and, hence, does not allow to draw conclusions 
regarding the direction of effect. For instance, it has been proposed that the association 
could be the result of self-medication, i.e. those with more severe psychopathology are 
more likely to use the drug in order to relieve their symptoms (Khantzian, 1985). 
However, this theory is not supported by the findings from my thesis. First, Paper 2 
showed that those who used cannabis continuously (i.e. using cannabis in each month of 
the two years following the onset) were more likely to relapse. This means that in those 
users, the cannabis use preceded the relapse event. Furthermore the effect remained 
significant when controlled for onset illness severity (indexed as care intensity at onset). 
Together, these findings do not support the notion that continued cannabis use is a 
consequence of a relapsing/more severe illness course. Similarly, the results from the 
path analysis (Paper 3) indicate that continued cannabis use predicted risk of 
subsequent relapse, while the association was not significant in the reverse direction 
(increased cannabis use following the event of a relapse). Studies that have examined 
the issue of reverse causation in those with pre-existing psychosis report either a bi-
directional relationship between cannabis use and symptom severity (Foti et al., 2010), 
or that frequency of cannabis use predicted an increase in subsequent psychotic 
symptoms, but not vice versa (Degenhardt et al., 2007; Henquet et al., 2010), indicating 





5.! Biological gradient: Does the effect of cannabis use on outcome reflect a dose-
response relationship? 
If cannabis was a causal risk factor for relapse, one would expect that the risk 
increases with increasing doses of cannabis exposure. A dose-response relationship is 
supported by all three analyses carried out in my thesis. First, in the meta-analysis 
(Paper 1) I found that those who continued to use cannabis were at higher risk for 
relapse when compared to non-users and when compared to those who discontinued 
following the onset. Since those who discontinued using cannabis following the onset 
were not at higher risk for poor outcome when compared to non-users, the results 
implicate that a reduction of use may reduce the risk of relapse, although caution in 
warranted since this analysis did not control for important confounders. The increased 
risk linked to increased dosages of cannabis exposure could therefore reflect the 
increase in risk of accompanying confounders, e.g. if increased cannabis use goes hand 
in hand with poorer compliance with medication and/or increased use of other drugs. 
However, in Paper 2, in which I controlled for those confounding factors, I found that 
the highest risk for relapse and poor outcome remained significantly present in those 
with the highest dosage of cannabis exposure (daily use of skunk-type cannabis 
throughout the two years following the onset), while an increased risk of relapse was 
not present for who continued to use it but consumed milder forms of cannabis (hash-
type), used it less frequently (less than daily), those used it only intermittently following 
the onset or those who had a history of premorbid cannabis use but did not use it 
following the onset. This finding suggests a dose-response relation, with the poorest 
outcome found in those users that were exposed to high doses of THC following the 
onset. Furthermore, premorbid cannabis use may have reversible effects with regard to 
psychotic symptoms, since patients with a history of premorbid regular use were not 
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different to those who never used it at a regular basis in their outcome. These results are 
therefore in accordance with epidemiological evidence of the adverse dose-dependent 
effects of cannabis and risk of relapse (Bergé et al., 2016; Hides et al., 2006; Linszen et 
al., 1994) and psychotic symptom severity (Degenhardt et al., 2007) and reversible 
effects of cannabis exposure following abstinence (Rabin et al., 2013). Paper 3 is in 
further support of this, since within-subject change (increase) in pattern of cannabis 
continuation over time was linked to increased risk of relapse, while controlling for 
unobserved time-invariant sources of confounding (e.g. premorbid genetic profile) and 
observed time-variant sources of confounding (medication adherence, other illicit drug 
use). This is similar to what was found by studies looking at cannabis use as a risk 
factor for onset of psychotic symptoms. For instance, a within-subject increase in 
cannabis use over time increased the risk of development of psychotic symptoms 
(David M Fergusson et al., 2005). This is consistent with independent evidence from a 
study in chronic methamphetamine users without a comorbid diagnosis of psychosis, in 
which change in frequency of cannabis use was linked to the risk of presence of 
psychotic symptoms (McKetin et al., 2013). This is also in accordance with a study that 
employed a sibling-pair design to control for some of the shared genetic (<50%) and 
environmental influence by J. McGrath et al. (2010), which found that duration of 
cannabis use was a significant predictor of psychotic outcome in young adults. To 
summarise, my results are in favour of a dose-response effect that persists beyond the 
effect of confounding and cannot be explained by shared-vulnerability. 
 
6.! Plausibility: Is there a plausible biological explanation for the link between 
cannabis use and exacerbation of psychotic symptoms?   
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My results suggest that those who were exposed to the highest doses of THC had the 
highest risk for psychotic symptom exacerbation following the onset. In line with this, 
the administration of THC has been consistently linked to the production of acute 
transient psychotic experiences in healthy human individuals with minimal previous 
cannabis exposure (Sagnik Bhattacharyya, Atakan, et al., 2015b; D'Souza et al., 2008; 
Englund et al., 2015; P. Morrison et al., 2009; Radhakrishnan, Skosnik, et al., 2015; 
Tunbridge et al., 2015) and in those who are current regular users of cannabis (Van Wel 
et al., 2015). THC administration also triggered the exacerbation of psychotic symptoms 
in those with a pre-existing psychotic disorder (D’Souza et al., 2005), despite chronic 
treatment with DA D2 receptor antagonists (D’Souza et al., 2005). At a neural level, 
cannabis may exerts its effects by causing functional changes in the brain structures 
implicated in the pathology of psychotic disorders, such as the striatum or midbrain (S 
Bhattacharyya et al., 2012; Sagnik Bhattacharyya, Falkenberg, et al., 2015; Sagnik 
Bhattacharyya et al., 2009; Bossong et al., 2009). However, the precise neurochemical 
mechanisms that underlie the psychotomimetic effects of THC are still relatively poor 
understood. For instance, most research has focused on the dopamine hypothesis as the 
underlying model of cannabinoid action (Kuepper et al., 2010). The hypothesis states 
that the emergence of psychotic symptoms, which are thought to derive from a state of 
aberrant salience, are the result of excessive stimulation of DA D2 receptor proteins in 
the brain (Howes & Kapur, 2009; Kapur, Mizrahi, & Li, 2005). Although abnormalities 
in multiple pathways may lead to psychosis, including glutamate and GABA, 
abnormality in dopamine neurotransmission, particularly in striatal regions, is proposed 
to mirror the final common pathway leading to psychosis (Howes & Kapur, 2009). 
Hence, one would therefore expect cannabis use to be linked to changes in 
dopaminergic signalling. However, experimental evidence from human studies 
[217] 
 
investigating this mechanism of cannabis action is rather inconclusive so far [cf. Sami et 
al. (2015) for a systematic summary of studies]: One single photon emission 
tomography (SPECT) study did not find an effect of a low dose of THC (2.5mg IV) on 
striatal dopamine release, despite the presence of psychotomimetic properties of THC, 
suggesting that the striatal DA system may not mediate the psychoactive effects of 
cannabis (Barkus et al., 2011). This is similar to another position emission tomography 
(PET) study administering 10mg oral THC, which did not find an effect on striatal 
binding, despite inducing psychotic symptoms (Stokes, Mehta, Curran, Breen, & 
Grasby, 2009). Those findings would also imply an ineffectivity of DA D2 blockers in 
preventing THC-psychosis, which was the case in one experimental study that reported 
that a D2 receptor antagonists (e.g. Haloperidol) failed to prevent from the 
psychotomimetic effects following THC-administration (D’Souza et al., 2008) and one 
epidemiological study that linked onset cannabis use to antipsychotic treatment failure 
(Patel R et al., 2016). Another acute challenge study reported increases in positive 
symptoms following THC administration in psychotic patients treated with D2 receptor-
based antipsychotic medication (D’Souza et al., 2005). However, latter study did not 
include a non-medicated control group, for which reason it cannot be concluded as to 
whether the induced symptoms following THC administration where in fact blunted or 
not. Overall, those findings in humans are somewhat incongruent with the dopamine-
hypothesis and are not supported by relatively consistent evidence from experimental 
studies in animals, in which THC increased dopamine levels in several brain areas such 
as striatal and prefrontal areas (Cheer, Wassum, Heien, Phillips, & Wightman, 2004; 
Ginovart et al., 2006; Kreitzer & Malenka, 2005; Tanda & Goldberg, 2003; Yin & 
Lovinger, 2006), increased central dopamine synthesis (Bloom, Johnson, & Dewey, 
1978) and inhibited dopamine uptake (Poddar & Dewey, 1980). Nevertheless, some 
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evidence from human studies is in support of this; using PET and a dopamine D2/D3 
tracer (raclopride), Bossong et al. (2009) reported that the tracer binding was modestly 
(~3%) but significantly decreased in the ventral striatum, implicating an increased 
release of endogenous dopamine in this region. However, it might be the case that 
significant effects of THC are more easily detectable in genetically predisposed 
individuals. For instance, a SPECT case study in a medication-free patient with 
psychosis reported a 20% decrease in striatal D2 receptor binding ratio following 
exposure to THC, suggesting increased synaptic dopamine release underlying the THC-
exacerbated psychotic symptoms (Voruganti, Slomka, Zabel, Mattar, & Awad, 2001). 
Another PET study reported THC induced dopamine release only in patients with 
psychosis and their unaffected siblings but not in healthy controls (Kuepper et al., 
2013). This is consistent with observational evidence that did not find a link between 
cannabis use and risk for antipsychotic treatment failure in patients with psychosis 
(Crespo-Facorro et al., 2007; Rais et al., 2010). A more recent RCT in humans reported 
that haloperidol inhibited the symptom-inducing effects of THC (including positive and 
negative symptoms), as well as the cognitive impairments following the administration 
of THC in healthy subjects (Marieke Liem-Moolenaar et al., 2010), which would be in 
further support of the hypothesis that THC exerts its effect via increased striatal DA 
release. In latter study, THC administration also affected prolactin levels - a biomarker 
for dopaminergic activity – and this effect was ameliorated by haloperidol treatment (M 
Liem-Moolenaar et al., 2010). Finally, CB1 blockers may be able to inhibit the 
psychoactive effects of excessive D2 stimulation. For instance, there is evidence that 
CBD inhibited the psychosis-inducing effects of L-DOPA (Zuardi et al., 2008) and a 
RCT comparing CBD with amisulpride reported equal effectivity between the two drugs 
in reducing psychotic symptoms (Leweke et al., 2012). It has therefore been suggested 
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that the antipsychotic effects of CBD stem from the attenuation of dopaminergic 
activity in brain.  
To summarise, although the neurochemical mechanisms by which cannabis induces 
it psychotomemtric effects are still not fully understood, some evidence suggests that 
the psychotomimetic effects of THC are potentially partly mediated by striatal 
dopamine release – at least in individuals with a genetic pre-disposition for psychotic 
disorders. Despite the uncertainties regarding the exact underlying neurochemical 
mechanisms of THC action, there is robust behavioural experimental evidence in 
humans and animals that is in support of the notion that the main psychoactive 
ingredient of cannabis – THC – can acutely induce and exacerbate psychotic symptoms 
in a dose-dependent manner. Therefore, it seems plausible to presume that the 
association between continued cannabis use and increased risk of exacerbation of 
psychotic symptoms as found in my papers (Paper 1, Paper 2, Paper 3) reflects a 
pharmacological effect of THC on brain-chemistry in FEP patients. 
 
7.! Confounding: Is the association between cannabis and relapse confounded by a 
third variable? 
The issue of confounding is one of the most heatedly debated topic within the 
research community interested in the epidemiology of cannabis use and mental health 
(Ksir & Hart, 2016b). For instance, cannabis users at onset of their first episode have 
been shown to be systematically different from non-users in various clinical and 
demographic measures (Baeza et al., 2009; L. Clausen et al., 2014; González-Blanch et 
al., 2015; González-Pinto et al., 2011; Patel R et al., 2016; B. Schimmelmann et al., 
2012; Seddon et al., 2015) and those who continue using the substance following the 
onset are more likely to have an earlier age of onset of psychosis (González-Pinto et al., 
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2011), use alcohol (González-Pinto et al., 2011) and other drugs (L. Clausen et al., 
2014; Faridi et al., 2012; González-Pinto et al., 2011; Maria Isaac, Isaac, & Holloway, 
2005a) and are non-adherent with their medication (Foglia et al., 2017).  This is similar 
to the findings reported in Paper 2, in which I found that the different cannabis groups 
were significantly different with regard to medication adherence, other drug use and age 
of onset, for which reason those differences could play a role within the cannabis-
relapse association. In the following section I therefore discuss the issue of confounding 
by looking at the role of various confounders that were highlighted in the previous 
literature, including: 
a.! Medication non-adherence: First, the results from Paper 2 indicate that high 
frequency skunk use remained a significant predictor for outcome including risk 
of relapse, length of relapse, time until a relapse occurred and care intensity at 
follow up, when controlled for medication non-adherence (Paper 2). This is 
similar to other studies that found that medication adherence did not explain the 
link between continued cannabis use and risk for non-remission, illness severity 
of functioning at follow up (B. Schimmelmann et al., 2012). In accordance, a 
recent study also found that frequency of cannabis use was not confounded by 
non-compliance to medication (Bergé et al., 2016) and there is evidence that the 
diagnosis of CUD following the onset was linked to risk of readmission and risk 
of compulsory admission when medication adherence was taken into 
consideration (Sorbara et al., 2003). Adverse effects of cannabis use also 
persisted independent from medication adherence with regard to severity of 
positive symptoms (Faridi et al., 2012; Hides et al., 2006). Nevertheless, the 
magnitude of effect of continued cannabis use that I found in simple analyses 
(Paper 2 and Paper 3) was reduced in the multiple analyses when medication 
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adherence was included as a covariate. To illustrate, the magnitude of effect 
identified in univariate analysis (OR 4.37, cf. Paper 2) dropped when 
medication adherence was included (OR 2.73, cf. Paper 2).  Furthermore, 
considering that continued cannabis users were less likely to be adherent to their 
medication (e.g. Paper 3: 41% vs. 21% classified as full adherent in non-users 
vs. continued users) and the independent effect of medication adherence on risk 
of relapse, it is plausible that some of the effects of cannabis may have been 
mediated by non-adherence to antipsychotic medication in those who also use 
cannabis. This is in line with other follow up studies in FEP patients, which (i) 
showed that cannabis users are less likely to adhere to their medication (Foglia 
et al., 2017) and (ii) in which medication non-adherence predicted risk of relapse 
(Barbeito et al., 2013; Caseiro et al., 2012; Coldham et al., 2002; Gearing et al., 
2009; Michele Hill et al., 2010; Hui et al., 2013; Martin Lambert et al., 2010; 
Levy et al., 2012; Morken et al., 2008; Üçok et al., 2006; H Verdoux et al., 
2000), involuntary readmission (H Verdoux et al., 2000), as well as number of 
days spent in hospital, number of hospitalisations and  days under section 
(Morken et al., 2008). In fact, medication non-adherence remained the strongest 
predictor for relapse when considered in multifactorial prediction models 
(Caseiro et al., 2012). Finally, my finding that adherent patients exposed to high 
doses of THC remain at higher risk for poor outcome is in line with studies 
implicating an ineffectiveness of antipsychotic treatment in reducing cannabis-
induced psychotic symptoms, e.g. experimental evidence reporting an 
exacerbation of psychotic symptoms following THC administration in patients 
treated with antipsychotic medication (D’Souza et al., 2005), the finding that 
haloperidol did not reduce the psychotogenic effects following THC 
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administration (D’Souza et al., 2008) and observational evidence supporting a 
link between onset cannabis use antipsychotic treatment failure (Patel R et al., 
2016). However, evidence in this regard is mixed, since there is experimental 
evidence that haloperidol was in fact effective in inhibiting the THC-induced 
symptoms (Marieke Liem-Moolenaar et al., 2010) and the absence of a link 
between cannabis use and antipsychotic treatment failure (Crespo-Facorro et al., 
2007; Rais et al., 2010). 
In summary, instead of concluding “FEP patients with an active 
cannabis use disorder may make a choice of either stopping cannabis and not 
taking medications or continuing cannabis but becoming more adherent to 
medications” [(Faridi et al., 2012), Abstract], it seems rather crucial to promote 
both abstinence from (high-potency) cannabis in combination with medication 
adherence as the more optimised treatment approach with regard to relapse 
prevention. 
b.! Other substance use: Although cigarette use and illicit drug use had some 
adverse effects on outcome (cf. Chapter 6.1 “3. Specificity” for a more detailed 
discussion on the effects of the different substances), my results indicate that the 
effect of continued cannabis use and changes in cannabis use remained 
independent predictors for risk of relapse (Paper 2 and Paper 3). The 
independent contribution of cannabis use on outcome when controlled for other 
substance use is in line with follow up studies in which the effect of cannabis 
use on outcome in FEP patients and patients with established psychosis, such as 
relapse (D. van Dijk, M. W. Koeter, R. Hijman, R. S. Kahn, & W. van den 
Brink, 2012a) and positive symptom severity (Degenhardt et al., 2007; Foti et 
al., 2010; González-Pinto et al., 2011; Henquet et al., 2010), as well as studies 
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that reported that frequency of cannabis use remained a significant predictor for 
onset of psychosis (Di Forti, Marconi, et al., 2015) and symptoms severity in the 
general population (David M Fergusson et al., 2005; J. McGrath et al., 2010), 
independent from other drug use. 
c.! “Shared-vulnerability”: Besides the potential confounding effect of the factors 
outlines above, the most recent debate is concerned with the “shared-
vulnerability” hypothesis, which proposed that the association reflects the result 
of a (genetic) liability for both cannabis use and the risk of developing psychosis 
(Ksir & Hart, 2016a). For instance, there is evidence for a genetic contribution 
to the initiation of cannabis use, as well as evidence indication genetic overlap 
between cannabis initiation and problematic use of cannabis (Verweij et al., 
2010). If there was a “shared-vulnerability” this genetic vulnerability for 
problematic cannabis use would then overlap with the vulnerability for 
psychosis. While there is some evidence suggesting the presence of some 
genetic risk for both cannabis use and onset of psychosis (J. Boydell et al., 2007; 
McGuire et al., 1995; R. A. Power et al., 2014; Proal et al., 2014), other studies 
suggest that a full genetic confounding effect is unlikely to be the case and that – 
if any genetic confounding exists – it would explain only a small proportion of 
the association between the two (Andréasson et al., 1989; Di Forti, Vassos, et 
al., 2015; Sherva et al., 2016b). 
Addressing the potential confounding effect of the genetic profile has 
been carried out in Paper 2 by taking into consideration family history of mental 
illness and in Paper 3, in which I used fixed effects models to control for the 
premorbid genetic profile. First, in Paper 2, I found that the different cannabis 
groups were not significantly different with regard to their family history of 
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mental illness. Based on the shared-vulnerability hypothesis, it can be 
hypothesized that those patients who continued using cannabis in a high-
frequency and high-dose (skunk-like) manner (i.e. those who were at highest 
risk for the experience of a relapse) would also have the highest genetic load 
when compared to never regular users/former regular users, which was not the 
case (p=0.61, cf. Paper 2: e.g.. 48% vs. 55%/44% that had a family history of a 
mental disorder). Problematically, the factor family history of mental illness 
may not fully capture the effect of “shared-vulnerability”. In fact, it has been 
suggested that an “unequivocal proof of cannabis exposure causing psychosis 
would require the experimental manipulation of cannabis use, with other 
confounding factors controlled for by random assignment of participants to 
different groups” [cf. Ksir and Hart (2016a), Page 3, Paragraph 4]. For this 
reason, Paper 3 adopted the sibling design approach – a quasi-experimental 
design – in which the same subject was used as its own control by comparing 
periods of non-exposure to cannabis to periods of exposure to cannabis. The 
results suggest that the risk of relapse was higher in periods of exposure, which 
was present in a dose-dependent fashion for level of continuity of use and while 
controlled for medication non-adherence and other illicit drug use. Although a 
genetic contribution might have attenuated the effect, these results clearly 
indicate that premorbid genetic confounding cannot explain the relationship 
between cannabis and risk of relapse. This is in accordance with other studies 
using such design, in which changes in frequency of cannabis use were linked to 
increases in psychotic symptoms in a population sample (David M Fergusson et 
al., 2005), a sample of methamphetamine abusers (McKetin et al., 2013) and 
evidence from an FEP sample, which showed that patients were characterised by 
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higher positive symptoms in periods of cannabis use when compared to periods 
of non-use (Foti et al., 2010). 
d.! Ethnicity: Differences in ethnicity did not confound the effects of continued 
cannabis on risk of relapse, neither when included as a covariate in multiple 
regression models (Paper 1), nor when considered as a time-invariant 
unobserved source of confounding in fixed effects analysis (Paper 2). However, 
non-white ethnicity independently predicted an increased risk of relapse, more 
numerous relapses, longer hospital stays, a shorter time until a relapse occurred 
and higher care intensity at follow up, implicating that this factor is an 
independent risk factor for poor outcome (Paper 1). This is in accordance with 
the finding that patients of black minority were more likely to relapse and to be 
detained under the mental health act throughout following their onset (N. Goater 
et al., 1999). The link with poorer outcome in this group may be discussed in the 
context of findings of an excess of psychotic disorders in migrant populations 
and minority ethnic groups. For instance, an early report noted that 
hospitalisation rates for psychosis were higher in Norwegian emigrants to the 
US (Minnesota), when compared to the Norwegian population in Norway or the 
American population born in America (Odegaard, 1932). Those trends have 
been replicated in subsequent studies (Cantor-Graae, Pedersen, McNEIL, & 
Mortensen, 2003; Selten et al., 2001), and there has been a particular interest in 
the high incidence rates among black Caribbean’s in the UK. For instance, a 
meta-analysis reported that the rates of schizophrenia were increased in various 
ethnic minority groups when compared to the (white) British population, 
including black Caribbean (RR 5.6), black African (RR 4.7) and Asian (RR 2.4) 
(Kirkbride et al., 2012). Several hypotheses have been proposed that might 
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explain the link with schizophrenia and could serve as a potential explanation as 
to why the non-white ethnic group in my sample was at risk for poor outcome, 
such a predisposition to psychosis in the first generation of migrants or socio-
environmental factors linked to the migration process and post-migratory 
experiences [cf. Kirkbride et al. (2012) for details]. Although it was beyond the 
scope of my thesis to further explore on those mechanisms, theories proposing 
that the increase in risk stems from higher rates of substance abuse in ethnic 
minorities, or gender and age differences (Kirkbride et al., 2012) are not in 
accordance with my findings, since the factor ethnicity remained an independent 
predictor when controlled for cannabis use and other illicit drug use, as well as 
gender and age of onset. 
e.! Diagnosis at onset: Neither were the rates of relapse significantly different 
between those with an onset diagnosis of affective psychotic disorder to those 
with a diagnosis of non-affective psychotic disorder, nor was the factor onset 
diagnosis (affective vs. non-affective) a predictor for any of the other outcomes 
that were assessed in my thesis (Paper 2). Furthermore, the different cannabis 
groups did not differ in their onset diagnosis, implicating that differences in 
diagnoses may not play an important role within the association between 
continued cannabis use and relapse. This is in line with other studies that did not 
find that diagnostic heterogeneity significantly predicted risk of relapse 
following the onset (Bergé et al., 2016; Castine et al., 1998; Gearing et al., 2009; 
Levy et al., 2012; Tarricone et al., 2014)  
f.! Onset severity: Onset severity as indexed as care intensity at onset was 
independently linked to risk of relapse but did not confound the relationship, 
which is supported by other studies that found an increased risk of relapse 
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predicted by onset clinical characteristics, including higher illness severity (D. 
Addington et al., 2010; Alvarez-Jimenez et al., 2011; Barrowclough et al., 2015; 
Möller et al., 2002; Üçok et al., 2006), lower level of functioning (D. Addington 
et al., 2010; Gearing et al., 2009; Üçok et al., 2006), poorer cognition at onset 
(Stirling et al., 2003) and longer duration of hospitalisation at onset (Hui et al., 
2013). 
g.! Age of onset: Cannabis use status following the onset was significantly linked to 
age of onset of psychosis, in which case continued cannabis users comprised the 
group with the youngest age of onset, which is in accordance with previous 
studies (González-Pinto et al., 2011; Maria Isaac et al., 2005a). Although some 
studies reported that an earlier age of onset was significantly linked to greater 
risk of relapse (D. Addington et al., 2010; Alvarez-Jimenez et al., 2011; Caseiro 
et al., 2012; Chi et al., 2016; Levy et al., 2012; A Malla et al., 2008; Üçok et al., 
2006) and longer durations of relapse (Lenior et al., 2005), my results do not 
suggest that this factors had an independent contribution that was beyond the 
effect of cannabis use, ethnicity, onset illness severity and medication 
adherence. 
h.! Gender: Gender did not significantly increase the risk of relapse, i.e. the risk of 
relapse was comparable between men and women. This is in line with the 
majority of studies looking at relapse in FEP patients, in which no significant 
effects of gender was reported (D. Addington et al., 2010; Chi et al., 2016; 
Lenior et al., 2005; Levy et al., 2012; A Malla et al., 2008; Tarricone et al., 
2014; Wiersma et al., 1998). Although the male patients in my sample were 
more likely to continue using cannabis following the onset, which is consistent 
with previous studies (L. Clausen et al., 2014; Moore et al., 2012; Patel R et al., 
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2016; Van Mastrigt et al., 2004), gender did not confound the effects continued 
cannabis use on risk relapse and related outcome. However, my analysis does 
not rule out that gender differences may moderate the effects of cannabis. For 
example, there is evidence suggestive of a dopaminergic sensitivity in the male 
brain when compared to the female one, in which case hormones such as 
oestrogen may play a protective role (Munro et al., 2006). Future research 
should therefore investigate gender-related sensitivities to cannabis use 
following the onset. 
To summarise, my results provide a solid ground to conclude that continued 
cannabis use has adverse effects on risk of relapse and related outcomes that are likely 
be causal in their nature. As shown in Figure 18. (cf. below), several mechanisms have 
been proposed that would explain the association between continued cannabis use and 
relapse. Hence, my results are in favour of a causal link between cannabis and relapse 
(Model A1, Model A2, Model A3), although based on my findings it is not possible to 
draw conclusions regarding the precise mechanisms of cannabis actions (Model A2), or 
the modulating effects of individual vulnerabilities (Model A3) in response to cannabis 
exposure. Within the wider literature, my findings are in accordance of a dose-response 
relationship between cannabis and psychotic symptoms in observational studies (Di 
Forti, Marconi, et al., 2015; David M Fergusson et al., 2005; Foti et al., 2010; J. J. 
McGrath et al., 2015) and laboratory-based studies (D’Souza et al., 2005; D’Souza et 
al., 2008; Marieke Liem-Moolenaar et al., 2010), an effect of cannabis use on brain 
function and chemistry (S Bhattacharyya et al., 2012; Sagnik Bhattacharyya, 
Falkenberg, et al., 2015; Sagnik Bhattacharyya et al., 2009; Bossong et al., 2009), a 
temporal relationship in which cannabis use is a preceding factor prior to the adverse 
outcome and is not the result of reverse causation (opposing Model B1) (David M 
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Fergusson et al., 2005; Foti et al., 2010; Henquet et al., 2010) and an independent effect 
that cannot be explained by potential confounders such as medication non-adherence, 
other illicit drug use (opposing Model B2) or a “shared-vulnerability” (opposing Model 
B3) (Foti et al., 2010; J. McGrath et al., 2010). 
 
Figure 18. Mechanisms linking continued cannabis use to risk of relapse 
 
Note. Adapted from Agrawal and Lynskey (2014): Mechanisms that may link continued 
cannabis use to risk of relapse, including causal effects of cannabis as shown in model 
A1[Cannabis use directly causes relapse], A2[Cannabis causes relapse via alterations in 
biological/environmental pathways] and A3[Cannabis causes relapse, while being 
modified by gene-environment interaction/environment-environment interaction)] and 
non-causal effects of cannabis as shown in model B1[Reverse causation, such as self-
medication], B2[Confounding by time-invariant factors such as other illicit drug use] 








6.2.1 CLINICAL IMPLICATIONS 
When assuming that continued cannabis use has a causal effect on risk of relapse 
within the first two years following onset of psychosis, this has important clinical 
implications. First, the results indicate that it is the continued high-frequency use 
(predominantly daily use in all 24 months) of high-potency cannabis (“skunk-like”), as 
well as the increase in cannabis continuation over time that links the substance to poor 
outcome. Since I provide evidence that former regular users who stopped after onset had 
the most favourable illness course with regard to relapse, the main interventional goal 
would therefore be to reduce cannabis use following the onset as early as possible in 
order to limit the progression to a more severe and treatment resistant form of illness. 
Early intervention is particularly important since, according to the “critical period” 
hypothesis (Birchwood et al., 1997), FEP patients may benefit the most especially in 
those first few years of their illness. Changes in cannabis use therefore comprise a 
crucial intervention target in those early stages of the illness. Considering that the 
proportion of cannabis users who started using cannabis following the onset of 
psychosis but had no history of premorbid regular use in my sample was relatively low 
(1.3%), this would implicate that there is no urgent need for early intervention services 
to focus on the implementation of novel treatments that aim to prevent the incidence of 
cannabis use following the onset, since this seems to be only rarely the case. Instead, 
since reductions in cannabis use may represent one of the most preventable causes of 
relapse, interventions may focus on persuading those who use cannabis when presenting 
with their first episode psychosis to reduce their use or shift to less potent forms of 
cannabis following their onset. Although there are numerous observations that indicate 
a naturalistic reduction following the onset (~ 46%, cf. Figure 9., Chapter 2.6), a large 
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proportion of patients continue to use cannabis (~ 46%, cf. Figure 9., Chapter 2.6) and 
cannabis remains the preferred drug of use and abuse within substance using patients 
(Lange et al., 2014; Levy et al., 2012; D Wade et al., 2006).  Discouragingly, none of 
the available treatments to date has been effective in treating comorbid cannabis use, 
either when targeted in psychological interventions (Christine Barrowclough et al., 
2014; Bonsack et al., 2011; Hjorthøj et al., 2013) or by means of pharmacological 
treatments (Wilson & Bhattacharyya, 2016). Since cannabis use – especially if used in a 
frequent manner such as daily – has established itself as an important activity in the 
patients everyday life, it is of crucial importance to better understand the biological and 
psychological mechanisms linked to continued cannabis use in order to develop more 
effective interventions.  
 
6.2.2 IMPLICATIONS FOR FUTURE RESEARCH 
The accumulation of evidence proposing a risk factor such as continued 
cannabis use as a causal factor for risk of relapse reflects only the first step in 
epidemiological research aiming to develop personalized prediction models for outcome 
in FEP patients. Cannabis use represents only a small part of a more complex scene. 
Based on the findings from my thesis, several lines of research should now carry out 
further investigations, in which (1) the precise mechanisms of actions are further 
explored, which would allow the development of novel and specialized intervention 
methods (cf. Figure 18., Model A2), (2) the issue of sensitivities to the effects of 
cannabis is further explored (cf. Figure 18., Model A3), which would allow to identify 
individuals that are at the highest risk for the adverse effects of cannabis and thereby 
help to develop personalised algorithms that can be implemented in clinical practise and 
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guide clinicians in their decision making, and (3) look at a wider range of outcomes in 
the context of continued cannabis use in FEP patients: 
(1)!First, with regard to the mechanisms by which cannabis increases the risk of 
relapse, this question has not yet been extensively investigated in clinical 
research looking at a brain, genetic or environmental level. For instance, 
from a biological perspective, it has been suggested that cannabis may lead 
to treatment failure of antipsychotic medication and thereby increases the 
risk for relapse (Patel R et al., 2016). Further studies should therefore focus 
on neurotransmission systems implicated in the psychopathology of 
schizophrenia such as dopamine, glutamate and the endocannabinoid system. 
Those findings would contribute to a better understanding of the 
neurobiological basis of cannabis action, which would help developing novel 
pharmacological treatments that aim to reduce cannabis use as well as 
cannabis-induced symptoms in patients with psychosis. There is also a huge 
unmet clinical need for individualised effective psychological treatments for 
patients with psychosis with a comorbid cannabis use disorder, considering 
recent attempts that failed to reduce cannabis use in patients with psychosis 
(Christine Barrowclough et al., 2014; Bonsack et al., 2011; Hjorthøj et al., 
2013). Hence, developing a deeper understanding regarding the reasons and 
motivations for cannabis use may allow the conceptualisation of more 
effective and tailored psychological intervention programs. Although studies 
have attempted to investigate reasons for use in patients with psychosis, in 
which they reported a need for “relaxation”, “feeling high” or “becoming 
intoxicated” as the most commonly reported reasons for use (Pérez-Solá, 
2014), this evidence does not easily lend itself to the development of 
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interventions to reduce/ limit continued cannabis use among patients with 
psychosis. Given the recent technological advances, new methods such as 
ecological momentary assessment techniques such as experience sampling 
method (ESM) may allow the capture of richer longitudinal data in real-time 
during the course of daily life on the state- and context-sensitive 
determinants of cannabis use preferences, experiences and reasons for 
continued cannabis use. The longitudinal assessment of cannabis use in my 
thesis has demonstrated its methodological superiority over cross-sectional 
investigations by looking at within-person differences in addition to 
between-person differences, and the applications of such design in a real-life 
context might have the potential to provide a deeper understanding into the 
mechanisms that may underlie the maintenance of cannabis use in patients 
with psychosis. 
(2)!Second, another important area of future research lies in identifying 
vulnerable individuals to the effects of cannabis in order to better provide 
individualized risk models based on the person’s clinical presentation and/or 
biomarker when presenting to the psychiatric services. This would contribute 
towards refined prediction models within the approach of personalized 
medicine, which should in turn lead to more economic and efficient 
treatment approaches. To illustrate, evidence suggests that (i) the risks 
associated with cannabis use may be higher if consumed during sensitive 
developmental periods (Arseneault et al., 2002; Di Forti et al., 2014; 
Malone, Hill, & Rubino, 2010) in which the brain is likely to be more 
sensitive to environmental insults, (ii) is dependent on the genetic profile of 
the person (S Bhattacharyya et al., 2012; D’Souza et al., 2005; Henquet et 
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al., 2004; Tunbridge et al., 2015; van Winkel, Genetic, & Outcome of 
Psychosis, 2011), and (iii) may show interactive effects with childhood 
adversity and recent life events (Craig Morgan et al., 2014; Murphy, 
Houston, Shevlin, & Adamson, 2013). Therefore, sensitivities to cannabis 
might be present in form of multiplicative (Zammit, Lewis, Dalman, & 
Allebeck, 2010) or synergistic models (Van Os, Rutten, & Poulton, 2008) as 
previously suggested, which has yet to be investigated in prediction models 
looking at relapse and related outcome in first episode psychosis. 
Furthermore, a deeper understanding on pharmacological modulators of 
cannabis action in psychosis is crucial for policy makers and health care 
providers, e.g. regarding the precise effects of changes in frequency of use or 
change in cannabis type (e.g. from skunk-type to hash-type cannabis). 
Especially since the number of countries in which cannabis has been 
legalised or is likely to be legalised in the future has risen, whereby cannabis 
becomes freely available to buy and to sell, questions on regulation issues 
may become more important than issues around criminalisation. Therefore, it 
seems particularly important to provide a deeper understanding on dose-
response relationships (especially the effect of the potency of the cannabis 
consumed) in the context of mental health. Hence, future studies should look 
more in detail on the THC:CBD ratio as a measure of potency of the 
cannabis consumed in  patients with psychosis, e.g. by close monitoring 
using saliva (C. J. Morgan et al., 2010) or hair samples (Hermann et al., 
2007). This would provide a much richer pool of information regarding the 
effect of the potency of the cannabis consumed. Finally, since the 
recreational use of synthetic cannabis has increased in recent years (Wells & 
[235] 
 
Ott, 2011), future studies should also investigate the effects of this cannabis 
product in FEP samples, which was not possible in my thesis due to the 
absence of users that consumed synthetic cannabis. 
(3)!Despite the fact that the data extracted from the clinical records is a reliable 
source for hospitalisation data, which allowed me to look at different but 
related measures of relapse, including number of hospitalisations, length of 
hospitalisation, time until a hospitalisation occurred and intensity care at 
follow up, I did not investigate the effects of changes in cannabis use on 
other mental health outcomes such as changes in cognition, depression, 
anxiety, or functioning – outcomes which have rarely been included in 
longitudinal studies in FEP samples, for which reason current knowledge is 
limited regarding the contributing role of continued cannabis use in this 
context. Considering that I found evidence suggesting that continued 
cannabis use may lead to cognitive impairments (Schoeler & Bhattacharyya, 
2013; Schoeler et al., 2015), mood and affective symptoms (Schoeler et al., 
under review), as well as deviant behaviour (Schoeler, Monk, et al., 2016) 
over the life-span, future longitudinal studies in FEP patients should 
therefore include multiple outcomes in order to compare the effects of 










One of the main strength of my investigation is its design as a follow up study of 
a cohort of patients that were all at the same stage of illness when recruited for 
inclusion, namely their first episode psychosis (therefore untreated with anti-psychotic 
medication for an episode of psychosis, no previous contact with health services for 
psychosis), i.e. this group of patients comprised a homogeneous group with regard to 
treatment history for psychosis. Furthermore, I used a fixed period of precisely two 
years of follow up for all variables of interest, including the relapse and outcome data 
derived from clinical records, as well as all data collected via face-to-face interviews. I 
focused on this early stage following onset of psychosis as this is considered as the 
“critical period” that determines long-term outcome in psychosis (Birchwood et al., 
1997). Using such a design addressed one of the main limitation from previous studies 
looking at cannabis use and relapse, in which patients were at different stages of their 
illness and cannabis using patients differed in their follow up durations from non-users, 
which could have led to bias in the results (Schoeler, Monk, et al., 2016).    
Furthermore, in this study, I used a reliable measure of relapse, defined as 
readmission to hospital. This can be extracted from clinical notes using data on hospital 
admission. Using the WHO life chart, this method has been shown to provide reliable 
results for outcome that is prospectively assessed in schizophrenia (Susser et al., 2000a). 
This relapse definition has been suggested as a valid measure for relapse (D. E. 
Addington et al., 2012), that is universally applicable (Burns, 2007), captures high rates 
of relapse that base on clinical judgement (D. E. Addington, Patten, et al., 2013; 
Almond et al., 2004) and that is comparable to other follow up studies since it remains 
the most commonly employed operationalization (J. F. M. Gleeson et al., 2010).  
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Finally, another important advantage of my study is that information on 
cannabis use as well as other patient data such as medication adherence and other 
substance use was collected via face-to-face interviews (or phone-interviews for a 
subset of patients that could not appear in person), which was further validated by 
screening each patient’s clinical records. With regard to the assessment of cannabis use, 
this approach made it possible classify patients into cannabis use groups based on their 
use patterns following their onset, taking into account parameters such as frequency of 
use, continuation of use, premorbid cannabis use, type of cannabis and changes in 
cannabis over time, which addresses limitation from previous studies that classified 
cannabis users based on relatively crude approximations with regard to ongoing 
cannabis use following the onset of illness. For instance, the non-consideration of 
cannabis use following the onset when looking at relapse may explain some of the 
inconsistencies in those studies that assessed cannabis use only at onset or looked only 
at lifetime cannabis use and outcome in FEP (Batalla et al., 2013b; Kivimies et al., 
2016; Koenders et al., 2014; Lenior et al., 2005; Manrique-Garcia et al., 2014c; Patel R 
et al., 2016) . Other studies relied on clinical register based information only, which 
hinder to extract a more detailed account of cannabis use patterns (Manrique-Garcia et 
al., 2014b; Patel R et al., 2016; Grant E Sara, Philip M Burgess, Gin S Malhi, Harvey A 
Whiteford, & Wayne C Hall, 2014a).  Although my approach comprises the limitation 
that refuser are not included in the follow up sample, I was thereby able to collect data 
on other time-varying information. Hence, given the large pool of collected covariates, I 
was able to control for a comprehensive amount of confounders that were previously 
not collectively considered in follow up studies exploring the relationship between 
cannabis use and outcome in FEP. The number of variables included in my analysis, as 
well as the fine-grained classification of the different cannabis groups was only possible 
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due to the large sample size of the study, which is one of the largest follow up studies in 




























It has been highlighted that threat to causality is the problem of bias (e.g. with 
measurements and/or sample selection), which could lead to incorrect estimates in risk 
prediction models (Suzanne H. Gage et al., 2016). First, the sample followed up 
comprised patients with a first episode psychosis presenting for the first time to 
psychiatric services in south London. Since most the patients included were admitted to 
hospital around the time of onset (78%), out of which about 60% required admission 
under section, the majority of the sample comprised individuals that are more likely to 
suffer from an acute/severe form of their first episode compared to those who were only 
referred to the community mental health teams or home treatment teams (22% of the 
sample). Furthermore, relapse was defined as admission to hospital, which captures 
only the more severe relapse episodes rather than exacerbations that can be managed 
within the community. Nevertheless, the use of rating scales may result in too inclusive 
criteria, leading to over-estimation and non-comparability of relapse rates reported by 
the studies (Suzuki et al., 2014). Furthermore, all patients were well enough to complete 
the baseline assessment around the time of their onset and to take part in a face-to-face 
or telephone interview at follow up. Another issue may lie in the fact that the date of 
first presentation to the psychiatric services for psychotic symptoms does not necessary 
reflect the onset of first symptoms and, hence, duration of untreated psychosis (DUP) 
could have affected the results. Although I did not control for DUP psychosis in my 
multiple prediction models (Paper 2), the within-subject analysis (Paper 3), in which 
premorbid confounding factors were controlled for did not indicate that this factor acted 
as a confounder that would explain the association between continued cannabis use and 
risk of relapse. Independent evidence is also not indicative that DUP is a significant risk 
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factor for relapse (D. Addington et al., 2010; Caseiro et al., 2012; T. J. Craig et al., 
2000; Levy et al., 2012; Tarricone et al., 2014; Üçok et al., 2006). Finally, as in any 
longitudinal study, I cannot rule out that this sample may comprise a selective subset of 
inner city first episode patients, which may limit its generalizability to services in more 
rural areas or areas outside of the UK. However, the rate of hospitalisation due to 
psychotic relapse in my sample (37% within two years following onset) is comparable 
when compared to hospitalisation data reported by other two-year follow up studies, 
including Canada (33% relapsed) (D. Addington et al., 2010), China (33% relapsed) (E. 
Y.-H. Chen et al., 2005), Denmark (39% relapsed) (Bertelsen et al., 2009) and US (56%  
relapsed) (T. J. Craig et al., 2000). 
As another limitation inherent to follow up studies in such populations, a 
proportion of patients refused to take part in follow up assessments (n=117), which 
could have biased the results if the relationship between cannabis use and relapse was 
dependent upon being a refuser or a participant, i.e. I cannot rule out the possibility that 
follow up data on cannabis use and relapse outcome was missing not at random 
(MNAR). However, I investigated whether being a participant (Completer) or not 
(Refuser) may have affected the relationship between cannabis use prior to the onset of 
psychosis and relapse. Data on relapse was collected for those who refused by 
extracting this information from their clinical notes. The results indicate that the risks of 
relapse were comparable in cannabis users across the two groups (Completers and 
Refusers). Furthermore, I compared those who participated in the follow-up with those 
who refused on several baseline measures, including premorbid cannabis use, age of 
onset of psychosis, ethnicity and gender, which revealed that there were no significant 
differences. Furthermore, the potential limitation of bias due to refusal may not be an 
issue in the fixed-effects analysis employed Paper 2, in which individuals where used 
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as their own controls (period of exposure vs. period of non-exposure), whereby all 
premorbid existing group differences were controlled for.  
Finally, it might be criticized that I included a heterogeneous group of patients 
that comprised all psychotic diagnoses, including affective and non-affective psychosis. 
Nevertheless, my thesis aimed to investigate the effect of cannabis use on risk of relapse 
regardless of the categorical diagnosis. Furthermore, the factor diagnosis (affective vs. 
non-affective) was not significantly linked to relapse, nor was it significantly linked to 
the different classifications of cannabis use, implicating that differences in diagnosis are 
unlikely to play a role in this association. This is in line with previous evidence that did 
not report an association between type of diagnosis and risk of relapse (Bergé et al., 
2016; Levy et al., 2012; Tarricone et al., 2014) or a link between type of diagnosis and 
cannabis use in patients with psychosis (Baeza et al., 2009; Elkins, 2004; B. 
Schimmelmann et al., 2012). 
 
Issues regarding the retrospective assessment of relapse-predictors 
Some limitations need to be outlined that refer to the nature of the retrospective 
nature of the assessments, as it was done to gather information on cannabis use patterns 
within the two years following the onset. Although this may have resulted in recall bias 
due to memory problems, my cannabis data is not indicative of this. For instance, to 
assess the reliability of the retrospective assessment of cannabis use, I compared data 
for n=207 subjects on premorbid cannabis use (ever used before onset) collected at 
onset of psychosis with data on premorbid cannabis use reported at follow up. In 92.8% 
of those compared, reporting of premorbid cannabis use was consistent across both 
assessments (i.e., at onset and at follow-up); 4.8 % those who denied premorbid use 
when assessed at the onset of psychosis admitted it when re-examined at the follow up 
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assessment, while 2.4% denied pre-morbid cannabis use at follow-up assessment 
although they had admitted use when assessed at onset. Furthermore, questions about 
cannabis use were asked in a face-to-face interview (telephone) instead of a self-
completion of questionnaires. I also chose a categorical approach in which cannabis 
users were grouped based on broader categories (e.g. by asking “Did you use cannabis 
at least once in each of the 24 months following the onset?” to classify a person as a 
continued user) rather using continuous (numerical) measures such as the cumulative 
number of joints smoked within the two years following the onset, which might be more 
susceptible to recall bias. Alternatively, it might be argued that cannabis use was 
underreported. However, interviews were conducted in research facilities and not within 
the clinical setting, while reinsuring the patient that this data was anonymized and only 
used for research purposes, for which reason patients may be more open to admit to 
their cannabis use. For instance, comparing the rates of self-reported cannabis use with 
the results from urine drug screens revealed a high overlap (94%) in previous 
investigations (Di Forti et al., 2014). Another potential limitation may lie within the 
assessment of type of cannabis, in which case I relied fully on information reported by 
the patients in order to separate “high-potency” (skunk-type) cannabis users from “low-
potency” (hash-type) cannabis users, instead of using more biological measures such as 
the THC:CBD ratio derived from saliva (C. J. Morgan et al., 2010) or hair samples 
(Hermann et al., 2007). Nevertheless, the grouping of “skunk-type” and “hash-type” 
was done according to the characteristics of the cannabis samples collected by the 
Police in South East London, in which skunk-type was found have an average of 17% 
THC (and virtually no CBC), compared with 4% THC present in hash-type cannabis 
(Potter et al., 2008). 
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It is also important to mention that medication adherence was assessed using 
rather crude measures by rating a patient’s adherence as either full, partial or non-
adherent within the two years following the onset, based on their average range of 
percentage of missed appointments. In this context, it would be more informative to 
have close regular monitoring that would allow the inclusion of a more fine-grained 
measure of adherence, e.g. in form of the quantitative dosage of antipsychotic 
medication that was missed. Furthermore, based on my classification of medication 
adherence, it cannot be concluded as to whether medication non-adherence was a 
preceding factor prior to cannabis use/relapse or an event that followed cannabis 
use/relapse. Nevertheless, the scope of my thesis was not the systematic evaluation of 
the causal (temporal) effects of medication non-adherence as a risk factor for 
relapse/cannabis use, but mainly to control for its effects within the cannabis-relapse 
prediction model, which I have done in my analyses. 
 
Issues regarding uncontrolled sources of confounding 
First, while the effects of time-invariant sources of confounding was not be an 
issue in Paper 3, in which all premorbid sources of cofounding were controlled for, 
time-varying factors such as changes in the environment (e.g. life events), post-onset 
genetic changes (e.g. epigenetics) or changes in the treatment of antipsychotic 
medication could still have affected the results. However, this seems unlikely to be the 
case; With regard to life events, there evidence that cannabis remained a significant 
predictor for psychotic experiences (Craig Morgan et al., 2014) when controlled for this 
factor. In fact, evidence is more in favour of interactive effects of life-stress and 
cannabis use on psychotic symptoms rather than a confounding effect (Craig Morgan et 
al., 2014). Although it is important to be aware of epigenetic phenomena in this context, 
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this factor may not play a crucial role in my prediction models, since my outcome was 
defined as relapse within the first two years of the illness – a relatively short period in 
which environmental induced changes in an individual’s genetic expression may not be 
strong enough to have an impact on outcome. Although change in medication is 
common following onset [e.g. mean number of antipsychotic medications prescribed 
following the onset was reported to be ~1.90 within the first two years of illness (Patel 
R et al., 2016)], there is little evidence to suggest that there are differences in efficacy 
between individual antipsychotic medications with regard to relapse prevention (Stefan 
Leucht et al., 2003).  
Second, one limitation comprised by Paper 2 is that some additional plausible 
confounding factors were not included in my prediction models. For instance, other 
relevant factors may include level of (premorbid) IQ, history of childhood adversity, 
duration of untreated psychosis and a more detailed assessment of dose-response 
relationships for different types of illicit drugs as well as for cigarette and alcohol use. 
However, those factors are most likely to contribute within an environment x 
environment interaction with cannabis use (cf. Model A3, Figure 18. above) rather than 
as full confounders. For instance, interactive effects with cannabis in predicting 
psychotic experiences have been reported with regard to childhood adversity and trauma 
(Craig Morgan et al., 2014; Murphy et al., 2013) and frequency of other illicit drug use 
(McKetin et al., 2013). In this context, little evidence is in support of a non-causal link 
between cannabis use and psychosis due to non-adjustment of those factors, which is 
indicated by studies that found that the association between cannabis and emergence of 
psychotic experiences or exacerbation of psychotic symptoms persisted when controlled 
for premorbid IQ (David M Fergusson et al., 2005), childhood adversity (Henquet et al., 
2004; Craig Morgan et al., 2014), frequency of other illicit drug use (Di Forti et al., 
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2014; David M Fergusson et al., 2005; Foti et al., 2010; Henquet et al., 2004) and 
frequency of cigarette use (Di Forti et al., 2014; David M Fergusson et al., 2005), as 
well as duration of untreated psychosis (Sorbara et al., 2003). Hence, the exclusion of 
those factors in the risk prediction models is unlikely to have affected the results. 
 
Issues in the statistical reporting 
First, it might be criticized that I did not report Bonferroni-corrected p-values in 
the multiple analysis carries out in Paper 2, in which 5 different prediction models were 
evaluated. However, there are potential issues associated with the indiscriminate use of 
Bonferroni-correction (Perneger, 1998), for which reason the choice of whether or not 
to make corrections for multiplicity is best decided according to the importance of the 
threat of type 1 or type 2 errors in the current investigation. In the present investigation, 
it seems that a type 2 error (accepting the null hypothesis although continued cannabis 
use is associated with a greater risk of relapse of psychosis compared to non-use) is of 
greater concern than type 1 error, as it would lead to clinicians ignoring the potential of 
harmful consequences from cannabis use for patients with psychosis. Committing type 
1 error (rejecting the null hypothesis although the risk of relapse of psychosis is not 
different between continued users of cannabis and non-users) seems to be less 
problematic in this context, as it would not necessarily have an adverse impact on 
illness course of psychosis patients using cannabis. 
Second, when evaluating the effect of different types of cannabis (skunk-type vs. 
hash-type), few subjects (n=8) in the continued hash(resin)-user group may have 
undermined our ability to detect harm related to ongoing hash use. Nevertheless, a 
similar finding was also reported in a case-control study, which did not find an 
increased risk of onset of psychosis linked to the use of hash-type cannabis (Di Forti, 
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Marconi, et al., 2015). Finally, I was unable to separately investigate those who started 
using cannabis following the onset of psychosis but had no history of premorbid regular 
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Evidence regarding the association between cannabis use and depression remain 
conflicting, especially as studies have not typically adopted a longitudinal design with a 
follow-up period that was long enough to adequately cover the risk period for onset of 




Males from the Cambridge Study in Delinquent Development (CSDD) (N=285) were 
assessed 7 times from age 8 to 48 years to prospectively investigate the association 
between cannabis use and risk of Major Depressive Disorder (MDD). A combination of 
multiple analyses (logistic regression, Cox regression, fixed-effects analysis) was 




Multiple regression revealed that early onset cannabis use (before age 18) but not late 
onset cannabis use (after age 27) was associated with a higher risk and shorter time until 
a subsequent MDD diagnosis. This effect was present in high-frequency ([Odds Ratio 
(OR) 8.84, 95% Confidence Interval (CI) 1.32-69.27]; [Hazard Ratio (HR) 7.66, 95%CI 
1.83-32.07]) and low-frequency early-onset users ([OR 2.55, 95%CI 1.30-4.99]; [HR 
2.22, 95%CI 1.24-3.97]). Effect of increased frequency of cannabis use on increased 
risk of subsequent MDD was observed only for use during adolescence (age 14-18) but 
not at later life stages, while controlling for observed and non-unobserved time-
invariant factors. Conversely, MDD in adulthood (age 18-32) was linked to a reduction 
in subsequent cannabis use (age 32-48). 
 
Interpretation 
The present findings provide evidence supporting a causal association between frequent 
cannabis use during adolescence and risk of later life depression.  
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8.2.1 INFORMATION AND CONSENT FORM 
Information and Consent Form (not for data entry)       
You have been asked to take part in a study being conducted in the South London 
and Maudsley NHS Trust. Before you decide whether to enter the study, it is 
important that you understand why the research is being done and what it will 
involve. Please take time to read the following information and ask any questions if 
something is not clear or you wish to know more. 
TITLE OF PROJECT: GENETICS AND PSYCHIATRIC ILLNESS (GAP) 
What are the aims of the study? 
In our research project we are interested in identifying what the main risk factors that predispose to 
psychosis are. In particular, we want to know whether there are any genes that increase the risk of 
developing a psychotic disorder, either alone or by interacting with environmental factors such as stress, 
cannabis, and infections. Part of the reason why some people become ill may lay in genetic differences 
between people, in the same way that we are different in the colour of our eyes, hair etc. To achieve 
this, we will compare the genetic make-up of people with a diagnosis of psychosis with the make-up of 
people with similar characteristics but no history of mental health problems. 
We also aim to establish whether some genes might influence the course of the illness and response to 
medication. Some patients experience an improvement of their psychiatric symptoms when they are 
treated with medications, whereas others do not do so well and/or experience severe side-effects. 
Therefore we aim to look at how genes can influence individual differences in response to drug 
treatment so that we may be able to choose better drugs for each person. The type of genetic analysis 
that we carry out is only for research purposes and does not at present produce clinically relevant 
results. 
Finally, an additional aim of the study is to understand how the social environment may contribute to 
the onset of illness and the illness experience. 
Why are we asking for your help? 
You have been invited to take part in this study because of the nature of the symptoms that you appear 
to have been experiencing. During the course of the study approximately 1000 people who have had 
symptoms like yours will be asked to take part. 
Note that a patient does not have to be involved in the GAP project research and, if they decide not to 
take part, it will not affect their current or future medical care in any way. 
What will we ask of you if you take part in the study? 
For this project we will ask from you a small sample of blood, about 20 mL (a few tablespoons full) or 
cheek swab and saliva samples for metabolic and genetic analysis. We may also use your blood and saliva 
sample to: 
1)! Measure the level of hormones and proteins contained in the blood serum and in the saliva. 
2)! Look at the expression of some genes of interest in the white cells contained in the blood. 
 
A medically trained researcher will take the blood sample using disposable sterile equipment. It will only 
take few minutes as for any routine blood sample. If you are unable or unwilling to give a blood sample 
it is also possible to perform genetic analysis from cheek swab samples, a simple procedure that (we can 
show you the kit and illustrate the procedure) collects dead cells present in your saliva and in your 
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mouth. From the cheek swab sample we cannot measure level of medication or look at expression of 
genes, we can only extract a small amount of DNA. Therefore we prefer to ask for a blood sample to 
guarantee a better quality of our results and make the most out of your generous help. 
A researcher will demonstrate how to collect the saliva sample and will provide you with the tubes 
required. The level of some proteins contained in the saliva can give us an indication of differences in the 
level of stress experienced by healthy volunteers and people suffering from mental illnesses. 
We will also ask for some of your time to collect clinical and socio-demographic information using 
standardised research instruments: diagnostic interview, symptoms rating scale, socio-demographic 
interview and neuropsychological tests. We may also ask you to participate in an interview asking about 
your own perspectives on your social environment and your health condition. 
If you have already taken part in other research projects at the Institute of Psychiatry, London that 
involved some of the assessment we are interested in, we will not ask you to undergo them again but 
we request your permission to use the existing data. 
Some people within the study will be invited to undergo an MRI scan of the head and of another region 
of the body (the adrenal gland, a small gland above the kidney).They will be presented with separate 
information and consent forms for this procedure. 
The sample collection and the clinical assessment will require approximately 3 hours of your time. 
Moreover we would like to contact you again for follow up (up to 24 months) to repeat the above 
assessments to investigate changes over time. We will also reimburse any travel expense related to your 
participation into the study. 
We will also ask for your consent to contact your GP, mother (or father) and a sibling.  This is 1) to 
collect information from your GP records and mother about events that may have occurred very early 
in your life, such as complications during pregnancy and neonatal infections, 2) to conduct some of the 
same assessments with your sibling that we have conducted with you, and 3) to ask your sibling similar 
questions that we have asked you about the environment in which you both grew up and experiences 
you may have had in childhood. We will only contact your GP and/or relative(s) with your explicit 
consent and we will not disclose any information we have collected from you to them.  If you agree for 
us to contact your mother (or father) and/or a sibling, we will only proceed to interview them if they 
provide consent.  
What are the risks? 
The risks involved are those of ordinary blood tests such as small pain and occasionally a small bruise 
around the area from where the sample has been taken. There is no risk involved in the collection of 
saliva. 
Is Confidentiality guaranteed? 
All personal information about you is regarded as strictly confidential; only researchers belonging to the 
study team, and not external collaborators, know which sample belongs to whom. All the information 
about you will be coded; you will not be identifiable in any research outcome. 
 
1)! The blood samples first and the DNA samples after extraction will be stored in the Institute of 
Psychiatry secured laboratory until reporting is complete. 
2)! The samples will be coded using bar codes (numbers and letters not referring to your name or date 
of birth) that will be entered on a secure computerized data base. 




4)! Nothing that you have told us will be mentioned to any relative you might give us permission to 
contact.  
 
The access to the samples and the related information will be restricted to the researchers involved in 
the study. In case of commercial collaborations only the coded data will be shared, therefore no 
researcher external to the study team will ever have access to personal data concerning participants. 
Any future work will pursue aims related to the topic of this project and any extension of the project 
beyond 5 years, will be subject to review by a research ethics committee. You are free to withdraw 
from this study at any point without giving a reason by contacting the researcher whose details are at 
bottom of the consent form. Withdrawal will not affect any of the care and treatment you receive. 
What are the benefits for you of taking part? 
This is a research project, looking at comparing a group of healthy volunteers with people experiencing 
their first psychotic episode. As mentioned before, this study will not produce individual test results for 
any of the data collected. Therefore we cannot offer direct benefits for you. We will be able to provide 
all participants with a general summary of our research, when the project is complete, through a project 
newsletter. Our research study is also described on the Institute of Psychiatry general website 
(www.iop.kcl.ac.uk), under the Department of Psychosis Studies section.  
Who is funding this project? 
This study is funded by the The Maudsley Charitable Fund, the Department of Health, the Wellcome 
Trust and the European Union.  Thank you very much for your time and once again please ask 
for more information on both the project and/or your illness/symptoms if it is still unclear. 
 
 
Contact details for research team: 
!
Dr Marta Di Forti 
Institute of Psychiatry 












If you have come to the decision to enter the study after carefully considering the 
information provided, please read and sign this form. 
!
TITLE OF PROJECT: GENETICS AND PSYCHIATRIC ILLNESS (GAP) 




the!opportunity! to!ask!questions.! I! understand!why! the! research! is! being!
done!and!the!risks!involved.!
!Yes!!!!!!!No 
 !   ! 
2)! I! agree! to! give! a! sample! of! blood/cheek! swab! and! saliva! samples! for!
research!in!the!above!project.!I!understand!how!the!sample!will!be!collected,!
that!giving!the!sample!is!voluntary!and!that!I!am!free!to!withdraw!at!any!time!




 !  ! 
3)! I!understand! that! research!using! the!sample! I!give!will! involve!genetic!
analysis!aimed!at!understanding!the!role!of!genes! in!disease!and!response!
to! drugs,! that! the! data! produced! are! for! research! rather! than! clinical!
purposes,!and!that!these!results!will!have!no!implications!for!me!personally.!
!Yes!!!!!!!!!No!
 !  ! 
4)! I!understand!I!will!not!receive!any!'test'!results!from!this!study,!because!
the!assessment!I!will!undergo,!does!not!produce!clinically!relevant!information!
but! just! research! data.! The! project! newsletter! will! describe! the! general!
importance!of!any!research!results!obtained.!
!Yes!!!!!!!!!No!
 !  ! 
5)! I!give!permission!for!my!previous!research!records!to!be!looked!at,!and!
information! from! them! to! be! analysed! in! strict! confidence! by!




 !  ! 
6)! I!agree!that!the!samples!I!have!given!and!the!information!gathered!about!
me! can! be! examined! and! stored! until! reporting! is! complete! at! the!
Institute!of!Psychiatry.!I!understand!that!future!authorised!research!may!be!
performed! by! researchers! other! than! those!who! conducted! the! first! project,!
including! researchers! from! commercial! organisations.! To! guarantee!
confidentiality,! I!agree! that! researchers!external! to! the!study! team,! including!
those!from!commercial!collaborators,!will!only!have!access!to!coded!data!and!




 !  ! 
7)! I!consent!to!the!input!of!coded!data!obtained!from!my!blood!sample!and!
from!the!information!gathered!about!me!into!a!computer,!to!be!used!for!
statistical! analysis! and! research.! I!understand! I!have! the!right! to! request,!
via! the! study!coJordinator,! to! review!data! concerning!me,!and! to!have!such!
data!modified!if!inaccurate,!or!deleted.!
!Yes!!!!!!!!!No!
 !  ! 
8)! I! consent! to! participate! in! a! digitallyArecorded! interview! about!my! own!




 !  ! 
9)! I understand I will not benefit financially if this research leads to the 
development of a new treatment of medical test but my travel expenses will be 
reimbursed.   
!Yes!!!!!!!!!No!
 !  ! 
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10)!I give permission for my GP records to be looked at.  !Yes!!!!!!!!!No!
 !  ! 
11)!I agree to my mother being approached to participate in this study. !Yes!!!!!!!!!No!






Phone Number  
 
12)!I agree to a sibling being approached to participate in this study. !Yes!!!!!!!!!No!























Contact details for research team: 
!
Dr Marta Di Forti 
Institute of Psychiatry 





8.2.2 CANNABIS-EXPERIENCE QUESTIONNAIRE (CEQ, MODIFIED VERSION) 
 
1.! Have you ever smoked cannabis? 
O1 Yes 
O0 No  
 
2.! If yes, how old were you when you first tried cannabis? ______ years 




Quantity prior onset 
Total number of joints smoked prior to onset:  ________ 
Total number of days cannabis used prior to onset:  ________ 
 
3.! Why did you first try cannabis? (You can tick more than one box) 
Yes  No 
My friends were using it    O  O 
My family members were using it   O  O 
To feel better (to get relief from    O  O 
either physical or psychological discomfort)  
Other, specify___________________________ O  O
  
 
4.! Have you ever had a period in which you smoked cannabis regularly (i.e. at 
least once per month)? 
O1 Yes (period lasted for about _______O weeks O months O years) 
O0 No  
 
5.! If yes, how old were you when you started using cannabis regularly (> 
1/month)? 
__________ years 
Pease rate: Did subject use cannabis regularly before the onset of illness: 
O1 Yes  
O0 No 
 




 If yes, why did you continue using cannabis? (You can tick more than one box) 
Yes  No 
I like the effect, it gives me a buzz   O  O 
It makes me feel relaxed    O  O 
It makes me feel less nervous and anxious  O  O 
It makes me feel more sociable   O  O  




If yes, how many grams of cannabis do you usually buy (for yourself):_____ 
grams 
If yes, how many grams of cannabis are on average contained in   
your primary delivery method (e.g. cones/joints/pipes): _____ grams 
If yes, how long does this amount of cannabis last for: _____ days 
If yes, how long does 1/8th of cannabis last you?   _____ days 
 
 
 If no, at what age did you stop using cannabis regularly? ___________ 
 Please state the reason why you stopped:_______________________________ 
If past user, did the participant stop using cannabis regularly (> once per 
months) before or after the onset. 
  O1 Before (stopped_____ O weeks O months  O years before onset) 
  O2 After (stopped _____ O weeks O months  O years  after onset) 
  O3  Continued use 
  O4  N/A never regular user since onset 
 
 When was the last time that you consumed cannabis:____________ days ago 
 
7.! Would you like to stop using cannabis one day? 




8.! Does/did cannabis affect your health in any way? 








10.!How did/do you mostly use cannabis? 
O1  I smoke/smoked it in a joint with tobacco  
O2  I smoke/smoked it in a joint without tobacco  
O3  I smoke/smoked it using a bong 
O4  I eat/ate or drink/drunk it 
11.!Relapse and cannabis? 
Following your first episode, did you have a readmission to hospital/contact 
with HTT while you were a regular cannabis user (i.e. cannabis use at least 
once per month)? 
 O1 Yes 
 O2 No 
 O3 N/A as not used at all or no regular use after onset 
 
12.!Duration of regular cannabis use throughout follow up in percentage 
Note: In cases of shared cannabis, divide the weight by the number of people it is shared with! 
[311] 
 
O 1 Continued/started regular cannabis use throughout follow up (use = 100% of 
the time) 
O 2 Infrequent regular cannabis use throughout FU (use = min. 60% of the time) 
O 3 Infrequent regular cannabis use throughout FU (use = min. 30% of the time) 
O 4 Stopped shortly after onset and remained abstinent from cannabis (use < 
10% of the time) 
O 5 Never regular user since onset 
Cannabis history since onset of illness [prior to onset] 
1.! Since onset of illness [now/in the past], how often do/did you use cannabis? 
O0 No use 
O1 Every day      
O2 More than once a week     
O3 At least once per month     
O4 A few times a year     
O5 Only once or twice 
Quantity of cannabis use (specify the number of joints smoked per occasion, 
e.g. 1 joint a few times a month) 
  O1  < 1 joint    
O2  1 joint 
O3 2 or 3 joints 






2.! Since onset of illness [now/in the past], when do/did you mostly use 
cannabis? 
O1  At weekends 
O2  During the day 
O3  During the evening 
O4  During the day and evening 
 
 
3.! Since onset of illness [now/in the past] , do you/did you mostly use cannabis: 
O 1 Socially 
O 2 On your own 
O 3 Both 
 
4.! Since onset of illness [now/in the past], how much money per week do/did 
you usually spend on cannabis? 
O 1  less than £2.50     O 4  £11 - £15 
O 2  £2.50 - £5     O 5  £16 - £20 
O 3  £6 - £10     O 6  above £20 
 
5.! Since onset of illness [now/in the past], what type of cannabis do/did you 
mostly use? 
O1 Hash (cannabis resin/solid) 
[312] 
 
O2 Imported herbal cannabis 
O3 Home grown skunk/Sensimilla 
O4 Super skunk 
O5 Synthetic cannabis 
O6 Other (please state): ____________________________ 
 
6.! Quantity since onset 
Total number of joints smoked since onset:   ________ 











































Drug Use History 
Please give participant prompt sheet and read out following instruction:  
“Please have a look at the list I handed to you and indicate which drugs you have used 












Tobacco    
Alcohol    
MDMA or ecstasy    
Cocaine    
Crack cocaine    
Khat or betel nut    
Heroin    
Morphine    
Codeine    
Opium    
LSD    
Mescaline    
Magic mushrooms    
Salvia    
Valium or diazepam    
Temazepam    
Lorazepam    
Glue    
Poppers    
Petrol    
Laughing gas    
Tuinal    
Legal highs    



















1 Year Follow Up Data 
 
Cannabis between onset and 1 year follow up 
 
Cannabis patterns   O0 No use (or only once/twice) 
    O1  Intermitted use 
    O2 Continued use (min 100% of time regular use) 
 
Percentage of use  O0 0%   
O1 1%-25%  
O2  26%-50% (at least regular use)  
 O3 51%-75%  
O4  76%-100% 
 
Cannabis frequency   O0 No use  
O1 Every day      
O2 More than once a week   
  
O3 At least once per month   
  
O4 A few times a year     
O5 Only once or twice 
 






Number of joints per occasion O1  < 1 joint    
O2  1 joint 
O3 2 or 3 joints 




















1 to 2 Year Follow Up Data 
 
Cannabis between 1 year follow up and 2 year follow up 
 
Cannabis patterns   O0 No use (or only once/twice) 
    O1  Intermitted use 
    O2 Continued use (min 100% of time regular use) 
 
Percentage of use  O0 0%   
O1 1%-25%  
O2  26%-50% (at least regular use)  
 O3 51%-75%  
O4  76%-100% 
 
Cannabis frequency   O0 No use  
O1 Every day      
O2 More than once a week   
O3 At least once per month  
O4 A few times a year     
O5 Only once or twice 
 




Number of joints per occasion O1  < 1 joint    
O2  1 joint 
O3 2 or 3 joints 
























2 Year Follow Up Data - Summary:  
 
Cannabis between onset and 2 year follow up 
 
Cannabis patterns   O0 No use (or only once/twice) 
    O1  Intermitted use 
    O2 Continued use (min 100% of time regular use) 
 
Percentage of use  O0 0%   
O1 1%-25%  
O2  26%-50% (at least regular use)  
 O3 51%-75%  
O4  76%-100% 
 
Cannabis frequency   O0 No use  
O1 Every day      
O2 More than once a week   
O3 At least once per month   
O4 A few times a year     
O5 Only once or twice 
 






Number of joints per occasion O1  < 1 joint    
O2  1 joint 
O3 2 or 3 joints 






















Other drug use between onset and 2 year follow up 
 
Cigarette daily   O0 No (<10%)    
O1 Intermitted (10%-50%)  
O2 Continued (>50%) 
 
Cigarette weekly     O0 No (<10%)    
O1 Intermitted (10%-50%)  
O2 Continued (>50%) 
         
         
Alcohol daily    O0 No (<1 months daily)  
O1 Daily (> 1 month daily)  
 
Alcohol weekly         O0 No (<10%)  
    O1 Intermitted (10%-50%) 
O2 Continued (>50%) 
 
Cocaine    O0 No use    
    O1 Experimental (1-5 times)    
O2 Regular use (>6 times)  
 
Amphetamines   O0 No use    
    O1 Experimental (1-5 times)    
O2 Regular use (>6 times) 
 
Hallucinogens   O0 No use    
    O1 Experimental (1-5 times)    
O2 Regular use (>6 times) 
 
Opioids    O0 No use 
O1 Experimental (1-5 times)    
O2 Regular use (>6 times) 
 
Ketamine   O0 No use    
O1 Experimental (1-5 times)    
O2 Regular use (>6 times) 
 
Poppers    O0 No use 
O1 Experimental (1-5 times)    










8.2.3 SERVICE USE AT ONSET: WHO LIFE CHART (MODIFIED VERSION) 
 
Onset of psychosis: ADMISSON to Hospital    
 
 
Date of Admission …………/…………/………. 
 
Date of Discharge …………/………/…………..  
 
 
Ward Type:   O 0 Acute 
    O 1 Rehabilitation 
     O 2 Secure/Forensic 
 O 3 Other, specify: 
______________________________ 
 
MHA Status: Section of Mental Health Act used – ON ADMISSION 
O 1 Section 2  O 6  Section 37  
O 2  Section 3  O 7  Section 37/41   
O 3 Section 4  O 8  Section 47 
O 4 Section 5 (2)  O 9  Section 48 
O 5  Section 5 (4)  O 10 Section 136 
    O 11 Informal 
 
MHA Status: Section of Mental Health Act used – ONCE ADMITTED 
O 1 Section 2  O 6  Section 37 
O 2  Section 3  O 7  Section 37/41   
O 3 Section 4  O 8  Section 47 
O 4 Section 5 (2)  O 9  Section 48 
O 5  Section 5 (4)  O 10 Section 136 
    O 11 Informal 
 
Source of Referral: What was the source of referral resulting in hospital 
admission?   
O 1  Psychiatrist or    O 4  Accident and Emergency 
other mental health professional  O 5 Emergency Clinic 
O 2  General practitioner    O 6  Police 
O 3   Nurse, other health worker   O 7  Courts/Prison 
or social worker    O 8 Other, specify:___________ 
 
Reason for Admission: What were the main reasons for admission? 
a)! Attempted suicide or bodily harm  O 0 No  O 1 Yes 
b)! Behaviour perceived as potential danger to himself (e.g., talked of killing or 
harming himself; refusal of food, etc.)   O 0 No O 1 Yes 
c)! Patient committed an assault, or other violent or hazardous act (e.g., setting 
fire or destroying property)    O 0 No O 1 Yes 
d)! Behaviour perceived by others as threatening or grossly annoying 
O 0 No O 1 Yes 
e)! Deterioration in mental health       
O 0 No O 1 Yes 
[319] 
 
f)! Other reason,      O 0 No O 1 Yes 
specify:______________________________________________________ 
 
Family Involvement: Were the patient’s family or friends involved in seeking 
help that resulted in hospital admission?  
O 0 No    O 1 Yes  
 
Police or CJA Involvement: Were the police or any other criminal justice 
agency involved in bringing about hospital admission?    
O 0 No    O 1 Yes  
 
































8.2.4 RELAPSE ASSESSMENT: WHO LIFE CHART (MODIFIED VERSION) 
 
Relapse Questionnaire (RQ) – Relapse No. ____ 
Have you had a relapse of your illness? 
        
O 1 Yes       
Defined as (pick one or both) 
O Re-admission to psychiatric hospital    
O Contact with home treatment team (HTT)  
 
Type of admission: 
O1 Involuntary     
O2 Voluntary   
   
Treatment of relapse (pick one or more) 
   O Drugs (specify: ____________________________) 
   O Other biological treatment  
     (specify: ____________________________) 
   O Psychosocial treatment   
(specify: ____________________________) 
   O Other     
(specify: ____________________________) 
 

























Relapse No. _____: ADMISSON to Hospital    
 
 
Date of Admission …………/…………/………. 
 
Date of Discharge …………/………/…………..  
 
 
Ward Type:   O 0 Acute 
    O 1 Rehabilitation 
     O 2 Secure/Forensic 
 O 3 Other, specify: 
______________________________ 
 
MHA Status: Section of Mental Health Act used – ON ADMISSION 
O 1 Section 2  O 6  Section 37  
O 2  Section 3  O 7  Section 37/41   
O 3 Section 4  O 8  Section 47 
O 4 Section 5 (2)  O 9  Section 48 
O 5  Section 5 (4)  O 10 Section 136 
    O 11 Informal 
 
MHA Status: Section of Mental Health Act used – ONCE ADMITTED 
O 1 Section 2  O 6  Section 37 
O 2  Section 3  O 7  Section 37/41   
O 3 Section 4  O 8  Section 47 
O 4 Section 5 (2)  O 9  Section 48 
O 5  Section 5 (4)  O 10 Section 136 
    O 11 Informal 
 
Source of Referral: What was the source of referral resulting in hospital 
admission?   
O 1  Psychiatrist or    O 4  Accident and Emergency 
other mental health professional  O 5 Emergency Clinic 
O 2  General practitioner    O 6  Police 
O 3   Nurse, other health worker   O 7  Courts/Prison 
or social worker    O 8 Other, specify:___________ 
 
Reason for Admission: What were the main reasons for admission? 
g)! Attempted suicide or bodily harm  O 0 No  O 1 Yes 
h)! Behaviour perceived as potential danger to himself (e.g., talked of killing or 
harming himself; refusal of food, etc.)   O 0 No O 1 Yes 
i)! Patient committed an assault, or other violent or hazardous act (e.g., setting 
fire or destroying property)    O 0 No O 1 Yes 
j)! Behaviour perceived by others as threatening or grossly annoying 
O 0 No O 1 Yes 
k)! Deterioration in mental health       
O 0 No O 1 Yes 





Family Involvement: Were the patient’s family or friends involved in seeking 
help that resulted in hospital admission?  
O 0 No    O 1 Yes  
 
Police or CJA Involvement: Were the police or any other criminal justice 
agency involved in bringing about hospital admission?    
O 0 No    O 1 Yes  
 











































Relapse Events (RE): Events around RELAPSE  No. ______  
 
1.! Where you using cannabis around the time of relapse (i.e. up to 4 weeks 
before relapse)?      O1Yes             O0 No (if No - go to question 4) 
O 2 Uncertain (Reason: 
_________________________________________________) 
 
Money per week spent on cannabis? 
O 1 less than £2.50    O 4 £11 - £15 
O 2 £2.50 - £5    O 5 £16 - £20 
O 3 £6 - £10    O 6 Above £20 
 
2.! How often?      Number of joints  
        (specify whether per 
day, week, month etc.) 
O 1 Every day     _________ 
O 2 More than once a week    _________ 
O 3 Few time a month    _________ 
O 4 Few times a year    _________ 
O 5 Only once or twice    _________ 
 
3.! What type of cannabis were you using?       
O1 Hash (cannabis resin/solid) 
                           O2 Imported herbal cannabis 
                    O3 Home grown skunk/Sensimilla 
                         O4 Super skunk 
O 5 Synthetic cannabis 
O 6 Other (please state) ____________________________ 
 
4.! Where you using any other drugs around the time of relapse?    O1 Yes           
O0 No 
(If yes, specify)     
Frequency    
(for code see frequency 
table) 
Cigarettes/Nicotine  O1 Yes           O0 No
 ________ 
Alcohol   O1 Yes           O0 No 
 ________ 
Inhalants                                O1 Yes           O0 No 
 ________ 
Amphetamines                       O1 Yes           O0 No ________ 
Crack                               O1 Yes           O0 No ________ 
Cocaine                           O1 Yes           O0 No ________                                                                     
Sedatives  
(not prescribed by doctor)  O1 Yes           O0 No  ________                    
Opioids 
(heroin,morphine,methadone) O1 Yes           O0 No ________ 
Hallucinogens                      O1 Yes           O0 No ________ 
Frequency codes 
1 Every day 
2 More than 
once/week 
3 Few times a month 
4 Few times a year 
5 Only once or twice 
6 No use 
[324] 
 
Ketamine                                O1 Yes           O0 No ________ 
Others - Specify                   O1 Yes           O0 No  ________ 
 
Urine drug screen around relapse?        O1Yes  O0 No    
Result: _____________________ 
 
5.! If alcohol every day, how much alcohol (in units as defined in AUDIT) did 
you use around the time of relapse?          
1 or 2   1 O   10 to 14  5 O 
3 or 4   2 O   15 to 19  6 O 
5 or 6   3 O   20 to 29  7 O 
7 to 9   4 O   30 or more  8 O 
 
 
6.! Did you stop any of your prescribed medication before the relapse? 
  
O1 Yes (specify: ________________________)           O0 No 
O2 Uncertain (Reason:_______________________________________) 
 
How long before did you stop: __________  O days (1) O weeks (2)  
O months (3) 
 
7.! In your opinion did you experience any life events or difficulty up to 1 
month before the relapse? 
 
O1 Yes           O0 No  



























1.! Compliance/Attendance between onset and 2 year follow up 
Rate patient’s compliance/attendance at community/follow-up services  
O 1 Regular compliance/attendance  [1-33% missed appointments]  
O 2 Irregular compliance/attendance [34-66% missed appointments]  
O 3  None compliance/attendance      [67-100% missed appointments]  
 
 
2.! Reason for Irregular or None Attendance  
























































aTable 1. Clinical and functional outcome following onset of FEP 
Study FU % N 
Symptomatic non-remission 
Greenstein, Wolfe, Gochman, Rapoport, and Gogtay (2008) 0.3 71 56 
Üçok et al. (2006) 1 37 74 
Haukvik et al. (2016) 1 42 79 
Hassan and Taha (2011) 2 49 37 
Fraguas et al. (2014) 2 47 80 
Gearing et al. (2009) 2 60 87 
Pencer et al. (2005) 2 49 69 
Wunderink et al. (2009) 2 48 125 
D. G. Robinson, Woerner, McMeniman, Mendelowitz, and 
Bilder (2004) 
5 53  118 
Henry et al. (2010) 7 59 651 
Eggers, Bunk, Volberg, and Röpcke (1999) 42 75 44 
L. Clausen et al. (2014) 5 45 314 
Faber et al. (2012) 2 48 124 
A Malla et al. (2008) 2 23 189 
Larsen, Moe, Vibe-Hansen, and Johannessen (2000) 1 44 43 
Wunderink, Nieboer, Wiersma, Sytema, and Nienhuis 
(2013) 
7 32 103 
D Wade et al. (2006) 1 5 103 
Langeveld et al. (2014) 10 45 178 
Levy et al. (2012) 1 10 140 
Colizzi et al. (2015) 1 55 205 
Crumlish et al. (2009) 8 51 67 
Wiersma et al. (1998) 3 65 82 
Wiersma et al. (1998) 15 73 82 
Simonsen et al. (2007) 1 44 301 
Schimmelmann et al. (2007) 1.5 42 363 
Ho, Andreasen, Flaum, Nopoulos, and Miller (2000) 0.5 62 47 
Holthausen et al. (2007) 2 75 103 
Prikryl et al. (2012) 4 43 68 
T. J. Craig et al. (2000) 2 48 149 
Verma et al. (2012) 2 46 1175 
Chang et al. (2016) 3 41 539 
Non-recovery 
Wunderink et al. (2009) 2 81 125 
D. G. Robinson et al. (2004) 5 86 118 
Faber et al. (2012) 2 81 124 
Wunderink et al. (2013) 7 71 103 
Manchanda, Norman, Malla, Harricharan, and Northcott 
(2005) 
2 58 159 
Renwick et al. (2015) 1 59 215 
Barbeito et al. (2013) 8 72 98 
Svedberg, Mesterton, and Cullberg (2001) 5 85 71 
Bertelsen et al. (2009) 1 99 265 
Bertelsen et al. (2009) 5 82 265 
Tarricone et al. (2014) 1 98 163 
Faber et al. (2012) 2 81 124 
N. Goater et al. (1999) 5 76 79 
Verma et al. (2012) 2 71 1175 
Chang et al. (2016) 3 83 539 
Depressive episode during follow up 
Sönmez et al. (2013) 1 35 198 
Jean Addington et al. (2003) 0.3 28 180 
Addington, Leriger et al. (2003) 0.5 17 180 
[329] 
 
Addington, Leriger et al. (2003) 1 14 180 
Upthegrove et al. (2010) 1 39 92 
Shepherd et al. (1989) 0.01 39  49 
Shepherd et al. (1989) 1 29 49 
Shepherd et al. (1989) 5 22 49 
Non-remission (negative symptoms) 
L. Clausen et al. (2014) 5 58 314 
Grech et al. (2005a) 4 56 89 
Möller et al. (2002) 15 59 146 
Suicide attempt 
J Addington, Williams, Young, and Addington (2004) 1 15 238 
J. Robinson et al. (2010) 8 22 282 
H Verdoux et al. (2001) 2 11 65 
Cotton et al. (2009) 1.5 19 661 
Upthegrove et al. (2010) 1 7 92 
Nordentoft et al. (2002) 1 11 275 
Ayesa-Arriola et al. (2015) 3 11 397 
Togay et al. (2015) 5 11 172 
Chow et al. (2005) 1 9 94 
Verma et al. (2012) 2 42 1175 
Unemployed 
Cotton, Lambert et al. (2009) 1.5 46 661 
Barbeito et al. (2013) 8 59 98 
Schimmelmann et al. (2007) 1.5 44 636 
Albert et al. (2011) 5 70 255 
Birchwood et al. (1992) 1 75 137 
Chow et al. (2005) 1 22 94 
Üçok et al. (2006) 1 53 74 
Functional non-remission 
Wunderink et al. (2009) 2 74 125 
Faber, Smid et al. (2012) 2 74 124 
Wunderink, Nieboer et al. (2013) 7 67 103 
Svedberg et al. (2001) 5 64 71 
Crumlish et al. (2009) 8 72 67 
Hodgekins et al. (2015) 0.5 74 764 
Hodgekins et al. (2015) 1 76 764 
Chang et al. (2016) 1 80 166 
Faber, Smid et al. (2012) 2 74 124 
Impaired social functioning 
D. G. Robinson et al. (2004) 5 75 118 
Henry et al. (2010) 7 69 651 
Hodgekins et al. (2015) 0.5 75 764 
Hodgekins et al. (2015) 1 71 764 
Crumlish et al. (2009) 8 67 67 
Continuous course (continuously psychotic) 
Hassan and Taha (2011) 2 24 37 
L. Clausen et al. (2014) 5 55 314 
Faridi et al. (2012) 1 57 48 
Rund et al. (2007) 1 14 111 
Rund et al. (2007) 2 13 111 
Larsen et al. (2000) 1 26 43 
Grech et al. (2005a) 4 44 89 
Wiersma et al. (1998) 3 24 82 
Simonsen et al. (2007) 1 23 301 
Bertelsen et al. (2009) 5 46 265 
Thara et al. (1994) 10 7 76 





Bachmann, Bottmer, and Schröder (2007) 1 5 40 
Holthausen et al. (2007) 2 7 103 
T. J. Craig et al. (2000) 2 34 149 
Suicide rate 
Dutta et al. (2011) 13 3 2132 
J Addington et al. (2004) 1 3 238 
Parker and Hadzi-Pavlovic (1995) 1 2 120 
Valevski et al. (2001) 17 4 351 
J. Robinson et al. (2010) 8 4 282 
Larsen et al. (2000) 1 0 43 
Mitter et al. (2013) 2 2 1397 
Opjordsmoen et al. (2010) 2 2 217 
Wiersma et al. (1998) 2 2 82 
Wiersma et al. (1998) 3 6 82 
Wiersma et al. (1998) 5 9 82 
Wiersma et al. (1998) 15 11 82 
Togay et al. (2015) 5 1 172 
Thara et al. (1994) 10 7 76 
Wunderink et al. (2009) 2 1 257 
Poor insight of mental illness 
Ayesa-Arriola et al. (2014) 3 45 224 
Schimmelmann et al. (2007) 1.5 17 636 
Violent behaviour 
Langeveld et al. (2014) 10 15 178 
Tseliou et al. (2015) 1 14 1098 
Chow et al. (2005) 1 5 94 
Milton et al. (2001) 3 10 168 
Non-adherence medication 
Michele Hill et al. (2010) 4 25 106 
Levy et al. (2012) 1 44 65 
Kamali et al. (2006) 0.5 33 60 
Miller et al. (2009) 1 19 112 
Martin Lambert et al. (2010) 1.5 66 265 
Colizzi et al. (2015) 1 44 205 
Coldham et al. (2002) 1 59 200 
Barbeito et al. (2013) 8 49 92 
Favre et al. (1997) 1 50 59 
Coldham et al. (2002) 1 20 186 
Svedberg et al. (2001) 1 18 71 
Svedberg et al. (2001) 5 33 71 
Schimmelmann et al. (2007) 1.5 61 636 
Birchwood et al. (1992) 1 29 137 
Linszen et al. (1994) 1 19 93 
Bachmann et al. (2007) 1 15 40 
Note. FU = Number of years of follow up, N = Number of subject included. 
adefined as convictions for murder, manslaughter, attempted murder and attempted manslaughter 
[331] 
 
aTable 2. Relapse rates in first episode psychosis 
Study Country FU  Outcome  % N 
D. Robinson et al. (1999) US 5 Relapse (CGI rating) 82 118 
D. Addington et al. (2010) Canada 1 Hospitalisation  23 279 
D. Addington et al. (2010) Canada 2 Hospitalisation  32 279 
D. Addington et al. (2010) Canada 3 Hospitalisation  36 279 
D. Addington et al. (2010) Canada 1 Hospitalisation  22 309 
D. Addington et al. (2010) Canada 2 Hospitalisation  30 309 
D. Addington et al. (2010) Canada 3 Hospitalisation  34 309 
T. K. J. Craig et al. (2004) UK 1.5 Hospitalisation 28 144 
Craig, Garety et al. (2004) UK 1.5 Relapse (clinical rating) 24 144 
D. E. Addington, Patten, et al. 
(2013) 
Canada 1 Relapse (clinical rating) 23 200 
Addington, Patten et al. (2013) Canada 2 Relapse (clinical rating) 45 200 
Nuechterlein et al. (2006) US 1 Relapse (BPRS rating) 21 77 
Hassan and Taha (2011) Saudi Arabia  2 Relapse (PANSS rating) 41 37 
Gearing et al. (2009) Canada 1 Hospitalisation 33 87 
Gearing, Mian et al. (2009) Canada 2 Hospitalisation 44 87 
Whitehorn, Richard, and Kopala 
(2004) 
Canada 1 Hospitalisation 17 434 
Parker and Hadzi-Pavlovic (1995) Australia 1 Hospitalisation 45 118 
Valevski et al. (2001) Israel 17 Hospitalisation 65 351 
Jarbin, Gråwe, and Hansson 
(2000) 
Sweden 1 Relapse (rating clinical 
notes)a 
53 15 
Jarbin, Gråwe et al. (2000) Sweden 2 Relapse (rating clinical 
notes)a 
73 15 
Üçok et al. (2006) Turkey 1 Relapse (BPRS rating) 34 74 
Üçok et al. (2006) Turkey 1 Hospitalisation 12 74 
Patel R et al. (2016) UK 1 Hospitalisation 21 2026 
Patel R et al. (2016) UK 2 Hospitalisation 29 1738 
Patel R et al. (2016) UK 3 Hospitalisation 34 1461 
Patel R et al. (2016) UK 4 Hospitalisation 36 1184 
Patel R et al. (2016) UK 5 Hospitalisation 39 926 
Caseiro et al. (2012) Spain 1 Relapseb  21 150 
Caseiro, Pérez-Iglesias et al. 
(2012) 
Spain 2 Relapseb  41 145 
Caseiro, Pérez-Iglesias et al. 
(2012) 
Spain 3 Relapseb  65 140 
Faber, Smid et al. (2012) Netherlands 2 Relapse (PANSS rating) 68 124 
Faridi et al. (2012) Canada 1 Relapse (PANSS rating) 51 48 
A Malla et al. (2008) Canada 2 Relapse (SAPS rating) 30 189 
Rund et al. (2007) Norway 1 Relapse (PANSS rating) 18 111 
Rund et al. (2007) Norway 2 Relapse (PANSS rating) 20 111 
Larsen et al. (2000) Norway 1 Relapse (clinical rating) 18 43 
Wunderink et al. (2013) Netherlands 7 Relapse (PANSS rating) 65 103 
D Wade et al. (2006) Australia 1 Hospitalisation 31 103 
D Wade et al. (2006) Australia 1 Relapse (BPRS rating) 36 98 
H. Jackson et al. (2008) Australia 1 Hospitalisation 18 57 
Turkington et al. (2009) Ireland 1 Relapse (PPHS rating) 34 187 
Michele Hill et al. (2010) Ireland 4 Hospitalisation 51 106 
Levy et al. (2012) Canada 1 Relapse (change in 
medication) 
14 65 
Levy et al. (2012) Canada 1 Relapse (SAPS rating) 22 65 
Bergé et al. (2016) Spain 0.2 Relapsec 5 133 
Bergé, Mané et al. (2016) Spain 0.5 Relapsec 26 105 
Bergé, Mané et al. (2016) Spain 1 Relapsec 31 81 
Bergé, Mané et al. (2016) Spain 2 Relapsec 43 62 
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Wiersma et al. (1998) Netherlands 1 Relapse (LCS) 43 82 
Wiersma et al. (1998) Netherlands 2 Relapse (LCS) 55 82 
Wiersma et al. (1998) Netherlands 3 Relapse (LCS) 63 82 
Wiersma et al. (1998) Netherlands 4 Relapse (LCS) 70 82 
Wiersma et al. (1998) Netherlands 5 Relapse (LCS) 72 82 
Simonsen et al. (2007) Denmark/Norway 1 Relapse (PANSS rating) 26 301 
Bertelsen et al. (2009) Denmark 1 Hospitalisation 23 265 
Bertelsen, Jeppesen et al. (2009) Denmark 2 Hospitalisation 39 265 
Kam et al. (2015) UK 1 Crisis intervention/ 
Hospitalisation 
23 163 
Baeza et al. (2009) Spain 0.5 Hospitalisation 18 101 
Chi et al. (2016) Taiwan 10 Hospitalisation 71 808 
Chi, Hsiao et al. (2016) Taiwan 0.3 Hospitalisation 25 808 
Tiihonen et al. (2011) Finland 3 Hospitalisation 58 2588 
Tarricone et al. (2014) Italy 1 Hospitalisation 36 163 
Faber et al. (2012) Netherlands 2 Relapse (PANSS rating) 68 124 
Birchwood et al. (1992) UK 1 Hospitalisation 34 137 
Chow et al. (2005) China 1 Hospitalisation 10 94 
Thara et al. (1994) India 10 Relapse (PPHS rating) 83 76 
Andreasen et al. (2013) US 5 Relapse (PANSS rating) 78 202 
Barrelet et al. (1990) Switzerland 0.8 Hospitalisation 24 46 
E. Y.-H. Chen et al. (2005) Hong Kong 1 Hospitalisation 21 93 
E. Y.-H. Chen et al. (2005) Hong Kong 2 Hospitalisation 33 93 
E. Y.-H. Chen et al. (2005) Hong Kong 3 Hospitalisation 40 93 
Strasser, Schmauss, and Messer 
(2004) 
Germany 1 Hospitalisation 38 75 
Holthausen et al. (2007) Netherlands 2 Relapse (PANSS rating) 42 103 
Shepherd et al. (1989) UK 5 Hospitalisation 55 49 
R. J. Drake et al. (2007) UK 1.5 Hospitalisation 33 257 
Drake, Dunn et al. (2007) UK 1.5 Relapse 51 236 
Tohen et al. (2000) US 0.5 Relapse (BPRS) 20 102 
T. J. Craig et al. (2000) US 2 Hospitalisation 56 149 
Singh et al. (2000) UK 3 Hospitalisation 46 164 
Note. FU = Number of years of follow up, N = Number of subject included. 
a based on ratings from clinical notes: exacerbation of symptoms accompanied by at least 2 weeks of 
functional impairment 
b Relapse (BPRS/CGI, hospitalisation, completed suicide) following clinical improvement (assessed with 
BPRS/CGI) 




aTable 3. Prevalence rates of cannabis use reported at onset 
Study % Cannabis definition N 
Lifetime use: Light use    
Seddon et al. (2015) 59 lifetime use (>1) of cannabis 1027 
Faber et al. (2012) 65 lifetime use (>1) of cannabis 124 
Di Forti, Marconi, et al. (2015) 67 lifetime use (>1) of cannabis 410 
Veen et al. (2004) 53 use (>3) at onset 133 
Jonsson et al. (2004) 69 history of regular (NS) cannabis use 90 
Hinton et al. (2007) 89 lifetime use (>1) of cannabis 130 
Barnes et al. (2006) 64 lifetime use (>1) of cannabis 148 
I. Harrison et al. (2008a) 63 lifetime use (>1) of cannabis 85 
Manrique-Garcia et al. (2014c) 20 lifetime use (>1) of cannabis 357 
Faber, Smid et al. (2012) 35 lifetime use (>1) of cannabis 124 
Paruk et al. (2016) 56 lifetime use (>1) of cannabis 45 
Lifetime use: Heavy use 
Faridi, Joober et al. (2012) 50 presence lifetime CUD 186 
Faber, Smid et al. (2012) 19 daily cannabis use for > 1 
months/lifetime 
124 
Miller et al. (2009) 44 presence lifetime CUD 112 
Grech et al. (2005a) 26 History of (regular/frequent) use 98 
Sarrazin, Louppe, Doukhan, and Schürhoff 
(2015) 
21 presence lifetime CUD without 
comorbid SUD 
171 
Onset use: Light use 
Seddon, Birchwood et al. (2015) 27 use (>1) in 3 months prior onset 1027 
Caseiro et al. (2012) 47 use (>1) at onset 166 
Patel R et al. (2016) 46 use (>1) at onset 2026 
J. Stone et al. (2014) 41 use (>1) at onset 502 
Faber, Smid et al. (2012) 35 use (>1) at onset 124 
Barbeito et al. (2013) 52 use (>1) at onset 98 
Foti et al. (2010) 10 use (>1) in 1 month prior onset 229 
Hinton, Edwards et al. (2007) 55 use (>1) in the months prior onset 130 
González-Pinto et al. (2011) 56 use (> slight problem) in 1 year prior 
onset 
92 
Ayesa-Arriola et al. (2014) 40 use (>1) at onset 224 
I. Harrison et al. (2008a) 32 use (>1) at onset 85 
Bergé et al. (2016) 49 use (>1/week) at onset 133 
Batalla et al. (2013b) 38 positive UDS at onset 58 
Baeza et al. (2009) 29 use (>1) in 1 month prior onset 110 
J Boydell et al. (2006) 50 use (>1) in 1 year prior onset 107 
Tarricone et al. (2014) 23 use (>2) in 1 month prior onset 163 
Bergh et al. (2016) 23 use (>1) in 1 month prior onset 273 
Crespo-Facorro et al. (2007) 47 use (>1/week) in 1 year prior onset 172 
Paruk et al. (2016) 38 use (>1) in 3 months prior onset 45 
Onset use: Heavy use 
B. Schimmelmann et al. (2012) 54 presence CUD at onset 99 
Stone, Fisher et al. (2014) 23 presence CUD at onset 502 
L. Clausen et al. (2014) 33 monthly use 1 year prior onset 578 
Faridi et al. (2012) 33 presence CUD at onset 186 
Di Forti, Marconi, et al. (2015) 30 use (daily) at onset 410 
Turkington et al. (2009) 21 presence CUD at onset 272 
Levy et al. (2012) 14 presence CUD at onset 65 
Van Mastrigt et al. (2004) 31 presence CUD at onset 357 
Martin Lambert et al. (2010) 44 presence CUD at onset 605 
Veen et al. (2004) 10 CUD in 1 year prior onset 133 
Hinton et al. (2007) 27 use (daily) in the months prior onset 130 










Ruiz-Veguilla et al. (2009) 55 Heavy cannabis use (daily) 92 
Faber et al. (2012) 19 Heavy cannabis use (daily for 1 months) 124 
Cantwell et al. (1999) 17 presence CUD at onset 168 
Wunderink et al. (2009) 24 presence CUD at onset 125 
Prior onset use: Cannabis in UHR 
Valmaggia et al. (2014)  74 lifetime use (>1) of cannabis 182 
Valmaggia et al. (2014) 20 use (>1) in 1 month prior assessment 182 
Auther et al. (2015) 13 presence CUD at first presentation 341 
aTable 4. Course of cannabis use following the onset of psychosis 
Study FU Discontinuer Continuer Starter N 
(Seddon et al., 2015)  1 32% 50% 18% 256 
J. Stone et al. (2014) 1 63% 37% - 128 
Faridi, Joober et al. (2012) 1 42% 58% 0% 48 
B. Schimmelmann et al. (2012) 1.5 55% 42% 3% 53 
Faber et al. (2012) 2 44% 56% - 43 
Caseiro et al. (2012) 3 66% 34% - 78 
L. Clausen et al. (2014) 5 59% 26% 15% 70 
González-Blanch et al. (2015) 5 50% 48% 2% 52 
Miller et al. (2009) 1 33% 63% 4% 112 
Grech et al. (2005a) 4 24% 43% 33% 37 
Barbeito et al. (2013) 8 49% 51% - 98 
Hinton, Edwards et al. (2007) 0.2 35% 52% 13% 83 
I. Harrison et al. (2008a) 1 44% 52% 4% 27 







aTable 5. Quality assessment (Paper 1) 
 1. 2. 3. 4. 5. 6. 7. Total score 
van der Meer and Velthorst (2015) 1 1 1 1 1 1 1 7 
G. E. Sara et al. (2014) 0 0 1 1 0 0 1 3 
Koenders et al. (2014) 0 0 1 0 1 1 0 3 
Barrowclough et al. (2013) 1 1 1 1 1 0 1 6 
van Dijk et al. (2012b) 0 1 1 1 1 1 1 6 
San et al. (2013b) 0 1 1 1 0 0 1 4 
Faridi et al. (2012) 0 1 1 1 1 1 1 6 
Rentzsch et al. (2011) 1 0 1 0 1 0 0 3 
González-Pinto et al. (2009) 0 1 1 1 1 1 1 6 
Ringen et al. (2010) 0 0 1 0 1 1 0 3 
Baeza et al. (2009) 0 1 0 1 1 1 0 4 
Rehman and Farooq (2007) 1 0 1 0 1 0 1 4 
Jockers-Scherubl et al. (2007) 0 0 0 0 1 1 0 2 
D Wade et al. (2006) 0 1 1 1 1 1 1 6 
M. Isaac and Holloway (2005) 0 0 1 0 0 0 0 1 
Maremmani et al. (2004) 0 0 1 0 0 0 0 1 
Sorbara et al. (2003) 0 1 0 1 1 1 1 5 
Bersani et al. (2002) 1 0 1 0 1 1 0 4 
Salyers and Mueser (2001) 0 1 1 0 0 1 1 4 
Caspari (1999) 1 1 1 1 0 0 1 5 
Martinez-Arevalo et al. (1994) 1 0 0 1 0 0 1 3 
Linszen et al. (1994) 0 1 0 1 1 1 1 5 
Peralta and Cuesta (1992) 1 0 0 0 1 1 1 4 
Negrete et al. (1986) 1 1 1 1 1 0 0 5 
Note. Quality rating scale (adopted and modified from previous meta-analyses (Mullin et al., 2012b)), 
with 1=higher quality and 0=lower quality 
1.! Use of patients with non-affective psychosis 
2.! Use of consecutive presentations 
3.! A sample of cannabis users of ≥25 people 
4.! Re-measurement after a period of follow-up rather than a strictly cross-sectional design 
5.! Use of structured or semi-structured methods for establishing the history of cannabis use 
6.! Use of structured or semi-structured methods for establishing the diagnosis of psychosis. 
7.! Quality of relapse assessment [Coded as 1 if comparable follow up duration  
between cannabis users and non-users AND relapse outcome measures in the specified  










aTable 6. Random Effects Models for cannabis groups  
Outcomes 
of interest 
(1) Continued user vs. Non-user (2) Continued user vs. Discontinued user (3) Discontinued user vs. Non-user  
p-
mod 
k N d p I 2 p  
Q-test 










Relapse  24 16157 0.36 <0.0001  84% <0.0001 0.0002 6 676 0.28 0.0005 0% 0.52 0.72 6 904 0.02 0.82 0% 0.76 0.34 0.043 
Time spent 
in hospital 
5 803 0.36 0.02 38% 0.14 0.93 0 0 n/a n/a n/a n/a n/a 0 0 n/a n/a n/a n/a n/a n/a 
Positive 
symptoms 
10 1224 0.15 0.04 16% 0.21 0.97 2 83 0.26 0.24 0% 0.76 n/a 2 152 -0.30 0.39 71% 0.06 n/a 0.054 
Negative 
symptoms 
10 1202 -0.09 0.37 56% 0.02 0.23 2 83 0.41 0.07 0% 0.37 n/a 2 152 -0.31 0.10 0% 0.65 n/a 0.407 
Functioning 
 
9 1198 0.04 0.68 41% 0.09 0.74 3 149 0.47 0.23 84% 0.002 0.76 3 220 -0.49 0.002 14% 0.33 0.91 0.0075 
Note. d= Cohen’s d; k=number of studies, N=number of subjects; p -ET= p-value for Egger’s Test for publication bias; p-mod = p-value for meta-regression comparing d 
between (1) and (3); p (Q test) = p-value for Q-test for heterogeneity. 
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aTable 7. Balance of covariates of Propensity Score Matched groups 








Continued cannabis usera 
(Hash-like)  
(n=16) 
Continued cannabis user 
(Skunk-like/low 
frequency)a (n=46) 




 OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Ethnicity (non-
white) 
1.27 (0.49 – 3.35) 0.63 0.87 (0.31 – 2.42) 0.80 1.00 (0.13 – 7.98) 1.00 1.27 (0.32 – 5.16) 0.73 2.10 (0.72 - 6.43) 0.18 
Gender (Female) 
 
1.00 (0.37 – 2.67) 1.00 1.00 (0.34 – 2.93) 1.00 2.33 (0.18 – 58.01) 0.53 0.60 (0.13 – 2.45) 0.48 0.84 (0.25 - 2.71) 0.77 
Other illicit drug 
use 
0.48 (0.02 – 5.30) 0.56 1.00 (0.22 – 4.63) 1.00 1.80 (0.21 – 18.29) 0.59 3.05 (0.82 – 13.20) 0.11 2.15 (0.39 - 16.48) 0.40 
Cigarette use 
 
0.79 (0.30 – 2.06) 0.63 1.18 (0.38 – 3.66) 0.78 1.00 (0.03 – 28.82) 1.00 2.53 (0.66 – 11.04) 0.19 1.00 (0.33 - 3.05) 1.00 
Age of onset 
 





0.64 0.80 (0.21 – 2.99) 0.74 0.43 (0.02 – 5.61) 0.53 1.32 (0.30 – 6.08) 0.71 2.36 (0.65 - 9.85) 0.20 
Onset care 
intensity 
0.69 (0.26 – 1.83) 0.46 0.52 (0.19 – 1.42) 0.21 1.80 (0.21 – 18.29) 0.59 0.84 (0.26 – 2.68) 0.77 1.00 (0.36 - 2.77) 1.00 
Medication non-
adherence 
1.12 (0.43 – 2.93) 0.81 1.30 (0.47 – 3.63) 0.61 1.00 (0.13 – 7.98) 1.00 2.53 (0.66 – 11.04) 0.19 1.71 (0.53 - 5.88) 0.37 
Note. CI = 95% Confidence Interval; OR = Odds Ratio estimated from logistic regression analysis, with dichotomized dependent variable [0 = Control group: former 





aTable 8.  Cannabis use pattern and relapse outcome: Multiple regression analyses 
 Risk of relapse Number of 
relapses 
Length of relapse Time to relapse Care intensity at 
follow up 
Model 1* (N=256) ORa 
95% 
CI p IRRb 
95% 
CI p bc 
95% 
CI p bc 95% CI p ORd 
95% 
CI p 
Former (regular) user 0.30 0.11-0.82 0.02 0.56 0.31-1.04 0.07 -0.61 -1.55-0.31 0.17 0.22 0.04-0.40 0.02 0.32 0.12-0.79 0.01 
Never (regular) user 0.38 0.14-0.99 0.05 0.72 0.41-1.25 0.24 -0.61 -1.48-0.22 0.16 0.21 0.04-0.39  0.02 0.63 0.27-1.51 0.30 
Intermittent user 0.53 0.19-1.49 0.24 0.69 0.38-1.27 0.24 0.17 -0.75-1.08 0.70 0.16 -0.03-0.35 0.11 0.88 0.34-2.22 0.78 
Continued user (Hash-like) 0.56 0.10-2.75 0.47 0.64 0.26-1.59 0.34 -0.94 -2.42-0.62 0.21 0.29 0.01-0.58 0.05 0.76 0.16-3.33 0.72 
Continued user (Skunk-like/low 
frequency) 0.74 0.23-2.33 0.60 0.63 0.33-1.12 0.17 -0.20 -1.21-0.83 0.68 0.27 0.06-0.48 0.01 0.99 0.34-2.82 0.98 
Ethnicity (non-white) 2.36 1.23-4.69 0.01 1.82 1.16-2.85 0.01 0.97 0.35-1.59 0.002 -0.12 -0.23-(-0.01) 0.03 1.94 1.08-3.54 0.03 
Gender (Female) 1.42 0.78-2.60 0.26 1.20 0.82-1.74 0.35 -0.27 -0.83-0.30 0.33 -0.04 -0.14-0.06 0.44 1.51 0.88-2.61 0.13 
Other illicit drug use 1.79 0.68-4.76 0.24 1.79 1.05-3.04 0.03 0.70 -0.17-1.60 0.10 -0.11 -0.28- 0.07 0.23 1.43 0.60-3.41 0.42 
Cigarette use 1.49 0.78-2.83 0.23 1.73 1.12-2.67 0.01 0.37 -0.17-0.92 0.20 -0.07 -0.18-0.04 0.24 1.66 0.92-3.02 0.09 
Age of onset 1.01 0.97-1.04 0.78 1.00 0.97-1.02 0.82 -0.02 -0.05-0.01 0.30 0.00 -0.01-0.00 0.42 0.99 0.96-1.03 0.71 
Alcohol use 1.72 0.75-3.94 0.20 1.14 0.69-1.88 0.60 -0.09 -0.85-0.69 0.81 -0.01 -0.15-0.14 0.90 1.96 0.95-4.08 0.07 
Onset care intensity 1.37 1.05-1.84 0.03 1.32 1.08-1.60 0.01 0.59 0.32-0.87 <0.001 -0.03 -0.07-0.02 0.22 1.33 1.03-1.73 0.03 
Model 2** (N=236) ORa 
95% 
CI p IRRb 
95% 
CI p bc 
95% 
CI p bc 95% CI p ORd 
95% 
CI p 
Former (regular) user 0.37 0.13-0.98 0.05 0.57 0.31-1.07 0.08 -0.98 
-1.90-(-
0.09) 0.04 0.2 0.01-0.38 0.03 0.34 0.13-0.85 0.02 
Never (regular) user 0.47 0.19-1.12 0.09 0.65 0.39-1.09 0.11 -0.78 -1.62-0.01 0.06 0.18 0.02-0.35 0.03 0.62 0.28-1.37 0.23 
Intermittent user 0.58 0.20-1.64 0.31 0.7 0.37-1.34 0.29 -0.2 -1.19-0.79 0.68 0.14 -0.06-0.34 0.16 0.84 0.33-2.17 0.72 
Continued user (Hash-like) 0.93 0.18-4.92 0.93 1.00 0.39-2.53 1.00 -0.41 -1.82-1.28 0.60 0.24 -0.06-0.54 0.13 1.13 0.23-5.13 0.88 
Continued user (Skunk-like/low 
frequency) 0.96 0.31-3.00 0.95 0.77 0.4-1.49 0.43 -0.09 -1.11-0.96 0.87 0.23 0.02-0.45 0.03 1.10 0.39-3.13 0.85 
Medication non-adherence 3.25 1.79-6.09 <0.001 2.29 1.46-3.57 <0.001 0.57 -0.01-1.15 0.05 -0.15 -0.25-(-0.05) 0.01 3.36 1.93-6.00 <0.001 
Note. Reference group = Continued user (Skunk-like/high frequency) 
*Medication non-adherence not included as a covariate 
**Only Medication non-adherence included as a covariate 
a OR = Odds Ratio estimates from multiple logistic regression analysis 
b IRR = Incidence Rate Ratio estimated from negative binomial regression 
c b = Coefficient estimate from negative binomial regression 





aSupplementary 1. Author’s rely 
The first study1 showed that a small proportion of cannabis use in the general 
population was explained by the polygenic risk score for schizophrenia.  The second2 
compared GWAS data concerning cannabis use with GWAS data on 5 different 
psychiatric disorders; they found a very small overlap with depression but none with 
schizophrenia. Thus, should there be any shared genetic vulnerability between cannabis 
use and schizophrenia, it could explain only a small proportion of the association 
between the two. Furthermore, in two independent studies, the association of cannabis 
use with psychotic symptomatology remained significant when the main effect of 
genetic predisposition was factored out3,4. Fergusson, Horwood (2005)3 and Foti, Kotov 
(2010)4 employed fixed effects models, which apply the principle of co-twin analysis to 
longitudinal observational data. In co-twin analysis, monozygotic (MZ) twin pairs who 
are discordant for the risk factor of interest (cannabis use) are compared on the outcome 
measure (psychosis). Since the pairs share common genes and common environment, 
these comparisons control for time-invariant sources of confounding (i.e. not time-
variant factors such as epigenetics, stressful life events following the onset etc.), even 
though the common genes and common environmental confounders are not observed5. 
Another study, which controlled for some of the shared genetic contribution (using a 
sibling design in which 100% of the common environment and 50% of the common 
genes are controlled for), is also consistent with this evidence6. Dose-response 
relationships in those controlled studies3,6 further oppose a shared-vulnerability 
hypothesis. This is in line with the results from RCT’s that aimed to reduce cannabis 
use in psychosis7,8. 
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